Louisiana Board of Pharmacy...9. Special Order of the Day – Presentation of Pharmacist Gold...

NOTE: Pursuant to the Open Meetings Law at La. R.S. 42:16, the Board may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, (4) discussions regarding personnel matters, or other purposes itemized at La. R.S. 42:17.

Louisiana Board of Pharmacy 3388 Brentwood Drive

Baton Rouge, Louisiana 70809-1700 Telephone 225.925.6496 ~ Facsimile 225.925.6499

www.pharmacy.la.gov ~ E-mail: [email protected]

Board Meeting

August 10, 2016

http://www.pharmacy.la.gov/

mailto:[email protected]





Table of Contents 1 – A. Table of Contents 002 1 – B. Agenda 004 1 – C. Meeting Notice & Arrangements 006 1 – D. Acronyms 007 2. Invocation & Pledge of Allegiance 3. Quorum Call 4. Call for Additional Agenda Items & Adoption of Agenda 5. Consideration of Minutes from Previous Meetings ~ May 4-5, 2016 011 6. Report on Action Items 033 7. Confirmation of Acts 8. Opportunity for Public Comment * Statement of Purpose & Mission of Board 9. Special Order of the Day – Presentation of Pharmacist Gold Certificates 10. Committee Reports

A. Finance – Mr. Pitre & Mr. Champagne, CPA 035 • Consideration of Final Report for Fiscal Year 2015-2016 037 • Consideration of Proposed Budget Amendment For Fiscal Year 2016-2017 071

B. Application Review – Mr. Soileau 076 • Consideration of Committee Recommendations re Applications 000

C. Reciprocity – Ms. Hall 077 • Consideration of Committee Recommendations re Applications 000

D. Violations – Mr. Bond 079 • Consideration of Proposed Voluntary Consent Agreements 080

E. Impairment – Mr. Rabb 100 • Consideration of Committee Recommendations re Applications 000

F. Reinstatement – Ms. Melancon 102 • Consideration of Committee Recommendations re Applications 000

G. Tripartite – Mr. Burch 106 H. Regulation Revision – Mr. McKay 107

• Consideration of Comments & Testimony from May 25 Public Hearing re Regulatory Project 2016-2 ~ Pharmacist-in-Charge in Nonresident Pharmacies 108

• Consideration of Regulatory Proposal 2016-A ~ Marijuana Pharmacies 113 I. Executive Committee – Mr. Aron 135

• Consideration of Committee Recommendations re New Legislation 136 11. Staff Reports J. Assistant Executive Director – Mr. Fontenot 145

• Quarterly Report from Prescription Monitoring Program (PMP) 000 • Consideration of Requests for Waivers from PMP Reporting Rule 146

K. General Counsel – Mr. Finalet 178 • Consideration of Proposed Voluntary Consent Agreements 179

(continued)




Board Meeting Binder August 10, 2016 Page 2 of 2 11. Staff Reports (cont.)

L. Executive Director – Mr. Broussard 200 • Narrative Report 201 • Census Reports 205 • Productivity Reports 210 • Exceptions Report 212 • Examination Program Reports

MPJE 219 NAPLEX 239

• Operations • Final Legislative Brief 261 • National Activities • International Activities

12. Request for Approval of Immunization Training Program 270 13. Announcements 279 14. Recess




www.pharmacy.la.gov ~ E-mail: [email protected] NOTICE IS HEREBY GIVEN that a meeting of the Board has been ordered and called for 10:00 a.m. on Wednesday, August 10, 2016 at the Board office, for the purpose to wit:

A G E N D A NOTE: This agenda is tentative until 24 hours in advance of the meeting, at which time the most recent revision becomes official.

Revised 07-26-2016 1. Call to Order 2. Invocation & Pledge of Allegiance 3. Quorum Call 4. Call for Additional Agenda Items & Adoption of Agenda 5. Consideration of Minutes from Previous Meeting – May 4, 2016 6. Report on Action Items 7. Confirmation of Acts 8. Opportunity for Public Comment 9. Special Order of the Day – Presentation of Pharmacist Gold Certificates PST.009101 – Harold Gerard Engle PST.009121 – Donald Lynn Middleton PST.009148 – Loudon David Yantis 10. Committee Reports

A. Finance – Mr. Pitre & Mr. Russell Champagne, CPA • Consideration of Final Report for Fiscal Year 2015-2016 • Consideration of Proposed Budget Amendment No. 1 for FY 2016-2017

B. Application Review – Mr. Soileau • Consideration of Committee Recommendations re Applications

C. Reciprocity – Ms. Hall • Consideration of Committee Recommendations re Applications

D. Violations – Mr. Bond • Consideration of Proposed Voluntary Consent Agreements

E. Impairment – Mr. Rabb • Consideration of Committee Recommendations re Applications

F. Reinstatement – Ms. Melancon • Consideration of Committee Recommendations re Applications

G. Tripartite – Mr. Burch H. Regulation Revision – Mr. McKay

• Consideration of Comments & Testimony from May 25, 2016 Public Hearing on Regulatory Project 2016-2 ~ Pharmacist-in-Charge in Nonresident Pharmacies

• Consideration of Regulatory Proposal 2016-A ~ Marijuana Pharmacies (Draft #4)

I. Executive – Mr. Aron • Consideration of Committee Recommendations re New Legislation from 2016

Legislature




Board Meeting August 10, 2016 Page 2 of 2 11. Staff Reports J. Assistant Executive Director – Mr. Fontenot

• Consideration of Requests for Waivers from PMP Reporting Requirement K. General Counsel – Mr. Finalet

• Consideration of Proposed Voluntary Consent Agreements L. Executive Director – Mr. Broussard 12. Request for Approval of Immunization Training Program (Arizona Pharmacy Association) 13. Announcements 14. Recess




M E M O R A N D U M To: Board Members & Staff From: Malcolm Broussard Date: August 4, 2016 Re: Board Meeting Schedule & Arrangements The next quarterly meeting of the Board and certain of its committees will be held at the Board office on May 3-5, 2016. The schedule of events is as follows: Tuesday, August 9, 2016

0830 Reinstatement Committee Boardroom 1200 Committee Luncheon Boardroom 1300 Impairment Committee Boardroom

1600 Regulation Revision Committee Boardroom 1630 Finance Committee Boardroom

1730 Executive Committee Boardroom Wednesday, August 10, 2016

0830 Reciprocity Committee Boardroom 1000 Board Meeting Boardroom

Thursday, August 11, 2016 0830 Administrative Hearing Boardroom

You should have already received your hotel reservation confirmations from Ms. Kelley Villeneuve via email. If you have any questions about those arrangements, please contact her directly at [email protected] or 225.925.6498.

Most of your meeting materials have been posted in the Boardroom Library. You may enter the library by visiting our website at www.pharmacy.la.gov, selecting the Login link at the right-sided margin of the horizontal menu bar, and entering your log-in and password information. At the Boardroom Library Lobby, select the link for the Main Reading Room, and then the 08-10-2016 link for the board meeting.

I anticipate completion of all the board meeting materials by Sunday afternoon the 7th, and we will advise you when all of the materials have been posted.





Revised 2014-0501

Acronyms AACP American Association of Colleges of Pharmacy AAPS American Association of Pharmaceutical Scientists AAPT American Association of Pharmacy Technicians ACA American College of Apothecaries ACCME Accreditation Council for Continuing Medical Education ACCP American College of Clinical Pharmacy ACE Advisory Committee on Examinations (NABP) ACPE Accreditation Council for Pharmacy Education ADA American Dental Association ADC automated dispensing cabinet ADS automated dispensing system AFDO Association of Food & Drug Officials AFPE American Foundation for Pharmaceutical Education AIHP American Institute of the History of Pharmacy AMA American Medical Association AMCP Academy of Managed Care Pharmacy AMS automated medication system APEC Australian Pharmacy Examining Council APhA American Pharmacists Association APPE advanced pharmacy practice experience ASAE American Society of Association Executives ASAP American Society for Automation in Pharmacy ASCP American Society of Consultant Pharmacists ASHP American Society of Health-System Pharmacists ASPL American Society for Pharmacy Law AVMA American Veterinary Medical Association AWARxE NABP consumer protection program BNDD Bureau of Narcotics and Dangerous Drugs BPS Board of Pharmacy Specialties CAC Citizen Advocacy Center CCAPP Canadian Council for Accreditation of Pharmacy Programs CCGP Commission for Certification in Geriatric Pharmacy CDC Centers for Disease Control and Prevention CDER Center for Drug Evaluation and Research CDTM collaborative drug therapy management CDS controlled dangerous substances CE continuing education CFR Code of Federal Regulations CHPA Consumer Healthcare Products Association CLEAR Council on Licensure, Enforcement and Regulation CMI consumer medication Information CMS Centers for Medicare and Medicaid Services CPD continuing professional development CPhA Canadian Pharmacists Association CPPA Center for Pharmacy Practice Accreditation CPSC Consumer Product Safety Commission DEA Drug Enforcement Administration DEQ La. Department of Environmental Quality DHH La. Department of Health and Hospitals

Revised 2014-0501

DME durable medical equipment DMEPOS durable medical equipment, prosthetics, orthotics, and supplies DNV Det Norske Veritas (Norwegian accreditation organization) DSM disease state management EDK emergency drug kit ELTP Electronic Licensure Transfer Program (NABP) EPA Federal Environmental Protection Agency EPCS Electronic Prescribing of Controlled Substances (DEA) ETS Educational Testing Service EU European Union ExCPT Examination for the Certification of Pharmacy Technicians FARB Federation of Associations of Regulatory Boards FBI Federal Bureau of Investigation FD&C Federal Food, Drug & Cosmetic Act FDA Federal Food & Drug Administration FIP Federation Internationale Pharmaceutique FMI Food Marketing Institute FPGEC Foreign Pharmacy Graduate Examination Committee (NABP) FPGEE Foreign Pharmacy Graduate Equivalency Examination (NABP) FSBPT Federation of State Boards of Physical Therapy FSMB Federation of State Medical Boards FRC Foreign Pharmacy Graduate Equivalency Examination Review Committee (NABP) FTC Federal Trade Commission GPhA Generic Pharmaceutical Association GPO US Government Printing Office gTLD generic top level domain (Internet addresses) HCFA Health Care Financing Administration HDMA Healthcare Distribution Management Association HIPAA Health Insurance Portability and Accountability Act (of 1996) HIPDB Healthcare Integrity and Protection Data Bank HMO health maintenance organization IACP International Academy of Compounding Pharmacists ICANN Internet Corporation for Assigned Numbers and Names ICPT Institute for the Certification of Pharmacy Technicians IDOI Internet Drug Outlet Identification (NABP) INEOA International Narcotic Enforcement Officers Association IOM Institute of Medicine IPPE introductory pharmacy practice experience ISMP Institute for Safe Medication Practices JCPP Joint Commission of Pharmacy Practitioners LAMP Louisiana Academy of Medical Psychologists LANP Louisiana Association of Nurse Practitioners LAPA Louisiana Academy of Physician Assistants LBP Louisiana Board of Pharmacy LDA Louisiana Dental Association LIPA Louisiana Independent Pharmacies Association LPA Louisiana Pharmacists Association LPTA Louisiana Physical Therapy Association LPTB Louisiana Physical Therapy Board LSBD Louisiana State Board of Dentistry LSBME Louisiana State Board of Medical Examiners

Revised 2014-0501

LSBN Louisiana State Board of Nursing LSBOE Louisiana State Board of Optometry Examiners LSBPNE Louisiana State Board of Practical Nurse Examiners LSBVM Louisiana State Board of Veterinary Medicine LSBWDD Louisiana State Board of Wholesale Drug Distributors LSHP Louisiana Society of Health-System Pharmacists LSMS Louisiana State Medical Society LSNA Louisiana State Nurses Association LTC long term care LTCF long term care facility LVMA Louisiana Veterinary Medical Association MPJE Multistate Pharmacy Jurisprudence Examination (NABP) MRC MPJE Review Committee (NABP) NABP National Association of Boards of Pharmacy NABP-F National Association of Boards of Pharmacy Foundation NABPLAW National Association of Boards of Pharmacy – Law Database NACDS National Association of Chain Drug Stores NAMSDL National Alliance for Model State Drug Laws NAPLEX North American Pharmacist Licensure Examination (NABP) NAPRA National Association of Pharmacy Regulatory Authorities (Canada) NASCSA National Association of State Controlled Substance Authorities NASPA National Alliance of State Pharmacy Associations NASPER National All Schedules Prescription Electronic Reporting Act NCC MERP National Coordinating Council for Medication Error Reporting and Prevention NCPA National Community Pharmacists Association NCPDP National Council for Prescription Drug Programs NCPIE National Council on Patient Information and Education NCPO National Conference of Pharmaceutical Organizations NCSBN National Council of State Boards of Nursing NCVHS National Committee on Vital and Health Statistics NDC National Drug Code NDMA Nonprescription Drug Manufacturing Association NIPCO National Institute for Pharmacist Care Outcomes NISPC National Institute for Standards in Pharmacist Credentialing NOCA National Organization for Competency Assurance NPA National Pharmacy Association NPC National Pharmaceutical Council NPDB National Practitioner Data Bank NPTA National Pharmacy Technician Association NRC NAPLEX Review Committee (NABP) Federal Nuclear Regulatory Commission OAL Optometry Association of Louisiana OBRA Omnibus Budget Reconciliation Act OIG Office of Inspector General ONDCP Office of National Drug Control Policy ONDD Office of Narcotics and Dangerous Drugs OSHA Occupational Safety and Health Administration PARE Pharmacy Assessment, Remediation and Evaluation (NABP) PBM pharmacy benefit management PCAB Pharmacy Compounding Accreditation Board PCCA Professional Compounding Centers of America

Revised 2014-0501

PCMA Pharmaceutical Care Management Association PCOA Pharmacy Curriculum Outcomes Assessment (NABP) PDMA Prescription Drug Marketing Act PEBC Pharmacy Examining Board of Canada PhRMA Pharmaceutical Research and Manufacturers of America PMP Prescription Monitoring Program PMP-i Prescription Monitoring Program Interconnect (NABP) PTCB Pharmacy Technician Certification Board PTCE Pharmacy Technician Certification Examination PTEC Pharmacy Technician Educators Council RFID/EPC Radio Frequency Identification / Electronic Product Code SAMSHA Federal Substance Abuse & Mental Health Services Administration TJC The Joint Commission TOEFL Test of English as a Foreign Language TOEFL iBT Test of English as a Foreign Language Internet-based Test TSE Test of Spoken English URAC Utilization Review Accreditation Commission USP United States Pharmacopeia / United States Pharmacopeial Convention USP DI US Pharmacopeia Dispensing Information USP-NF US Pharmacopeia – National Formulary VAWD Verified-Accredited Wholesale Distributors (NABP) Vet-VIPPS Veterinary-Verified Internet Pharmacy Practice Sites (NABP) VIPPS Verified Internet Pharmacy Practice Sites (NABP) VPP Verified Pharmacy Practice (NABP) WHO World Health Organization WHPA World Health Professions Alliance

NOTE: Pursuant to the Open Meetings Law, at LRS 42:6.1, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, or (4) discussions regarding personnel matters.




Consideration of Minutes from Previous Meetings



- 1 –




Minutes Regular Meeting Wednesday, May 4, 2016 at 9:00 a.m. & Administrative Hearing Thursday, May 5, 2016 at 8:30 a.m. Location: Louisiana Board of Pharmacy 3388 Brentwood Drive Baton Rouge, Louisiana 70809-1700



- 2 –

Table of Contents Wednesday, May 4, 2016 Agenda Item No. Description Page No. 1. Call to Order 04 2. Invocation & Pledge of Allegiance 04 3. Quorum Call 04

4. Call for Additional Agenda Items & Adoption of Agenda 05

5. Consideration of Minutes from Previous Meeting 05 6. Report on Action Items 05 7. Confirmation of Acts 05 8. Opportunity for Public Comment 05 * Statement of Purpose 06 9. Committee Reports

A. Finance 07 B. Application Review 07 C. Reciprocity 08 D. Violations 08 E. Impairment 09 F. Reinstatement 10 G. Tripartite 10 H. Regulation Revision 13 I. Executive 10

10. Staff Reports J. Assistant Executive Director 11

K. General Counsel 12 L. Executive Director 15

11. Request for Approval of Proposed Policy re After-Hours Access to Pharmacy – LSU Veterinary Teaching Hospital Pharmacy 06

12. CDS License for Third Party Logistics (3PL) Entities 16 13. Announcements 16 14. Recess 16

- 3 –

Table of Contents Thursday, May 5, 2016 Agenda Item No. Description Page No.

A. Call to Order 17 B. Invocation & Pledge of Allegiance 17 C. Quorum Call 17 D. Call for Additional Agenda Items &

Adoption of Agenda 17 * Statement of Purpose 17

E. Opportunity for Public Comment 17 F. Formal Hearings 18 G. Adjourn 21

- 4 –

A regular meeting of the Louisiana Board of Pharmacy was held on Wednesday, May 4, 2016 in the Boardroom of the Board’s office, located at 3388 Brentwood Drive in Baton Rouge, Louisiana. The meeting was held pursuant to public notice, each member received notice, and notice was properly posted. 1. Call to Order Mr. Carl Aron, President, called the meeting to order at 9:05 a.m. 2. Invocation & Pledge Mr. Aron called upon Mr. Brian Bond, and he delivered the invocation. Ms. Pamela Reed then led the group in the recitation of the Pledge of Allegiance. 3. Quorum Call Mr. Aron called upon the Secretary, Mr. Bond, to call the roll to establish a quorum. Members Present:

Mr. Carl W. Aron Mr. Brian A. Bond Mr. Clovis S. Burch Mr. Ryan M. Dartez

Mr. Marty R. McKay (late arrival) Ms. Chris B. Melancon Ms. Diane G. Milano Mr. Ronald E. Moore Mr. Blake P. Pitre

Mr. T. Morris Rabb Ms. Pamela G. Reed Mr. Don L. Resweber (late arrival) Dr. Deborah H. Simonson Mr. Richard A. Soileau (early departure) Mr. Rhonny K. Valentine Members Absent: Ms. Jacqueline L. Hall Mr. Richard M. Indovina Staff Present: Mr. Malcolm J. Broussard, Executive Director (late arrival) Mr. Carlos M. Finalet, III, General Counsel Mr. M. Joseph Fontenot, Assistant Executive Director Guests: Mr. C. Bevan Callicott Ms. Traci Perry – Dept. of Health & Hospitals – Office of Public Health Ms. LeeAnn Eddleman – LSU Veterinary Teaching Hospital Mr. Al Desselle – LSU Veterinary Teaching Hospital

- 5 –

Ms. Sonya Boss – LSU Veterinary Teaching Hospital Mr. Colin Mitchell – LSU Veterinary Teaching Hospital

Mr. Ben J. Sims – Brookshire Grocery Co. Mr. Kevin LaGrange – Professional Arts Pharmacy Mr. Joseph L. Adams Dr. Kirk Ryan, DVM – La. Veterinary Medical Association Dr. Trish Marullo, DVM – La. Veterinary Medical Association Dr. Patrick Thistlethwaite, DVM – La. Veterinary Medical Association Mr. Kyle McKay – La. Independent Pharmacies Association Ms. Mary Staples – NACDS Mr. Michael Weber – Roadrunner Pharmacy

Mr. Bond certified 13 of the 17 members were present, constituting a quorum for the conduct of official business. 4. Call for Additional Agenda Items & Adoption of Agenda Mr. Aron asked if there were any additional agenda items, but none were offered. With no objection, the Board adopted the posted agenda dated April 21, 2016. Mr. Aron then requested authority from the Board to reorder the agenda as necessary for the purpose of accommodating certain guests. There were no objections to that request. 5. Consideration of Minutes Mr. Aron reminded the members they had received the draft minutes from the Regular Board Meeting on February 24, 2016 and the Administrative Hearing on February 25, 2016, both of which were held in Baton Rouge, Louisiana. With no objections, he waived the reading thereof. With no requests for amendment or any objection to their approval, Mr. Aron declared the minutes were approved as presented. Mr. Bond reminded the members to sign the Minute Book. 6. Report on Action Items Mr. Aron called on Mr. Fontenot for the report. Mr. Fontenot reviewed the action items contained in the report which was posted in the meeting binder. There were no questions from the members. 7. Confirmation of Acts Pursuant to Mr. Aron’s declaration that the officers, committees, and executive director had attended to the business of the Board since the last meeting in accordance with policies and procedures previously approved by the Board, Mr. Moore moved,

Resolved, that the actions taken and decisions made by the Board officers, Board committees, and Executive Director in the general conduct and transactions of Board business since February 25, 2016 are approved, adopted, and ratified by the entire Board.

The motion was adopted after a unanimous vote in the affirmative. 8. Opportunity for Public Comment Mr. Aron reminded the members and guests the Open Meetings Law requires all public bodies to provide an opportunity for public comment at all meetings and for each

- 6 –

agenda item upon which a vote is to be taken. He solicited general comments on non-agenda items from the guests present, but none were offered. * Statement of Purpose Mr. Aron reminded the members of the purpose and mission of the Board of Pharmacy by reciting the relevant portion of the Louisiana Pharmacy Practice Act. He urged the members to keep their mission in mind as they considered all the matters before them.

At this point, Mr. Aron informed the members and guests that Mr. Broussard was attending a meeting of the Senate Health & Welfare Committee to provide information on HB 671 relative to the re-dispensing of drugs for offenders in correctional facilities and that he would return to the Board meeting as soon as he was able to do so. In Mr. Broussard’s absence, Mr. Aron requested Mr. Fontenot to introduce two new employees who had joined the staff since the last meeting in February. Mr. Fontenot introduced Mr. Daniel Dennis, a pharmacist compliance officer for the Florida Parishes area of the state as well as Ms. Vantrinette Williams, a licensing assistant in the credentials division of the office. Mr. Aron and the members welcomed both staff members with a round of applause. Mr. Aron then recognized Mr. Joseph Adams in the audience, noting he was a former member of the Board, and was currently completing his term of office as Past President and Chairman of the Executive Committee of the National Association of Boards of Pharmacy (NABP). At the request of the members, Mr. Aron requested all of the guests present identify themselves and their affiliation.

Mr. Aron indicated he would re-order the agenda to accommodate certain guests and called for Agenda Item 11. 11. Request for Approval of Policy for After-Hours Access to Pharmacy – Ms. Sonya Boss (LSU Veterinary Teaching Hospital Pharmacy) Mr. Aron recognized Ms. Sonya Boss in the audience and invited her and her colleagues from the LSU Veterinary Teaching Hospital to the witness table to make their presentation to the members. Mr. Aron directed the members to the draft policy submitted for the Board’s review by Ms. Boss, which was posted in the meeting binder. Following Ms. Boss’s presentation, she responded to questions from the members. Mr. Moore then moved,

Resolved, that the Board authorize the LSU Veterinary Teaching Hospital Pharmacy operate a pilot project for after-hours access to the pharmacy by hospital staff veterinarians utilizing the relevant policy from the University of North Carolina, and further, to authorize the operation of the pilot project for one year.

The motion was adopted after a unanimous vote in the affirmative. In the one-year interim, Mr. Aron directed the Regulation Revision Committee to review the Board’s rules as well as the proposed policy and develop a relevant proposal for the Board’s consideration. It was noted Mr. Broussard arrived at the meeting during the guests’ presentation.

- 7 –

Mr. Aron then resumed the posted meeting agenda and called for the committee reports. 9. Committee Reports A. Finance Committee

Mr. Aron called upon Mr. Pitre for the committee report. Mr. Pitre reviewed the financial report for the third quarter which ended on March 31, 2016. There were no questions from the members, and Mr. Pitre tendered the report for information only. Finally, Mr. Pitre expressed his appreciation to the other committee members for their ongoing efforts.

B. Application Review Committee Mr. Aron called upon Mr. Soileau for the committee report. Mr. Soileau

reported the committee met on April 19 to consider seven referrals from the staff. Following their interviews of the applicants and subsequent deliberations, the committee authorized the issuance of one PNT registration and one PHY permit without restriction, and deferred consideration of two applications for PHY permits until a later date. The committee also recommended the denial of one PTC application; however, the due process notice requirements delayed the Board’s consideration of that recommendation until the Board’s next administrative hearing in August. Mr. Soileau then presented the following files to the Board for their consideration of the committee recommendations. Quitney Raynard Toussaint (Applicant for PTC Registration) Mr. Soileau moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board authorized the issuance of the PTC registration as well as any other credential for which he might qualify, then immediately suspended the registration (and any subsequent credential) for one year and stayed the execution of the suspension, then placed the registration (and any subsequent credential) on probation for one year, effective on the date of issuance, subject to certain terms enumerated in the consent agreement. Taquincion Diara Watson (Applicant for PTC Registration) Mr. Soileau moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board authorized the issuance of the PTC registration as well as any other credential for which she might qualify, then immediately suspended the registration (and any subsequent credential) for eighteen months and stayed the execution of the suspension, then placed the registration (and any subsequent credential) on probation for eighteen months, effective on the date of issuance, subject to certain terms enumerated in the consent agreement.

Finally, Mr. Soileau expressed his appreciation to the other members of

the committee for their ongoing efforts.

- 8 –

C. Reciprocity Committee

In the absence of Ms. Hall, the committee chair, Mr. Aron called upon Mr. Moore for the committee report. He reported the staff had evaluated 76 applications for pharmacist licensure by reciprocity and that none of them contained information that warranted a committee-level review. In conformance with policies and procedures previously approved by the Board, the staff approved the applications and issued the credentials.

Finally, he closed the report with appreciation to the other committee members for their ongoing efforts.

D. Violations Committee

Mr. Aron called upon Mr. Bond for the committee report. Mr. Bond reported the committee held an informal conference on March 9-10, 2016 to consider their posted agenda which included 21 cases: 5 pharmacists, 6 pharmacy technicians, 4 pharmacy technician candidates, and 5 pharmacy permits. Prior to the meeting date, the chair granted continuances for two of the respondents. After interviews and deliberations at the meeting, the committee granted two additional continuances and took no formal action against eight of the respondents. The committee entered into a non-disciplinary agreement with one of the respondents, and then offered proposed voluntary consent agreements to the remaining eight respondents. Of that number, four executed their agreements for the Board’s consideration that day. Of the four respondents who did not execute their proposed agreements, two have requested a re-hearing, which have been granted, and the final two respondents have been scheduled for the administrative hearing scheduled the following day. Mr. Bond directed the members to copies of the proposed consent agreements in their meeting binder, and then presented the following files to the members for their consideration. Shantell Marie Chriss (CPT.011329) Mr. Bond moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board assessed a fine of $250 plus administrative costs. Allergy Choices, Inc. d/b/a AllergyChoices Pharmacy (PHY.005859) Mr. Bond moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board assessed the permit owner a fine of $5,000 plus administrative costs. Khaliah Nicole Smith (CPT.007760) Mr. Bond moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board assessed a fine of $250 plus administrative costs. Chasity Nicole Green (PTC.021688) Mr. Bond moved to approve the proposed voluntary consent agreement. The motion was adopted after a

- 9 –

unanimous vote in the affirmative. The Board revoked the registration, and further, permanently prohibited the acceptance of any future application for the reinstatement of the registration or any other application for any other credential issued by the Board.

Mr. Bond reported the committee will meet on June 8-9 to consider that docket of 25 cases, which includes 8 pharmacists, one pharmacy intern, 5 pharmacy technicians, 4 pharmacy technician candidates, and 7 pharmacy permits. Finally, Mr. Bond concluded his report with appreciation to the other committee members for their ongoing efforts.

E. Impairment Committee

Mr. Aron called upon Mr. Rabb for the committee report. Mr. Rabb reported the committee met the previous day to consider five referrals from the staff. Following their interviews of the applicants and subsequent deliberations, the committee took no action for two of the respondents. Mr. Rabb then presented the following files to the members for their consideration. Christi Lynn Louviere (CPT.006838) Mr. Rabb moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board approved the applicant’s request for reinstatement of the previously lapsed certificate, then immediately suspended the certificate for five years and stayed the execution thereof, then placed the certificate on probation for five years, effective May 4, 2016, contingent upon the completion of certain requirements identified in the consent agreement. Justin Matthew Scalfano (PST.018787) Mr. Rabb moved to extend the current period of probation by an additional five years. The motion was adopted after a unanimous vote in the affirmative. The Board extended the current period of probation by an additional five years, noting the extended probationary period was scheduled to conclude on August 17, 2021. John Sherwood Bannister (PST.015778) Mr. Rabb moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board suspended the license for five years and stayed the execution thereof, then placed the license on probation for five years, effective May 4, 2016, subject to certain terms enumerated in the consent agreement. Mr. Rabb then reported the committee had conducted its annual review of the Board’s Roster of Approved Addictionists and determined that no changes were in order at that time. He then moved,

Resolved, to renew the Board’s approval of the Roster of Approved Addictionists for Fiscal Year 2016-2017.

- 10 –

The motion was adopted after a unanimous vote in the affirmative. Finally, Mr. Rabb closed his report with appreciation to his fellow committee members for their work the previous day and for the ongoing staff support.

F. Reinstatement Committee

Mr. Aron called upon Ms. Melancon for the committee report. Ms. Melancon reported the committee had not met since the previous Board meeting,

G. Tripartite Committee

Mr. Aron called upon Mr. Burch for the committee report. Mr. Burch reported the committee met on March 30. He reported the highlights of the reports from ULM School of Pharmacy and Xavier College of Pharmacy, as well as from La. Pharmacists Association and La. Society of Health-System Pharmacists. Following those reports, the committee discussed two the regulatory proposals pending relative to practical experience requirements for pharmacy interns as well as accreditation of pharmacy technician training programs. Mr. Burch reported an NACDS representative made a request to reconsider the apparent elimination of employer-sponsored training programs. Mr. Burch closed his report with appreciation for his fellow committee members and their anticipated participation.

At this point, Mr. Aron re-ordered the agenda to delay the report from the Regulation Revision Committee until after lunch, giving audience members notice and opportunity for a reasonable lunch period. He then called for the next item on the agenda. I. Executive Committee

Mr. Aron reported the committee had met the previous day to consider their posted agenda. He reminded the members of their usual procedure of performing the annual review of policy and procedure documents during the spring meeting of the Board. He indicated Mr. Rabb would offer several motions on behalf of the committee. Mr. Rabb then moved,

Resolved, that the Board approve the proposed revision of Policy No. LPM.I.G.1 ~ Quarterly Inspection Form in the Board’s Loss Prevention Manual.

The motion was adopted after a unanimous vote in the affirmative. Mr. Rabb then moved,

Resolved, that the Board renew its approval of the updated Loss Prevention Manual for Fiscal Year 2016-2017.


Resolved, that the Board renew its approval of the updated Policy & Procedure Manual for Fiscal Year 2016-2017.

The motion was adopted after a unanimous vote in the affirmative. Mr. Rabb

- 11 –

then moved, Resolved, that the Board renew its approval of the updated Roster of Accredited Colleges & Schools of Pharmacy for Fiscal Year 2016-2017.


Resolved, that the Board approve the Roster of Accredited Pharmacy Technician Training Programs for Fiscal Year 2016-2017.


Resolved, that the Board approve the Audit Engagement Letter for the 2016 Audit by the Legislative Auditor, and further, to authorize the President and Executive Director to execute that document on our behalf.


Resolved, that the Board approve the Management’s Representation Letter for the 2016 Audit by the Legislative Auditor, and further, to authorize the President and Executive Director to execute that document on our behalf.

The motion was adopted after a unanimous vote in the affirmative. Mr. Aron reported the committee also reviewed the administrative

operations, found everything to be in order, and had no recommendations for any changes.

Mr. Aron closed his report with appreciation to the other committee members for their work the previous day.

With all of the committee reports except for Regulation Revision completed, Mr. Aron requested the staff reports. 10. Staff Reports J. Report of Assistant Executive Director

Mr. Aron called upon Mr. Fontenot for his report. Mr. Fontenot then directed the members to a copy of the quarterly report on the Prescription Monitoring Program (PMP) report in their electronic meeting binder. He reviewed the report and all of the performance metrics.

Mr. Fontenot then directed the members to the requests for exemption from the PMP reporting requirements. Mr. Rabb moved,

Resolved, to authorize the issuance of PMP reporting waivers to: > PHY.002850-NR – Apria Pharmacy Network (PA); > PHY.007275-NR – Aureus Pharmacy (PA); > PHY.006741-NR – BioFusion (CA); > PHY.006631-NR – Conception Pharmacy (TN); > PHY.006950-NR – Leedstone Pharmacy (MN); > PHY.007238-NR – Meijer Pharmacy No. 463 (IN); > PHY.007273-NR – Onco360 (KY);

- 12 –

> PHY.007287-HOS – P&S Surgical Hospital Pharmacy (LA); > PHY.005609-NR – Rx Direct, Inc. (TX); > PHY.006455-NR – TLC Pharmacy (FL); and > PHY.007289-NR – Walgreens Specialty Pharmacy (OR)

once they have executed the standard consent agreement for that purpose.

The motion was adopted after a unanimous vote in the affirmative. Mr. Fontenot reported he was requested to participate on a national level task force composed of representatives from several national organizations which will be revising the model law and rules for state prescription monitoring programs. He reported the advisor for the task force had reviewed Louisiana’s laws, rules, policies and procedures and found them to be well-constructed and would be including several sections almost verbatim in the model documents. Mr. Aron informed the members that participation on that task force was by invitation only, and that Mr. Fontenot’s selection reflected very well on him personally as well as Louisiana’s program. Finally, Mr. Fontenot indicated completion of his report.

K. Report of General Counsel

Mr. Aron called upon Mr. Finalet for the report. Mr. Finalet then presented the following files to the Board for its consideration.

Benjamin Michael Myatt (PST.020062) Mr. Burch moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board issued a Letter of Reprimand, and further, assessed a fine of $1,000 plus administrative costs. Carepoint Healthcare, LLC d/b/a Carepoint Pharmacy (PHY.006678) Mr. Burch moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board issued a Letter of Warning, and further, assessed a fine of $10,000 plus administrative costs. Steven Arthur Levin (PST.020926) Mr. Burch moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board issued a Letter of Reprimand, and further, assessed a fine of $1,000 plus administrative costs. Kimanh Thi Truong (CPT.010191) Mr. Burch moved to accept the voluntary surrender of the credential. The motion was adopted after a unanimous vote in the affirmative. The Board accepted the voluntary surrender of the certificate, resulting in the active suspension of the certificate for an indefinite period of time, effective April 6, 2016. Roy Edward Berkowitz (CDS.033853-MD) Mr. Burch moved to suspend the CDS license due to the suspension of the physician’s medical license by the La. State Board of Medical Examiners. The motion was adopted after a

- 13 –

unanimous vote in the affirmative. The Board suspended the CDS license for an indefinite period of time, effective January 11, 2016. Maurice Jean Gremillion (CDS.006091-MD) Mr. Pitre moved to suspend the CDS license due to the suspension of the physician’s medical license by the La. State Board of Medical Examiners. The motion was adopted after a unanimous vote in the affirmative. The Board suspended the CDS license for an indefinite period of time, effective January 11, 2016. Terrica Terrell Williams (CDS.044842-APN) Mr. Bond moved to suspend the CDS license due to the voluntary surrender of the nurse’s federal registration to the DEA. The motion was adopted after a unanimous vote in the affirmative. The Board suspended the CDS license for an indefinite period of time, effective March 24, 2016. Charles Bertram Morrison (CDS.032937-DDS) Mr. Bond moved to suspend the CDS license due to the dentist’s failure to remedy his NSF payment for the renewal of his CDS license, despite multiple notices from the staff. The motion was adopted after a unanimous vote in the affirmative. The Board suspended the CDS license for an indefinite period of time, effective May 4, 2016.

Finally, Mr. Finalet indicated the completion of his report. At this point, Mr. Aron declared a luncheon recess. It was noted the members recessed at 11:10 a.m. and then reconvened at 12:40 p.m. Mr. Aron returned to the committee reports on the agenda and requested the one remaining committee report. It was noted that Mr. Soileau departed the meeting during the luncheon recess, and further, that Mr. McKay arrived at 12:40 p.m. 9. Committee Reports

H. Regulation Revision Committee Mr. Aron called upon Mr. McKay for the committee report. Mr. McKay

noted the committee met on March 30 and April 21. During those meetings, the members completed their work on several agenda items that would be reported during this meeting. Consideration of Comments & Testimony from April 19 Public Hearing re Regulatory Project 2015-4 ~ Compounding for Office Use for Veterinarians Mr. McKay began by reminding the members of their work on the proposed rule relative to compounding for office use for veterinarians at the last Board meeting, during which they approved a revision to the original proposal, placing pharmacists on notice as to the lack of clear federal authority for that activity. Mr. McKay reported staff had published that proposed revision and conducted a public hearing on April 19 to receive comments and testimony on the proposed revision. Mr. McKay directed the

- 14 –

members to their meeting binder for a compilation and summary of those comments. He advised the members the task for them was to consider the comments and determine whether any additional changes to the original proposal were in order, or whether they should submit the project documents to the legislative oversight committee and complete the regulatory project. Mr. Aron recognized Dr. Ryan and Dr. Marullo from the La. Veterinary Medical Association, who reiterated their support for the Board’s proposed revision. Following additional discussion from the members, Mr. McKay moved

Resolved, to instruct the executive director to transmit appropriate replies to the three letters offered at the April 19, 2016 public hearing, to then compile and transmit the Second Report to the Joint Legislative Oversight Committee on Health & Welfare, and to then publish the revised original proposal as a Final Rule in the Louisiana Register.

The motion was adopted after a unanimous vote in the affirmative. Marketing Activities by Pharmacies (Act 409 of the 2015 Legislature) Mr. McKay reminded the members they had referred this item to the committee during the August 2015 Board meeting with a request to determine whether any additional rulemaking was required. Following multiple discussions during their meetings, the committee members determined the existing statutory language was clear enough and that no additional rulemaking was required. Mr. McKay informed the board members the committee was returning this assignment to the Board with no regulatory proposal. The Board members accepted the return without comment. Regulatory Proposal 2015-J ~ Accreditation of Pharmacy Technician Training Programs (Draft #4) Mr. McKay reminded the members they had referred this item to the committee during the November 2015 meeting, following their adoption of an emergency rule to delay the implementation of the accreditation requirement for one year, in order to revise the chapter of rules. In particular, the members desired to re-locate the requirement – from completion of an accredited program as a qualification for the pharmacy technician certificate to enrollment in an accredited program as a qualification for the pharmacy technician candidate registration. Mr. McKay reported the committee developed a proposal to accomplish that task, and further, the Board had engaged additional stakeholder input by discussing the proposal at the Tripartite Committee meeting. Mr. McKay then moved,

Resolved, to approve Regulatory Proposal 2015-J ~ Accreditation of Pharmacy Technician Training Programs (Draft #4), and further, to authorize the Executive Director to promulgate the proposed rule amendments upon the instruction of the President, and further, to authorize the President to approve acceptable amendments as may become necessary during the promulgation process.

The motion was adopted after a unanimous vote in the affirmative.

- 15 –

Regulatory Proposal 2016-B ~ Internship Requirements (Draft #5) Mr. McKay reported this topic was referred to the committee to determine whether it was appropriate to still require additional hours of practical experience beyond that which is offered during the professional pharmacy degree curriculum. An earlier version of the proposal was also shared with the Tripartite Committee to obtain additional stakeholder input from the pharmacy educators and practitioners. Mr. McKay then moved,

Resolved, to approve Regulatory Proposal 2016-B ~ Internship Requirements (Draft #5), and further, to authorize the Executive Director to promulgate the proposed rule amendments upon the instruction of the President, and further, to authorize the President to approve acceptable amendments as may become necessary during the promulgation process.


Regulatory Proposal 2016-D ~ Equivalent Drug Product Interchange (Draft #1) Mr. McKay reminded the members of the referral of this item to the committee pursuant to Act 391 of the 2015 Legislature, which concerned the dispensing of certain interchangeable biological products. The committee developed a proposal to revise the current rule and voted to recommend the proposal to the Board. Mr. McKay then moved,

Resolved, to approve Regulatory Proposal 2016-D ~ Equivalent Drug Product Interchange (Draft #1), and further, to authorize the Executive Director to promulgate the proposed rule amendments upon the instruction of the President, and further, to authorize the President to approve acceptable amendments as may become necessary during the promulgation process.

The motion was adopted after a unanimous vote in the affirmative. It was noted Mr. Resweber arrived at the meeting at approximately 1:15 p.m.

Mr. McKay closed his report by identifying the remaining agenda topics and expressing his appreciation to the other committee members for their ongoing efforts, as well as the staff’s assistance.

10. Staff Reports L. Report of Executive Director

Mr. Aron called upon Mr. Broussard for the report. Mr. Broussard directed the members to his report which was posted in the Boardroom Library prior to the meeting; it was also included in the meeting binder. He reviewed the following topics:

• Meeting Activity • Reports

Census Reports – Credentials & Compliance Divisions

- 16 –

Production Reports – Credentials Division Exceptions Report

• Examinations MPJE NAPLEX PARE PTCB

• Operations Credentials Division Compliance Division

• State Activities 2016 Regular Session of Louisiana Legislature eQHealth, Partner, Quality Improvement Network

• National Activities National Association of Boards of Pharmacy (NABP) NABP-AACP District 6 MALTAGON

• International Activities International Pharmaceutical Federation (FIP) World Health Professions Alliance (WHPA) Finally, Mr. Broussard indicated the completion of his report. 12. CDS License for Third-Party Logistics (3PL) Providers Mr. Aron requested Mr. Broussard review the memorandum he prepared for the members relative to third-party logistics providers. Following his review and a short discussion, Mr. Aron referred the matter to the Regulation Revision Committee, for the development of legislative and regulatory proposals necessary to properly regulate those entities’ activities with respect to controlled dangerous substances. 13. Announcements Mr. Aron directed the members to the announcements in their meeting binder. 14. Recess Having completed the tasks itemized on the posted agenda, with no further business pending before the Board, and without objection, Mr. Aron recessed the meeting at 1:40 p.m. * * * * * An Administrative Hearing was convened on Thursday, May 5, 2016 in the Boardroom of the Board’s office, located at 3388 Brentwood Drive in Baton Rouge, Louisiana. The hearing was held pursuant to public notice, each member received notice, each respondent received notice (unless specifically stated otherwise in the official transcript), and notice was properly posted.

- 17 –

A. Call to Order Mr. Aron called the meeting to order at 8:35 a.m. B. Invocation & Pledge of Allegiance Mr. Aron called upon Mr. Bond for the invocation, and then Mr. Pitre led the group in the recitation of the Pledge of Allegiance C. Quorum Call Mr. Aron called upon Secretary Bond and he called the roll. After doing so, he certified Ms. Hall, Mr. Indovina, and Ms. Reed were absent; however, the remaining 14 members were present, constituting a quorum for the conduct of official business. D. Call for Additional Agenda Items & Adoption of Agenda Mr. Aron asked if there were any additional agenda items, and none were requested. With no objection, the Board adopted the posted agenda for the meeting. He then requested authority to re-order the agenda as may become necessary, and there was no objection to that request. * Statement of Purpose Mr. Aron reminded the members of the purpose and mission of the Board of Pharmacy by reciting the relevant portion of the Louisiana Pharmacy Practice Act. He urged the members to keep their mission in mind as they considered all the matters before them. E. Opportunity for Public Comment Mr. Aron reminded the members and guests the Open Meetings Law requires all public bodies to provide an opportunity for public comment at all meetings and prior to the vote on each agenda item. He solicited comments from the guests, but none were offered. Appearances Mr. Aron indicated he would serve as the Hearing Officer, Ms. Celia R. Cangelosi and Mr. Carlos Finalet as the Prosecuting Attorneys, Ms. Susan Erkle as the Official Recorder, and Mr. Malcolm Broussard as the Hearing Clerk. Without objection, Mr. Aron waived the reading of the posted agenda and instead directed the insertion thereof into these minutes. The posted agenda is re-created here.


Revised 04-30-2016 A. Call to Order B. Invocation & Pledge of Allegiance C. Quorum Call D. Call for Additional Agenda Items & Adoption of Agenda E. Opportunity for Public Comment

- 18 –

F. Formal Hearings

01. PHY.006186 – Fairview Pharmacy Services, LLC d/b/a Fairview Specialty Services Pharmacy Case No. 15-0239

+ 02. PST.019686 – Paul Andrew Fischer Case No. 15-0322

03. PTC.021391 – Ashley Kristen Simon Case No. 15-0318 04. CPT.011200 – Shernarriane Quintelle Marshall Case No. 15-0254

G. Adjourn F. Formal Hearings

Mr. Aron asked Mr. Finalet if he was prepared to begin and he informed the members the first two respondents listed on the agenda had just accepted their proposed voluntary consent agreements. If the members were prepared to approve the agreements, then the formal hearings for those two cases would be cancelled. Fairview Pharmacy Services, LLC d/b/a Fairview Specialty Services Pharmacy (PHY.006186) Mr. Pitre moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board assessed the permit owner fine of $10,000 plus administrative, investigative, and prosecutorial costs. Paul Andrew Fischer (PST.019686) Mr. McKay moved to approve the issuance of a non-disciplinary Letter of Noncompliance in lieu of taking formal disciplinary action. The motion was adopted after a unanimous vote in the affirmative. The Board issued a non-disciplinary Letter of Noncompliance in lieu of taking formal disciplinary action. Ashley Kristen Simon (PTC.021391) Mr. Finalet appeared for the Board and noted the absence of the respondent or counsel. After verifying the absence of the respondent, Mr. Aron ruled the hearing would proceed as scheduled in the form of a default proceeding. Mr. Finalet presented an opening statement, no witnesses, and six exhibits (one of which was placed under seal). He then offered a closing statement, proffered proposed findings of fact, conclusions of law, and board order, and then tendered the matter to the hearing panel for its consideration. Mr. McKay moved to enter into executive session for the purpose of deliberating the disciplinary matter and discussing the respondent’s professional competency. The motion was adopted after a unanimous roll call vote in the affirmative.

It was noted the hearing panel entered executive session at 8:45 a.m. and then reconvened in open session at 9:00 a.m. Mr. McKay moved,

Resolved, that the Board’s hearing panel, having heard the

- 19 –

testimony and considered the evidence, accept the Findings of Fact as proposed by the Prosecuting Attorney, adopt them as our own, and then enter them into the hearing record.

The motion was adopted after a unanimous vote in the affirmative. Mr. McKay then moved,

Resolved, that the Board’s hearing panel accept the Conclusions of Law as proposed by the Prosecuting Attorney, adopt them as our own, and then enter them into the hearing record.


Resolved, that the hearing panel enter the following order at this time:

It is ordered, adjudged, and decreed that Louisiana Pharmacy Technician Candidate Registration No. 21391, held by Ashley Kristen Simon, shall be and is hereby revoked, effective on the entry of this order, and further, the respondent shall pay the following assessments: (1) A fine of $500; (2) The administrative hearing fee of $250; and (3) The investigative and hearing costs, including the

costs of the prosecuting attorney, and the official recorder; and

It is further ordered the acceptance of any future application for the reinstatement of this registration, or any application for any other credential issued by the Board, shall be conditioned upon the satisfaction of the following terms: (1) Respondent shall have paid all assessments levied

herein; (2) Respondent shall have no pending legal or

disciplinary actions against her in any jurisdiction; and

(3) Respondent shall have received a favorable recommendation for her return to the practice of pharmacy without posing a threat to the public’s health, safety, or welfare pursuant to a medical evaluation from an addiction medicine specialist approved by the Board.


Shernarriane Quintelle Marshall (CPT.011200) Mr. Finalet appeared for the Board and noted the absence of the respondent or counsel. After verifying the absence of the respondent, Mr. Aron ruled the hearing would proceed as scheduled in the form of a default proceeding. Mr. Finalet presented an opening statement, no witnesses, and eight exhibits (one of which was placed under seal). He then offered a closing statement, proffered proposed findings of fact, conclusions of law, and board order, and then tendered the matter to the hearing panel for its consideration. Mr. Soileau moved to enter into executive session for

- 20 –

the purpose of deliberating the disciplinary matter and discussing the respondent’s professional competency. The motion was adopted after a unanimous roll call vote in the affirmative.

It was noted the hearing panel entered executive session at 9:15 a.m., that Dr. Simonson departed the hearing during the executive session, and that the panel reconvened in open session at 9:25 a.m. Mr. McKay moved,

Resolved, that the Board’s hearing panel, having heard the testimony and considered the evidence, accept the Findings of Fact as proposed by the Prosecuting Attorney, modify them by amending Item 8 to clarify the final sentence to read as follows: “Neither the regular mailing nor the certified mailing were returned to the board office.”, and further, to adopt the amended findings as our own, and then enter them into the hearing record.


Resolved, that the Board’s hearing panel accept the Conclusions of Law as proposed by the Prosecuting Attorney, adopt them as our own, and then enter them into the hearing record.


Resolved, that the hearing panel enter the following order at this time:

It is ordered, adjudged, and decreed that Louisiana Pharmacy Technician Certificate No. 11200, held by Shernarriane Quintelle Marshall, shall be and is hereby revoked, effective on the entry of this order, and further, the respondent shall pay the following assessments: (1) A fine of $500; (2) The administrative hearing fee of $250; and (3) The investigative and hearing costs, including the

costs of the prosecuting attorney and the official recorder; and

It is further ordered the acceptance of any future application for the reinstatement of this certificate, or any application for any other credential issued by the Board, shall be conditioned upon the satisfaction of the following terms: (1) Respondent shall have paid all assessments levied

herein; (2) Respondent shall have no pending legal or

disciplinary actions against her in any jurisdiction; and

(3) Respondent shall have received a favorable recommendation for her return to the practice of pharmacy without posing a threat to the public’s

- 21 –

health, safety, or welfare pursuant to a medical evaluation from an addiction medicine specialist approved by the Board.

The motion was adopted after a unanimous vote in the affirmative. Mr. Finalet indicated completion of the formal hearings scheduled for that day. Mr. Aron expressed his appreciation to Ms. Erkle for her services that day. G. Adjourn Having completed the tasks itemized on the posted agenda, with no further business pending before the Board, and without objection, Mr. Aron adjourned the meeting at 9:30 a.m. Respectfully submitted, __________________________________ Brian A. Bond Secretary





Report on Action Items






August 10, 2016 Agenda Item 6: Report on Action Items During your last Board meeting, you considered a request to approve a policy relative to after-hours access to the pharmacy at LSU Veterinary Teaching Hospital. You approved a pilot project and also requested a referral of the topic to the Regulation Revision Committee. The agenda for the committee has been updated to include this topic. During the report from the Regulation Revision Committee at your last Board meeting, you considered the comments and testimony from the April 19 public hearing relative to the proposed revision of the original proposed rule to authorize the compounding of medications for veterinary office use. You determined that no additional revisions were necessary, directed the formal replies to all of the commentators, and also directed the submission of the comprehensive report to the Joint Legislative Oversight Committee on Health & Welfare. We submitted that report on May 10. With no legislative intervention, we submitted the revised proposal to the state register for publication. The Final Rule was published on June 20, 2016 and became effective that same day. With the publication of the Final Rule, the Revised Emergency Rule was cancelled. During that same report, you approved three new regulatory proposals: (1) accreditation of pharmacy technician training programs, (2) internship requirements, and (3) equivalent drug product interchange. We are still working on the required fiscal and other impact statements. As soon as they are completed, we will submit the Notices of Intent for publication and schedule their public hearings. Finally, you responded to a staff request for guidance relative to CDS licenses for third-party logistics providers by requesting the Regulation Revision Committee to prepare the required legislative and regulatory proposals. The topic was added to the committee’s agenda. Respectfully submitted, Malcolm J Broussard Executive Director







Finance Committee






www.pharmacy.la.gov ~ E-mail: [email protected] NOTICE IS HEREBY GIVEN that a meeting of the Finance Committee has been ordered and called for 4:30 p.m. on Tuesday, August 9, 2016 in the Board office, for the purpose to wit:

A G E N D A NOTE: This agenda is tentative until 24 hours in advance of the meeting, at which time the most recent revision becomes final.

Revised 07-26-2016 1. Call to Order 2. Quorum Call 3. Call for Additional Agenda Items & Adoption of Agenda 4. Opportunity for Public Comment 5. Consideration of Final Report for Fiscal Year 2015-2016 6. Consideration of Proposed Budget Amendment No. 1 for Fiscal Year 2016-2017 7. Adjourn






Finance Committee

Final Report for Fiscal Year 2015-2016

August 10, 2016

Blake P. Pitre Chair



Louisiana Board of Pharmacy Finance Committee

Final Report for Fiscal Year 2015-2016

Table of Contents Statement of Assets, Liabilities, & Equity 03 Statement of Revenue, Expenses, & Budget Performance 05 Summary of Income & Fund Balance Changes 07 Budget Variance Report 08 Schedule A – Hurricane Katrina/Rita Pharmacy Relief Fund 10 Summary of Board Actions 11 Iberia Bank – General Reserve Fund Statement 12 Iberia Bank – OPEB Reserve Fund Statement 20 Iberia Bank – Pension Reserve Fund Statement 27 Cumulative Fund Balance Report 34

Louisiana Board of PharmacyFY 2015-2016

Statement of Assets, Liabilities and Equity

FY 14-15 FY 15-16Q4 06/30/2015 Q4 06/30/2016

ASSETS> Current Assets * Cash

General OperationsWhitney Bank 160,513 160,674Iberia Bank 928,695 977,494

Hurricane Relief Fund - Whitney Bank 83,221 83,305Reserve Funds

General Account 1,920,602 1,250,999OPEB Account 1,047,038 1,113,112Pension Account 0 992,198

* Total Cash 4,140,069 4,577,782

** Prepaid Expenses 3,000 29,900 ** Total Prepaid Expenses 3,000 29,900

*** Accounts Receivable 0 330 *** Total Accounts Receivable 0 330

Total Current Assets 4,143,069 4,608,012

> Fixed AssetsLand: Lot 5-A, Towne Center Business Park 709,080 709,080Land: Lot 1-A-2, Leonard Place Subdivision 295,860 295,860Office Building - 3388 Brentwood Drive 1,057,861 1,057,861Office Equipment 216,119 222,949Furniture 154,198 156,785Software: Licensure & Website 408,560 408,560Accumulated Depreciation (762,358) (826,997)

Total Fixed Assets 2,079,320 2,024,098

TOTAL ASSETS 6,222,389 6,632,110

DEFERRED OUTFLOWS OF RESOURCES 644,896 598,982

TOTAL ASSETS & DEFERRED OUTFLOWS 6,867,285 7,231,092

LIABILITIES> Current Liabilities

Accrued salaries and benefits 82,372 27,169Unemployment taxes payable 57 69State taxes withheld 3,365 4,820Accounts payable 2,225 5,097Compensated absences (ST) 64,373 43,997Pharmacy Education Support Fee 0 0Interest payable 2,469 0Building Loan @ Iberia Bank (ST) 474,134 0

Total Current Liabilities 628,995 81,152


Statement of Assets, Liabilities and Equity

FY 14-15 FY 15-16Q4 06/30/2015 Q4 06/30/2016

> Long Term LiabilitiesCompensated absences (LT) 53,962 76,420Other Post Employment Benefits (OPEB) Payable 1,096,000 1,172,029Net Pension Liability 4,117,091 4,545,653

Total Long Term Liabilities 5,267,053 5,794,102

TOTAL LIABILITIES 5,896,048 5,875,254

DEFERRED INFLOWS OF RESOURCES 607,441 61,980

EQUITYFund Balance at End of Prior Fiscal Year (2,408,223) (1,844,591)Fund Balance - Designated 182,952 184,290Invested in Fixed Assets 1,605,186 2,024,098Net Income/Loss 983,881 930,061

TOTAL EQUITY 363,796 1,293,858

TOTAL LIABILTIES, DEFERRED INFLOWS, & EQUITY 6,867,285 7,231,092


Statement of Revenue, Expenses, and Budget Performance

FY 14-15 FY 15-16 FY 15-16Q4 06/30/2015 Q4 06/30/2016 Budget (A#1) Notes

Licenses & PermitsPharmacist Renewals 782,525 811,750 770,000 1New Pharmacist Licensing Fee 193,100 183,600 190,500 2Technician Renewals 315,900 334,150 316,000 3Technician Candidate Registrations 37,725 36,000 25,000 4Lapsed Credential Fees 66,600 46,400 55,000 5Student Registrations 3,050 2,890 3,000 6Permits - Pharmacies 275,675 301,175 270,000 7Permits - CDS 454,215 466,580 450,000 8Permits - Emergency Drug Kits 13,400 11,875 12,500 9Permits - Automated Medication Systems 23,250 20,100 20,000 10Permits - Durable Medical Equipment 82,600 84,275 80,000 11

ExaminationsReciprocity 54,600 54,000 50,000 12Technicians 55,900 63,500 50,000 13

PenaltiesLicenses and Certificates 8,633 8,450 8,000 14Permits 12,150 11,815 11,000 15

Administrative FeesDocuments: Copies and Certification Fees 4,903 5,686 5,000 16Duplicate Credentials 5,710 5,450 5,000 17Silver Certificates 400 300 400 18Original Certificates 8,700 8,560 7,500 19NSF Fees 450 550 500 20Handling & Mailing Fees 190 270 100 21

Sale of Goods & ServicesLaw Books 5,125 2,445 6,000 22Official Lists of Licensees 10,800 12,450 7,500 23USCPSC Inspection Fee 4,800 2,400 2,000 24

Enforcement ActionsHearing Fees 21,000 22,250 22,000 25Fines 631,500 448,000 200,000 26Investigative Costs 30,320 14,246 30,000 27

Prescription Monitoring ProgramAssessments 482,225 512,000 475,000 28

Miscellaneous 940 2,205 1,000 29

TOTAL REVENUE 3,586,386 3,473,372 3,073,000 30

Revenue


Statement of Revenue, Expenses, and Budget Performance


Operations Rentals - Office & Equipment 14,535 15,218 17,000 31Equipment Maintenance 2,579 2,754 3,000 32Telephone 19,634 19,029 20,000 33Printing 22,443 23,951 25,000 34Postage 48,112 56,467 52,000 35Civil Service Assessment 6,074 6,323 6,400 36Office Insurance (ORM) 7,112 8,931 8,400 37Dues & Subscriptions 10,613 5,832 20,000 38Office Supply Expenses 21,175 19,008 21,000 39Financial Service Charges 47,541 50,755 50,000 40Depreciation of Fixed Assets 99,091 64,639 64,000 41Interest Payments on Building Loan 44,882 11,296 15,000 42Office Meeting Expenses 538 829 500 43Utilities 10,614 9,714 11,000 44Miscellaneous 0 0 0

Acquisitions 3,662 0 75,000 45

Personal ServicesSalaries 1,258,895 1,257,374 1,357,400 46Payroll Taxes (FICA + FUTA) 22,117 22,653 28,000 47Retirement Contributions 403,453 384,560 505,000 48Health Insurance (SEGBP) 119,813 139,728 135,800 49Other Post Employment Benefits (OPEB) 79,132 76,029 156,000 50Board Member Per Diem 29,400 29,850 31,000 51

Professional Services Accounting 22,519 26,143 25,000 52Legal 8,189 14,489 30,000 53Information Systems 93,011 108,316 128,000 54Property Management 20,350 18,745 42,000 55Temp. Labor 15,507 9,240 20,000 56Prescription Monitoring Program 77,300 76,100 80,000 57

Staff Expenses ED - Travel 4,264 9,204 10,000 58GC - Travel 10,212 9,483 10,000 59AED - Travel 1,956 6,025 10,000 60CO - Travel 3,774 6,268 5,000 61CO - Rental Cars & Fuel 15,886 16,227 17,500 62CO - Education 8,514 4,669 10,000 63House Staff - Travel 199 75 1,000 64Mileage 15,327 13,009 20,000 65

Board ExpensesMeeting Expenses 12,070 12,760 15,000 66Committee Expenses 5,315 6,720 8,000 67Conventions 22,668 17,742 15,000 68Mileage 12,483 13,411 15,000 69President's Expenses 10,192 9,063 10,000 70

TOTAL EXPENSES 2,631,151 2,582,629 3,073,000 71

Expenses


Summary of Income Fund Balance Changes


Income Statement

Total Revenue 3,586,386 3,473,372 3,073,000 72

Total Expenses 2,631,151 2,582,629 3,073,000 73

Net Ordinary Income 955,235 890,743 0

Other Income & ExpensesInvestment 28,347 39,318 0 74Disposal of Assets 300 0 0

Net Income 983,882 930,061 0 75

FY 14-15 FY 15-16 FY 15-16Q4 06/30/2015 Q4 06/30/2016 Budget (A#1)

Fund Balance

Beginning Fund Balance (620,086) 363,796 363,796

Total Income 3,615,033 3,512,690 3,073,000

Total Expenses 2,631,151 2,582,629 3,073,000

Ending Fund Balance 363,796 1,293,857 363,796

Reservations of Fund Balance 1,272,000 772,000 1,237,000

Unreserved Fund Balance (908,204) 521,857 (873,204)

Notes on Reservation of Fund Balance

FY 14-15 Other Post Employment Benefits Payable 572,000Debt Service Payable 450,000Continuing Payroll Obligations 150,000Homeland Maintenance 100,000

TOTAL 1,272,000

FY 15-16 Other Post Employment Benefits Payable 572,000Debt Service Payable 0Continuing Payroll Obligations 150,000Homeland Maintenance 50,000

TOTAL 772,000

Summary


Budget Variance Report

Notes Acct. No. % Variance

Revenue

1 4201 Pharmacist Renewals 5.40 Underestimated by 417 pharmacists2 4206 New Pharmacist Licensing Fee (3.60) Overestimated by 23 applicants3 4204 Technician Renewals 5.74 Underestimated by 363 technicians4 4208 Tech Candidate Registrations 44.00 Underestimated by 440 applicants5 4205 Lapsed Credential Fees (16.44) Overestimated reinstatement applications6 4350 Student Registrations (3.67) Overestimated by 11 applicants7 4301 Permits - Pharmacies 11.55 Underestimated by 250 permits8 4302 Permits - CDS 3.68 Underestimated growth and renewals9 4303 Permits - EDK (5.00) Overestimated by 25 permits10 4304 Permits - AMS 0.50 Underestimated by 1 permit11 4306 Permits - DME 5.34 underestimated by 34 permits12 4153 Exams - Reciprocity 8.00 Underestimated by 26 applicants13 4152 Exams - Technicians 27.00 Underestimated by 135 applicants14 4252 Penalties - Licenses 5.63 Underestimated reinstatements15 4251 Penalties - Permits 7.41 Underestimated reinstatements16 4460+62 Documents: Copies + Certified 13.72 Underestimated demand17 4452 Duplicate credentials 9.00 Underestimated demand18 4453 Pharmacist Silver Certificates (25.00) Overestimated demand by 1 certificate19 4459 Pharmacist Original Certificates 14.10 Underestimated demand by 14 certificates20 4454 NSF Fees 10.00 Underestimated incidence21 4463 Handling & Mailing Fees 1700.00 Underestimated demand22 4402 Law Books (59.25) Overestimated demand for supplements23 4461 Lists of Licensees (66.00) Underestimated demand by 33 lists24 4458 Inspection Fees (20.00) Underestimated demand from U.S. CPSC25 4102 Administrative Hearing Fees (1.14) Underestimated caseload by one case26 4501 Fines 124.00 Underestimated amount of sanctions27 4502 Investigative Costs (52.51) Overestimated cost recoveries28 4660 PMP Assessments (7.79) Underestimated by 689 accounts29 4455 Miscellaneous 120.50 Underestimated demand30 Total Revenue 13.03 Exceeded budget, but less than FY 15.

CommentAccount Name


Budget Variance Report

Notes Acct. No. % Variance

Expenses

31 5321 Rentals - Office & Equipment (10.48) Timing issue on office equipment leases32 5330 Equipment Maintenance (8.20) Overestimated need for some + timing issue33 5370 Telephone (4.86) Deliberate reduction in favor of emails34 5305 Printing (4.20) Overestimated demand + e-newsletter35 5300 Postage 8.60 Underestimated demand36 5125 Civil Service Assessment (1.20) Annual fee, based in part on size of staff37 5230 Office Insurance (ORM) 6.32 Annual fee, based in part on size of staff38 5190 Dues & Subscriptions (70.84) Deferral of $9900 Melissa Data til FY 1739 5280 Office Supply Expenses (9.49) Overestimated demand40 5381 Financial Service Charges 1.51 Close estimate of online renewal fees41 5180 Depreciation 0.99 Close estimate from depreciation schedules42 5385 Interest Payments on Bldg Loan (24.69) Less interest due after extra payments43 5260 Office Meetings 65.80 Underestimated demand44 5390 Utilities (11.69) Overestimated demand45 5115 Acquisitions * Deliberate deferrals + timing issue46 5350 Salaries (7.37) Staff turnovers47 5290 Payroll Taxes (FICA + FUTA) (19.10) Staff turnovers + less temporary staff48 5340 Retirement Contributions (23.85) Staff turnovers49 5220 Health Insurance (SEGBP) 2.89 Plan premium changes + plan choice change50 2400 OPEB (51.26) Premium decreased by state51 5152 Board Member Per Diem (3.71) Overestimated meeting activity52 5110 Accounting Services 4.57 Audit fee increase53 5250 Legal Services (51.70) Overestimated demand for services54 5295 Information Systems (15.38) Delayed planned upgrade55 5297 Property Management (55.37) Deferred roof and A/C replacement56 5296 Temporary Labor (53.80) Less robust labor pool in high school57 5600 Prescription Monitoring Program (4.88) Contracted amount58 5361 Staff Travel - Executive Director (7.96) Close estimate59 5365 Staff Travel - General Counsel (5.17) Close estimate60 5373 Staff Travel - Asst Exec Dir (39.75) More external funding of travel61 5363 Staff Travel - Compliance Offcrs 25.36 Underestimated demand62 5371-72 Staff Travel - Rental Cars & Fuel (7.27) Overestimated demand63 5368 Staff Educ - Compliance Officers (53.31) Limited to USP-797 inspection training64 Staff - Office staff travel (92.50) House staff educational seminars65 62+64+67 Mileage - entire staff (34.96) Overestimated travel demands66 5153 Board - Meeting Expenses (14.93) Overestimated meeting travel67 5155 Board - Committee Expenses (16.00) Overestimated meeting travel68 5154 Board - Convention Expenses 18.28 Underestimated conference travel69 5151 Board - Mileage (10.59) Overestimated meeting travel70 86+87+88 Board - President's Expenses (9.37) Overestimated meeting travel71 Total Expenses (15.96) 16% under budget

Summary

72 Total Revenue 13.03 3.2% decrease from FY 15 revenue73 Total Expenses (15.96) 1.84% decrease from FY 15 expenses74 6003 Investments * 64% from dividends; 36% from market value75 Net Income/Loss * 5.5% reduction from FY 15 net income

Account Name Comment


Schedule A - Hurricane Katrina/Rita Pharmacy Relief Fund

Statement of Assets, Liabilities & Equity FY 14-15 FY 15-16Q4 06/30/2015 Q4 06/30/2016

ASSETSCurrent Assets

Whitney Bank - Checking Account 83,221 83,305

TOTAL ASSETS 83,221 83,305

LIABILITIESCurrent Liabilites 0 0

EQUITYRetained Earnings 83,137 83,221Net Income 84 84

TOTAL LIABILITIES & EQUITY 83,221 83,305

Statement of Revenues & Expenses FY 14-15 FY 15-16Q4 06/30/2015 Q4 06/30/2016

RevenuesFEMA - Funds for payment of claims 8,920,812 8,920,812FEMA - Administrative allowance 81,103 81,103Pharmacies - reversal of claims 430,138 430,138Interest income 22,146 22,230

Total Revenues 9,454,199 9,454,283

ExpensesClaims paid to pharmacies 8,920,812 8,920,812Reversed claim funds returned 430,138 430,138Reversed administrative allowance returned 7,338 7,338Interest earned on reversed admin. allowance returned 12,690 12,690

Total Expenses 9,370,978 9,370,978

FUND BALANCE 83,221 83,305

Note: These funds are held in an account separate and apart from the Board'soperating funds. Further, all recordkeeping is kept separate from the Board'sgeneral fund records. At the conclusion of the audit exposure period, anyfunds remaining will be transferred to the Board's operating account.


Summary of Board Actions

Date Action

11/12/2014 Original Budget - Finance Committee Approval

11/13/2014 Original Budget - Board Approval

8/11/2015 Budget Amendment #1 - Finance Committee Approval

8/12/2015 Budget Amendment #1 - Board Approval

Budget Amendment #2 - Finance Committee Approval

Budget Amendment #2 - Board Approval

8/10/2016 Acceptance of Final Report

IBE

RIA

FIN

AN

CIA

L5E

RV

ICE

S,LL

C

2coW

estC

ongr

ess

Stre

et1s

tFl

ocw

lafa

yette

, IA

7050

1In

Tl

823.

9666

II

I

Acc

ount

Num

ber:

H5E

-049

797

Stat

emen

tPe

riod

:08

1011

2015

.06

/30/

2016

Ass

etS

um

mar

yCa

sh,M

on

eyF

un

ds,

and

Ban

kD

epo

sits

Fix

edIn

com

e

Account

Tota

l

This

Perio

d%

Alloc

ation

1955.1

51%

Ple

ase

levi

ewyo

ural

loca

tion

peri

odic

ally

will

,yo

urA

ccou

ntE

xecu

tive.

A0c

111

938c3r3

0017

Go

pap

eri

ess

ft.E

.dL

.ctI

I.nt

CII’flR

P.,...•

LA

G..

)E

wv

V.,

,S

w,c

.2007

—a)

..._

...,...,v

.,.

.c......qsny..

DA

LS

AR

RA

TE

DC

OkA

JAU

NIC

AT

ION

Sn.a

,..a

ufl.

ea.F

’).

‘aaS

t‘C

—C

LL

L[N

CE

Secu

ritie

sof

fere

dth

roug

hB

rokera

ge

Ess

exN

atio

nalS

ecur

ities

, LLC

________________________

Account S

tate

ment

LO

UIS

IAN

AB

OA

RD

OF

PHA

RM

AC

Y33

88B

RE

NT

WO

OD

DR

BA

TO

NR

OU

GE

LA

70809-1

700

Your

Account

Exe

cuti

ve:

JOS

EP

HB

AR

RE

CA

,JR

.

(504)

310-1

346

Port

foli

oat

aG

lanc

eB

egin

nin

gA

ccou

ntV

alue

Div

iden

ds,

Inte

rest

and

Olh

er

Inco

me

inP

orl

foli

oF

I)li

Tif

li

__

__

__

__

__

__

__

__

__

__

__

__

__

__

__

__

__

__

__

__

__

__

__

__

__

__

End

ing

Acc

ount

Val

ue$1

,246

.71

8.52

This

Perio

d$

1,2

29

,28

0.8

7

1,8

54.9

9

15.5

82

.66

[sli

male

dA

nn

ual

Inco

me

$16,

223.

19

1,2

44

. 16

3.3

7

$1,2

46,7

18.5

2

99%

100%

Pag

e1

ala

PA

R-0

2-R

OL

I

Cli

ent

Ser

vice

Info

rmat

ion

You

rA

ccou

ntEx

ecut

ive:

1(51

Con

tact

Info

rmat

ion

JOSE

PHBA

RREC

A,JR

.T

elep

hone

Num

ber:

(504

)31

0-13

46IB

ERIA

FINA

NCIA

LSE

RVIC

ES29

00RI

DGEL

.AKE

DRIV

EM

fAlR

lELA

1000

2-49

23

Tax

LotD

efau

ltD

ispo

sitio

nM

etho

dD

efau

ltM

eiho

dfo

rM

utua

lFu

nds:

AVER

AGE

COST

(USI

NGFI

RST

INFI

RST

OUT)

Def

ault

Met

hod

for

Stoc

ksin

aDi

vide

ndR

einv

estm

entP

lan:

FIRS

TIN

FIRS

TOU

TD

efau

ltM

etho

dfu

rall

Oth

erSe

curil

ies:

FIRS

TIN

FIRS

TOU

TB

ond

Am

ortiz

atio

nEl

ectio

ns:

Am

ortiz

epr

emiu

mon

taxa

ble

bond

sba

sed

onC

onst

ant

Yield

Met

hod:

Yes

Acc

wal

mar

ketd

isco

unt

met

hod

for a

llot

her

bond

type

s:C

onst

antY

ield

Met

hod

Incl

ude

mar

ketd

isco

unt i

nin

com

ean

nuaf

lTNo

Cop

ies

ofSt

atem

entS

ent

KOLD

ER,

CHAM

PAGN

E,SL

AVEN

&CO

Atyo

urre

ques

tcop

ies

olth

isst

atem

ent

have

been

sent

10th

eab

ove.

Elec

troni

cD

eliv

ery

E-m

ail

nDtil

icat

ions

are

deliv

ered

toth

efo

llow

ing

e-m

ail

addr

ess(

es):

You

are

curre

ntly

enro

lled

tore

ceiv

eIh

eFo

llowi

ngac

coun

tcom

mun

icat

ions

via

elec

troni

cde

liver

y:k#

####

####

@ph

arm

acy.

la.g

ovSt

atem

ents

and

Repo

rtsTh

eab

ove

e-m

ail

addr

ess

ispa

rtial

lym

aske

dfo

ryo

urse

curit

y.Pl

ease

log

Trad

eCo

nfirm

atio

nsin

toyo

urac

coun

tto

revi

ewth

elu

lle-

mai

lad

dres

s.Ta

tD

ocum

ents

Not

ifica

tions

Plea

selo

gin

toyo

urac

coun

tto

mak

ean

ych

ange

sto

your

elec

troni

cde

liver

ypr

efer

ence

s.

Act

ivit

yS

um

mar

y(A

IIam

ount

ssh

own

arc

inba

secu

trenc

y)

Cred

itsTh

isPe

riod

Debi

tsTh

isPe

riod

NetT

hisPe

riod

Cred

itsY

ear-t

o-D

ate

Debi

tsY

ear-t

o-D

ate

NetY

ear-t

o-D

ate

Secu

ritie

sSe

curit

ies

Boug

ht00

0-1

5063

645

-150

,636

.45

0,00

-610

,980

11-6

1098

0.17

Secu

ritie

sSo

ld00

00,

000-

0045

5200

300.

0045

5,20

030

Secu

ritie

sW

ithdr

awn

0,00

0,00

0,00

0.00

-676

,100

.10

-676

1801

0

Tota

lSe

curit

ies

$0.0

0-$

150,

636.

45-$

150,

636.

45$4

55,2

00.3

0-$

1,28

7,76

0.27

-$83

2559

97

Div

iden

dsan

dIn

tere

st$1

,854

.99

$0.0

0$1

,854

.99

$6,1

02.4

7$0

.00

$6,1

02.4

7

Dis

tribu

tions

$140

,000

.00

$0.0

0$1

40,0

00.0

0$1

50,0

00.0

0$0

.00

$150

,000

MD

Tota

ls$1

41,8

54.9

9-$

150,

636.

45-$

8,78

1.46

$611

,302

.77

-$1,

287,

760.

27-$

676,

457.

50

Page

2of

8

You

rA

ccou

ntIn

form

atio

n

AG

09199

0C

sP

30

017

Acc

ount

Num

ber:

HSE

-049

791

LOUI

SIAN

ABO

ARD

OFPH

ARM

ACY

Go

pap

erle

ssA

sA

•flU

7.b

tLIv

tRv

4R

aL

.d1-c

ell

ent

cl.

.,fl

t,..w

,P

hb

gL

AG

..%

)rn

,yY

.,

c*

2007

c_,’

en

tO

AL

SA

RR

AT

rDC

OM

MU

NIC

AT

IO.n

c,.,.flu

fl-,,rw

.A

.n,L

—-

—IX

CIL

LE

NC

E

PA

RO

201l

.20

0W

est C

ongr

ess

Stre

et

I.afa

yetie

. LA

7050

1FI

NA

NC

IAL

SER

VIC

ES,

LLC

(8T

t823

-956

6

BOND

INTE

REST

RECE

IVED

4508

3MV

4

BOND

INTE

REST

RECE

IVED

0642

61HE

2

SECU

RITY

REDE

EMED

0642

6TH

E2

MON

EYM

ARKE

TFU

NDIN

COM

ERE

CEIV

ED31

0990

228

BOND

INTE

REST

RLCU

VFD

9128

28X

H8

II

II

Secu

ritie

sof

fere

dth

roug

hB

rokera

ge

Ess

exN

atio

nalS

ecur

ities

, LL

CA

cco

un

t Sta

tem

en

t

Sta

tem

ent

Per

iod:

0610

1/20

16-

06/3

0/20

16

Tra

nsa

ctio

ns

inD

ate

Seq

uen

cePr

oces

s!Tr

ade!

Settl

emen

tIr

ansa

dion

Dat

eDa

teAc

livity

Type

Des

crip

tion

Qua

ntity

Pric

eAc

crue

dIn

tere

stA

mom

tC

uner

q

0610

1/16

1000

0IB

ERIA

BANK

LAFA

YEtT

ELA

CTF

DEl’

ACT

/365

115.

00US

D0.

000%

05/3

1/16

B/F

DID

05/3

1/11

RD05

/14

PD05

/31/

16

06/1

0/16

1400

00BA

NK01

CHIN

ANE

WYO

RKCI

TYBR

HCT

F56

1.53

USD

DEP

ACT/

365

0.40

0%06

/10/

16W

EDT

D06

/10/

15RD

06/0

9PD

06/1

0/16

06/1

0/16

BANK

01CH

INA

NEW

YORK

CITY

BRH

CTF

DEl’

-110

000.

000

140,

000.

0005

0AC

T/36

50.

400%

06/1

0/16

B/E

DTD

06/1

0/15

ACCO

UNT

REDE

MPT

ION

06/2

0/16

06/1

7/16

PURC

HASE

DUN

ITED

STAl

ESTR

EAS

N1S

1.62

5%06

/30/

20B/

F11

5,00

0.00

010

3.11

79-1

113.

39-1

50,6

36.4

5US

DS1

2B2B

XHB

DTD

06/3

0/15

SOLI

CflE

DOR

DER

YLD

.836

TOM

AT

06/3

0/16

GENE

RAL

MNY

MK1

CL8

0.33

USD

06/3

0/16

1450

00UN

ITED

STAT

ESTR

EAS

NTS

1.62

5%06

/30/

201,

118.

13US

DB/

EDT

D06

/30/

15RD

06/2

9PD

06/3

0/16

Tota

lV

alue

ofTr

ansa

ctio

ns-$

1,11

3.39

-$6,

701.

46US

D

The

pric

ean

dqu

antit

ydi

spla

yed

may

have

been

roun

ded.

Po

rtfo

lio

Ho

ldin

gs

Ope

ning

Clos

ing

Accr

ued

Inco

me

30-D

ayD

escr

iptio

nQ

uant

ityB

alan

ceBa

lanc

eIn

com

eTh

isYe

arYi

eld

Cas

h,M

oney

Fund

s,an

dB

ank

Dep

osits

1.00

%of

Por

tfol

ioC

ash

Bal

ance

10,0

00.0

01,

178.

13

Mon

eyM

arke

tGE

NERA

LM

NYM

KTFU

NDCL

B77

7.02

073

6.61

777.

020.

000.

690.

01%

Tota

lM

oney

Mar

ket

$736

.61

$777

.02

$0.0

0$0

.69

Tota

lC

ash,

Mon

eyFu

nds,

and

Ban

kD

epos

its$1

0,73

6.61

$1,9

55.1

5$0

.00

$0.6

9 Page

3olB

aO

09

19

9B

CS

F3

00

11

Acc

ount

Num

ber:

HSE

-049

791

Go

pap

erle

ss[efc,2O

O7

AS

KA

SO

UT

K-U

LL

NK

RV

0A

L8A

RR

AT

ED

CO

MM

UN

ICA

TIO

NS

r..I.f

lUn

.,.,rn

’*

Kfl

PA

P-0

2-N

OL

LLO

UISI

ANA

BOAR

DOF

PHAR

MAC

Y

Po

rtfo

lio

Hol

ding

s(c

onti

nued

)

Accr

ued

Estim

ated

Estim

ated

Des

crip

tion

Inte

rest

Ann

ual

Inco

me

Yield

U.S

Jrea

sury

Secu

ritie

sUN

ITED

STAT

ESTR

EAS

NTS

0.00

2,35

6.25

1.58

%1.

525%

0613

0/20

BIE

DTD

06/3

0/15

151

CPN

DTE

12/3

1115

CPN

PMT

SEM

IANN

UAL

ONJU

N30

AND

DEC

31M

oody

Ratin

gM

ASe

curit

yId

entif

ier:

9128

28X

H8

6UNI

TED

STAT

ESTR

EAS

PITS

INFL

ATIO

NIN

DEXE

DNO

TES

TIPS

1.25

0%07

/15/

20Ol

EDT

D07

/15/

10M

oody

Ratin

gM

ASe

curit

yId

entif

ier:

9128

28N

M8

Fact

or:

1.09

6930

00Ef

fect

ive

Dat

e:06

/30/

16Cu

rrent

Face

Valu

e:27

.423

.250

UNIT

EDST

ATES

TREA

SNT

S1.

375%

08/3

1/20

B/E

DTD

08/3

1/15

1ST

CPN

DTE

02/2

9/16

CPN

PMT

SEM

IANN

UAL

ONFE

B29

AND

AUG

31M

oody

Ratin

gA

MSe

curit

yId

entif

ier:

9128

28L3

2UN

ITED

STAT

ESTh

EMNT

S12

50%

03/3

1/21

DIE

DTD

0313

1/16

1ST

CPN

DT[

09/3

0/16

CPN

PMT

SEM

IANN

UAL

ONM

AR31

AND

SEP

30M

oody

Ratin

gM

ASe

curit

yId

entif

ier:

9128

2803

7

6C

urre

ntFa

ceva

lue

repr

esen

tsth

eou

tsta

ndin

gpr

inci

pal

bala

nce

orth

eun

derly

ing

secu

rity.

The

Cur

rent

Face

valu

eis

dete

rmin

edby

mul

tiply

ing

the

curr

ent f

acto

rtim

esth

eor

igin

alla

ceam

ount

ofth

ese

curit

y.Fa

ctor

sm

aych

ange

over

time

and

are

obta

ined

from

sour

ces

we

belie

velo

bere

liabl

e.

Port

foli

oH

oldi

ngs

Dis

clos

ures

Pric

ing

This

sect

ion

incl

udes

the

net

mar

ket

valu

eof

the

secu

ritie

sin

your

acco

unt

ona

settl

emen

t dat

eba

sis,

incl

udin

gsh

ortp

ositi

ons,

atth

ecl

ose

ofth

est

atem

ent

peiio

d.Th

em

arke

tpr

ices

, unl

ess

othe

rwis

eno

ted.

Pago

4of

8

Account

Num

ber

H5[049797

Rate

dD

,cell

en

tcI.,,.,.ee,.eP

.hm

gL

lfl..e,,eIv.ed...w

a.,y

Go

pap

erle

ssE

nvea,

Sin

ce1001

LOUI

SIAN

AHO

ARD

OFPH

ARM

ACY

AS

kA

CO

UT

E.O

tLtv

tMv

—.

DA

LB

AR

RA

TE

DC

OA

MU

NIC

AT

ION

SP

.t.

Fixe

dIn

com

e99

.00%

ofP

ort

foli

ofin

Ma/

un’y

Dal

eSe

quen

ce)Q

uant

ityM

arke

t Pric

eM

arke

tValu

e

145,

000.

000

102.

8360

149,

112.

20

25,0

00.0

0010

7.45

6029

,467

.93

157.

27

593,

000.

000

101.

8320

603,

863.

762,

703.

158,

153.

751.

35%

457,

000.

000

101.

1640

462,

319.

481,

420.

325,

712.

501.

23%

Tota

lU.

S.T

reas

ury

Secu

ritie

s1,

220,

000.

000

$1,2

44,7

63.3

7$4

,280

.74

$16,

222.

50To

tal

Cur

rent

Face

Val

ue:

27,4

23.2

50

Tota

lFi

xed

Inco

me:

1,22

0,00

0.00

0$1

,244

,763

.37

$4,2

80.7

4$1

6,22

2.50

Accr

ued

Estim

ated

Mat

het V

alue

Inte

rest

Ann

ual

Inco

me

Tota

lPo

rtfo

lioH

oldi

ngs

$1,2

46,7

18.5

2$4

,280

.74

$16,

223.

19

PA

R0

2R

OlL

. flII

I_?I

}20

0wes

tcon

gres

sst

reet

lstr

toc,

Lafa

yene

, LA

7Usd

FIN

AN

CIA

LSE

RV

ICES

,LL

C80

0182

3966

6

___________________________________________

Sta

tem

ent

Per

iod:

0610

1120

16-

0613

0/20

16

Port

foli

oH

old

ing

sD

iscl

osu

res

(con

tinu

ed)

Pric

ing

(con

tinue

d)ha

vebe

enob

tain

edfr

omin

depe

nden

tve

ndor

serv

ices

,w

hich

we

belie

veto

bere

liabl

e.M

arke

tpr

ices

dono

tco

nstit

ute

abi

dor

anoi

ler,

and

may

diff

erfr

omth

eac

tual

sale

pric

e.Se

curi

ties

For w

hich

apr

ice

isno

tav

aila

ble

are

mar

ked

‘NIA

and

arc

omitt

edho

rnth

eTo

tal.

THE

AS

OF

PRIC

ED

ATE

ON

LYA

PPE

AR

SW

HEN

THE

PRIC

ED

ATE

DO

ES

NO

TEQ

UA

LTH

EST

ATE

MEN

TD

ATE

.

Est

imat

edA

nnua

lF

igur

esT

hees

timat

edan

nual

inco

me

(EA

I)an

des

timat

edan

nual

yiel

d(E

AY

)fi

gure

sar

ees

tim

ates

and

for

info

rmat

iona

lpu

rpos

eson

ly.

The

sefi

gure

sar

eno

tco

nsid

ered

tobe

afo

reca

stor

guar

ante

eof

Futu

rere

sults

,T

hese

figu

res

are

com

pute

dus

ing

info

rmat

ion

from

prov

ider

sbe

lieve

dto

bere

liabl

e;ho

wev

er,

noas

sura

nce

can

bem

ade

asto

the

accu

racy

.Si

nce

inte

rest

and

divi

dend

rale

sar

esu

bjec

tto

chan

geat

any

time,

and

may

beaf

fect

edby

curr

ent

and

futu

reec

onom

ic,

polit

ical

,an

dbu

sine

ssco

nditi

ons,

they

shou

ldno

tbe

relie

don

for

mak

ing

inve

stm

ent,

tradi

ng,

orta

xde

cisi

ons.

The

sefi

gure

sas

sum

eth

atth

epo

sitio

nqu

antit

ies,

inte

rest

and

divi

dend

rate

s,an

dpr

ices

rem

ain

cons

tant

.A

capi

tal

gain

orre

turn

ofpr

inci

pal

may

bein

clud

edin

the

figu

res

for

cert

ain

secu

ritie

s,th

ereb

yov

erst

atin

gth

em,

Ref

erto

vAw

J.pe

rshi

ng.c

omlb

usin

ess_

cont

inui

ty.h

tml

for

spec

ific

deta

ilsas

toFo

rmul

asus

edto

calc

ulat

eth

efi

gure

s.A

ccru

edin

tere

stre

pres

ents

inte

rest

earn

edbu

tno

tye

tre

ceiv

ed,

Rei

nves

tmen

tT

hedo

llar

amou

ntof

Mut

ual

Fund

dist

ribu

tions

,M

oney

Mar

ket

Fund

divi

dend

inco

me,

Ban

kO

epos

itin

tere

stin

com

e,or

divi

dend

sfo

rot

her

secu

ritie

ssh

own

onyo

urst

atem

ent

may

have

been

rein

vest

ed.

You

will

not

rece

ive

conf

irm

atio

nof

thes

ere

inve

stm

ents

.U

pon

writ

ten

requ

est

toyo

urfi

nanc

ial

inst

itutio

n,in

form

atio

npe

rtai

ning

toth

ese

tran

sact

ions

,in

clud

ing

the

time

ofex

ecut

ion

arid

the

nam

eof

the

pers

onfr

omw

hom

your

secu

rity

was

purc

hase

d,m

aybe

obta

ined

.In

divi

dend

rein

vest

men

ttr

ansa

ctio

ns,

Pers

hing

acts

asyo

urag

ent

and

rece

ives

paym

ent

For

orde

rflo

w.

Opt

ion

Dis

clos

ure

InFo

rmat

ion

with

resp

ect

toco

mm

issi

ons

and

othe

rch

arge

sin

curr

edin

conn

ectio

nw

ithth

eex

ecut

ion

oFop

tion

tran

sact

ions

has

been

incl

uded

inco

nfirm

atio

nspr

evio

usly

furn

ishe

dto

you.

Asu

mm

ary

ofth

isin

form

atio

nis

avai

labl

eto

you

prom

ptly

upon

your

writ

ten

requ

est

dire

cted

toyo

urin

trodu

cing

firm

.In

orde

rto

assi

styo

urin

trodu

cing

firm

inm

aint

aini

ngcu

rren

tba

ckgr

ound

and

finan

cial

info

rmat

ion

conc

erni

ngyo

urop

tion

acco

unts

,pl

ease

prom

ptly

advi

seth

emin

writ

ing

ofan

ym

ater

ial c

hang

ein

your

inve

stm

ent

obje

ctiv

esor

finan

cial

situ

atio

n.Ex

pirin

gop

tions

whi

char

eva

luab

lear

eex

orci

sed

auto

mat

ical

lypu

rsua

ntto

the

exer

cise

byex

cept

ion

proc

edur

eof

the

Opt

ions

Cle

arin

gC

orpo

ratio

n.A

dditi

onal

info

rmat

ion

rega

rdin

gth

ispr

oced

ure

isav

aila

ble

upon

writ

ten

requ

est t

oyo

urin

trodu

cing

firm

.Fo

reig

nC

urre

ncy

Tra

nsac

tions

Pers

hing

may

exec

ute

fore

ign

curr

ency

tran

sact

ions

aspr

inci

pal

fory

our

acco

unt.

Pers

hing

may

auto

mat

ical

lyco

nver

tFo

reig

ncu

rren

cyto

orfro

mU

.S. d

olla

rsfo

r div

iden

dsan

dsi

mila

rco

rpor

ate

actio

ntr

ansa

ctio

nsun

less

you

inst

ruct

your

finan

cial

orga

niza

tion

othe

rwis

e.Pe

rshi

ng’s

curr

ency

conv

ersi

onra

tewi

llno

texc

eed

the

high

est

inte

rban

kco

nver

sion

rate

iden

tifie

dfro

mcu

stom

ary

bank

ing

sour

ces

onth

eco

nver

sion

date

orth

epr

ior

busi

ness

day,

incr

ease

dby

upto

1%,

unle

ssa

parti

cula

rra

teis

requ

ired

byap

prlc

able

law

.Y

our

Fina

ncia

l org

aniz

atio

nm

ayal

soin

crea

seth

ecu

rren

cyco

nver

sion

rate

.Th

isco

nver

sion

rate

may

diffe

r fro

mra

tes

inef

fect

onth

eda

teyo

uex

ecut

eda

trans

actio

n,in

curr

eda

char

ge,

orre

ceiv

eda

cred

it.Tr

ansa

ctio

nsco

nver

ted

byag

ents

(suc

tsas

depo

sito

ries)

will

bebi

lled

atth

era

tes

such

agen

tsus

e.

Prox

yV

ote

Secu

ritie

sno

tfu

llypa

idfo

rin

your

mar

gin

acco

unt

may

bele

ntby

Pers

hing

toits

elf

orot

hers

inac

cord

ance

with

the

term

sou

tline

din

the

Mar

gin

Agr

eem

ent.

The

right

tovo

teyo

ursh

ares

held

onm

argi

nm

aybe

redu

ced

byth

eam

ount

ofsh

ares

onlo

an.T

hePr

oxy

Vot

ing

Inst

ruct

ion

Form

sent

toyo

um

ayre

flect

asm

alle

rnu

mbe

rof

shar

esen

title

dto

vote

than

the

num

ber

ofsh

ares

inyo

urm

argi

nac

coun

t.

Mon

eyM

ark

etF

und

Det

ail

Date

Activ

ityTy

peDe

scrip

tion

Amou

ntBa

lance

Sw

eep

Mon

eyM

arke

tF

und

GENE

RAL

MNY

MKT

FUND

Ct.B

Curre

ntYi

eld:

0.01

%Ac

tivity

Endi

ng: 0

6/30

/16

06/0

1/16

Ope

ning

Bal

ance

136.

6173

6.61

06/0

1/16

Dep

osit

MO

NEY

FUN

DPU

RCHA

SE10

,000

.00

10,7

36.6

1

Page

5of

B

Ao

r9

I9

9B

r3

oo

s’

Acc

ount

Num

ber:

H5E

-049

797

Go

pap

erl

ess

%22oO

7

AseA

.OU

TE

DtL

Ivte

YnA

LB

AR

RA

TrO

cO

MM

UN

IcA

TiO

NS

,‘JL

UIP

WIV

b

Secu

ritie

sof

fere

dth

roug

hB

rokera

ge

Ess

exN

atio

nal S

ecur

ities

, LLC

_______________________________________

-—

I-

F—

AccountS

tate

men

t

PA

R-0

Z.R

OIL

LOU

IStA

NA

BOAR

DO

FPH

ARM

ACY

Mon

eyM

arket

Fun

dD

etai

l(c

on

tin

ued

)

Dal

eAc

tivity

Type

Des

crip

tion

Swee

pM

oney

Mar

ket

Fund

(con

tinue

d)

GENE

RAL

MNY

MKT

FUND

CLB

(con

tinue

d)06

102/

16D

epos

itM

ONEY

FUND

PURC

HASE

115.

0010

,851

6106

/13/

16D

epos

itM

ONEY

FUND

PURC

HASE

140,

561.

5315

1,41

3.14

06/2

0/15

Wilh

draw

alM

ONEY

FUND

RFDE

MPT

ION

-150

,636

.45

116.

6906

/30/

16D

epos

itIN

COM

ERE

INVE

ST0.

3371

7.02

06/3

0/16

Clo

sing

Bal

ance

$777

.02

Tota

lAl

lM

oney

Mar

ket

Fund

s$7

77.0

2

Mes

sages

Alth

ough

am

oney

mar

ket

mut

ual

lund

seek

sto

pres

erve

the

valu

eof

your

inve

stm

ent a

t $1

per

shar

e,it

ispo

ssib

leto

lose

mon

eyby

inve

stin

gin

am

oney

mar

ket m

utua

lfu

nd.S

hare

sof

am

oney

mar

ket

mut

ual

fund

orth

eba

lanc

eol

aba

nkde

posi

tpr

oduc

the

ldin

your

brok

erag

eac

coun

tm

aybe

liqui

date

dup

onre

ques

tw

ithth

epr

ocee

dscr

edite

dto

your

brok

erag

eac

coun

t.Pl

ease

see

the

mon

eym

arke

tm

utua

lfu

nds

pros

pect

usor

the

bank

depo

sit

prod

uct’

sdi

sclo

sure

docu

men

tor

cont

act

your

advi

sor

Fora

dditi

onal

inFo

rmat

ion.

Purs

uant

toSE

CR

ule

lOb-

10(b

)(1)

conf

irm

atio

nsar

eno

tsen

tToT

purc

hase

sin

tom

oney

mar

ket m

utua

lfun

dspr

oces

sed

onth

esw

eep

plat

lorm

.

Imp

ort

ant

Info

rmat

ion

and

Dis

clo

sure

sTh

eR

ole

ofPe

rshi

ng•

Pers

hing

carr

ies

your

acco

unt

ascl

earin

gbr

oker

purs

uant

toa

clea

ring

agre

emen

t with

your

fina

ncia

lin

stitu

tion.

Pers

hing

may

acce

ptfro

myo

urfin

anci

alin

stitu

tion

with

out

inqu

iryor

inve

stig

alio

n(i)

orde

rsfo

rthe

purc

hase

and

sale

oFse

curit

ies

and

othe

rpr

oper

tyan

d(ii

)an

yot

her

inst

ruct

ions

conc

erni

ngyo

urac

coun

t.Pe

rshi

ngis

not

resp

onsi

ble

orlia

ble

for

any

acts

orom

issi

ons

ofyo

urFi

nanc

ial i

nstit

utio

nor

itsem

ploy

ees

and

itdo

esno

tsu

perv

ise

them

.Pe

rshi

ngpr

ovid

esno

inve

stm

ent a

dvic

eno

rdo

esit

asse

ssth

esu

itabi

lity

ofan

ytra

nsac

tion

oror

der.

Pers

hing

acts

asth

eag

ent o

fyo

urfin

anci

alin

stitu

tion

and

you

agre

eth

atyo

uwi

llno

tho

ldPe

rshi

ngor

any

pers

onco

ntro

lling

orun

der

com

mon

cont

rolw

ithit

liabl

eFo

rany

inve

stm

ent

loss

esin

curr

edby

you.

•Pe

rshi

ngpe

rfor

ms

seve

ral

key

func

tions

atth

edi

rect

ion

ofyo

urFi

nanc

ial i

nstit

utio

n.It

acts

ascu

stod

ian

for

Fund

san

dse

curit

ies

you

may

depo

sit

with

itdi

rect

lyor

thro

ugh

your

finan

cial

inst

ilutio

nor

that

itre

ceiv

esas

the

resu

ttof

secu

ritie

str

ansa

ctio

nsit

proc

esse

s.•

You

rfin

anci

alin

stitu

tion

isre

spon

sibl

efo

r adh

eren

ceto

the

secu

ritie

sla

ws,

regu

latio

nsan

dru

les

whi

chap

ply

toit

rega

rdin

gits

own

oper

atio

nsan

dth

esu

perv

isio

nof

your

acco

unt,

ilssa

les

repr

esen

tativ

esan

dot

her

pers

onne

l.Y

our

finan

cial

inst

itutio

nis

also

resp

onsi

ble

for a

ppro

ving

the

open

ing

ofac

coun

tsan

dob

tain

ing

acco

unt

docu

men

ts;

the

acce

ptan

cean

d,in

certa

inin

stan

ces,

exec

utio

nof

secu

ritie

sor

ders

:th

eas

sess

men

tof

the

suita

bilit

yof

thos

etr

ansa

ctio

ns,w

here

appl

icab

le:t

tiere

nder

ing

oFin

vest

men

tad

vice

,iF

any,

toyo

uan

din

gene

ral.

[or

the

ongo

ing

rela

tions

hip

that

itha

sw

ithyo

u.•

Inqu

iries

conc

erni

ngth

epo

sitio

nsan

dba

lanc

esin

your

acco

unt

may

bedi

rect

edto

the

Pers

hing

Cus

tom

erSe

rvic

eD

epar

tmen

t at

(201

)41

3-33

33. A

llot

her

inqu

iries

rega

rdin

gyo

urac

coun

t or

activ

itysh

ould

bedi

rect

edto

your

finan

cial

inst

itutio

n.Y

our

finan

cial

orga

niza

tion’

sco

ntac

tin

form

atio

nca

nbe

foun

don

the

first

page

ofth

isst

atem

ent.

•Fo

ra

desc

riptio

nof

othe

rfu

nctio

nspe

rfor

med

byPe

rshi

ngpl

ease

cons

ult t

heD

iscl

osur

eSt

atem

ent

prov

ided

toyo

uup

onth

eop

enin

gof

your

acco

unt.

This

notic

eis

not

mea

ntas

ade

finiti

veen

umer

atio

noF

ever

ypo

ssib

leci

rcum

stan

ce,

buta

sa

gene

ral

disc

losu

re.

IFyo

utia

vean

yqu

estio

nsre

gard

ing

ttus

notic

eor

ifyo

uw

ould

like

addi

tiona

lco

pies

ofth

eD

iscl

osur

eSt

atem

ent,

plea

seco

ntac

tyo

urFi

nanc

ial

inst

itutio

n.•

Pers

hing

isa

mem

ber

oFth

eSe

curit

ies

Inve

stor

Prot

ectio

nC

orpo

ratio

n(S

IPC

9.P

leas

eno

teth

atSI

PCdo

esno

tpr

otec

tag

ains

tto

ssdu

eto

mar

ket

fluct

uatio

n.In

addi

tion

toSI

PCpr

otec

tion.

Pers

hing

prov

ides

cove

rage

inex

cess

oFSI

PClim

its.

For

mor

ede

taile

din

form

atio

npl

ease

visit

:w

ww

.per

shin

g.co

m/a

bouU

stre

nglh

-and

-sta

bilit

y.•

This

stat

emen

t will

bede

emed

conc

lusi

ve.

You

are

advi

sed

tore

port

any

inac

cura

cyor

disc

repa

ncy

(incl

udin

gun

auth

oiiz

edtra

ding

)pr

ompt

ly,

but

nola

ter

than

ten

days

afte

rre

ceip

t oF

this

stat

emen

t,to

your

finan

cial

orga

niza

tion

and

Pers

hing

.Pl

ease

bead

vise

dth

atan

yor

alco

mm

unic

atio

nsh

ould

bere

-con

firm

edin

writ

ing

toFu

rther

prot

ect y

our

right

s,in

clud

ing

your

right

sun

der

the

Secu

ritie

sIn

vest

orPr

otec

tion

Act

.•

You

rfin

anci

alor

gani

zatio

nsco

ntac

t inf

orm

atio

nca

nbe

foun

don

the

first

page

ofth

isst

atem

ent.

Pers

hing

’sco

ntac

tin

Form

atio

nis

asfo

llow

s:Pe

rshi

ngL

IC,

Lega

lD

epar

tmen

t,O

nePe

rshi

ngPl

aza,

Jers

eyC

ity, N

ewJe

rsey

0739

9;(2

01)

413•

3330

.Er

rors

and

Om

issi

ons

exce

pted

.Im

port

ant

Psbi

trat

ion

Dis

clos

ures

•Al

lpar

ties

toth

isag

reem

ent

are

givi

ngup

the

right

tosu

eea

chot

her

inco

urt,

incl

udin

gth

erig

htto

atri

alby

jury

,ex

cept

aspr

ovid

edby

the

rule

sof

the

arbi

tratio

nfo

rum

inw

hich

acl

aim

isFi

led.

•A

rbitr

atio

naw

ards

are

gene

rally

final

and

bind

ing;

apa

rty’s

abili

tyto

have

aco

urt r

ever

seor

mod

ilyan

arbi

tratio

naw

ard

isve

rylim

ited.

•Th

eab

ility

ofth

epa

rties

toob

tain

docu

men

ts, w

itnes

sst

atem

ents

and

othe

rdi

scov

ery

isge

nera

llym

ore

limite

din

arbi

ttalio

nth

anin

cour

tpr

ocee

ding

s.

Page

6of

B

AO

O91998cS

F30017

Acc

ount

Num

ber:

HSE

-049

197

Go

pap

erle

ss..

,,&

.rv

”et.2

oo

iA

KA

SO

U1E

.DE

Llv

EM

v3

,,,J

.D

AL

BA

RR

AT

ED

CO

AM

UN

ICA

TIO

NS

‘st—

uC

.fla

Afl

SE

src

mom

ttB

alan

ce

P.A

R.0

2-R

011

LOUI

SIAN

ABO

ARD

OFPH

ARM

ACY

. ffl

200W

est

Con

gres

sS

tree

t1s

tfl

Ds

Laf

ayet

te,

LA70

501

FIN

AN

CIA

LSE

RV

ICE

S.11

0IB

OC

)823

-956

6

Stat

emen

t Per

iod:

0610

1120

16-

0613

0/20

16

Import

ant

Info

rmat

ion

and

Dis

closu

res

(con

tinue

d)Im

port

ant

Arb

itrat

ion

Dis

clos

ure5

(con

tinue

d)

•Th

ear

bitra

tors

dono

tha

veto

expl

ain

the

reas

on(s

)fo

r the

iraw

ard,

unle

ss,

inan

elig

ible

case

,aj

oint

requ

est f

oran

expl

aine

dde

cisi

onha

sbe

ensu

bmitt

edby

allpa

rties

toth

epa

nel

atle

ast

20da

yspr

ior

toth

efir

stsc

hedu

led

hear

ing

date

.•

The

pane

lof

arbi

trato

rswi

llty

pica

llyin

clud

ea

min

ority

ofar

bitra

tors

who

wer

eor

are

affil

iate

dw

ithth

ese

curit

ies

indu

stry

.•

The

rule

sof

som

ear

bitra

tion

foru

ms

may

impo

setim

elim

itsfo

rbr

ingi

nga

clai

min

arbi

tratio

n.In

som

eca

ses,

acl

aim

that

isin

elig

ible

for

arbi

tratio

nm

aybe

brou

ght

inco

urt.

•Th

eru

les

ofth

ear

bitra

tion

foru

min

whi

chth

ecl

aim

isfil

ed, a

ndan

yam

endm

ents

ther

eto,

shal

lbe

inco

rpor

ated

into

this

agre

emen

t.Im

port

ant

Arb

itrat

ion

Agr

eem

ent

Any

conb

over

sybe

twee

nyo

uan

dPe

rshi

ngLL

Csh

all

besu

bmitt

edto

arbi

tratio

nbe

fore

the

Fina

ncia

lIn

dust

ryR

egul

ator

yA

utho

rity.

Nope

rson

shal

lbr

ing

apu

tativ

eor

certi

fied

clas

sac

tion

toar

bitra

tion,

nor

seek

toen

forc

ean

ypr

edis

pute

arbi

tratio

nag

reem

ent a

gain

stan

ype

rson

who

has

initi

ated

inco

urt

apu

tativ

ecl

ass

actio

n,w

hois

am

embe

rof

apu

tativ

ecl

ass

who

has

not

opte

dou

tof

the

clas

sw

ithre

spec

tto

any

clai

ms

enco

mpa

ssed

byth

epu

tativ

ecl

ass

actio

nun

til;

(I)th

ecl

ass

certi

ficat

ion

isde

nied

;(II

)th

ecl

ass

isde

certi

rted;

or(II

I)lh

ecl

ient

isex

clud

edfro

mth

ecl

ass

byth

eco

urt.

Such

lorb

eara

nce

toen

forc

ean

agre

emen

tto

arbi

trate

shal

lno

tcon

stitu

tea

wai

ver

ofan

yrig

hts

unde

rth

isag

reem

ent

exce

ptto

the

exte

ntst

ated

here

in. T

hela

ws

ofth

eSt

ate

ofN

ewY

ork

gove

rn.

Pers

hing

’sco

ntac

tin

form

atio

nis

asfo

llow

s:Pe

rshi

ngLL

C,Le

gal

Dep

artm

ent,

One

Pers

hing

Plaz

a,Je

rsey

City

,N

ewJe

rsey

0739

9;(2

01)

413-

3330

.

Page

7of

8

Ato

9jg

9n

csr

3t0

1A

ccou

ntN

umbe

r:H

5E-0

4919

1G

op

aper

less

WUI

SIAN

ABO

ARD

OFPH

ARM

ACY

AS

eA

BO

UT

4)

RaL

eUi*

c&

Ient

C,_

.T

B.h

PB

’sh

BU

fl.5

•7•d

e£

n.y

Yea,

Sin

c.

2007

n,.

e,,

,..d

Ia,—

Y,I

S’.,,c

.,p,B

.s,

a”

.,...,,I

-O

AL

BA

RR

AtL

OC

OM

MU

NIC

AT

ION

S‘sta.I

afl

,—,e

.,rw

n,n

sa

-

“E

XC

EL

LE

NC

E

Secu

ritie

sof

fere

dth

roug

hB

rokera

ge

Ess

exN

atio

nal S

ecur

ities

,LLC

_______________________________________

I-—

iA

cco

un

tSta

tem

en

t

PA

p-0

2-R

OL

L

TER

MS

AN

DC

ON

DIT

ION

S

WA

NB

AC

hG

INS

ALL

OR

DE

RS

AN

)T

RA

NSA

CT

ION

SSH

AL

LH

ESO

LE

LY

FOR

YO

UR

AC

CO

UN

TA

ND

RIS

KSH

AL

LB

ES

UB

JEC

TT

OT

HE

CO

NST

ITU

TIO

N.

RU

LE

S,R

EG

UL

AT

KH

S.C

US

1IS

,U

SA

DE

S,

RU

LIN

GS

AN

DIN

TE

RPR

ET

AT

ION

SO

FT

HE

EX

CH

AN

GE

OR

MA

RK

ET

AN

DT

IEC

LE

AR

ING

FAC

ILIT

Y,

IFA

NY

,W

HE

RE

TH

ET

RA

NSA

CT

ION

SA

RE

EX

EC

UT

ED

MID

IOR

SE

UE

ED

.O

RIF

APP

LIC

AB

LE

OF

TH

EFI

NA

NC

IAL

INC

UST

EY

RE

GU

LA

TO

RY

AU

TH

OR

ITY

AN

DT

OA

LLM

PE

ICA

BL

EL

AW

SA

ND

RE

GU

LA

TIO

NS

•TI

TLE

TO

SE

CU

RIT

IES

SOL

DT

OY

OU

WH

ER

EPE

RSH

ING

HA

SA

CT

ED

AS

PRIN

CIP

AL

.SH

AL

LR

EM

AIN

WIT

HP

ER

SH

ING

UN

TIL

TH

EE

NT

IRE

PU

RC

HA

SE

PRIC

EIS

RE

CE

WE

DO

RU

NT

ILTH

ESE

TT

LE

ME

NT

DA

TE

.W

HIC

HE

VE

RIS

LA

TE

R.

•Y

OU

MA

YH

AV

ER

EC

EIV

ED

CO

NFI

RM

AT

ION

SFO

RT

RA

NSA

CT

ION

SW

HIC

HD

ON

OT

AP

PE

AR

ON

YO

UR

STA

TE

ME

NT

IFS

QTH

ET

RA

NSA

CT

ION

SW

ILL

AP

PE

AR

ON

YO

UR

NE

XT

PE

RIO

DIC

STA

TE

ME

NT

SUC

HT

RA

NSA

CT

ION

SM

UST

BE

CO

NS

IDE

RE

DB

YY

OU

WH

EN

CO

MPU

TIN

GT

HE

VA

LU

EO

FY

OU

RA

CC

OU

NT

TH

ISIS

ESP

EC

IAL

LY

TR

UE

IFY

OU

HA

VE

WR

ItT

EN

OP

TIO

NS

WH

ICH

HA

VE

BE

EN

EX

ER

CIS

ED

.

FR

EE

CR

ED

ITB

AL

AN

CE

S:

AN

YF

RE

EC

RE

DIT

BA

LA

NC

EC

AR

RIE

DFC

RY

OU

RA

CC

OU

NT

RE

PR

ES

EN

TS

FUN

DS

PAY

AB

LE

UPO

ND

EM

AN

DW

HIC

H,

AL

TH

OU

GH

PR

OP

ER

LY

AC

CO

UN

TE

DF

OR

ON

PE

RS

HIN

GS

BO

OK

SO

FR

EC

OR

D,

AR

EN

OT

SE

GR

EG

AT

ED

AN

DM

AY

BE

USE

DIN

TH

EC

ON

DU

CT

OF

ITS

BU

SIN

ES

S

DE

BIT

BA

I.A

NC

ES

:IN

TE

RE

STC

HA

RG

ED

ON

DE

BIT

BA

LA

NC

ES

INY

OU

RA

CC

OU

NF

AP

PE

AR

SO

NT

HE

STA

TE

ME

NT

TH

ER

AT

EO

FIN

TE

RE

ST

AN

DPE

RIO

DC

OV

ER

ED

AR

EIN

DIC

AT

ED

.T

HE

RA

TE

MA

YC

HA

NG

EFR

OM

TIM

ET

OT

IME

DU

ET

OFL

UC

TU

AT

ION

SIN

MO

NE

YR

AT

ES

OR

CT

HE

RR

EA

SO

NS

.IN

TE

RE

STIS

CO

MPU

TE

DA

SD

ES

CR

IBE

DIN

MA

TE

RIA

LPR

EV

IOU

SLY

FUR

NIS

HE

DT

OY

OU

.P

LE

AS

EC

ON

TA

CT

YO

UR

FIN

AN

C’A

LIN

STIT

UT

ION

IFY

OU

DE

SIR

EA

DD

ITIO

NA

LC

OP

IES

MA

RG

ININ

FOR

MA

TIO

N:

IFY

OU

MA

INTA

INA

MA

RG

INA

CC

OU

NT

,T

hIS

ISA

CO

MB

INE

DST

AT

EM

EN

TO

FY

OU

RG

EN

ER

AL

AC

CO

UN

TA

ND

ASP

EC

LA

LM

EM

OR

AN

DU

MA

CC

OU

NT

MA

INT

AIN

ED

FOR

YO

UU

ND

ER

RE

GU

LA

TIO

NT

OF

TH

EB

OA

RD

OF

GO

VE

RN

OR

SO

FT

HE

FED

ER

AL

RE

SE

RV

ES

YsT

EM

.T

hEPE

RM

AN

EN

TR

EC

OR

DO

FT

HE

SE

PA

RA

TE

AC

CO

UN

TA

SR

EO

UT

TE

DB

YR

EG

UL

AT

ICN

TIS

AV

AIL

AB

LEFO

RY

OU

RIN

SPE

CT

ION

UPO

NR

EQ

UE

ST

TA

XIN

FO

RM

AT

iON

•A

FTE

RY

EA

RE

ND

.P

ER

SH

ING

ISR

EQ

UT

TE

DTO

PR

DV

TJE

TAX

INFO

RM

AT

ION

TO

TH

EIN

TE

RN

AL

RE

VE

NU

ESE

RV

ICE

AN

DO

TtE

RG

OV

ER

NM

EN

TA

LA

UT

HO

RIT

ILS.

AT

TH

AT

TIN

EP

ER

SH

INGW

PR

OV

flE

TH

AT

INFO

RM

AT

ION

ON

TH

EA

NN

UA

LTA

XIN

FOR

MA

TIO

NST

AT

EM

EN

TT

OY

OU

,U

SE

TH

AT

STA

TE

ME

NT

TO

PR

EP

AR

EY

OU

RTA

XF

LIN

GS

.T

HE

TAX

STA

TE

ME

NT

AL

SOIN

CL

UD

ES

OT

HE

RU

SEFU

LIN

FOR

MA

TIO

NT

OA

SS

IST

INA

CC

UM

UL

AT

ING

TE

ED

AT

AT

OP

RE

PA

RE

YO

UR

TAX

RE

TU

RN

S.

•D

IVID

EN

DS,

LN

TE

RE

ST

N4D

OT

hER

DIS

WU

TIO

NS

SHO

WN

ON

TH

ISS

TA

TE

ME

NT

WE

RE

CL

AS

SIP

ED

AS

TA

XA

BL

EO

RN

ON

TA

XA

DL

EB

ASE

DO

NC

ER

TA

TI

INFO

RM

AT

ON

KN

OW

NA

SO

FTH

ED

IST

RIB

UT

ION

DA

TE

.T

HIS

CI.

ASS

WIC

AT

ION

ISS

UB

IEC

TT

OC

HA

NG

EA

ND

ISSO

LE

LY

INT

EN

DE

DF

OR

USE

AS

GE

NE

RA

LIN

FOR

MA

TIO

N

•P

ER

SH

ING

DO

ES

NO

TPR

OV

IDE

TAX

,IN

VE

SThI

EN

TO

RL

EG

AL

AD

VIS

OR

YS

ER

VIC

ES

AN

DN

DO

NE

AS

SO

CIA

TE

DW

ITH

PE

RS

HIN

GIS

AU

TH

OR

IZE

DT

OR

EN

DE

RSU

CH

AD

VIC

E.

DO

NO

TR

EL

YU

PON

AN

YSU

CH

AD

VIC

C,

IFO

WE

NIN

VE

STO

RS

AR

EE

NC

OU

RA

GE

DTO

CO

NS

UL

TT

HE

IRT

AX

AD

VIS

OR

ST

OD

ET

ER

MIN

ET

hEA

PP

RO

PR

IAT

ETA

XT

RE

AH

IEN

TO

FT

HE

IRB

US

INE

SS

.

GE

NE

RA

LIN

FOR

MA

TIO

N

•W

HE

NE

VE

RY

OU

AR

EIN

DE

BT

ED

TO

PE

RS

HIN

GLL

CP

ER

SH

ING

’)F

OR

AN

YA

MO

UN

TA

LLS

EC

UR

ITIE

SH

EL

DB

YIT

FOR

YO

UIN

AN

YA

CC

OU

NT

INW

HIC

HY

OU

HA

VE

AM

YIN

TE

RE

ST

SHA

LL

SE

CU

RE

ALL

YO

UR

LIA

BIL

ITIE

ST

OP

ER

SH

ING

,A

ND

PE

RS

HIN

GM

AY

NIT

SD

ISC

RE

TIO

NA

TA

NY

TIM

E,W

FIH

OU

TT

EN

DE

R,

DE

MA

ND

OR

NO

TIC

ET

OY

OU

,C

LO

SE

OR

RE

DU

CE

AN

YO

RA

LLO

FY

OU

RA

CC

OU

NT

SB

YPU

BL

ICO

RPR

IVA

TE

SAL

EO

RP

UR

CH

AS

EO

RB

OT

HO

FA

LLO

RA

NY

SE

CU

RIT

IES

CA

RR

IED

INSU

CH

AC

CO

UN

TS;

AN

YB

AL

AN

CE

RE

MA

ININ

GD

UE

PE

RS

HIN

GTO

BE

PRO

MPT

LY

PAID

BY

YO

U.

•W

HE

NE

VE

RY

OU

AR

EIN

DE

BT

ED

TO

PE

RS

HIN

GFO

RA

NY

AM

OU

NT

,A

LLS

EC

UR

ITIE

SC

AR

RIE

DFO

RY

OU

RA

CC

OU

NT

AR

EO

RM

AY

BE

,WIT

HO

UT

FUR

TH

ER

NO

TIC

ETO

YO

UL

OA

NE

DC

RP

LE

BG

EO

BY

PE

RS

HIN

G,

EIT

HE

RSE

PAR

AT

EL

YO

RU

ND

ER

CIR

CU

MS

TA

NC

ES

WH

ICH

WL

LPE

RM

ITT

HE

CO

MM

ING

LIN

GT

HE

RE

OF.

WIT

HO

TH

ER

SE

CU

RIT

IES

FOR

AN

YA

MO

UN

TL

ES

ST

hAN

,E

OU

AL

TOO

RG

RE

AT

ER

THA

NY

OU

RLL

AB

ILIT

IES

TO

PE

RS

HIN

G.

BU

TN

OT

UN

DE

RC

IRC

UM

STA

NC

ES

FOR

AN

AM

IZJN

TP

RO

HIB

ITE

OB

YLA

W

•P

ER

SIE

NG

MA

YT

RA

DE

FOR

ITS

OW

NA

CC

OU

NT

AS

AM

AR

KE

TM

AK

ER

,SP

EC

IAL

IST

,O

DD

LO

TD

EA

LE

R,

BL

OC

KP

OS

ITIO

NE

R,

AR

BIT

RA

GE

UR

OR

INV

EST

OR

CO

NS

EQ

UE

NT

LY

, AT

TH

ETI

ME

OF

AN

YIR

AN

SA

CT

ICN

YO

UM

AY

MA

KE

,P

ER

SN

NG

MA

YH

AV

EA

POSI

TIO

NIN

SUC

HS

EC

UR

ITIE

S,W

HIC

HP

O5

mO

NM

AY

BE

PAR

TIA

LL

YO

RC

OM

PLE

TE

LY

HE

DG

ED

.

•IF

AV

ER

AG

EP

RIC

ET

RA

NSA

CT

ION

ISIN

DIC

AT

ED

ON

TH

EF

RO

NT

OF

TH

ISS

TA

TE

ME

NT

YO

UR

FIN

AN

CIA

LIN

STIT

UT

ION

OR

PE

RS

HIN

GM

AY

HA

VE

AC

TE

DA

SPR

INC

IPA

L.

AG

EN

TO

RB

OT

HD

ET

AIL

SA

VA

ILA

BLE

UPO

NR

EQ

UE

ST

•A

FIN

W1C

LAL

STA

TE

ME

NT

OF

PE

RS

HIN

GIS

AV

AIL

AB

LE

FOR

YO

UR

PE

RS

ON

AL

INSP

EC

TIO

NA

TP

ER

SH

ING

’SO

FF

ICE

S.

AC

OPY

OF

ITW

LL

BE

MA

’LED

UPO

NY

OU

RW

RW

TE

NR

EQ

UE

ST

OR

YO

UC

AN

VIE

WIT

ON

LIN

EA

TW

WV

1P

ER

SH

ING

CC

M

FOR

BU

SIN

ES

SC

ON

TIN

UR

YA

ND

AU

DIT

ION

AL

DIS

CL

OS

’JR

ES

:WW

WP

ER

SK

ING

CO

IVD

ISC

LD

SU

RE

S

TH

ISST

AT

EM

EN

TSH

OU

LD

BE

RE

TA

INE

DF

DR

YO

UR

RE

CO

RD

S.

PA

YN

CN

TF

OR

OR

DE

RF

LO

WA

ND

OR

DE

RR

OU

TIN

GP

OL

ICIE

SD

ISC

LO

SU

RE

SL

RE

CU

LA

TIO

NN

MS

—R

UL

ZG

Ofl

A)t

lH2

)J

PE

RS

HIN

GS

EN

DS

CE

RT

AIN

EQ

UIT

YO

RD

ER

ST

OE

XC

HA

NG

ES

,E

LE

CT

RO

NIC

CO

MM

LN

ICA

TIO

NN

ET

WO

RK

S.

OR

BR

OK

ER

.D

EA

LE

RS

DU

RIN

GN

OR

MA

LB

US

INE

SS

HO

UR

SA

ND

DU

RIN

GE

XT

EN

DE

DT

RA

ON

GS

ES

SIO

NS

.C

ER

TA

INO

FT

HE

SEV

EN

UE

SP

RO

VE

PAY

NE

NT

ST

OP

ER

SH

ING

OR

CH

AN

CE

AC

CE

SS

FE

ES

TO

PE

RS

HIN

GD

EPE

ND

ING

UPO

NT

HE

CH

AR

AC

TE

RIS

TIC

SO

FT

HE

OR

DE

RA

ND

AN

YS

UB

SE

QU

EN

TE

XE

CU

TIO

N.

TH

ED

ET

AIL

SO

FT

HE

SE

PAY

ME

NT

SA

ND

FE

ES

AR

EA

VA

.tAB

LE

UPO

NW

RW

FEN

RE

QU

ES

T.

PC

RS

FeJ

GR

EC

EIV

ES

PAY

ME

NT

SFO

RD

IRE

CT

ING

LIS

TE

DO

PT

ION

SO

RD

ER

FLO

WTO

CE

RT

AIN

OPT

ION

EX

CH

AN

GE

S‘N

AD

DIT

ION

.P

ER

SH

ING

RO

UT

ES

CE

RT

AIN

EQ

UIT

YA

ND

OPT

ION

OR

DE

RS

TO

US

AFF

ILIA

TE

.O

NY

ME

LL

ON

CA

PIT

AL

MA

RK

ET

S,(I

C,

FOR

EX

EC

UT

ION

AS

PRIN

CIP

AL

CO

MPE

NSA

TIO

NIS

GE

NE

RA

LL

YN

TH

EFO

RM

OF

AP

ER

OPT

IOH

CO

NT

RA

CT

CA

SHPA

YM

EN

T.

BE

ST

EX

EC

uTIo

N:

NO

TW

ITH

STA

ND

ING

TH

EP

RE

VIO

US

PAR

AG

RA

PHR

EG

AR

DIN

GPA

YM

EN

TFO

RO

RD

ER

FLO

W,

PE

RS

HIN

GSE

LE

GT

SC

ER

TA

INM

AR

KE

TC

EN

TE

RS

TO

PRO

VID

EE

XE

CU

TIO

NO

FO

VE

R.T

UE

,00U

NT

ER

AN

DE

XC

HA

NG

E-L

IST

ED

SE

CU

RIT

IES

TR

AH

SA

CT

ION

SW

HIC

HA

GR

EE

TO

AC

CE

PT

OR

DE

RS

,T

RA

NSM

ITT

ED

EL

EC

TR

ON

ICA

LL

YU

PT

OA

SP

EC

IFIE

DSI

ZE

,A

ND

TO

EX

EC

UT

ET

HE

MA

TO

RB

ET

TE

RT

HA

NT

HE

NA

TIO

NA

LB

ES

TB

IDO

RO

FF

ER

(HO

BO

).O

NC

ER

TA

INL

AR

GE

RO

RD

ER

S,

OR

IFTH

ED

ESI

GN

AT

ED

MA

RK

ET

CE

NT

ER

SD

ON

OT

MA

KE

AM

AR

KE

TIN

ThE

SU

BJE

CT

SEC

UR

ITY

,P

ER

SH

ING

DIR

EC

TL

YC

ON

TA

CT

SM

AR

KE

TC

EN

TE

RS

TO

OO

TA

IHM

IE

XE

CU

TIO

N.

TH

ED

ESI

GN

AT

ED

MA

RK

ET

CE

NT

ER

ST

OW

HIC

HO

RD

ER

SA

RE

AU

TO

MA

TIC

AL

LY

RO

UT

ED

AR

ES

EL

EC

TE

DB

ASE

DO

NT

HE

CO

NS

IST

EN

TH

IGH

OU

AL

ITY

OF

TH

EIR

EX

EC

UT

ION

SIN

ON

EO

RM

OR

EM

AR

KE

TS

EG

ME

NT

SA

ND

TH

EIR

AB

ILIT

YT

OPR

OV

IDE

OP

PO

RT

UN

ITIE

SFO

RE

XE

CU

TIO

NS

AT

PR

ICE

SS

UP

ER

IOR

TO

TH

EN

BB

O.

PE

RS

HIN

GA

LSO

RE

GU

LA

RL

YR

EV

IEW

SR

EP

OR

TS

FO

RC

UA

LIT

YO

FE

XE

CU

TIO

NP

UR

PO

SE

S.

WR

AP

AC

CO

UN

TC

US

TO

ME

RS

WH

OE

LE

CT

ED

NO

TT

OR

EC

EIV

EIM

ME

DIA

TE

CC

NF

1RM

AT

ION

OF

TR

AN

SA

CT

ION

S

TH

EFO

LL

OW

ING

TE

RM

SA

ND

CO

ND

ITIO

NS

AR

EA

PPL

ICA

BL

EO

NL

YIF

YO

UR

AC

CO

UN

TIS

AN

INV

ES

TR

EN

TA

DV

ISO

RY

AC

CO

UN

TA

ND

TH

ET

RA

NSA

CT

ION

CO

NFI

RM

AT

ION

SA

RE

NO

TS

EN

TT

OY

OU

(SE

NT

ON

LY

TO

YO

UR

FID

UC

IAR

Y)

PUR

SUA

NT

TOY

OU

RIN

STR

UC

TIO

N:

WR

AP

AC

CO

UN

TT

RA

)aA

CT

iON

S

•T

HE

FOL

LO

WIN

GIN

FO

RA

IAT

IGN

VL

LB

EFU

RN

ISH

ED

TO

YO

UU

PON

RE

QU

ES

TT

OY

OU

RFI

NA

NC

IAL

INST

ITU

TIO

NrI

NT

RO

CU

CIN

GF

IRM

’)W

ITlI

RE

SP

EC

TT

OA

NY

TR

AN

SAC

TIO

NFO

RW

HIC

HA

CO

MIR

AtA

TIC

tJW

AS

NO

TS

EN

TTO

YO

UT

HE

MA

RK

ET

UPO

NW

HIC

HA

NY

TR

AN

SAC

TIO

NW

AS

EX

EC

UT

ED

;T

hET

IME

OF

DA

YT

HA

TA

NY

TR

AN

SAC

TIO

NW

AS

EX

EC

UT

ED

.TH

EN

AM

EC

FT

HE

PE

RS

ON

FR

OK

IWH

OI

AN

YSE

CU

RIT

YW

AS

PU

RC

4AS

ED

OR

TO

WH

a.I

SU

CH

SEC

UR

ITY

WA

SSO

LD

:T

HE

SO

UR

CE

AN

DA

MO

UN

TO

FO

TH

ER

CO

MM

ISSI

ON

SR

EC

EIV

ED

INC

ON

NE

CT

ION

WIT

HA

NY

TR

AN

SAC

TIO

N.

AN

DA

CO

PYO

FT

HE

TR

AN

SAC

TIO

NC

ON

FR

MA

TIO

N.

•Y

OU

RIN

TR

OD

UC

ING

FR

ME

FF

EC

TE

DE

AC

HT

RA

NSA

CT

ION

FOR

WH

ICH

AC

ON

FIR

MA

TIO

NW

AS

NO

TS

EN

TT

OY

OU

AS

YO

UR

AG

EN

T

•IN

CO

NN

EC

TIO

NW

ITH

EA

CH

EQ

UIT

YSE

CL

WT

R’Y

AN

BC

ER

TA

INO

TH

ER

SE

CU

RIT

IES

SOL

D,

YO

UR

INT

RO

DU

CIN

GF

IlM

CH

AR

GE

STO

YO

U,

AN

DR

EM

ITS

TO

AR

EG

UL

AT

OR

YO

RG

AN

IZA

TIO

NO

RN

AT

ION

AL

SE

CU

RIT

IES

EX

CH

AN

GE

,A

TR

AN

SFE

E.

PER

SHIN

GC

AL

CU

LA

TE

ST

HIS

FEE

BA

SED

ON

AM

OU

NT

SPA

IDB

YY

OU

RIN

TR

OD

UC

ING

FIR

MT

OT

HE

APP

LIC

AB

LE

RE

GU

LA

TO

RY

OR

GA

NIZ

AT

ION

OR

NA

TIO

NA

LS

EC

UR

ITIE

SE

XC

HA

NG

E.

HIS

,IN

TU

RN

,IS

BA

SED

ON

TH

EV

AL

UE

DF

TH

EA

PPL

ICA

BL

ES

EC

UR

ITIE

SSO

LD

.T

OD

ET

ER

MIN

ETH

EE

XA

CT

AM

OU

NT

OF

TH

ISFE

EW

ITH

RE

SP

EC

TT

OA

NY

TR

AN

SAC

TIO

N.

PL

EA

SE

CO

NT

AC

TY

OU

RIN

TR

OD

UC

ING

FIR

M

•IF

AN

YT

RA

NSA

CT

ION

INV

DL

VE

SA

NA

SS

ET

,BA

CK

ED

SEC

UR

ITY

,IN

CL

UD

ING

AM

UN

ICIP

AL

CO

LL

AT

ER

AL

IZE

DM

OR

TG

AG

EO

BL

IGA

TIO

N,

WH

ICH

RE

PR

ES

EN

TS

AN

INT

ER

EST

INO

RIS

SE

CU

RE

DB

YA

POO

LO

FR

EC

EIV

AB

LE

SO

RO

TH

ER

FIN

AN

CIA

LA

SS

ET

ST

HA

TA

RE

SU

BJE

CT

CO

NT

INU

OU

SLY

TO

PRE

PAY

ME

NT

,T

HE

NT

HE

AC

TU

AL

YIE

LD

OF

SUC

HSE

CU

RIT

YM

AY

VA

RY

AC

CO

RD

ING

TO

TH

ER

AT

EA

TW

HIC

HT

HE

UN

DE

RL

YIN

GR

EC

EIV

AB

LE

SO

RO

TH

ER

FIN

AN

CLA

LA

SS

ET

SA

RE

PRE

PAJD

INFO

RM

AT

ION

CO

NC

ER

NIN

GT

HE

FAC

TO

RS

TTLA

TA

FF

EC

TY

IEL

D(I

NC

LU

DIN

GA

TA

MIN

IMU

ME

STIM

AT

ED

YIE

LD,

WE

IOH

TE

DA

VE

RA

GE

LIFE

.A

ND

TH

EP

RE

PA

YM

EN

TA

SS

UM

PT

ION

SO

FU

ND

ER

LY

ING

YIE

LD

)WIL

LB

EFU

RN

ISH

ED

TOY

OU

UPO

NR

EQ

UE

ST

TO

YO

UR

INT

RO

DU

CIN

GFI

RM

.

WR

AP

AC

CO

UN

TO

RO

ER

FLO

W:

YO

UR

INT

RO

DU

CIN

GFI

RM

DO

ES

NO

TR

EC

EIV

EA

NY

PAY

ME

NT

FOR

OR

DE

RFL

OW

FO

RA

NY

TR

AN

SAC

TIO

NFO

RW

HIC

HA

CO

NFI

RM

A’I

ON

WA

SN

OT

SE

NT

TOY

OU

WR

AP

AC

CO

UN

TC

AL

LF

EA

TU

RE

S:

CA

LLFE

AT

UR

ES

MA

YE

XIS

TFO

RS

EC

UR

ITIE

S.

CA

LLFE

AT

UR

ES

FOR

FIX

ED

INC

OM

ES

EC

UR

ITIE

SW

AY

AFF

EC

TY

IEL

D.

CO

MPL

ET

EF

4FO

RM

AT

ION

WL

LB

EPR

OV

IDE

DU

PON

RE

QU

ES

T

WR

AP

AC

CO

UN

TR

AT

iNG

S:

TH

ER

AT

’NG

ST

HA

TA

PP

EA

RIN

TH

ED

ESC

RIP

TIO

NO

FSO

ME

FIX

ED

INC

OM

ES

EC

UR

IT’E

SH

AV

EB

EE

NO

BT

AIN

ED

FRO

MR

AT

EIG

SS

ER

VIC

ES

WH

ICH

PE

RS

HIN

GB

EL

IEV

ES

TOB

ER

EL

IAB

LE

;H

OW

EV

ER

,P

ER

SH

ING

CA

NN

OT

GU

AR

AN

TE

ET

HE

IRA

CC

UR

AC

YS

EC

UR

mE

SFO

RW

HIC

HA

RA

ThG

ISN

OT

AV

AIL

AB

LE

AR

EM

AR

KE

DU

NR

AT

ED

.

IFA

NY

OF

THE

AB

OV

ET

ER

MS

AN

DC

EN

DIT

ION

SA

BE

UN

AC

CE

PTA

BL

ETO

YO

U,

FEE

ASE

NO

TIFY

PER

SHIN

GIM

ME

DIA

TaY

INW

RIT

ING

BYC

ER

TIF

IED

MA

ILTO

ON

EPE

RSH

ING

PLA

ZA,J

ER

SEY

CIT

Y.

NJ

0739

9.sf

lN:

LEG

AL

DE

PT

Page

8aI

D

AB

D9

LT

9IC

SF

JTO

L7

Acc

ount

Num

ber:

HSE

-049

791

Go

pap

erle

ssA

SK

AIQ

UT

E.D

EL

IVIM

V4

Rate

dE

,c.I

In

t.,.

Eae,y

Yea,S

inc.2

00

7D

AL

OA

RR

AT

IOC

OA

MU

NIC

AT

ION

S-

—E

XC

EL

LE

NC

E

CIt

Kfl

O,S

,flP

hb

,gL

LC

.•

,.a

—IS

aIK

1K

bIIK

’C

Kp

K••b

KIa

YK

I

,‘a

tIC

.‘‘tK

rflt

Ansa

SW

CP

AR

-Cl-

RO

LL

LOUI

SIAN

ABO

ARD

OFPH

ARM

ACY

IBE

RIA

FIN

AN

CIA

LSE

RY

ICE

S,LL

C

200

Wes

tCongre

jaSt

reet

1st

FIoc

.La

faye

tte, I

A70

501

BOO)

813-

0566

II

kC

ItIC

IMfl

dI

4II.d

’I

Acc

ount

Num

ber:

H5E

-077

160

Stat

emen

tPe

riod

:05

101/

2016

-06

/30/

2016

Port

foli

oat

aG

lanc

ePe

riod

LAR

DO

FPH

AR

MA

CY

OP

EB

RE

SA

CT

3388

BR

EN

TW

OO

DD

RIV

EB

AT

ON

RO

UG

ELA

7080

9-17

00

Vow

Acc

ount

Exec

utiv

e:JO

SEPH

BARR

ECA,

JR.

(504

)31

0-13

46

Ass

etS

um

mar

yCa

sh,

Mon

eyFu

nds,

and

Bank

Dep

osits

Fixe

dIn

com

eA

ccou

ntTo

tal

Beg

inni

ngA

ccou

ntV

alue

-—

$1,0

91.1

45.6

0D

ivid

ends

,In

tere

stan

dO

ther

Inco

me

Net

Cha

noc

inPo

rtfol

ioE

ndin

gA

ccou

ntV

alue

$1,1

09,7

50.2

9

Go

pap

erl

ess

Ask

Aeflu

tE

Dt

LIV

ER

Y4

Ratd

Lc.l

Ien

tE

ev

y.,

S,n

c.

2007

DA

LR

AR

RA

TE

DC

OM

MU

NIC

AT

ION

S—

DIC

LIL

EN

CE

—T

i——

—C

R’..—

TI—

VR

RR

Sec

uri

ties

offe

red

thro

ugh

Bro

kera

ge

Ess

exN

atio

nal S

ecur

ities

, LLC

Account S

tate

ment

1,44

7.31

11,1

51.3

2

$14,

0350

0Es

timat

edA

nnua

l Inc

ome

This

Perio

d%

Allo

catio

n

1,59

7.05

1%Pl

ease

revi

ewyo

ural

loca

tion

perio

dica

llyw

ithyo

urA

ccou

ntEx

ecut

ive.

1,10

8,15

3.24

99%

$1,1

09,1

50.2

910

0%

Page

1of

?

PA

RO

2-R

OL

L

Cli

ent

Ser

vic

eIn

form

atio

nY

our

Acc

ount

Exec

utiv

e:X5

7C

onta

ctIn

Form

atio

nJO

SEPH

BARR

ECA,

JR.

Tel

epho

neN

umbe

r:(5

04)

310-

1346

IBER

IAFI

NANC

IAL

SERV

ICES

2900

RIDG

ELAK

EDR

IVE

MET

AIRI

ELA

1000

2-49

23

You

rA

ccou

ntIn

form

atio

nTa

xLo

tD

efau

ltD

ispo

sitio

nM

etho

dD

elau

llM

etho

dfo

rM

utua

lFun

ds: A

VERA

GECO

ST(U

SING

FIRS

TIN

FIRS

TOU

T)D

elau

ltM

etho

dfo

rSt

ocks

ina

Div

iden

dR

einv

estm

entP

lan:

FIRS

TIN

FIRS

TOU

TD

efau

ltM

etho

dfo

rall

Oth

erSe

curit

ies:

FIRS

TIN

FIRS

TOU

TB

ond

Am

ortiz

atio

nEl

ectio

ns:

Am

ortiz

epr

emiu

mon

taxa

ble

bond

sba

sed

onC

onst

ant

Yield

Met

hod:

Yes

Accr

ual

mar

ket

disc

ount

met

hod

Fora

llot

her

bond

type

s:C

onst

ant Y

ield

Met

hod

Incl

ude

mar

ketd

isco

unt i

nin

com

ean

nual

ly:

No

Cop

ies

ofS

tate

men

tSe

ntKO

OLER

.CH

AMPA

GNE,

SIR

VEN

&CO

Atyo

urre

ques

t cop

ies

ofth

isst

atem

ent h

ave

been

sent

toth

eab

ove.

Ele

ctro

niC

Del

iver

yE-

mai

lno

tific

atio

nsar

ede

liver

edto

the

lotlo

win

ge-

mai

lad

dres

s(es

):Yo

uar

ecu

rrent

lyen

rolle

dto

rece

ive

the

follo

win

gac

coun

tco

mm

unic

atio

nsvi

ael

ectro

nic

deliv

ery:

k###

####

###@

phar

mac

y.la

.gov

Stat

emen

tsan

dRe

ports

The

abov

ee-

mai

lad

dres

sis

parti

ally

mas

ked

fory

our

secu

rity.

Plea

selo

gTr

ade

ConF

irmat

ions

into

your

acco

unt t

ore

view

the

full

e-m

ail

addr

ess.

Ta2

Doc

umen

tsN

otifi

catio

nsPl

ease

log

into

your

acco

unt

tom

ake

any

chan

ges

toyo

urel

ectro

nic

deliv

ery

pref

eren

ces.

Act

ivit

yS

um

mar

y(A

IIam

ount

ssiw

rwn

are

inba

seC

Uff

ency

)

Cred

itsth

isPe

riod

Debi

tsth

isPe

riod

Net T

hisPe

riod

Cred

itsY

ear-t

o-D

ate

Debi

tsY

ear-t

o-D

ate

Nety

ear-

to-D

ate

Secu

ritie

sSe

curit

ies

Boug

ht0.

00-1

2141

229

-127

,412

290.

00-8

60,1

31.6

5-8

60,1

31.6

5Se

curit

ies

Sold

0.00

0.00

0.00

508,

4525

00_

Do50

8,45

2.50

Tota

lSe

curit

ies

$0.0

0-$

121,

412.

29-$

127,

412.

29$5

08,4

52S0

-$86

0,73

7.65

-$35

2,28

5.15

Div

iden

dsan

dIn

tere

st$1

,447

.37

$0.0

0$1

,447

.37

$3,1

04.2

5$0

.00

$3,1

04.2

5

Dis

tribu

tions

$127

,000

.00

$0.0

0$1

27,0

00.0

0$1

27,0

00.0

0$0

.00

$127

,000

.00

Tota

ls$1

28,4

47.3

7-$

121,

412.

29$1

,035

.08

$638

,556

.15

-$86

0,73

7.65

-$22

2,18

0.90

Page

2of

7

Acc

ount

Num

ber-

H5E

-071

160

Pi0

93

63

1C

SP

30

01

-6

4)

pap

erle

ssv

.S

n.

2007

—

IABD

OFPH

ARM

ACY

OPEB

RES

ACT

&b

tWM

v,,,

,,,,)

OA

LB

AR

PA

TE

DC

Oft

WU

NIC

*fl

ON

S)_

Ut.

PA

R-O

20I

[

IBE

RIA

FIN

AN

CIA

LSE

RV

ICE

S.LL

C

200W

estC

ongr

ess

Stre

et1s

tFl

oor

LaFa

yette

,LA

7050

800)

813-

9566

FI

.o

—’

I

Tra

nsa

ctio

ns

inD

ate

Seq

uen

cePr

oces

s!Tr

ade!

Settl

emen

tTr

ausa

clio

n

Sta

tem

ent

Per

iod:

0510

1fl0

15-

05/3

0120

16

Dat

eD

ale

Activ

ityTy

pe

06/0

9/16

BOND

INTE

REST

RECE

IVED

0606

2A3P

2

06/0

9/16

SECU

RITY

REDE

EMED

0606

2A3P

2

06/2

0/16

06/1

7/16

PURC

HASE

D91

2828

1124

Des

crip

tion

1270

00BA

NKBA

RODA

NEW

YORK

BRH

GTE

DEP

ACT/

365

0.50

0%06

/09/

16B/

EDT

D06

/09/

15RD

06/0

8PD

06/0

9/16

BANK

BARO

DANE

WYO

RKBR

HGT

EDE

PAC

T/36

50.

500%

06/0

9/16

WE

0100

6/09

/15

ACCO

UNT

REDE

MPT

ION

UNIT

EDST

ATES

TREA

SNT

S1.

000%

06/3

0/19

WE

DID

06/3

0/12

SOLI

CITE

DOR

DER

YLD

.607

TOM

AT

06/2

0/16

06/1

7/16

PURC

HASE

D91

2828

XH

8UN

ITED

STAT

ESTR

EAS

NTS

1.62

5%06

/30/

20W

ED

ID06

/30/

15SO

LICI

TED

ORDE

RYL

D.8

35TO

MAT

61,0

00.0

0010

3.11

19-4

68.3

9-6

3,37

2.35

USD

Go

pap

erle

ssA

SK

flo

urto

ILIV

IRY

Secu

ritie

sof

fere

dth

roug

hS

iofr

eta

ge

Ess

exN

atio

nalS

ecur

ities

, LLC

Account S

tate

ment

Price

Accr

ued

Inle

rest

Amot

mt

CurT

elKy

-121

,000

.000

63,0

00.0

0010

1115

0

636.

14US

D

121,

0000

0US

D

-297

.69

-64,

039,

94US

D

06/3

0/16

BOND

INTE

REST

RECE

IVED

6300

0UN

ITED

STAT

ESTR

EAS

NTS

1.00

0%06

/30/

1931

5.00

USD

9128

28TC

4W

ED

ID06

/30/

12RD

06/2

9PD

06/3

0/16

06/3

0/16

BOND

INTE

REST

RECE

IVED

6100

0UN

ITED

STAl

ESTR

EAS

NTS

1.62

5%06

/30/

20.

495.

63US

D91

2828

XH

8B/

EDT

D06

/30/

15RD

06/2

9PD

06/3

0/16

Tota

lV

alue

ofTr

ansa

ctio

ns-$

766.

08$1

,035

.08

USD

The

pric

ean

dqu

antit

ydi

spla

yed

may

have

been

roun

ded.

Po

rtfo

lio

Ho

ldin

gs

Ope

ning

Clos

ing

Accr

ued

30-D

ayD

escr

iptio

nQ

uant

ityBa

lanc

eBa

lanc

eIn

com

eYi

eld

Cas

h,M

oney

Fund

s,an

dB

ank

Dep

osits

1.00

%of

Port

foli

oC

ash

Bal

ance

0.00

810.

63

Mon

eyM

arke

tFE

DERA

TED

CAPI

TAL

RESE

RVES

786.

420

561.

9778

6.42

0.00

0.00

%To

tal

Mon

eyM

arke

t$5

61.9

1$7

86.4

2$0

.00

Tota

lC

ash,

Mon

eyFu

nds,

and

Ban

kD

epos

its$5

61.9

7$1

,597

.05

$0.0

0

Page

3of

1

Acc

ount

Num

ber:

H5E

-077

160

A0

09

3631C

SF

30017

4.

RM

dctIjen

IE

nry

Yea

,5,n

ce

2007

anaa,,R

.,,v.,.

DA

LR

AR

RA

TE

DC

0.O

AU

NIC

AT

ION

SK

..i.

..a

US

.‘‘.

WA

EC

LL

LE

NC

E

PA

R-0

2-R

OIE

LABO

OFPH

ARM

ACY

OPEB

RES

ACT

Port

foli

oH

old

ings

(co

nti

nu

ed)

Des

aipl

imi

U.S

.Tre

asur

ySe

curit

ies

UNIT

EDST

ATES

ThEM

NTS

1.00

0%06

/30/

19DI

EDT

D06

/30/

121S

TCP

NDT

E12

)31/

12CP

NPM

TSE

MI

ANNU

ALON

JUN

30AN

DDE

C31

Moo

dyRa

ting

MA

Secu

rity

Iden

tiFier

: 912

8?BT

C4UN

ITED

STAT

ESTR

EAS

NTS

1.62

5%06

/30/

20BI

ED

ID06

/30/

151S

TCP

ND

IE12

/31/

15CP

NPM

TSE

MI

ANNU

ALON

JUN

30AN

DD

EC31

Moo

dyRa

ling

MA

Secu

rity

Iden

tiFier

:912

82BX

HBUN

ITED

STAT

ESTR

EAS

NTS

1.31

5%08

/31/

20DI

ED

ID08

/31/

151S

TCP

NDT

E02

/29/

16CP

NPM

TSE

MI

ANNU

ALON

FEB

29AN

DAU

G31

Moo

dyRa

ling

MA

Secu

rity

Iden

lifie

r:91

2828

L32

UNIT

EDST

ATES

TREA

SNT

S12

50%

03/3

1/21

8/E

DID

03/3

1/15

151

CPN

DIE

09/3

0/16

CPN

PMT

SEM

IANN

UAL

ONM

AR31

AND

SEP

30M

oody

Ratin

gM

ASe

curit

yId

entif

ier:

9128

28Q

37

AO

O9

36

flfl

DO

I7A

ccou

ntN

umbe

r:H

5E07

1160

peri

ess

LABD

OFPH

ARM

ACY

OPEB

R[S

ACT

ASK

A•0

4JT

FD

ttIv

Lw

Y4

PsI.d

EII.’

tyea,S

,nce

20

01

DA

LS

AR

RA

TL

OC

OM

MU

NIC

AT

ION

S—

[xcaL

EN

cr

IK

RgL

LC

byfl

1—

WI

—U

S.—

FnS

Fixe

dIn

com

e99

.00%

ofP

ort

foli

o(I

nMat

unfy

Dat

eSe

quen

ce)Q

uant

ityM

arke

t Pric

eM

arke

t Valu

eA

caiiM

Inte

rest

Estim

ated

Estim

ated

fimua

lIn

com

eYi

eld

63,0

00.0

0010

0.84

8063

,534

.24

0.00

630.

OD

0.99

%

61,0

00.0

0010

2.83

6062

,729

.96

D.00

991.

251.

58%

241,

000.

000

101.

8320

245,

415.

121,

098.

583,

3133

51.

35%

?28,

DD

D.0

0010

1.16

4073

6,47

3.92

2,26

2.57

9,10

0.00

1.23

%

Tota

lU.

S.Tr

easu

rySe

curit

ies

1,09

3,00

0.00

0$1

,108

,153

.24

$3,3

61.1

5$1

4,03

5.00

Tota

lFi

xed

Inco

me:

1,09

3,00

0.00

0$1

,108

,153

.24

$3,3

61.1

5$1

4,03

5.00

Aca

ved

Estim

ated

Mar

ket V

alue

Inte

rest

Atm

ual I

ncom

e

Tota

lPo

rtfo

lioH

oldi

ngs

$1,1

09,1

50.2

9$3

,361

.15

$14,

035.

00

Port

foli

oH

old

ings

Dis

closu

res

Pric

ing

This

sect

ion

incl

udes

the

net

mar

ket

vatu

eoF

the

secu

ritie

sin

your

acco

unto

na

settl

emen

tda

teba

sis,

incl

udin

gsh

ort p

ositi

ons,

atth

ecl

ose

ofth

est

atem

ent

perio

d.Th

em

arke

tpr

ices

,un

tess

othe

rwis

eno

ted,

have

been

obta

ined

from

inde

pend

ent

vend

orse

rvic

es,

whi

chw

ebe

tieve

tobe

relia

ble.

Mar

ket p

rices

dono

tcon

stitu

tea

bid

oran

oile

r,an

dm

aydi

ffer f

rom

the

actu

alsa

lepr

ice.

Secu

ritie

sFo

rwhi

cha

pric

eis

not

avai

labl

ear

em

arke

d‘N

/A’

and

are

omitt

edfro

mth

eTo

tal.

THE

AS

OF

PRIC

EDA

TEON

LYA

PPEA

RS

WH

ENTH

EPR

ICE

DA

TED

OES

NO

TEQ

UA

LTH

EST

ATE

MEN

TD

ATE

.E

stim

ated

Ann

ual

Figu

res

The

estim

ated

annu

alin

com

e(E

AI)

and

estim

ated

annu

alyi

eld

(EAY

)fig

ures

are

estim

ates

and

fori

nfor

mat

iona

l pur

pose

son

ly.

The

sefig

ures

are

notc

onsi

dere

dto

bed

Fore

cast

orgu

aran

tee

ofFu

ture

resu

lts.

Page

4of

7

PA

RO

2R

OL

L

. fl3I

j]/’

2OO

Wet

Con

qre,

1st[

Iou

Lafa

yette

. IA

7050

FIN

AN

CIA

LS

ER

VIC

ES

,L

LC

(8

I6

23

.9

66

6

___________________________________________

Stat

emen

t Per

iod:

05/0

1/20

16-

06/3

0/20

16

Po

rtfo

lio

Hold

ing

sD

iscl

osu

res

(con

tinue

d)E

stim

ated

Ann

ual

Figu

res

(con

tinue

d)T

hese

figur

esar

eco

mpu

ted

usin

gin

form

atio

nfro

mpr

ovid

ers

belie

ved

tobe

relia

ble;

how

ever

,no

assu

ranc

eca

nbe

mad

eas

toth

eac

cura

cy.

Sinc

ein

tere

stan

ddi

vide

ndra

tes

are

subj

ectt

och

ange

atan

ytim

e,an

dm

aybe

affe

cted

bycu

rren

tan

dfu

ture

econ

omic

,po

litic

al,

and

busi

ness

cond

ition

s,th

eysh

ould

not

bere

lied

onfo

rm

akin

gin

vest

men

t.tra

ding

, or t

axde

cisi

ons.

The

sefig

ures

assu

me

that

the

posi

tion

quan

lilie

s,in

teie

stan

ddi

vide

ndra

tes,

and

pric

esre

mai

nco

nsta

nt.

Aca

pita

lga

inor

retu

rnol

prin

cipa

lm

aybe

incl

uded

inth

efig

ures

for

certa

inse

curit

ies,

ther

eby

over

stat

ing

them

.Re

Fer

tow

ww

.per

shin

g.co

mib

usin

ess.

.con

tinui

ty.h

tml

brsp

ecifi

cde

tails

asto

form

ulas

used

toca

lcul

ate

the

figur

es. A

ccru

edin

tere

stre

pres

eots

inte

rest

earn

edbu

tnot

yet

rece

ived

.R

einv

estm

ent

The

dolla

ram

ount

ofM

utua

lFu

nddi

strib

utio

ns,

Mon

eyM

arke

t Fun

ddi

vide

ndin

com

e,B

ank

Dep

osit

inte

rest

inco

me,

ordi

vide

nds

for

othe

rse

curit

ies

show

non

your

stat

emen

tm

ayha

vebe

enre

inve

sted

.Y

ouwi

llno

tre

ceiv

eco

nfirm

atio

noF

tties

ere

inve

stm

ents

.U

pon

writ

ten

requ

est t

oyo

urfin

anci

alin

stitu

tion,

info

rmat

ion

perta

inin

gto

thes

etr

ansa

clio

ns,

incl

udin

gth

etim

eof

exec

utio

nan

dth

ena

me

oFth

epe

rson

from

who

myo

urse

curit

yw

aspu

rcha

sed,

may

beob

tain

ed.

Indi

vide

ndre

inve

stm

ent t

rans

actio

ns,

Pers

hing

acts

asyo

urag

enta

ndre

ceiv

espa

ymen

tfo

ror

der

flow

.O

ptio

nD

iscl

osur

eIn

form

atio

nw

ithre

spec

tto

com

mis

sion

san

dot

her

char

ges

incu

rred

inco

nnec

tion

with

the

exec

utio

noF

optio

ntr

ansa

ctio

nsha

sbe

enin

clud

edin

conf

irmat

ions

prev

ious

lyFu

rnish

edto

you.

Asu

mm

ary

oFth

isin

form

atio

nis

avai

labl

eto

you

prom

ptly

upon

your

writ

teo

requ

est d

irect

edto

your

intro

duci

ngfir

m.

Inor

der

toas

sist

your

intro

duci

ngfir

min

mai

ntai

oing

curr

ent

back

grou

ndan

dfin

anci

alin

form

atio

nco

ncer

ning

your

optio

nac

coun

ts,

plea

sepr

ompt

lyad

vise

them

inw

ritin

goF

any

mat

eria

lch

ange

inyo

urin

vest

men

tob

ject

ives

orfin

anci

alsi

tuat

ion.

Expi

ring

optio

nsw

hich

are

valu

able

are

exer

cise

dau

tom

atic

ally

purs

uant

toth

eex

erci

seby

exce

ptio

npr

oced

ure

ofth

eO

ptio

nsC

lear

ing

Cor

pora

tion.

Add

ition

alin

form

atio

nre

gard

ing

this

proc

edur

eis

avai

labl

eup

onw

ritte

nre

ques

t to

your

intro

duci

ngfir

m.

Fore

ign

Cur

renc

yT

rans

actio

nsPe

rshi

ngm

ayex

ecut

efo

reig

ncu

rren

cytr

ansa

ctio

nsas

prin

cipa

lFo

ryou

rac

coun

t.Pe

rshi

ngm

ayau

tom

atic

ally

conv

ert

Fore

ign

curr

ency

toor

From

U.S

.do

llars

ford

ivid

ends

and

sim

ilar

corp

orat

eac

tion

tran

sact

ions

unle

ssyo

uin

stru

ctyo

urfin

anci

alor

gani

zatio

not

herw

ise.

Pers

hing

’scu

rren

cyco

nver

sion

rate

will

not e

xcee

dth

ehi

ghes

t int

erba

nkco

nver

sion

rate

iden

tifie

dfro

mcu

stom

ary

bank

ing

sour

ces

onth

eco

nver

sion

date

orth

epr

ior

busi

ness

day,

incr

ease

dby

upto

1%,

unle

ssa

parti

cula

rra

teis

requ

ired

byap

plic

able

law

.Y

our

rman

ciat

orga

niza

tion

may

also

incr

ease

the

curr

ency

conv

ersi

onra

te.

This

conv

ersi

onra

tem

aydi

lferf

rom

rate

sin

effe

cton

Ihe

date

you

exec

uted

atra

nsac

tion,

incu

rred

ach

arge

,or

rece

ived

acr

edit.

Tra

nsac

tions

conv

erte

dby

agen

ts(s

uch

asde

posi

torie

s)wi

llbe

bille

dat

the

rate

ssu

chag

ents

use.

Prox

yV

ote

Secu

ritie

sno

tfu

llypa

idfo

rin

your

mar

gin

acco

unt

may

bele

ntby

Pers

hing

toits

elf

orot

hers

inac

cord

ance

with

the

term

sou

tline

din

the

Mar

gin

Agr

eem

ent.

The

right

tovo

teyo

ursh

ares

held

onm

argi

nm

aybe

redu

ced

byth

eam

ount

ofsh

ares

onlo

an. T

hePr

oxy

Vot

ing

Inst

ruct

ion

Form

sent

toyo

um

ayre

flect

asm

alle

rnu

mbe

rof

shar

esen

title

dto

vote

than

the

num

ber

ofsh

ares

inyo

urm

argi

nac

coun

t.

Mon

eyM

ark

etF

und

Det

ail

Dat

eAc

tivity

Type

Des

crip

tion

Amou

ntBa

lanc

e

Swee

pM

Dne

yM

arke

t Fun

d

FEDE

RATE

DCA

PITA

LRE

SERV

ESCu

rrent

Yield

:0.

00%

Activ

ityEn

ding

:06

/30/

1604

/30/

16O

peni

ngBa

lanc

e56

1.91

561.

9706

/10/

16D

epos

itM

ONEY

FUND

PURC

HASE

121,

636.

1412

8,19

8.11

06/2

0/16

With

draw

alM

ONEY

FUND

REDE

MPT

ION

-127

,412

.29

186.

4?06

1301

16C

losi

ngB

alan

ce$7

86.4

2To

tal

All

Mon

eyM

arke

t Fun

ds$7

86.4

2

Page

5oF

7

Acc

ount

Num

ber;

HSE

-011

160

HaI.

dtn

.yY

.,S

I,,c

e2W

)G

opap

erle

ssD

AL

BA

RR

AT

rOcO

AM

UN

ICA

TIO

NS

fl..t—

aU

C.-

—.,fl

‘n

sa

.V

Ab

OU

TE

.OIL

IVT

RV

EX

CE

LL

EN

CE

Secu

ritie

sof

fere

dth

roug

hB

rokera

ge

Ess

exN

atio

nal S

ecur

ities

, LLC

I-—

—I

AccountS

tate

men

t

PA

R.0

2-R

OtL

LABD

OFPH

ARM

ACY

OPEB

RES

ACT

Mes

sages

Alth

ough

am

oney

mar

ket m

utua

lfu

ndse

eks

topr

eser

veth

eva

lue

ofyo

urin

vest

men

tat$

1pe

rsh

are,

itis

poss

ible

tolo

sem

oney

byin

vest

ing

ina

mon

eym

arke

tmut

ual

fund

.Sha

res

ofa

mon

eym

arke

tmut

ual

fund

orth

eba

lanc

eof

aba

nkde

posi

tpr

oduc

the

ldin

your

brok

erag

eac

coun

tmay

beliq

uida

ted

upon

requ

est

with

the

proc

eeds

cred

ited

toyo

urbr

oker

age

acco

unt.

Plea

sese

eth

em

oney

mar

ketm

utua

lfu

nd’s

pros

pect

usor

the

bank

depo

sit

prod

uct’

sdi

sclo

sure

docu

men

tor

cont

acty

our

advi

sor

for

addi

tiona

lin

form

atio

n.Pu

rsua

ntto

SEC

Rul

elO

b.10

(b)(

1)co

nfir

mat

ions

are

nots

ent

for

purc

hase

sin

tom

oney

mar

ket

mut

ual

fund

spr

oces

sed

onth

esw

eep

plat

form

.

Import

ant

Info

rmat

ion

and

Dis

closu

res

The

Rol

eof

Pers

hing

Pers

hing

carr

ies

your

acco

unta

scl

earin

gbr

oker

purs

uant

toa

clea

ring

agre

emen

t with

your

finan

cial

inst

itutio

n.Pe

rshi

ngm

ayac

cept

from

your

finan

cial

inst

itutio

nw

ithou

tin

quiry

orin

vest

igat

ion

(0or

ders

fort

hepu

rcha

sean

dsa

leof

secu

ritie

san

dot

her

prop

erty

and

(ii)an

yot

her

inst

ruct

ions

conc

erni

ngyo

urac

coun

t.Pe

rshi

ngis

not

resp

onsi

ble

orlia

ble

for

any

acts

orom

issi

ons

ofyo

urfin

anci

alin

stitu

tion

orits

empl

oyee

san

dit

does

not s

uper

vise

them

.Pe

rshi

ngpr

ovid

esno

inve

stm

enta

dvic

eno

rdo

esii

asse

ssth

esu

itabi

lity

ofan

ytra

nsac

tion

oror

der.

Pers

hing

acts

asth

eag

ent

ofyo

urfin

anci

alin

stitu

tion

and

you

agre

eth

atyo

uwi

llno

tho

ldPe

rshi

ngor

any

pers

onco

ntro

lling

orun

der

com

mon

cont

rolw

ithit

liabl

efo

ran

yin

vest

men

tlo

sses

incu

red

byyo

u.•

Pers

hing

perf

orm

sse

vera

lke

yfu

nctio

nsat

the

dire

ctio

nof

your

Fina

ncia

lin

stitu

tion.

Itac

tsas

cust

odia

nFo

rfun

dsan

dse

curit

ies

you

may

depo

sitw

ithit

dire

ctly

orth

roug

hyo

urfin

anci

alin

stitu

tion

orth

atit

rece

ives

asth

ere

sult

ofse

curit

ies

tran

sact

ions

itpr

oces

ses.

•Y

our

finan

cial

inst

itutio

nis

resp

onsi

ble

for

adhe

renc

eto

the

secu

ritie

sla

ws,

regu

latio

nsan

dru

les

whi

chap

ply

toit

rega

rdin

gits

own

oper

atio

nsan

dth

esu

perv

isio

nof

your

acco

unt,

itssa

les

repr

esen

tativ

esan

dot

her

pers

onne

l.Y

our

finan

cial

inst

itutio

nis

also

resp

onsi

ble

fora

ppro

ving

the

open

ing

ofac

coun

tsan

dob

tain

ing

acco

unt

docu

men

ts;

the

acce

ptan

cean

d,in

certa

inin

stan

ces,

exec

utio

nof

secu

ritie

sor

ders

;th

eas

sess

men

tof

the

suita

bilit

yof

thos

etr

ansa

ctio

ns,w

here

appl

icab

le:

the

rend

erin

gof

inve

stm

ent a

dvic

e,if

any,

toyo

uan

din

gene

ral,

fort

heon

goin

gre

latio

nshi

pth

atit

has

with

you.

•In

quiri

esco

ncer

ning

the

posi

tions

and

bala

nces

inyo

urac

coun

tm

aybe

dire

cted

toth

ePe

rshi

ngC

usto

mer

Serv

ice

Dep

artm

ent a

t(20

1)41

3-33

33. A

llot

her

inqu

iries

rega

rdin

gyo

urac

coun

t or

activ

itysh

ould

bedi

rect

edto

your

finan

cial

inst

itutio

n.Y

our

finan

cial

orga

niza

tion’

sco

ntac

tin

form

atio

nca

nbe

foun

don

the

first

page

ofth

isst

atem

ent.

•Fo

ra

desc

riptio

nof

othe

rFu

nctio

nspe

rfor

med

byPe

rshi

ngpl

ease

cons

ultt

heD

iscl

osur

eSt

atem

ent

prov

ided

toyo

uup

onth

eop

enin

gof

your

acco

unt.

This

notic

eis

not

mea

ntas

ade

finiti

veen

umer

atio

nof

ever

ypo

ssib

leci

rcum

stan

ce,

but

asa

gene

ral

disc

losu

re.

Ifyo

uha

vean

yqu

estio

nsre

gard

ing

this

notic

eor

ifyo

uw

ould

like

addi

tiona

lcop

ies

ofth

eD

iscl

osur

eSt

atem

ent,

plea

seco

ntac

t you

rtin

anci

atin

stitu

tion.

•Pe

rshi

ngis

am

embe

rof

the

Secu

ritie

sIn

vest

orPr

otec

tion

Cor

pora

tion

(SIP

C9.

Plea

seno

teth

atSI

PCdo

esno

tpr

otec

t aga

inst

loss

due

tom

arke

tflu

ctua

tion.

Inad

ditio

nto

SIPC

prot

ectio

n,Pe

rshi

ngpr

ovid

esco

vera

gein

exce

ssof

SIPC

limits

.Fo

rm

ore

deta

iled

info

rmat

ion

plea

sevi

sit:M

wI.p

erst

ling.

conV

abou

tlstre

nglh

-and

-sta

bilit

y.•

This

stat

emen

t will

bede

emed

conc

lusi

ve.

You

are

advi

sed

tore

port

any

inac

cura

cyor

disc

repa

ncy

(incl

udin

gun

auth

oriz

edtra

ding

)pr

ompt

ly,

but

nola

ter

than

ten

days

afte

rre

ceip

t oft

his

stat

emen

t,to

your

finan

cial

orga

niza

tion

and

Pers

hing

.Pl

ease

bead

vise

dth

atan

yor

alco

mm

unic

atio

nsh

ould

bere

-con

firm

edin

writ

ing

tofu

rther

prot

ect y

our

right

s,in

clud

ing

your

right

sun

der

the

Secu

ritie

sIn

vest

orPr

otec

tion

Act

.•

You

rfin

anci

alor

gani

zatio

n’s

cont

act

info

rmat

ion

can

befo

und

onth

efir

stpa

geof

this

stat

emen

t.Pe

rshi

ng’s

cont

act

info

rmat

ion

isas

follo

ws:

Pers

hing

Li_C

.Le

gal

Dep

artm

ent,

One

Pers

hing

Plaz

a,Je

rsey

City

,N

ewJe

rsey

0739

9;(2

01)

413-

3330

.Er

rors

and

Om

issi

ons

exce

pted

.Im

port

ant

Arb

itrat

ion

Dis

clos

ures

•Al

l par

ties

toth

isag

reem

enta

regi

ving

upth

erig

htto

sue

each

othe

rin

cour

t,in

clud

ing

the

right

toa

trial

byju

ry,e

xcep

tas

prov

ided

byth

eru

les

ofth

ear

bitra

tion

foru

min

wtii

cha

clai

mis

tiled

.•

Arb

itrat

ion

awar

dsar

ege

nera

llyfin

alan

dbi

ndin

g:a

party

’sab

ility

toha

vea

cour

tre

vers

eor

mod

ifyan

arbi

tratio

naw

ard

isve

rylim

ited.

•Th

eab

ility

ofth

epa

rties

toob

tain

docu

men

ts,

witn

ess

stat

emen

tsan

dot

her

disc

over

yis

gene

rally

mor

elim

ited

inar

bitra

tion

than

inco

urt

proc

eedi

ngs.

•Th

ear

bitra

tors

dono

tha

veto

expl

ain

the

reas

on(s

)fo

rthe

iraw

ard,

unle

ss,

inan

elig

ible

case

,aj

oint

requ

est

Fora

nex

plai

ned

deci

sion

has

been

subm

itted

byall

parti

esto

the

pane

lat

leas

t 20

days

prio

r to

the

first

sche

dule

dhe

arin

gda

te.

•Th

epa

nel

ofar

bitra

tors

wilt

typi

cally

incl

ude

am

inor

ityof

arbi

trato

rsw

how

ere

orar

eaf

filia

ted

with

the

secu

ritie

sin

dust

ry.

•Th

ew

les

ofso

me

arbi

tratio

nfo

rum

sm

ayim

pose

time

limits

for

brin

ging

acl

aim

inar

bitra

tion.

Inso

me

case

s,a

clai

mth

atis

inel

igib

lefo

rarb

itrat

ion

may

bebr

ough

tin

cour

t.•

The

rule

sof

the

arbi

tratio

nFo

rum

inw

hich

the

clai

mis

filed

, and

any

amen

dmen

tsth

eret

o,sh

all

bein

corp

orat

edin

toth

isag

reem

ent.

Impo

rtan

tA

rbitr

atio

nA

gree

men

t

Any

cont

rove

rsy

betw

een

you

and

Pers

hing

LLC

shal

lbe

subm

itted

toar

bitra

tion

befo

reth

eFi

nanc

ial

Indu

stry

Reg

ulat

ory

Aut

horit

y.No

pers

onsh

all

brin

ga

puta

tive

orce

rtifie

dcl

ass

actio

nto

arbi

tratio

n,no

rse

ekto

enfo

rce

any

pred

ispu

tear

bitra

tion

agre

emen

tag

ains

tan

ype

rson

who

has

initi

ated

inco

urta

puta

tive

clas

sac

tion,

who

isa

mem

ber

ofa

puta

tive

clas

sw

hoha

sno

t opt

edou

toft

hecl

ass

with

resp

ect

toan

ycl

aim

sen

com

pass

edby

the

puta

tive

clas

sac

tion

until

;(I)

the

clas

sce

rtific

atio

nis

deni

ed;

(II)

the

clas

sis

dece

rtifie

d;or

(III)

the

clie

ntis

excl

uded

from

the

clas

sby

the

cour

t.Su

chfo

rbea

ranc

eto

enfo

rce

anag

reem

ent

toar

bitra

tesh

all

not

cons

titut

ea

wai

ver

ofan

yrig

hts

unde

rth

isag

reem

ent

exce

ptto

the

exte

ntst

ated

here

in.T

hela

ws

ofth

eSt

ate

ofN

ewY

ork

gove

rn.

Pers

hing

’sco

ntac

tin

form

atio

nis

asfo

llow

s:Pe

rshi

ngLL

C,Le

gal

Dep

artm

ent,

One

Pers

hing

Plaz

a,Je

rsey

City

,New

Jers

ey07

399;

(201

)41

3-33

30.

Page

6of

7

Ao

oS

3ra

lCsr

30

0lv

pA

R.O

’.fl

QA

ccou

ntN

umbe

r:H

SE-0

7716

0G

opap

erle

ssE

Of2

oO

7

L.ABD

OFPH

ARM

ACY

OPEB

RES

ACT

ASK

flO

UT

ED

LI

WR

Y4,)

OA

LB

AR

RA

TrD

CO

MM

UN

ICA

TIO

NS

PR

J-N

Unn

-’

Ew

e-a

nsa

swC

TER

MS

AN

DC

ON

DIT

ION

S

TRA

NSA

CTI

ON

S

ALL

OR

DE

RS

AN

DT

RA

NSA

CT

ION

SSH

AL

LB

ESO

LE

LY

FOR

YO

UR

AC

CO

UN

TA

ND

RIS

KS

HA

HB

ES

UB

JEC

TTO

TH

EC

ON

STIT

UT

ION

.R

UL

ES,

RE

GU

LA

TIO

NS,

CU

ST

OM

SU

SA

GE

S.

RU

LIN

GS

AN

DIN

TE

RP

RE

TA

TIO

NS

OF

TH

EE

XC

HA

NG

EO

RM

AR

KE

TA

ND

TU

EC

LE

AR

ING

FAC

ILIT

Y,

IFA

NY

WH

ER

ET

IlE

TR

AN

SAC

TIO

NS

AR

EE

XE

CU

TE

DA

NO

IOR

SE

TtL

ED

.O

RIF

APP

LIC

AB

LE

,O

FT

HE

FIN

AN

CIA

LIN

DU

STR

YR

EG

UL

AT

OR

YA

UT

HO

RIT

YA

ND

TO

ME

APP

LIC

AB

LE

LA

WS

AN

DR

EG

UL

AT

ION

S.

TIT

LE

TO

SE

CU

RIT

ES

SOL

DT

OY

OU

,WH

ER

EP

ER

SH

ING

HA

SA

CT

ED

AS

PRIN

CIP

AL

.SH

AL

LR

EV

AN

WIT

HP

ER

SH

ING

UN

TIL

THE

EN

TIR

EP

UR

CH

AS

EPR

ICE

ISR

EC

EIV

ED

OR

UN

TIL

TU

ESE

TT

LE

ME

NT

DA

TE

.W

HIC

HE

VE

RIS

LA

TE

R.

YO

UM

AY

HA

VE

RE

CE

IVE

DC

ON

FIR

MA

TIO

NS

FOR

TR

AN

SAC

TIO

NS

WH

ICH

CO

NO

TA

PPE

AR

ON

YO

UR

STA

TE

ME

NT

FS

O.

TH

ET

RA

NSA

CT

ION

SV

/Ia

AP

PE

AR

OR

YO

UR

NE

XT

PER

IOD

ICST

AT

EM

EN

TSU

CH

TR

AN

SAC

TIO

NS

MU

STB

EC

ON

SIR

ER

EO

BY

YO

UW

HE

NC

OM

PUT

ING

TH

EV

AL

UE

Cf

YO

UR

AC

CO

UN

TT

HIS

ISE

SPE

CL

AL

LY

TR

UE

IFY

OU

HA

VE

WR

ITtE

NO

PT

ION

SW

HIC

HH

AV

EB

EE

NE

XE

RC

ISE

D.

FR

EE

CR

ED

ITB

AL

AN

CE

S:

AN

YF

RE

EC

RE

DIT

BA

LA

NC

EC

AR

RIE

DFC

RY

OU

RA

CC

OU

NT

RE

PR

ES

EN

TS

FUN

DS

PAY

AO

LE

UPO

ND

EM

AN

DW

HIC

HA

LT

HO

UG

HP

RO

PE

RL

YA

CC

OU

NT

ED

FO

RO

NP

ER

SH

ING

’SR

OO

KS

OF

RE

CO

RD

.A

RE

ND

TS

EG

RE

GA

TE

DA

ND

MA

YB

EU

SED

INTH

EC

ON

DU

CT

OF

ITS

BU

SIN

ES

S.

DE

BIT

BA

I.A

NC

CS

:IN

TE

RE

STC

HA

RG

ED

ON

DE

BT

IB

AL

AN

CE

SIN

YO

UR

AC

CO

UN

TA

PP

EA

RS

ON

THE

STA

TE

ME

NT

11€

RA

TE

CF

INT

ER

ES

TA

ND

PER

IOD

CO

VE

RE

DA

RE

IND

ICA

TE

D.

TH

ER

AT

EM

AY

CH

AN

GE

FRO

MTI

ME

TOTI

ME

DU

ET

OFL

UC

TU

AT

iON

SIN

MO

NE

YR

AT

ES

OR

OT

HE

RR

EA

SO

NS

.IN

TE

RE

STIS

CO

MPU

TE

DA

SD

ES

CR

IBE

DIN

ItA

TE

RL

AL

PRE

VIO

USL

YFU

RN

ISH

ED

TO

YO

U.

PL

EA

SE

CO

NT

AC

TY

OU

RFI

NA

NC

IAL

INST

ITU

TIO

NIF

YO

UD

ESI

RE

AD

OIT

ION

AL

CO

PIE

S.

MA

RG

ININ

FO

RM

AT

1Oft

FY

OU

MA

INTA

INA

MA

RG

INA

CC

OU

NT

,T

HIS

ISA

CO

MB

INE

DST

AT

EM

EN

TO

FY

OU

RG

EN

ER

AL

AC

CO

UN

TA

NO

ASP

EC

IAL

ME

MO

RA

ND

UM

AC

CO

UN

TM

AIN

TA

INE

DFO

RY

OU

LIN

DEN

RE

GU

LA

TIO

NT

OF

TH

EB

OA

RD

OF

GO

VE

RN

OR

SO

FT

HE

FED

ER

AL

RE

SE

RV

ESY

STE

M.

TH

EPE

RM

AN

EN

TR

EC

OR

DO

FT

HE

SEPA

RA

TE

AC

CO

UN

TA

SR

EQ

UIR

ED

MY

RE

GU

LA

TIO

NT

ISA

VA

ILA

BL

EFO

RY

OU

RIN

SPE

CT

ION

UPO

NR

EQ

UE

ST

.

TMC

INF

OR

MA

TiO

N

AFT

ER

YE

AR

EN

D,

PE

RS

HIN

GIS

RE

QU

IRE

DTO

PRO

VID

ETA

lCIN

FOR

MA

TIO

NT

OT

HE

INT

ER

NA

LR

EV

EN

UE

SER

VIC

EA

ND

DT

HE

RG

OV

ER

NM

EN

TA

LA

UT

HO

RIT

IES.

AT

TH

AT

TIM

EP

ER

SH

ING

WIL

LPR

DV

IOE

TH

AT

INFD

RM

AT

ION

ON

TH

EA

NN

UA

LTA

XIN

FOR

MA

TIO

NST

AT

EM

EN

TT

OY

OU

.U

SET

HA

TST

AT

EM

EN

TT

OP

RE

PA

RE

YO

UR

TAX

FIL

ING

S.TH

ETA

XS

TA

TE

ME

NT

AL

SO

INC

LU

DE

SO

TH

ER

USE

FUL

INFO

RM

AT

ION

TO

AS

SIS

TIN

AC

CU

MU

LA

TIN

GT

HE

DA

TA

TO

PR

EP

AR

EY

OU

RTA

XR

ET

UR

NS

•D

IVID

EN

DS,

INT

ER

ES

TA

ND

OT

HE

RD

IST

RIB

UT

ION

SS

HO

WN

ON

TH

ISS

TA

TE

ME

NT

WE

RE

CL

ASS

IFIE

DA

ST

AX

AB

LE

OR

NO

NT

AX

AO

LE

BA

SED

ON

CE

RT

AIN

INFO

RM

AT

ION

KN

OW

NA

SO

FT

HE

DIS

TR

IBU

TIO

ND

AT

E.

TH

ISC

LA

SSIF

ICA

TIO

NIS

SU

BJE

CT

TO

CH

AN

GE

AN

DIS

SOL

EL

YIN

TE

ND

ED

FOR

USE

AS

GE

NE

RA

LIN

FOR

MA

TIO

N

•P

ER

SH

ING

DO

ES

NO

TPR

OV

IDE

TAX

,IN

VE

STM

EN

TO

RL

EG

AL

AD

VIS

OR

YS

ER

VIC

ES

AN

DN

OO

NE

ASS

OC

LA

TE

DW

ITH

PE

RS

HIN

GIS

AU

TH

OR

IZE

DT

OR

EN

DE

RSU

CH

AD

VIC

E.

DO

NO

TR

EL

YU

PON

AN

YSU

CH

AD

VIC

E.

IFO

WE

N.

INV

EST

OR

SA

RE

EN

CO

UR

AG

ED

TO

CO

NS

UL

TT

HE

IRTA

XA

DV

ISO

RS

TO

DE

TE

RM

INE

THE

AP

PR

OP

RIA

TE

TAX

TR

EA

TN

EN

TO

FT

HE

IRB

US

INE

SS

.

GE

NE

RA

LIN

FO

RM

AT

ION

•W

HE

NE

VE

RY

OU

AR

EIN

DE

BT

ED

TO

PE

RS

HIN

GL

LC

rPE

RS

HIN

G-I

FO

RA

HY

AM

OU

NT

ALL

SE

CU

Rm

ES

HE

LD

BY

ITFO

RY

OU

INA

NY

AC

CO

UN

TIN

WH

ICH

YO

UH

AV

EA

NY

INT

ER

ES

TSH

AL

LS

EC

UR

EA

LLY

OU

RL

IAB

ILIT

IES

TO

PE

RS

HIN

G,

AN

DP

ER

SH

ING

MA

YN

ITS

DIS

CR

ET

ION

AT

AN

YTI

ME,

WIT

HO

UT

TE

ND

ER

.D

EM

AN

DO

RN

OT

ICE

TO

YO

U,

CL

OSE

OR

RE

DU

CE

AN

YO

RA

LLO

FY

OU

RA

CC

OU

NT

SB

YPU

BL

ICO

RPR

IVA

TE

SAL

EO

RP

UR

CH

AS

EO

RB

OT

HO

FA

LLO

RA

NY

SE

CU

RIT

IES

CA

RR

IED

INSU

CH

AC

CO

UN

TS;

AN

YB

AL

AN

CE

RE

MA

ININ

GD

UE

PE

RS

HIN

GTO

BE

PRO

MPT

LY

PAID

BY

YO

U.

•W

HE

NE

VE

RY

OU

AR

EIN

DE

BT

ED

TO

PE

RS

HIN

GFO

RA

NY

AM

OU

NT

,A

LLS

EC

UR

ITIE

SC

AR

RIE

DFO

RY

OU

RA

CC

OU

NT

AR

EO

RM

AY

BE

,WIT

HO

UT

FU

RT

HE

RN

OT

ICE

TO

YO

U,

LO

AN

ED

OR

PL

ED

GE

DB

YP

ER

SH

ING

,E

ITH

ER

SEPA

RA

TE

LY

OR

UN

DE

RC

IRC

UM

ST

AN

CE

SW

HIC

HW

LL

PER

MIT

TH

EC

OM

MIN

GL

ING

TH

ER

EO

F.

WIT

HO

TH

ER

SE

CU

RIT

IES

FOR

AN

YA

MO

UN

TL

ES

ST

HA

N,

EQ

UA

LTO

OR

GR

EA

TE

RT

HA

NY

CU

RL

IAB

ILIT

IES

TO

PE

RS

HIN

G,

Bil

lN

OT

UN

OE

RC

IRC

UM

STA

NC

ES

FOR

AN

AM

OU

NT

PRO

HIB

ITE

DB

YLA

W

•P

ER

SH

ING

MA

YT

RA

DE

FOR

ITS

OW

NA

CC

OU

NT

AS

AM

AR

KE

TM

AK

ER

,SP

EC

IAL

IST

,O

DD

LO

TD

EA

LE

R,

BL

OC

KP

OS

ITIO

NE

R.

AR

BIT

RA

GE

UR

OR

INV

EST

OR

.C

ON

SE

QU

EN

TL

Y. A

TT

HE

TIM

EO

FA

NY

TR

AN

SAC

TIO

NY

OU

MA

YM

AK

E,

PE

RS

HIN

GM

AY

HA

VE

APO

SIT

ION

INSU

CH

SE

CU

RIT

IES

,W

HIC

HPO

SIT

ION

MA

YB

EPA

RT

IAL

LY

OR

CO

MPL

ET

EL

YH

EO

OE

O.

•IF

AV

ER

AG

EP

RIC

ET

RA

NSA

CT

iON

ISIN

DIC

AT

ED

ON

THE

FR

ON

TO

FT

HIS

ST

AT

EM

EN

TY

OU

RFI

NA

NC

IAL

INST

ITU

TIO

NO

RP

ER

SH

ING

MA

YN

AV

EA

CT

ED

AS

PRIN

CIP

AL

,A

GE

NT

OR

BO

TH

.D

ET

AIL

SA

VA

ILA

BL

EU

PON

RE

QU

ES

T

•A

FIN

AN

CIA

LST

AT

EM

EN

TO

FP

ER

SH

ING

ISA

VA

ILA

BL

EF

OR

YO

UR

PE

RS

ON

AL

INSP

EC

TIO

NA

TP

ER

SH

ING

’SO

FF

ICE

S.

AC

OPY

Of

TW

ILL

BE

MA

ILED

UPO

NY

OU

RW

RIT

TE

NR

EO

UE

ST

OR

YO

UC

AN

VIE

WIT

ON

LIN

EA

TW

VN

/P

ER

SH

ING

CC

M.

FOR

BU

SIN

ES

SC

ON

TIN

UIT

YA

ND

AD

DIT

ION

AL

DIS

CL

OS

UR

ES

VJV

NJ

PER

SHIN

GC

DK

VB

ISC

LO

S’JR

ES

TH

ISST

AT

EM

EN

TSH

OU

LD

BE

RE

TA

INE

DFO

RY

OU

RR

EC

OR

OS

.

PAY

MEN

TF

OR

OR

DE

RFE

OW

AN

DO

RD

ER

RO

UTI

NG

PO

liC

IES

DIS

CL

OS

UR

ES

IRE

GU

LA

T1O

NM

IS—

RU

LE

607(A

)(1H

2)J

PE

RS

HIN

GS

EN

DS

CE

RT

AIN

EQ

UF

TY

OR

DE

RS

TO

EX

CH

AN

GE

S,E

LE

CT

RO

NIC

CO

MM

UN

ICA

TIO

NN

EW

JOP

J<S

,O

RB

RO

KE

R.

DE

AL

ER

SD

UR

ING

NO

RM

AL

BU

SIN

ES

SH

OU

RS

AN

DD

UR

ING

EX

TE

ND

ED

TR

AD

ING

SE

SS

ION

S.

CE

RT

AIN

OF

TH

ES

EV

EN

UE

SPR

OV

IDE

PAY

ME

NT

ST

OP

ER

SH

ING

OR

CH

AR

GE

AC

CE

SS

FE

ES

TOP

ER

SH

ING

DE

PE

NO

INO

UPO

NT

HE

CH

AR

AC

TE

RIS

TIC

SO

FTH

EO

RD

ER

AN

DA

NY

SU

BS

EQ

UE

NT

EX

EC

UT

ION

.T

HE

RE

TA

ILS

OF

TH

ESE

PAY

ME

NT

SA

ND

FE

ES

AR

EA

VA

ILA

BL

EU

PON

WR

[TT

EN

RE

QU

ES

TP

ER

SH

ING

RE

CE

IVE

SPA

YM

EN

TS

FOR

DIR

EC

TIN

GL

IST

ED

OP

TIO

NS

OR

DE

RFL

OW

TOC

ER

TA

RO

PTIO

NE

XC

HA

NG

ES.

INA

DD

ITIO

N.

PE

RS

HIN

GR

OU

TE

SC

ER

TA

INE

OU

ITY

AN

DO

PTIO

NO

RD

ER

ST

O[I

SA

EFL

IAT

E.

BN

YM

EL

LO

NC

API

TA

LM

AR

KE

TS,

LL

C,

FOR

EX

EC

UT

ION

AS

PR

INC

IPA

LC

OM

PEN

SAT

ION

ISG

EN

ER

AL

LY

NT

HE

FOR

MO

FA

PE

RO

PTIO

NC

ON

TR

AC

TC

ASH

PAY

ME

NT

BE

ST

EX

EC

UT

IOft

NO

ThV

ITH

STA

NO

NG

TH

EPR

EV

IOU

SPA

RA

GR

APH

RE

GA

RD

ING

PAY

ME

NT

FOR

OR

DE

RFL

OW

,PE

RSH

ING

SE

LE

CT

SC

ER

TA

INM

AR

KE

TC

EN

TE

RS

TO

PRO

VID

EE

XE

CU

TIO

NO

FO

VE

R’T

HE

.CO

UN

TE

RA

ND

EX

CH

AN

GE

’LIS

TE

DS

EC

UR

ITIE

SW

AN

SA

CT

ION

SW

NIC

HA

GR

EE

TOA

CC

EP

TO

RO

ER

ST

RA

NS

MIT

tED

EL

EC

TR

ON

ICA

LL

YU

PT

OA

SP

EC

IFE

DSI

ZE

,A

ND

TO

EX

EC

UT

ET

HE

MA

TD

RB

ET

TE

RT

HA

NT

HE

NA

TIO

NA

LB

ES

TB

R)

OR

OF

FE

R(N

BB

OI.

ON

CE

RT

A’N

LA

RG

ER

OR

DE

RS

,O

RIF

TH

ED

ESI

GN

AT

ED

MA

RK

ET

CE

NT

ER

SD

ON

OT

MA

KE

AM

AR

KE

TIN

TH

ES

UB

JEC

TSE

CU

RIT

Y,

PE

RS

HIN

GD

IRE

CT

LY

CO

NT

AC

TS

MA

RK

ET

CE

NT

ER

ST

OO

BT

AIN

AN

EX

EC

UT

ION

.T

HE

DE

SIG

NA

TE

DM

AR

KE

TC

EN

TE

RS

TO

WH

ICN

OR

DE

RS

AR

EA

UT

GM

AII

CA

LL

YR

OU

IED

AR

ESE

LE

CT

ED

BA

SED

OH

TH

EC

ON

SIS

TE

NT

HIG

HD

UA

LIT

YO

FT

HE

IRE

XE

CL

TU

ON

SIN

ON

EO

RM

OR

EM

AR

KE

TS

EG

ME

NT

SA

ND

TH

EIR

AB

ILIT

YT

OPR

OV

IDE

OP

PO

RIU

NIE

IES

FO

RE

XE

CU

TIO

NS

AT

PR

ICE

SS

UP

ER

IOR

TO

THE

NO

BO

.P

ER

SH

ING

AL

SOR

EG

UL

AR

LY

RE

VIE

WS

RE

PO

RT

SF

OR

CU

AL

ITY

OF

EX

EC

UT

ION

PU

RP

OS

ES

.

WR

AP

AC

CO

UN

TC

uST

OM

ER

SW

HO

EL

EC

TE

DN

aT

OR

EC

EIV

EIM

ME

DIA

TE

CO

Nfl

RM

AP

ON

OF

TR

AN

SA

CT

1ON

S

TH

EFO

LL

OW

ING

TE

RM

SA

NO

CO

ND

ITIO

NS

AR

EA

PPL

ICA

BL

EO

NL

YIF

YO

UR

AC

CO

UN

TIS

AN

INV

EST

ME

NT

AD

VIS

OR

YA

CC

OU

NT

AN

DT

HE

TR

AN

SAC

TIO

NC

ON

FIR

MA

TiO

NS

AR

EN

OT

SE

NT

IDY

OU

(SE

NT

ON

LY

TO

YO

UR

FID

UC

IAR

Y)

PIJ

RE

CA

NT

TO

YO

UR

INST

RU

CT

ION

WR

AP

AC

CO

UN

TT

RA

NS

AC

TiO

NS

•T

HE

FOL

LO

WIN

GIN

FOR

MA

TIO

NV

LL

BE

FUR

NIS

HE

DT

DY

OU

UPO

NR

EQ

UE

ST

TO

YO

UR

FEJA

NC

LAL

INST

Tfl

JTIO

N(‘

INT

RO

DU

CIN

GF

IRIE

)W

ITH

RE

SP

EC

TT

OA

NY

TR

AN

SAC

TIO

NFO

RW

HIC

HA

CO

NFI

RM

AT

ION

WA

SN

OT

SE

NT

TOY

OU

:T

HE

MA

RK

ET

UPO

NW

HIC

HA

NY

TR

AN

SAC

TIO

NW

AS

EX

EC

UT

ED

;T

HE

TIM

EO

FD

AY

TH

AT

AN

YT

RA

NSA

CT

ION

WA

SE

XE

CU

TE

D.

TH

EN

AM

EO

FT

HE

PE

RS

ON

FR

OK

iWH

OM

AN

YSE

CU

RIT

YW

AS

PU

RC

{AS

EO

OR

TO

WH

OM

SUC

HSE

CU

RIT

YW

AS

SOL

D:

THE

SO

UR

CE

AN

DA

MO

UN

TO

FO

TH

ER

CO

MM

ISSI

ON

SR

EC

EIV

ED

INC

ON

NE

CT

ION

WIT

HA

NY

TR

AN

SAC

TIO

N.

AN

DA

CO

PYO

FTH

ET

RA

NSA

CT

ION

CO

NFI

RM

AT

ION

.

•Y

OU

RIN

TR

OD

UC

ING

FIR

ME

FF

EC

TE

DE

AC

HT

RA

NSA

CT

ION

FOR

WH

ICH

AC

ON

FIR

MA

TIO

NW

AS

NO

TS

EN

TT

OY

OU

AS

YO

UR

AG

EN

T

•IN

CO

NN

EC

TIO

NW

ITH

EA

CH

EQ

UIT

YS

EC

UR

HY

AN

BC

ER

TA

INO

TH

ER

SE

CU

RIT

IES

SOL

DY

OU

RIN

TR

OD

UC

ING

FIR

MC

HA

RG

ES

TO

YO

U,

AN

DR

EM

ITS

TO

AR

EG

JLA

TO

RY

OR

GA

NIZ

AT

ION

OR

NA

TIO

NA

LS

EC

UR

ITIE

SE

XC

HA

NG

E.

A’T

RA

NS

.F

EE

.’P

ER

SH

ING

CA

LC

UL

AT

ES

TH

ISFE

EB

ASE

DO

NA

MO

UN

TS

PAID

BY

YO

UR

INT

RO

DU

CIN

GFI

RM

10

TH

EA

PPL

ICA

BL

ER

EG

UL

AT

OR

YO

RG

AN

IZA

TIO

NO

RN

AT

ION

AL

SE

CU

RIT

IES

EX

CH

AN

GE

.T

HIS

.IN

TU

RN

,IS

BA

SED

ON

TH

EV

AL

UE

OF

TH

EA

PPL

ICA

BL

ES

EC

UR

mE

SSO

LD

.T

OD

ET

ER

MIN

ET

HE

EX

AC

TA

MO

UN

TO

FT

HIS

FE

EW

ITH

RE

SP

EC

TT

OA

NY

TR

AN

SAC

TIO

N.

PL

EA

SE

CO

NT

AC

TY

OU

RIN

TR

OD

UC

ING

FIR

M.

•IF

AN

YT

RA

NSA

CT

ION

INV

OL

VE

SA

NA

SS

EtO

AC

KE

DSE

CU

RIT

Y,

INC

LU

DIN

GA

MU

NIC

IPA

LC

OL

LA

TE

RA

LIZ

ED

MO

RT

GA

GE

OB

LIG

AT

ION

.W

HIC

HR

EP

RE

SE

NT

SA

NIN

TE

RE

STIN

OR

ISS

EC

UR

ED

OY

APO

OL

OF

RE

CE

IVA

BL

ES

DR

OT

HE

RFI

NA

NC

IAL

AS

SE

TS

TH

AT

AR

ES

UB

JEC

TC

ON

TIN

UO

USL

YT

OPR

EPA

YM

EN

T,

TH

EN

TH

EA

CT

UA

LY

IEL

DO

FSU

CH

SEC

UR

ITY

MA

YV

AR

YA

CC

OR

DIN

GT

OT

HE

RA

TE

AT

WH

ICH

TH

EU

NO

ER

LY

ING

RE

CE

IVA

BL

ES

OR

OT

HE

RFI

NA

NC

IAL

AS

SE

TS

AR

EP

RE

PA

IDIN

FOR

MA

TIO

NC

ON

CE

RN

ING

TH

EFA

CT

OR

ST

HA

TA

FF

EC

TY

IEL

D(I

NC

LU

DIN

GA

TA

MIN

IMU

ME

STIM

AT

ED

YIE

LD

WE

IGH

TE

DA

VE

RA

GE

LIF

E.

AN

OTH

EP

RE

PA

YM

EN

TA

SS

UM

PT

ION

SO

FU

NO

ER

LY

ING

YIE

LD

)W

ILL

BE

FUR

NIS

HE

DTO

YO

UU

PON

RE

QU

ES

TT

OY

OU

RIN

TR

OD

UC

ING

FIR

M.

WR

AP

AC

CO

UN

TO

RD

ER

FLO

W:

YO

UR

INT

RO

DU

CIN

GFI

RM

DO

ES

NO

TR

EC

EW

EA

NY

PAY

ME

NT

FOR

OR

DE

RFL

OW

FOR

AN

YT

RA

NSA

CT

ION

FOR

WH

ICH

AC

ON

FIR

MA

TIO

NW

AS

NO

TS

EN

TT

OY

OU

.

WR

AP

AC

CO

UN

TC

AL

LF

EA

TU

RE

S:

CA

LLFE

AT

UR

ES

MA

YE

XIS

TFO

RS

EC

UR

ITIE

S.

CA

LLFE

AT

UR

ES

FOR

FIX

ED

INC

OM

ES

EC

UR

ITIE

SM

AY

AF

FE

CT

YIE

LD

CO

MPL

ET

EIN

FOR

MA

TIO

NW

ILL

BE

PRO

VIO

ED

UPO

NR

EQ

UE

ST

WR

AP

AC

CO

UN

TR

AT

iNG

S:

TH

ER

AT

ING

ST

HA

TA

PP

EA

RIN

TH

ED

ESC

RIP

TIO

NO

FSO

ME

FIX

ED

INC

OM

ES

EC

UR

InE

SH

AV

EB

EE

NO

BT

AIN

CO

FRO

MR

AT

ING

SS

ER

VIC

ES

WH

ICH

PE

RS

HIN

GB

EL

IEV

ES

TO

BE

RE

LIA

BL

E.

HO

WE

VE

R.

PE

RS

HIN

GC

AN

NO

TG

UA

RA

NT

EE

TH

EIR

AG

CU

RA

CY

SE

CU

RIT

IES

FOR

WH

ICH

AR

AT

ING

ISN

OT

AV

AIL

AO

LE

AR

EM

AR

KE

O‘U

NR

AT

EB

.

FA

NY

OF

THE

AB

OV

ET

ER

MS

AN

DC

EN

OFI

tON

SAN

EU

NA

OD

EPTA

BLE

TOY

OU

.H

&A

SEN

OTI

FYPE

RSH

ING

INIE

OIA

TT

EY

INW

RIT

ING

BYC

ER

TIF

IED

MA

ITO

ON

EPE

RT

HFI

GPL

AZA

. JE

RSE

YC

ITY

.Ni

B73

99. A

nN

:LE

GA

LD

EPT

Page

7of

7

AB

BII

63T

CS

P300IT

Acc

ount

NU

mbe

r:H

SE-0

7116

0G

opap

erle

ssLA

BDO

FPH

ARM

ACY

OPE

BRE

SAC

TA

SK

flO

UT

L’U

KL

IdK

RY

.4P

sie

dL

‘celI

tnI

,[“try

Y.a

wB

nc.

2007

DA

LB

AR

RA

TIO

CO

MM

Ue4IC

AT

ION

SF

TC

CE

LL

EN

CE

C,.

—,.

(M

m_

•4

sL

ic,•••

——

n,

str

Aci—

v.—

C.,.—

,Isa

—U

t.F

fl,.

Sec

PA

R’O

2’R

OL

L

I IBE

RIA

FIN

AN

CIA

LSE

RV

ICE

S,LL

C

200W

estC

ongr

ess

Stre

et1s

tFlo

orLa

faye

tte,L

A70

501

(BOO

)8)3

-966

6I

I—

t’c—

I

Acc

ount

Num

ber:

H5E

-102

679

Stat

emen

tPe

riod

:05

1011

2016

-06

/30/

2016

LA

BD

OF

PHA

RM

AC

YP

EN

SIO

NR

ES

AC

T33

88B

RE

NT

WO

OD

DR

BA

TO

NR

OU

GE

LA70809-1

700

You

rA

ccou

ntEx

ecut

ive:

JOSE

PHBA

RREC

A,JR

.(5

04)

310-

1346

Ass

etS

um

mar

yCa

sh,

Mon

eyFu

nds,

and

Bank

Dep

osits

Fixe

dIn

com

eA

ccou

ntTo

tal

Port

foli

oat

aG

lanc

eB

egin

ning

Acc

ount

Val

ueD

ivid

ends

,In

tere

stan

dO

lher

Inco

me

-N

et”

““0

Estim

ated

Ann

ualI

ncom

e

This

Perio

d%

Alloc

ation

868,

061%

Ple

ase

revi

ewyo

ural

loca

tion

peri

odic

ally

with

your

Acc

ount

Exe

cutiv

e.

A009

646

0C

SF

]00

17G

opaperl

ess

AS

KA

SO

UT

[-O

KL

IVL

RY

c4)R

ted

Eveell

ent

Ever

yy

ea,

since

2007

DA

LS

AR

RA

TF

OC

OM

MU

NIC

AT

ION

S-

—E

XC

Ell

EN

CE

t—

l_

•N

eh

,.h

S0

LA

S-C

eq,S

eTe,e

rde..ld

.?Y

—fl

_C

.e&

el

Wee

Tee

C.S

.le

NT

Ieee,Y

‘e.f

leu

tin.e,te,

FS

YA

NY

SE

WC

Secu

ritie

sof

fere

dth

roug

hB

rokera

ge

Esse

xN

atio

nalS

ecur

ities

,LLC

Acco

un

tSta

tem

en

t

LIr

.I11

111

III

lIII

t0N

l

End

ing

Acc

ount

Val

ue$9

88,4

90.1

2

This

Perio

d$9

76,0

83.9

335

603

12,0

50,1

6

$12,

6558

6

981,

622.

06$9

88,4

90.1

299

%10

0%

Page

1ci

?

PA

R’0

2-R

OL

E

Cli

ent

Ser

vice

Info

rmat

ion

You

rA

ccou

ntEx

ecut

ive:

X57

Con

tact

Info

rmat

ion

JOSE

PHBA

RREC

A,JR

.T

elep

hone

Num

ber:

(504

)31

0-13

46IB

ERIA

FINA

NCIA

LSE

RVIC

ES29

00RI

DGEL

AKE

DRIV

EM

ETAI

RIE

LA70

002-

4923

You

rA

ccou

ntIn

form

atio

nTa

xLo

tDef

ault

Dis

posi

tion

Met

hod

Def

ault

Met

hod

forM

utua

lFu

nds:

AVER

AGE

COST

(USI

NGFI

RST

INFI

RST

OUT)

Def

ault

Met

hod

forS

tock

sin

aD

ivid

end

Rei

nves

tmen

t Pla

n:FI

RST

INFI

RST

OUT

Def

ault

Met

hod

fora

llO

ther

Secu

ritie

s:FI

RST

INFI

RST

OUT

Bon

dA

mor

tizat

ion

Elec

tions

:A

mor

tize

prem

ium

onta

xabl

ebo

nds

base

don

Con

stan

t Yiel

dM

etho

d:Ye

sA

ccw

alm

arke

tdis

coun

tm

etho

dfo

rall

othe

rbo

ndty

pes:

Con

stan

tYiel

dM

etho

dIn

clud

em

arke

t dis

coun

tin

inco

me

annu

ally

:No

Elec

troni

cD

eliv

ery

E-m

ail

notif

icat

ions

are

deliv

ered

toth

efo

llow

ing

e-m

ail

addr

ess(

es):

You

are

curre

ntly

enro

lled

tore

ceiv

eth

efo

llow

ing

acco

untc

omm

unic

atio

nsvi

ael

ectro

nic

deliv

eiy:

k###

####

###@

phar

mac

y.la

.gov

Stat

emen

tsan

dRe

ports

The

abov

ee-

mai

lad

dres

sis

parti

ally

mas

ked

fory

our

secu

rity.

Plea

selo

gTr

ade

Conf

irmat

ions

into

your

acco

unt t

ore

view

the

full

e-m

ail

addr

ess.

Tax

Doc

umen

tsN

otifi

catio

nsPl

ease

log

into

your

acco

unt

tom

ake

any

chan

ges

toyo

urel

ectro

nic

deliv

ery

pref

eren

ces.

Act

ivit

yS

um

mar

y(A

llam

ount

ssh

own

are

inba

secu

rren

cy)

Cred

itsTh

isPe

riod

Debi

tsTh

isPe

riod

NetT

hisPe

riod

Cred

itsY

ear-t

o-D

ate

Debi

tsY

ear-t

o-D

ate

NetY

ear-t

o-D

ate

Secu

ritie

sSe

curit

ies

Boug

ht0.

00-3

0,12

8.89

-30,

128.

890.

00-9

82,8

54.1

3-9

82,8

5413

Secu

ritie

sSo

ld0.

000.

000.

0065

0,11

5.37

0.00

650,

115.

37Se

curit

ies

Dep

osite

d0.

000.

000.

0061

6,18

0.10

0.00

676,

780.

10

Tota

lSe

curit

ies

$0.0

0-$

30,1

28.8

9-$

30,1

28.8

9$1

,326

,895

.47

-598

2,85

413

$344

,041

.34

Div

iden

dsan

dIn

tere

st$3

56.0

3$0

110

$356

.03

$3,6

06.8

2$0

.00

$3,6

06.8

2

Dis

trib

utio

ns$3

0,00

0.00

$011

0$3

0,00

0.00

$30,

000.

00$0

.00

$30,

000.

00

Cas

h Dep

osits

0.00

0.00

0.00

300,

000.

000.

0030

0000

.00

Tota

lC

ash

$0.0

0$0

.00

$0.0

0$3

00,0

00.0

0$0

.00

$300

,000

.00

Tota

ls$3

0,35

6.03

-$30

,128

.89

$227

.14

$1,6

60,5

02.2

9-$

982,

854.

13$6

77,6

48.1

6

Page

2of

7

R0095168C

5F

30017

Acc

ount

Num

ber:

HSE

-102

679

Go

pap

erle

ss2007

LABD

OFPH

ARM

ACY

PENS

ION

RES

AS

KA

oU

TF

.btu

vtH

YC

AL

SA

RR

AT

ED

CO

MM

UN

ICA

TIO

NS

UC

..tF

flA

PA

R.0

?-R

O[I

.

. IBE

RIA

FIN

AN

CIA

LSE

RV

ICE

S,LL

C

200

Wes

tC

ongr

ess

Str

eet

1stn

onU

laye

tte. I

A70

501

(OX

)82

3-96

66I

w.e

’tic

i—..

II

Tra

nsa

ctio

ns

inD

ate

Seq

uen

cePr

oces

s?Tr

ade!

Settl

emen

tTr

ansa

ctio

n

Sta

tem

ent

Per

iod:

0510

1120

16-

06/3

0120

16

06/1

0115

0611

0116

MON

EYM

ARKE

T[U

ND

INCO

ME

RECE

IVED

3109

9022

8BO

NDIN

TERE

STRE

CEIV

ED06

4261

HE2

SECU

RITY

REDE

EMED

0642

61H

E2

GENE

RAL

MNY

MKT

CLB

3000

0BA

NKOF

CHIN

ANE

WYO

RKCI

TYBR

HCT

[DE

PAC

T/36

504

00%

06/1

0/16

AlE

DTD

06/1

0/15

RD06

/09

P006

/10/

16BA

NKOF

CHIN

ANE

WYO

RKCI

TYBR

HCT

FDE

PAC

T/36

50.

400%

0611

0/16

A/E

DID

06/1

0/15

ACCO

UNT

REDE

MP1

ION

UNIT

EDST

ATES

TREA

SN

B1.

625%

06/3

0/20

AlE

DTD

05/3

0/15

SOLI

CI1E

DOR

DER

YLD

.834

TOM

AT

Qua

ntity

-30,

000.

000

29.0

00.0

0010

3117

9

AnwI

mt

Cun

erty

0.01

USD

1203

3US

D

30,0

00.0

0US

D

-222

.68

-30,

1288

9US

D

06/3

0/16

MON

EYM

ARKE

TFU

NDIN

COM

ERE

CEIV

ED3)

0990

228

05/3

0/16

BOND

INTE

REST

RECE

IVED

9128

28X

H8

GENE

RAL

MNY

MKI

CLB

2900

0UN

ITED

STAl

ESTR

[AS

NTS

1.62

5%06

/30/

20Al

EDT

D06

/30/

15RD

06/2

9P0

06/3

0/16

Acc

ount

Num

ber:

H5E-

102

619

Secu

ritie

sof

fere

dth

mug

hB

roker

age

Ess

exW

atio

nal S

ecur

ities

, LLC

Acco

un

t Sta

tem

en

t

Dat

e-

Dat

eAc

tivity

Type

05/3

1/16

Des

crip

tion

06/2

0/15

06/1

7/16

PURC

HASE

D91

2828

XH

8

Price

Acc

wed

Inte

rest

0.06

050

235.

63US

D

Tota

lV

alue

ofTr

ansa

ctio

ns-$

2226

8$2

27.1

405

0

The

pric

ean

dqu

antit

ydi

spla

yed

may

have

been

roun

ded.

Port

foli

oH

old

ings

Ope

ning

Clos

ing

Accr

ued

Inco

me

30-D

ayD

escr

iptio

nQ

uant

ityBa

lanc

eBa

lanc

eIn

com

eTh

isY

ear

Yield

Cas

h,M

oney

Fun

ds,

and

Ban

kD

epo

sits

1.00

%of

Por

tfol

ioC

ash

Bal

ance

0.00

235.

63

Mon

eyM

arke

tGE

NERA

LM

NYM

KTFU

NDCL

B53

2.43

064

0.92

63

43

000

0.86

0,01

%To

tal

Mon

eyM

arke

t$6

40.9

2$5

32.4

3$0

00$0

.86

Tot

alC

ash,

Mon

eyF

unds

,an

dB

ank

Dep

osi

ts$6

40.9

2$8

6806

$000

$0.8

6 Page

3ot7

AG

0954

GB

CS

P3

00

I.7

Go

pap

erl

ess

LA3D

OFPH

ARM

ACY

PENS

ION

RES

4R

.t.d

[-cry

Y..

5..c.2

007

flA

Lg

AS

RA

TE

DC

OIA

K*U

NIC

AT

ION

S[C

BL

L[N

C[

c__

u.—

P—

’-.

LA

C.

——

—B

——

-,—

y—

c_—

B—

..*

B—

ufl,,.-

t..F

nB

AB

cS

LS

.CP

AR

-02

-RO

[I.

Port

foli

oH

old

ing

s(c

on

tin

ued

)

Des

crip

tion

Qua

ntity

Mar

ketP

rice

-

Fixe

dIn

com

e99

.00%

ofP

ort

foli

o(In

Ala

tuaf

yDat

eSe

quen

ce)

Accn

iedEs

timat

edEs

timat

edM

arke

tValu

eIn

tere

stA

nnua

lIn

com

eYi

eld

U.S

.Tre

asui

ySe

curit

ies

UNIT

EDST

ATES

TREA

SNT

S1.

625%

06/3

0/20

B/E

DTD

05/3

0/15

1ST

CPN

DTE

12/3

1/15

CPN

PMT

SEM

I ANN

UAL

ONJU

N30

AND

DEC

31M

oody

Ratin

gM

ASe

curit

yId

entiF

ier: 9

1282

8XH

8UN

ITED

STAT

ESTR

EAS

NTS

1.31

5%01

/31/

21W

EDT

D01

/31/

161S

TCP

NDT

E07

/31/

16CP

NPM

TSE

MI

ANNU

ALON

JAN

31AN

DJU

L31

Moo

dyHa

ling

MA

Secu

rity

Iden

tifie

r:91

2828

N89

UNIT

EDST

ATES

TREA

SNT

S1.

250%

03/3

1/21

H/F

DTD

03/3

1/16

1ST

CPN

DTE

09/3

0/16

CPN

PMT

SEM

IAN

NUAL

ONM

AR3

1AN

DSE

P30

Moo

dyRa

ting

MA

Secu

rity

Iden

tifie

r:91

2828

Q37

29,0

00.0

0010

2.83

6029

,822

.44

0.00

471.

251.

58%

297,

000.

000

101.

7700

302,

256.

901,

694.

084,

083.

751.

35%

648,

000.

000

101.

1640

655,

542.

122,

013.

938,

100.

001.

23%

Tota

lU.

S.Tr

easu

rySe

curit

ies

974,

000.

000

$987

,622

.06

$3,7

08.0

1$1

2,65

5.00

Tota

lFi

xed

Inco

me:

974,

000.

000

$987

,622

.06

$3,7

08.0

1$1

2,65

5.00

Accr

ued

Estim

ated

Mar

ketV

alue

Inte

rest

Annu

alIn

com

e

Tota

lPo

rtfo

lioH

oldi

ngs

$988

,490

.12

$3,7

08.0

1$1

2,65

5.86

Po

rtfo

lio

Hold

ing

sD

iscl

osu

res

Pric

ing

This

sect

ion

incl

udes

the

nel

mar

ketv

alue

ofth

ese

curit

ies

inyo

urac

coun

t on

ase

ttlem

ent

date

basi

s,in

clud

ing

shor

t pos

ition

s,at

the

clos

eoF

the

stat

emen

tpe

riod.

The

mar

ket

pric

es,

unle

ssot

herw

ise

note

d,ha

vebe

enob

tain

edFr

omin

depe

nden

tve

ndor

serv

ices

.w

hich

we

belie

veto

bere

liabl

e.M

arke

tpr

ices

dono

tcon

stitu

tea

bid

oran

oile

r,an

dm

aydi

fferf

rom

the

actu

alsa

lepr

ice.

Secu

ritie

sFo

r whi

cha

pric

eis

nota

vaila

ble

are

mar

ked

‘N/A

flan

dar

eom

illed

from

the

Tota

l.TH

EA

SO

FPR

ICE

DA

TEON

LYA

PPEA

RS

WH

ENTH

EPR

ICE

DA

TED

OES

NO

TEQ

UA

LTH

EST

ATE

MEN

TD

ATE

.E

stim

ated

Ann

ual

Figu

res

The

estim

ated

annu

alin

com

e(E

AI)

and

estim

ated

annu

alyi

eld

(EAY

)fig

ures

are

estim

ates

and

for i

nfor

mat

iona

lpu

rpos

eson

ly.

The

sefig

ures

are

notc

onsi

dere

dto

bea

fore

cast

orgu

aran

tee

offu

ture

resu

lts.

The

sefig

ures

are

com

pute

dus

ing

info

rmat

ion

from

prov

ider

sbe

lieve

dto

bere

liabl

e:ho

wev

er,

noas

sura

nce

can

bem

ade

asto

tImac

cura

cy.

Sinc

ein

tere

stan

ddi

vide

ndra

tes

are

subj

ect

toch

ange

atan

ytim

e,an

dm

aybe

affe

cted

bycu

rren

tan

dfu

ture

econ

omic

,po

litic

al,

and

busi

ness

cond

ition

s,th

eysh

ould

not

bere

lied

onfo

rm

akin

gin

vest

men

t,tra

ding

,or

tax

deci

sion

s.T

hese

Figu

res

assu

me

that

the

posi

tion

quan

titie

s,in

tere

stan

ddi

vide

ndra

tes,

and

pric

esre

mai

nco

nsta

nt.

Aca

pita

lga

inor

retu

rnof

prin

cipa

lm

aybe

incl

uded

inth

efig

ures

for

certa

inse

curit

ies,

ther

eby

over

stat

ing

them

.Re

Fert

ow

m.p

ersh

inq.

com

!bus

ines

s_co

ntin

uity

.htm

l for

spec

ific

deta

ilsas

tofo

rmul

asus

edto

calc

ulat

eth

efig

ures

. Acc

rued

inte

rest

repr

esen

tsin

tere

stea

rned

but

noty

etre

ceiv

ed.

Rei

nves

tmen

tTh

edo

llar

amou

ntoF

Mut

ual

Fund

dist

ribut

ions

,M

oney

Mar

ket

Fund

divi

dend

inco

me,

Ban

kD

epos

itin

tere

stin

com

e,or

divi

dend

sfo

roth

erse

curit

ies

show

non

your

stat

emen

tm

ayha

vebe

enre

inve

sted

. You

will

Page

4of

1

A0

03

5460C

3F

30017

Acc

ount

Num

ber:

HSE-

107

679

Go

pape

rl€s

sLA

BDOF

PHAR

MAC

YPE

NSIO

NRE

S(4

)Raced

E.c

ell

ent

L.e

ryV

ea,

Sin

ce2007

DA

LB

AR

RA

TE

DC

OM

MU

NIC

AT

ION

S—

.-

—E

XC

EU

EN

CE

aa

Ta.k

M.a

...

IB.I

Yre..

,.,,

Un

.e,t..

Efl

IAn

sa

swC

PA

R0

2-R

DL

L

. IBE

RIA

FIN

AN

CIA

L5E

RV

ICE

S.

LLC

200W

estC

onqr

es5

Stre

etle

tFl

oor

lafa

yette

, LA

7050

1(8

I82

3-96

66

Po

rtfo

lio

Ho

ldin

qs

Dis

closu

res

(con

tinu

ed)

Stat

emen

tPe

riod

:05

/01/

2016

-06

/30/

2016

Rei

nves

tmen

t(c

ontin

ued)

not

rece

ive

conr

irmal

ion

ofIh

ese

rein

vest

men

ls.

Upo

nM

ilton

requ

est

loyo

urfin

anci

alin

slilu

tion,

info

rmat

ion

perta

inin

g10

thes

etr

ansa

ctio

ns,

incl

udin

gIh

elim

eoF

exec

utio

nan

dth

ena

me

ofIh

epe

rson

from

who

myo

urse

curit

yw

aspu

rcha

sed,

may

beob

tain

ed.

Indi

vide

ndre

inve

stm

ent t

rans

actio

ns,

Pers

hing

acts

asyo

urag

ent a

ndre

ceiv

espa

ymen

tFo

ror

der

flow.

Opt

ion

Dis

clos

ure

Info

rmat

ion

with

resp

ect

10co

mm

issi

ons

and

alhe

rch

arge

sin

curr

edin

conn

ectio

nw

ithth

eex

ecut

ion

oFop

tion

tran

sact

ions

has

been

incl

uded

inco

nrim

atio

nspr

evio

usly

Furn

ished

toyo

u.A

sum

mar

yof

Ibis

info

rmat

ion

isav

aila

ble

10yo

upr

ompt

lyup

onyo

urw

ritte

nre

ques

tdire

cted

toyo

urin

trodu

cing

firm

.In

orde

rto

assi

styo

urin

lrodu

cing

firm

inm

aint

aini

ngcu

rren

tba

ckgr

ound

and

rman

cial

info

rmat

ion

conc

erni

ngyo

urop

tion

acco

unts

,pl

ease

prom

ptly

advi

seIh

emin

writ

ing

oFan

ym

ater

ial

chan

gein

your

inve

stm

ent o

bjec

tives

orfi

nanc

ial

silu

atio

n.Ex

pirin

gop

tions

wtii

char

eva

luab

lear

eex

erci

sed

auto

mat

ical

lypu

rsua

ntto

the

exer

cise

byex

cept

ion

pioc

edur

eof

the

Opt

ions

Cle

arin

gC

orpo

ratio

n.A

ddili

onal

inFe

rmal

ien

rega

rdin

gIh

ispr

oced

ure

isav

aila

ble

upon

wril

len

requ

estt

oyo

urin

trodu

cing

firm

.Fo

reig

nC

urre

ncy

Tra

nsac

tions

Pers

hing

may

exec

ute

Fore

ign

curr

ency

tran

sact

ions

aspr

inci

pal f

oryo

urac

cotm

t.Pe

rshi

ngm

ayau

tom

atic

ally

conv

ert

Fore

ign

curr

ency

toor

from

U.S

.do

llars

for d

ivid

ends

and

simila

rco

rpor

ate

actio

ntr

ansa

ctio

nsun

less

you

insl

ruct

your

finan

cial

orga

niza

lion

othe

rwis

e.Pe

rshi

ng’s

curr

ency

conv

ersi

onra

tewi

llno

t exc

eed

the

high

est

inte

rban

kco

nver

sion

rate

iden

tifie

dfro

mcu

stom

ary

bank

ing

sour

ces

onth

eco

nver

sion

date

orth

epr

ior

busi

ness

day,

incr

ease

dby

uplo

1%.

unle

ssa

parti

cula

rra

leis

requ

ired

byap

plic

able

law

.Y

our

finan

cial

orga

niza

tion

may

also

incr

ease

Ihe

curr

ency

conv

eisi

onra

te,

This

conv

ersi

onra

lem

aydi

ffer

horn

rate

sin

efFe

clen

the

date

you

exec

uled

atra

nsac

tion,

incu

rred

ach

arge

,or

rece

ived

acr

edit.

Tran

sacl

ions

conv

erte

dby

agen

ts(s

uch

asde

posi

torie

s)wi

llbe

bille

dat

Ihe

rate

ssu

chag

ents

use.

Prox

yV

ote

Secu

ritie

sno

llu

llypa

idFo

rin

your

mar

gin

acco

unt

may

bele

ntby

Pers

hing

toits

elf

oret

hers

inac

cord

ance

with

the

term

sou

lline

din

11w

Mar

gin

Agr

eem

ent.

The

right

tovo

teyo

ursh

ares

held

onm

algi

nm

aybe

redu

ced

byIh

eam

ount

cish

ares

onlo

an. T

hePr

oxy

Vot

ing

lnst

wct

ion

Form

sent

10yo

um

ayre

flecl

asm

alle

rnu

mbe

rof

shar

esen

title

dIa

vote

than

Ihe

num

ber

oFsh

ares

inyo

urm

argi

nac

ceun

t.

Mon

eyM

ark

etF

und

Det

ail

a—,.

...,.

ac.

..4

..,—

1—

—C

-—

——

Ufl—

Ffl

flS

S.C

Secu

ritie

sof

fere

dth

roug

hS

tOeI

a9’e

Ess

exN

atio

nal S

ecur

ities

, LLC

__

__

__

__

__

__

__

__

__

__

__

__

__

__

__

__

__

__

__

__

__

I—

I-‘

Acco

un

t Sta

tem

en

t

Dat

eAc

tivity

Type

Des

crip

tion

Amou

ntBa

lanc

e

Swee

pM

oney

Mar

ket

Fund

GENE

RAL

MNY

MItT

FUND

CLB

Curre

ntYi

eld:

0.01

%Ac

livily

Endi

ng: 0

6/30

/16

04/3

0/16

Ope

ning

Bala

nce

640.

9264

0.92

05/3

1/16

Dep

osit

INCO

ME

REIN

VEST

0.01

640.

9306

/13/

16D

epos

itM

ONEY

FUND

PURC

HASE

30.1

2033

3076

1.26

06/2

0/16

With

draw

alM

ONEY

FUND

REDE

MPT

ION

-30,

128.

8963

2.37

06/3

0/16

Dep

osit

INCO

ME

REIN

VEST

0.06

632.

4306

/30/

16C

losi

ngB

alan

ce$6

32.4

3T

otal

All

Mon

eyM

arke

tFu

nds

$632

.43

Mes

sages

AS

0954

60

CS

P3

00

U

Alth

ough

am

oney

mar

ket

mut

ual

Fund

seek

sto

pres

erve

the

valu

eof

your

inve

stm

ent a

t$1

per

shar

e,it

ispo

ssib

leto

lose

mon

eyby

inve

stin

gin

am

oney

mar

ketm

utua

lfu

nd.S

hare

sof

am

oney

mar

ket m

utua

lfu

ndor

Ihe

bala

nce

ofa

bank

depo

sit

prod

uct

held

inyo

urbr

oker

age

acco

unt

may

beliq

uida

ted

upon

requ

est

with

the

proc

eeds

cred

ited

toyo

urbr

oker

age

acco

unt.

Plea

sese

eth

em

oney

mar

ketm

utua

lFu

nd’s

pros

pect

usor

the

bank

depo

sit

prod

uct’

sdi

5clo

5ure

docu

men

tor

cont

act y

our

advi

sor

for

addi

tiona

lin

form

atio

n.Pu

rsua

ntto

SEC

Rul

elO

biO

(b)(

1)co

nfin

natio

nsar

ePa

ge5

cli

Acc

ount

Num

ber:

HSE

-102

679

Go

pap

erle

ssLA

HOOF

PHAR

MAC

YPE

NSIO

NRE

S4)

Rate

dL

’ceII

en

tE

neyY

.-S

Inca20O

7-

flA

LO

AR

RA

TF

DC

OR

4M

UN

ICA

TIC

rn—

c,c

rLL

LN

cr

PA

RO

2R

0L

Mes

saqes

(con

tinue

d)no

tse

ntfo

rpu

rcha

ses

into

mon

eym

arke

t mut

ual

fund

spr

oces

sed

an(h

esw

eep

plat

form

.

Import

ant

Info

rmat

ion

and

Dis

clos

ures

The

Rol

eof

Pers

hing

Pers

hing

carr

ies

your

acco

unt a

scl

earin

gbi

cker

purs

uant

toa

clea

ring

agre

emen

tw

ithyo

urfi

nanc

ial

inst

itutio

n.Pe

rshi

ngm

ayac

cept

lion

your

finan

cial

inst

ilutio

nw

ithou

tin

quiry

orin

vest

igat

ion

(0or

ders

for t

hepu

rcha

sean

dsa

leof

secu

ritie

san

dot

her

prop

erty

and

(ii)a

nyot

her

inst

ruct

ions

conc

erni

ngye

wac

coun

t.Pe

rshi

ngis

not

resp

onsi

ble

orlia

ble

for

any

acts

orom

issi

ons

ofyo

urfin

anci

alin

stitu

lion

orits

empl

oyee

san

dii

does

not

supe

rvis

eth

em.

Pers

hing

prov

ides

noin

vest

men

lad

vice

nor

does

itas

sess

the

suita

bilit

yof

any

trans

actio

nor

orde

r.Pe

rshi

ngac

tsas

the

agen

tof

your

finan

cial

insl

itulio

nan

dyo

uag

ree

that

you

will

not

hold

Pers

hing

oran

ype

rson

cont

rolli

ngor

unde

rco

mm

onco

nlro

lwith

itlia

ble

for

any

inve

stm

ent

loss

esin

curr

edby

you.

•Pe

rshi

ngpe

rfor

ms

seve

ral

key

func

tions

atth

edi

rect

ion

ofyo

urfin

anci

alin

stitu

tion.

IIac

tsas

cust

odia

nfo

rfu

nds

and

secu

ritie

syo

um

ayde

posi

lw

ithit

dire

ctly

orth

roug

hyo

urfin

anci

alin

stitu

tion

orth

atit

rece

ives

asth

ere

sult

ofse

curit

ies

tran

sact

ions

itpr

oces

ses.

•Y

our

finan

cial

inst

itutio

nis

resp

onsi

ble

for

adtie

renc

eto

the

secu

ritie

sla

ws,

regu

latio

nsan

dru

les

whi

chap

ply

toit

rega

rdin

gits

own

oper

alio

nsan

dth

esu

perv

isio

nof

your

acco

unt,

itssa

les

repr

esen

tativ

esan

dot

her

pers

onne

l.Y

our

fuia

ncia

lin

stitu

tion

isal

sore

spon

sibl

efo

rap

prov

ing

the

open

ing

ofac

coun

tsan

dob

tain

ing

acco

unt d

ocum

ents

;th

eac

cept

ance

and,

ince

rtain

inst

ance

s,ex

ecut

ion

ofse

curit

ies

orde

rs:

the

asse

ssm

ent

ofth

esu

itabi

lity

ofth

ose

trans

actio

ns,

whe

reap

plic

able

:the

rend

erin

gof

inve

stm

ent a

dvke

,if

any,

toyo

uan

din

gene

ral,

for

the

ongo

ing

rela

tions

hip

that

itha

sw

ithyo

u.•

Inqu

iries

conc

erni

ngth

epo

sitio

nsan

dba

lanc

esin

your

acco

unt m

aybe

dire

cted

toth

ePe

rshi

ngC

usto

mer

Serv

ice

Dep

artm

ent a

t(2

01)

4133

333.

Allo

ther

inqu

iries

rega

rdin

gyo

urac

coun

tor

activ

itysh

ould

bedi

rect

edto

your

finan

cial

inst

itutio

n.Y

our

finan

cial

orga

niza

tions

cont

act

info

rmat

ion

can

befo

und

onth

eru

stpa

geof

this

stat

emen

t.•

For

ade

scrip

tion

ofot

her

func

tions

perf

orm

edby

Pers

hing

plea

seco

nsul

tth

eD

iscl

osur

eSt

atem

ent

prov

ided

toyo

uup

onth

eop

enin

gof

your

acco

unt.

This

notic

eS

not

mea

ntas

ade

finiti

veen

umer

atio

nof

ever

ypo

ssib

leci

rcum

stan

ce,

but

asa

gene

ral

disc

losu

re.

Ifyo

uha

vean

yqu

estio

nsre

gard

ing

this

notic

eor

ifyo

uw

ould

like

addi

tiona

lco

pies

ofth

eD

iscl

osur

eSt

atem

ent,

plea

seco

ntac

tyo

urfin

anci

alin

stitu

tion.

•Pe

rshi

ngis

am

embe

roh

the

Secu

ritie

sIn

vest

orPr

otec

tion

Cor

pora

tion

(SIP

C’)

.Pl

ease

note

that

SIPC

does

not

prot

ect

agai

nst

loss

due

tom

arke

t flu

ctua

tion.

Inad

ditio

nto

SIPC

prot

ectio

n.Pe

rshi

ngpr

ovid

esco

vera

gein

exce

ssof

SIPC

limits

.Fo

rm

ore

deta

iled

info

rmat

ion

plea

sevi

sit:.

pers

hing

.com

/abo

uUst

reng

th-a

ndsI

abil

ity.

•Th

isst

atem

ent

will

bede

emed

conc

lusi

ve.

You

are

advi

sed

tore

port

any

inac

cura

cyor

disc

repa

ncy

(incl

udin

gun

auth

oriz

edtra

ding

)pr

ompt

ly,

but

nola

ter

than

ten

days

afte

rre

ceip

tof

this

stat

emen

t,to

your

finan

cial

orga

niza

tion

and

Peis

hing

.Pl

ease

bead

vise

dth

atan

yor

alco

mm

unic

atio

nsh

ould

bere

-con

firm

edin

writ

ing

tofu

rther

prot

ect

your

right

s,in

clud

ing

your

right

sun

der

the

Secu

ritie

sIn

vest

orPr

otec

tion

Act

.•

You

rfin

anci

alor

gani

zatio

n’s

cont

acti

nfor

mat

ion

can

befo

und

onth

efir

stpa

geof

this

stat

emen

t.Pe

rshi

ng’s

cont

act

info

rmat

ion

isas

follo

ws:

Pers

hing

LLC,

Lega

lD

epar

tmen

t,O

nePe

rshi

ngPl

aza,

Jers

eyC

ity.N

ewJe

rsey

0739

9;(2

01)

413-

3330

.Er

rors

and

Om

issi

ons

exce

pted

.Im

port

ant

Arb

itrat

ion

Dis

clos

ures

•Al

lpar

ties

toth

isag

reem

ent a

regi

ving

upth

erig

htto

sue

each

othe

rin

cour

t,in

clud

ing

the

right

toa

trial

byju

ry,

exce

ptas

prov

ided

byth

eru

les

ofth

ear

bitra

tion

foru

min

whi

cha

clai

mis

riled

.•

Arb

itrat

ion

awar

dsar

ege

nera

llyfin

alan

dbi

ndin

g;a

party

’sab

ility

toha

vea

cour

tre

vers

eor

mod

ifyan

arbi

tratio

naw

ard

isve

rylim

ited.

•Th

eab

ility

ofth

epa

rties

toob

tain

docu

men

ts, w

itnes

sst

atem

ents

and

othe

rdi

scov

ery

isge

nera

llym

ore

limite

din

arbi

tratio

nth

anin

cour

tpr

ocee

ding

s.•

The

arbi

trato

rsdo

not

have

toex

plai

nth

ere

ason

(s)

for

thei

raw

ard,

unle

ss,

inan

elig

ible

case

,a j

oint

requ

estf

oran

expl

aine

dde

cisi

onha

sbe

ensu

bmitt

edby

allpa

rties

toth

epa

nel

atle

ast2

0da

yspr

iort

oth

efir

stsc

hedu

led

hear

ing

date

.•

The

pane

lof

arbi

trato

rswi

llty

pica

llyin

clud

ea

min

ority

ofar

bitra

tors

who

wer

eor

are

affil

iate

dw

ithth

ese

curit

ies

indu

stry

.•

The

rule

sof

som

ear

bitra

tion

foru

ms

may

impo

setim

elim

itsfo

rbr

ingi

nga

clai

min

arbi

tratio

n.In

som

eca

ses,

acl

aim

that

isin

elig

ible

for

arbi

tratio

nm

aybe

brou

ght

inco

urt.

•Th

eru

les

ofth

ear

bitra

tion

foru

min

whi

chth

ecl

aim

isril

ed,

and

any

amen

dmen

tsth

eret

o,sh

all

bein

corp

orat

edin

toth

isag

reem

ent.

Impo

rtan

tA

rbitr

atio

nA

gree

men

t

Any

cont

rove

rsy

betw

een

you

and

Pers

hing

LLC

shal

lbe

subm

itted

toar

bitra

tion

befo

reth

eFi

nanc

ial

Indu

stry

Reg

ulat

ory

Aut

horit

y.No

pers

onsh

all

brin

ga

puta

tive

orce

rtifie

dcl

ass

actio

nto

arbi

tratio

n,no

rse

ekto

enfo

rce

any

pred

ispu

tear

bitra

tion

agre

emen

tag

ains

tan

ype

rson

who

has

initi

ated

inco

urt

apu

tativ

ecl

ass

actio

n,w

hois

am

embe

rof

apu

tativ

ecl

ass

who

has

noto

pted

out o

fth

ecl

ass

with

resp

ect

toan

ycl

aim

sen

com

pass

edby

the

puta

tive

clas

sac

tion

until

;(I)

the

clas

sce

rtific

atio

nis

deni

ed;

(II)

the

clas

sis

dece

rtitie

d;or

(Ill)

the

clie

ntis

excl

uded

frnm

the

clas

sby

the

cour

t.Su

chfo

rbea

ranc

eto

enfo

rce

anag

reem

ent t

oar

bitra

tesh

all

not

cons

titut

ea

wai

ver

ofan

yrig

hts

unde

rth

isag

reem

ent e

xcep

tto

the

exte

ntst

ated

here

in.

The

law

sof

the

Stat

eof

New

Yor

kgo

vern

.

Pers

hing

’sco

ntac

tin

tom

atio

nis

asfo

llow

s:Pe

rshi

nghG

,Le

gal

Dep

artm

ent,

One

Pers

hing

Plaz

a,Je

rsey

City

, New

Jers

ey07

399;

(Wi)

413-

3330

.

Page

Bof

7

Ao

D9s46ecsF

3oO

Acc

ount

Num

ber:

H5E

-102

879

Go

pap

erle

ssE

-ryY

wS

’nce2007

[ALID

OFPH

ARM

ACY

PENS

ION

RES

Ask

AO

UT

r.D

4tI

wL

.Yt,,,

OA

LA

flA

T€D

CO

MM

UN

ICA

TIO

NS

S.C

PA

R-0

2.R

OL

L

TE

RM

SA

ND

CO

ND

ITIO

NS

TR

AN

SA

CT

ION

S

ALL

OR

DE

RS

AN

DT

RA

NSA

CT

ION

SSH

AL

LB

ESO

LE

LY

FOR

YO

UR

AC

CO

UN

TA

ND

RIS

KSH

AL

LB

ES

UB

JEC

TT

OT

HE

CO

NST

ITU

TIO

N.

RU

LE

S,R

EG

UL

AT

ION

S,C

US

TO

MS

.U

SA

OE

S,

RU

LIN

GS

AN

DIN

TE

RPR

ET

AT

ION

SO

FT

HE

EX

CH

AN

GE

OR

MA

RK

ET

AII

DT

HE

CL

EA

RIN

GFA

CIL

ITY

IFA

NY

,W

HE

RE

ThE

TR

AR

SAC

TIO

NS

AR

EE

XE

CU

TE

DA

IID

IOR

SET

TL

ED

.O

RIF

APP

LIC

AB

LE

.O

FT

HE

FIN

AN

CIA

LIN

DU

STR

YR

EG

UI.

AT

OR

YA

UT

hOR

ITY

AN

DT

OA

LLA

PPL

ICA

BL

EL

AW

SA

ND

RE

GU

LA

TIO

NS.

•T

IRE

TO

SE

CU

RIT

iES

SOL

DT

OY

OU

,W

HE

RE

PE

RS

HIN

GH

AS

AC

TE

DA

SPR

INC

IPA

L.

SHA

LL

RE

MA

INW

ITH

PE

RS

HIN

GU

NT

ILT

hEE

NT

IRE

PU

RC

HA

SE

PR

ICE

ISR

EC

EIV

ED

OR

UN

TIL

WE

SET

TL

EM

EN

TD

AT

E,

WH

ICH

EV

ER

ISL

AT

ER

.

•Y

OU

MA

YH

AV

ER

EC

EIV

ED

CO

NFI

RM

AT

ION

SFO

RT

RA

NSA

CT

iON

SW

HIC

HD

ON

OT

AP

PE

AR

ON

YO

UR

STA

TE

ME

NT

IFS

O,

ThE

TR

AN

SAC

TIO

NS

WIL

LA

PP

EA

RO

NY

OU

RN

EX

TPE

RIO

DIC

STA

TE

ME

NT

SUC

HT

RA

NSA

CT

ION

SM

UST

BE

CO

NS

IDE

RE

DB

YY

OU

WH

EN

CO

MPU

TIN

GT

hEV

AL

UE

CF

YO

UR

AC

CO

UN

T.

Til

lSIS

ESP

EC

LA

LL

YT

RU

EIF

YO

UH

AV

EW

RIT

TE

NO

PT

ION

SW

HIC

HH

AV

EB

EE

NE

XE

RC

ISE

D

FR

EE

CR

ED

ITB

AL

AN

CE

S:

AN

YF

RE

EC

RE

DIT

BA

LA

NC

EC

AR

RIE

DFO

RY

OU

RA

CC

OU

NT

RE

PR

ES

EN

TS

FUN

DS

PAY

AB

LE

UPO

ND

EM

AN

DW

HIC

H,

AL

TH

OU

GH

PR

OP

ER

LY

AC

CO

UN

TE

DFO

RD

NP

ER

SH

IN&

SB

OO

KS

OF

RE

CO

RD

,A

RE

ND

TS

EG

RE

GA

TE

DA

ND

MA

YB

EU

SED

INT

HE

CO

ND

UC

TO

FIT

SB

US

INE

SS

.

DE

BIT

BA

LA

NC

ES

:IN

TE

RE

STC

HA

RG

ED

ON

DE

BIT

BA

LA

NC

ES

INV

OU

RA

CC

OU

NT

AP

PE

AR

SO

NT

HE

STA

TE

ME

NT

TH

ESA

TE

OF

INT

ER

ES

TA

ND

PER

IOD

CO

VE

RE

DA

RE

IND

ICA

TE

D.

WE

RA

TE

MA

YC

HA

NG

EFR

OM

TIM

ET

OT

IME

DU

ET

OFL

UC

TU

AT

ION

SIN

MO

NE

YR

AT

ES

OR

OT

HE

RR

EA

SO

NS

.IN

TE

RE

STIS

CO

MPU

TE

DA

SD

ESC

RIB

ED

INM

AT

ER

IAL

PRE

VID

USL

YFU

RN

ISH

ED

TO

YO

U.

PL

EA

SE

CO

NT

AC

TY

OU

RFI

NA

NC

IAL

INST

ITU

TIO

NIF

YO

UD

ES

IRE

AD

DIT

ION

AL

CO

PIE

S,

MA

RG

ININ

FOR

MA

TID

NIF

YO

UM

AIN

TA

INA

MA

RG

INA

CC

OU

NT

.T

hIS

ISA

CO

MB

INE

DST

AT

EM

EN

TO

FY

OU

RG

EN

ER

AL

AC

CO

UN

TA

ND

AS

PE

CIA

LM

EM

OR

AN

DU

MA

CC

OU

NT

MA

INT

AIN

ED

FOR

YO

UU

ND

ER

RE

GU

LA

TIO

NT

OF

TH

EB

OA

RD

CF

GO

VE

RN

OR

SO

FT

HE

FED

ER

AL

RE

SE

RV

ESY

STE

M.

ThE

PER

MA

NE

NT

RE

CO

RD

OF

TH

ES

EP

AR

AT

EA

CC

OU

NT

AS

RE

OU

IRE

DD

YR

EG

UL

AT

ION

TIS

AV

AIL

AB

LE

FOR

YO

UR

INSP

EC

TIO

NU

PON

RE

QU

ES

T.

TA

XIN

FOR

MA

TIO

N

AFT

ER

YE

AR

EN

DP

ER

SH

ING

ISR

EO

UIR

ED

TOPR

OV

IDE

TAX

INFO

RM

AT

ION

TO

TH

EIN

TE

RN

AL

RE

VE

NU

ESE

RV

ICE

AN

DO

TH

ER

GO

VE

RN

ME

NT

AL

AU

ThO

RIT

IES

.A

TT

HA

TTI

ME

PE

RS

HIN

GW

ILL

PRO

VID

ET

HA

TIN

FOR

MA

TIO

NO

NT

HE

AN

NU

AL

TAX

INFO

RM

AT

ION

STA

TE

ME

NT

TOY

OU

;U

SE

TH

AT

STA

TE

ME

NT

TO

PR

EP

AR

EY

OU

RTA

XF

LIN

GS

-T

HE

TAX

ST

AT

EM

EN

TA

LS

OIN

CL

UD

ES

OT

hER

US

EF

UL

INFO

RM

AT

ION

TO

AS

SIS

TIN

AC

CU

MU

LA

TIN

GT

HE

DA

TA

TO

PR

EP

AR

EY

OU

RTA

XR

ET

UR

NS

.

•D

IVID

EN

DS,

INT

ER

ES

TA

ND

OT

hER

DIS

TR

IBU

TIO

NS

SH

OW

NO

NT

HIS

STA

TE

ME

NT

WE

RE

CL

ASS

IFIE

DA

ST

AX

AB

LE

OR

NO

NT

AX

AB

LE

BA

SED

ON

CE

RT

AIN

INFO

RM

AT

ION

KN

OW

NA

SO

FT

hED

IST

RIB

UT

ION

DA

TE

.T

HIS

CL

ASS

IFIC

AT

ION

ISS

UD

JEC

TT

OC

HA

NG

EA

ND

ISSO

LE

LY

INT

EN

DE

DF

OR

USE

AS

GE

NE

RA

LIN

FOR

MA

TIO

N

•P

ER

SH

ING

DO

ES

NO

TPR

OV

IDE

TAX

,IN

VE

STM

EN

TO

RL

EG

AL

AD

VIS

OR

YS

ER

VIC

ES

AN

DN

DO

NE

AS

SO

CIA

TE

DW

ITH

PE

RS

HIN

GIS

AU

TH

OR

IZE

DT

OR

EN

DE

RS

UC

HA

DV

ICE

.D

ON

OT

RC

LY

UPO

NA

NY

SUC

HA

DV

ICE

,IF

GW

EN

INV

EST

OR

SA

RE

EN

CO

UR

AG

ED

TO

CO

NS

UL

TT

HE

IRT

AX

AD

VIS

OR

ST

OD

ET

ER

MIN

ET

HE

AP

PR

OP

RIA

TE

TAX

TR

EA

TN

EN

TO

FT

HE

IRB

US

INE

SS

.

GE

NE

RA

LIN

FOR

MA

TIO

N

•W

HE

NE

VE

RY

OU

AR

EIN

DE

BT

ED

TO

PE

RS

HIN

GLL

CC

PE

RS

HIN

G9

FO

RA

NY

AM

OU

NT

ALL

SE

CU

Rm

ES

HE

LD

BY

ftFO

RY

OU

INA

NY

AC

CO

UN

TIN

WH

ICH

YO

UH

AV

EA

NY

INT

ER

ES

TSH

AL

LS

EC

UR

EA

LLY

OU

RL

IAB

ILIT

IES

TO

PE

RS

HIN

G,

AN

DP

ER

SH

ING

MA

YSN

ITS

DIS

CR

ET

ION

AT

AN

YTI

ME,

WIT

HO

UT

TE

ND

ER

.D

EM

AN

DO

RN

OT

ICE

TO

YO

U,

CL

OS

ED

RR

ED

UC

EA

NY

OR

ALL

OF

YO

UR

AC

CO

UN

TS

BY

PUB

LIC

DR

PRIV

AT

ESA

LE

OR

PU

RC

HA

SE

OR

BO

TH

OF

ALL

OR

AN

YS

EC

UR

ITIE

SC

AR

RIE

DIN

SUC

HA

CC

OU

NT

S;A

NY

BA

LA

NC

ER

EM

AIN

ING

DU

EP

ER

SH

ING

TO

BE

PRO

MPT

LY

PAID

BY

YO

U.

•W

HE

NE

VE

RY

OU

AR

EIN

DE

BT

ED

TO

PE

RS

HIN

GFO

RA

NY

AM

OU

NT

.A

LLS

EC

UR

ITIE

SC

AR

RIE

DFO

RY

OU

RA

CC

OU

NT

AR

EO

RM

AY

BE

,WIT

HO

UT

FUR

TH

ER

NO

TIC

ET

OY

OU

,L

OA

NE

DO

RPL

ED

GE

DB

YP

ER

SH

ING

.E

ITH

ER

SEPA

RA

TE

LY

OR

UN

DE

RC

IRC

UM

ST

AN

CE

SW

HIC

HW

ILL

PER

MIT

ThE

CO

MM

ING

LIN

GT

HE

RE

OF.

Win

’O

ThE

RS

EC

UR

mE

SFO

RA

NY

AM

OU

NT

LE

SS

TH

AN

,E

OU

AL

TOO

RG

RE

AT

ER

ThA

NY

OU

RL

IAB

ILIT

IES

TO

PE

RS

HIN

G.

BU

TN

OT

UN

DE

RC

IRC

UFI

STA

NC

ES

FOR

AN

AM

OU

NT

PRO

HIB

ITE

DB

YLA

W

•P

ER

SH

ING

MA

YT

RA

DE

FOR

ITS

OW

NA

CC

OU

NT

AS

AM

AR

KE

TM

AK

ER

.SP

EC

IAL

IST

,O

DD

LO

TD

EA

LE

R,

BL

OC

KP

OS

ITIO

NE

R,

AR

BIT

RA

GE

UR

OR

INV

EST

OR

.C

ON

SE

QU

EN

TL

Y.A

TT

HE

TIM

EO

FA

NY

TR

AN

SAC

TIO

NY

OU

MA

YM

AK

E,

PE

RS

HIN

GM

AY

HA

VE

APO

SIT

ION

INS

UC

HS

EC

UR

ITIE

S,

WH

ICH

POSI

TIO

NM

AY

BE

PAR

TIA

LL

YO

RC

OM

PLE

TE

LY

HE

DG

ED

.

•IF

AV

ER

AG

EP

RIC

ET

RA

NSA

CT

ION

ISIN

DIC

AT

ED

ON

TH

EF

RO

NT

OF

TH

ISST

AT

EM

EN

TY

OU

RFN

AN

CL

AL

INST

ITU

TIO

NO

RP

ER

SH

ING

MA

YR

AV

EA

CT

ED

AS

PRIN

CIP

AL

,A

GE

NT

OR

BO

TR

DE

TA

ILS

AV

AIL

AB

LE

UPO

NR

EQ

UE

ST

•A

FIN

AN

CIA

LST

AT

EM

EN

TO

PP

ER

SH

ING

ISA

VA

ILA

BL

EFO

RY

OU

RP

ER

SO

NA

LIN

SPE

CT

ION

AT

PE

RS

HIN

G’S

OF

FIC

ES

.A

CO

PY

OF

TW

ILL

BE

MA

ILE

DU

PON

YD

UR

WR

EIT

EN

RE

QU

ES

TO

RY

OU

CA

NV

IEW

ifO

NL

INE

AT

WW

WP

ER

SH

ING

CO

M

FO

RB

US

INE

SS

CO

NT

INU

ITY

AN

DA

DD

ET

ION

AL

DIS

CL

OS

UR

ES

,WW

W.P

ER

SH

ING

.CO

MID

ISC

LO

SU

RE

S

TH

ISST

AT

EM

EN

TSH

OU

LD

BE

RE

TA

INE

DF

OR

YO

UR

RE

CO

RD

S.

PAY

ME

NT

FO

RO

RD

ER

FL

OW

AN

DO

RD

ER

RO

UT

ING

PO

LIC

IES

DIS

CL

OS

UR

ES

(RE

GU

LA

TIO

NN

MS

—R

UL

E6O

7(A

MIH

2)J

PE

RS

HIN

GS

EN

DS

CE

RT

AIN

EO

UIT

YO

RD

ER

ST

OE

XC

HA

NG

ES

,E

LE

CT

RO

NIC

CO

MM

UN

ICA

TIO

NN

ET

WO

RK

S.

DR

BR

OK

ER

’D

EA

LE

RS

DU

RIN

GN

OR

MA

LB

US

INE

SS

HO

UR

SA

ND

DU

RIN

GE

XT

EN

DE

DW

AG

ING

SE

SS

ION

S.

CE

RT

AIN

OF

TH

ES

EV

EN

UE

SPR

OV

IDE

PAY

ME

NT

ST

OP

ER

SH

ING

OR

CH

AR

GE

AC

CE

SS

FE

ES

TO

PE

RS

HIN

GD

EPE

ND

ING

UPO

NT

HE

CH

AR

AC

TE

RIS

TIC

SD

FT

HE

OR

DE

RA

ND

AN

YS

UB

SE

QU

EN

TE

XE

CU

TIO

N.

ThE

DE

TA

ILS

OF

TH

ES

EPA

YM

EN

TS

AN

DF

EE

SA

RE

AV

AIL

AB

LE

UPO

NW

RrT

IFN

RE

QU

ES

TP

ER

SH

ING

RE

CE

IVE

SPA

YM

EN

TS

FO

RD

IRE

CT

ING

LIS

TE

DO

PTIO

NS

OR

DE

RFL

OW

TO

CE

RT

AIN

OPT

ION

EX

CH

AN

GE

S.IN

AD

DIT

ION

,P

ER

SH

ING

RO

UT

ES

CE

RT

AIN

EQ

UIT

YA

ND

OPT

ION

OR

DE

RS

TO

ITS

AFF

ILIA

TE

.B

NY

ME

LL

ON

CA

PIT

AL

MA

RK

ET

S.L

LC

,FO

RE

XE

CU

TIO

NA

SPR

INC

IPA

L.

CO

MPE

NSA

TIO

NIS

GE

NE

RA

LL

YIN

TH

EFO

RM

OF

AP

ER

OPT

ION

CO

NT

RA

CT

CA

SHPA

YM

EN

T.

BE

BT

BC

EC

UT

IDN

:N

OT

WIT

HST

AN

DIN

GT

HE

PR

EV

IOU

SPA

RA

GR

APH

RE

GA

RD

ING

PA

YM

EN

TF

OR

OR

DE

RFL

OW

,P

ER

SH

ING

SE

LE

CT

SC

ER

TA

INM

AR

KE

TC

EN

TE

RS

TO

PRO

VID

EE

XE

CU

TIO

NO

FO

VE

R’T

HE

.CO

UN

TE

RA

ND

EX

CH

AN

GE

.LIS

TE

OS

EC

UR

ITIE

ST

RA

NSA

CT

ION

SW

HIC

HA

GR

EE

TO

AC

CE

PT

OR

GE

RS

.T

RA

NSM

ITT

ED

EL

EC

TR

ON

ICA

LL

YU

PT

DA

SP

EC

IFIE

DSI

ZE

.A

ND

TO

EX

EC

UT

ET

HE

MA

TO

RB

ET

TE

RT

HA

NT

HE

NA

TIO

NA

LB

ES

TB

IDO

RO

FF

ER

(ND

BO

I.O

NC

ER

TA

INL

AR

GE

RO

RD

ER

S,

OR

IFT

HE

DE

SIG

NA

TE

DM

AR

KE

TC

EN

TE

RS

DO

NO

TM

AK

EA

MA

RK

ET

INT

hES

UB

JEC

TSE

CU

RIT

Y,

PE

RS

HIN

GD

IRE

CT

LY

CO

NT

AC

TS

MA

RK

ET

CE

NT

ER

ST

OO

BT

AIN

MI

EX

EC

UT

ION

.T

UE

DE

SIG

NA

TE

DM

AR

KE

TC

EN

TE

RS

TO

WH

ICH

OR

DE

RS

AR

EA

UT

OM

AT

ICA

LL

YR

OU

TE

DA

RE

SE

LE

CT

ED

BA

SED

ON

ThE

CO

NS

IST

EN

TH

IGH

OU

AL

RV

OF

TH

EIR

EX

EC

UT

iON

SIN

ON

ED

RM

OR

EM

AR

KE

TS

EG

ME

NT

SA

ND

TH

EIR

AB

ILIT

YT

OPR

OV

IDE

OP

PO

RT

UN

ITIE

SFO

RE

XE

CU

TIO

NS

AT

PR

ICE

SS

UP

ER

IOR

TOT

HE

N000.

PE

RS

HIN

GA

LSO

RE

GU

LA

RL

YR

EV

IEW

SR

EP

OR

TS

FO

RC

UA

LIT

YO

FE

XE

CU

TIO

NP

UR

PO

SE

S.

WT

TA

PA

CC

OU

NT

CU

ST

OM

ER

SW

HO

EL

EC

TE

DN

DT

TO

RE

CE

IVE

IMM

ED

IAT

EC

ON

BR

MA

TIO

NO

FT

RA

NS

AC

TIO

NS

TH

EFO

LL

OW

ING

TE

RM

SA

ND

CO

ND

ITIO

NS

AR

EA

PPL

ICA

BL

EO

NLY

IFY

OU

RA

CC

OU

NT

ISA

NIN

VE

STM

EN

TA

DV

ISO

RY

AC

CO

UN

TA

ND

TU

ET

RA

NSA

CT

ION

CO

NFI

RM

AT

ION

SA

RE

NO

TS

EN

TT

OY

OU

(SE

NT

ON

LY

TO

YO

UR

FID

UC

IAR

Y)

PUR

SUA

NT

TO

YO

UR

INST

RU

CT

ION

.

WR

AP

AC

CO

UN

TT

RA

NS

AC

BO

NS

•T

HE

FOL

LO

WIN

GIN

FOR

MA

TIO

NW

ILL

DC

FUR

NIS

HE

DT

OY

OU

UPO

NR

EQ

UE

ST

TO

YO

UR

FIN

AN

CIA

LIN

STIT

UT

ION

CIN

TB

DD

UC

ING

FIR

M’)

WFT

hR

ES

PE

CT

TO

AN

YT

RA

NSA

CT

ION

FO

RW

HIC

HA

CO

NFI

RM

AT

ION

WA

SN

OT

SE

NT

TO

YO

U:

WE

MA

RK

ET

UPO

NW

HIC

HA

NY

TR

AN

SAC

TIO

NW

AS

EX

EC

UT

ED

;T

HE

TIM

EO

FD

AY

TR

AT

AN

YT

RA

NSA

CT

ION

WA

SE

XE

CU

TE

D;

TH

EN

AM

EO

FT

HE

PE

RS

ON

FRO

MW

HO

MA

NY

SEC

UR

ITY

WA

SP

UR

CH

AS

ED

DR

TO

WH

OM

SU

CH

SEC

UR

ITY

WA

SSO

LD

:T

HE

SO

UR

CE

AN

DA

MO

UN

TO

FO

ThE

RC

OM

MIS

SIO

NS

RE

CE

IVE

DIN

CO

NN

EC

TIO

NW

ITH

AN

YT

RA

NSA

CT

ION

;A

ND

AC

OPY

OF

TH

ET

RA

NSA

CT

ION

CO

NFI

RM

AT

IOFt

•Y

OU

RIN

TR

OD

UC

ING

FIR

ME

FF

EC

TE

DE

AC

HT

RA

NSA

CT

ION

FO

RW

NIC

HA

CO

NFI

RM

AT

ION

WA

SN

OT

SE

NT

TO

YO

UA

SY

OU

RA

GE

NT

•IN

CO

NN

EC

TIO

NW

ITH

EA

CH

EO

UIT

YSE

CU

RIT

YA

ND

CE

RT

AIN

OT

HE

RS

EC

UR

ITIE

SSO

LD

.Y

OU

RIN

TR

OD

UC

ING

FIR

MC

HA

RG

ES

TO

YO

U.

AN

DR

EM

ITS

TO

AR

EG

JLA

TO

RY

OR

GA

NIZ

AT

ION

OR

NA

TIO

NA

LS

EC

UR

ITIE

SE

XC

HA

NG

E,

A’W

AN

SFE

E-’

PE

RS

HIN

GC

AL

CU

LA

TE

ST

HIS

FE

EB

ASE

DO

NA

MO

UN

TS

PAID

BY

YO

UR

INT

RO

DU

CIN

GFI

RM

TO

TH

EA

PPL

ICA

BL

ER

EG

UL

AT

OR

YO

RG

AN

IZA

TIO

ND

RN

AT

ION

AL

SE

CU

RIT

IES

EX

CH

AN

GE

.T

HIS

,IN

TU

RN

,IS

BA

SED

ON

ThE

VA

LU

EO

FT

HE

APP

LIC

AB

LE

SEC

UR

ITIE

SSO

LD

.T

OD

ET

ER

MIN

ET

HE

EX

AC

TA

MO

UN

TO

FT

HIS

FEE

WIT

HR

ES

PE

CT

TO

AN

YT

RA

NSA

CT

IDN

,P

LE

AS

EC

ON

TA

CT

YO

UR

INT

RO

DU

CIN

GFI

RM

•IF

AN

YT

RA

NSA

CT

ION

INV

OL

VE

SA

NA

SS

ET

.BA

CK

ED

SEC

UR

ITY

,IN

CL

UD

ING

AM

UN

ICIP

AL

CO

LL

AT

ER

AL

IZE

DM

OR

TG

AG

EO

BL

IGA

TID

N.W

HIC

HR

EP

RE

SE

NT

SA

NIN

TE

RE

ST

IND

RIS

SE

CU

RE

DD

YA

POO

LO

FR

EC

EIV

AB

LE

SO

RO

TH

ER

FIN

AN

CIA

LA

SS

ET

ST

hAT

AR

ES

UB

JEC

TC

ON

TIN

UO

USL

YT

OPR

EPA

YM

EN

T.

TH

EN

TH

EA

CT

UA

LY

IEL

DO

FS

UC

HSE

CU

RIT

YM

AY

VA

RY

AC

CO

RD

ING

TO

TH

ER

AT

EA

TW

HIC

HT

hEU

ND

ER

LY

ING

RE

CE

IVA

BL

ES

OR

OT

HE

RFI

NA

NC

IAL

AS

SE

TS

AR

EPR

EPA

JDIN

FOR

MA

TIO

NC

ON

CE

RN

ING

TH

EFA

CT

OR

ST

HA

TA

,PFE

CT

YIE

LD

(IN

CL

UD

ING

AT

AM

INIM

UM

EST

IMA

TE

DY

IELD

,W

EIG

HT

ED

AV

ER

AG

EL

IFE

.A

ND

TH

EPR

EPA

YM

EN

TA

SS

UM

PT

ION

SO

FU

ND

ER

LY

ING

YIE

LD

)WIL

LB

EFU

RN

ISH

ED

TOY

OU

UPO

NR

EQ

UE

ST

TO

YO

UR

INT

RO

DU

CIN

GFI

RM

WR

AP

AC

CO

UW

TO

RD

ER

FLO

W:

YO

UR

INT

RO

BU

CIN

GFI

RM

DO

ES

NO

TR

EC

EW

EA

NY

PAY

ME

NT

FOR

OR

DE

RFL

OW

FO

RA

NY

TR

AN

SAC

TIO

NFO

RW

HIC

HA

CO

NFI

RM

AT

ION

WA

SN

OT

SE

NT

TO

YO

U.

WR

AP

AC

CO

UN

TC

AL

LF

EA

TU

RE

S:

CA

LLFE

AT

UR

ES

MA

YE

XIS

TFO

RS

EC

UR

ITIE

S.

CA

LLFE

AT

UR

ES

FOR

FIX

ED

INC

OM

ES

EC

UR

ITIE

SM

AY

AF

FE

CT

YIE

LD-

CO

MPL

ET

EIN

FOR

MA

TIO

NW

ILL

BE

PRO

VID

ED

UPO

NR

EQ

UE

ST

WR

AP

AC

CO

UN

TR

AT

ING

S:

WE

RA

TIN

GS

TH

AT

AP

PE

AR

INT

hED

ESC

RIP

TIO

NO

FSO

ME

FIX

ED

INC

OM

ES

EC

UR

ITIE

SH

AV

EB

EE

NO

BT

AIN

ED

FRO

MR

AT

ING

SS

ER

VIC

ES

WH

ICH

PE

RS

HIN

GB

EL

IEV

ES

TO

BE

RE

LIA

BL

E,

HO

/lE

VE

R,

PE

RS

HIN

GC

AN

NO

TG

UA

RA

NT

EE

TH

EIR

AC

CU

RA

CY

SE

CU

RIT

iES

FOR

WH

ICH

AR

AT

ING

ISN

DT

AV

AIL

AB

LE

AR

EM

AR

KE

DU

NR

AT

ED

IFA

NY

OF

TH

EA

BO

VE

TE

RM

SA

ND

CO

ND

ITIO

NS

AN

EU

NA

CC

EPT

AB

LE

TO

YO

U.

RL

EA

SEN

OT

IFY

PE

RS

HIN

GIM

MED

IATE

LYIN

WR

ITIN

GB

YC

ER

TIF

IED

MA

ILTO

ON

EP

ER

SH

ING

PLA

ZA

,JE

RS

EY

CIT

Y,

NJ

0739

9,A

nTI:

LE

GA

LD

EF

T

Page

?of

?

AD

095468C

SF

30017

Ivcr

yY

ear

Sin

ce2

DO

)G

Opa

perl

€ss

-

‘D

AIB

AR

RA

TE

DC

OM

MU

NIC

AT

ION

S

ACCO

UH1

NU

mbe

l:H

5E-1

028T

h

[ABD

OFPH

ARM

ACY

PENS

ION

RES

AS

EA

SO

UT

E.D

EtI

VE

MY

‘.

EX

CE

LL

EN

CE

c•__t•

p—

ac,c—

fl—

—..—

IT

he•I

1v

eet—

—C

n,e

..W

NY

EIe

e)

r’h

e4

Ufl

rRn

vft

sa

WC

PA

R”O

2’R

GL

L

Louisiana Board of Pharmacy

Cumulative Fund Balance Reports

FY 98-99 FY 99-00 FY 00-01 FY 01-02 FY 02-03 FY 03-04 FY 04-05 FY 05-06 FY 06-07 FY 07-08Actual Actual Actual Actual Actual Actual Actual Actual Actual Actual

Beginning Fund Balance 910,394 1,127,239 1,267,076 1,351,191 1,521,807 1,588,141 1,478,412 1,587,349 1,677,669 2,077,236

Total Income 984,414 1,030,423 1,168,798 1,200,575 1,223,872 1,274,804 1,524,411 1,627,306 2,228,918 2,657,168

Total Expenses 767,569 890,586 1,084,683 1,029,959 1,170,252 1,384,533 1,415,474 1,536,986 1,829,351 2,184,076

Ending Fund Balance 1,127,239 1,267,076 1,351,191 1,521,807 1,588,141 1,478,412 1,587,349 1,677,669 2,077,236 2,550,328

Reservations of Fund Balance 48,884 102,368 476,000 524,000 1,210,000 1,245,000 1,300,000 1,300,000 1,400,000 2,050,000

Unreserved Fund Balance 1,078,355 1,164,708 763,515 997,807 378,141 233,412 287,349 377,669 677,236 500,328

FY 08-09 FY 09-10 FY 10-11 FY 11-12 FY 12-13 FY 13-14 FY 14-15 FY 15-16 FY 16-17 FY 17-18Actual Actual Actual Actual Actual Actual Actual Actual Actual Actual

Beginning Fund Balance 2,550,328 2,607,575 2,715,185 2,810,463 2,936,874 3,225,350 (620,086) 363,796 1,293,857

Total Income 2,570,282 2,706,829 2,808,468 2,775,418 2,849,249 3,059,394 3,615,033 3,512,690

Total Expenses 2,513,035 2,599,219 2,713,190 2,649,007 2,560,773 2,764,020 2,631,151 2,582,629

GASB-68 Restatement 4,140,810

Ending Fund Balance 2,607,575 2,715,185 2,810,463 2,936,874 3,225,350 (620,086) 363,796 1,293,857

Reservations of Fund Balance 1,900,000 1,650,000 1,650,000 500,000 750,000 2,162,000 1,272,000 772,000

Unreserved Fund Balance 707,575 1,065,185 1,160,463 2,436,874 2,475,350 (2,782,086) (908,204) 521,857




Finance Committee

Proposed Budget Amendment No. 1 Fiscal Year 2016-2017

August 9, 2016

Blake P. Pitre Chair



Louisiana Board of PharmacyFY 2016-2017 Budget

FY 16-17 FY 16-17Acct. No. Original Amend. #1 Notes

Licenses & Permits4201 Pharmacist Renewals 780,000 815,000 14206 New Pharmacist Licensing Fee 195,000 185,000 24204 Technician Renewals 316,000 335,000 34208 Tech Candidate Registrations 25,000 35,000 44205 Lapsed Credential Fees 30,000 30,0004350 Student Registrations 3,000 3,0004301 Permits - Pharmacies 275,000 300,000 54302 Permits - CDS 455,000 465,000 64303 Permits - Emergency Drug Kits 13,000 12,000 74304 Permits - Automated Medication Systems 20,000 20,0004306 Permits - Durable Medical Equipment 80,000 85,000 8

Examinations4153 Reciprocity 50,000 55,000 94152 Technicians 50,000 60,000 10

Penalties4252 Licenses and Certificates 9,000 9,0004251 Permits 12,000 12,000

Administrative Fees4460+4462 Documents: Copies and Certification Fees 5,000 5,000

4452 Duplicate Credentials 5,000 5,0004453 Pharmacist Silver Certificates 400 300 114459 Pharmacist Original Certificates 7,500 7,5004454 NSF Fees 500 5004463 Handling & Mailing Fees 100 200 12

Sale of Goods & Services4402 Law Books 6,000 3,000 134461 Official Lists of Licensees 7,500 12,000 144458 USCPSC Inspection Fee 0 2,000 15

Enforcement Actions4102 Hearing Fees 21,000 22,000 164501 Fines 200,000 300,000 174502 Investigative Cost Recoveries 30,000 20,000 18

Prescription Monitoring Program4660 Assessments 482,000 510,000 19

4455 Miscellaneous 1,000 1,000

TOTAL REVENUE 3,079,000 3,309,500 20

Revenue


FY 16-17 FY 16-17Acct. No. Original Amend. #1 Notes

5321 Operations Rentals - Equipment 17,000 17,0005330 Equipment Maintenance 3,000 3,0005370 Telephone 20,000 20,0005305 Printing 25,000 25,0005300 Postage 52,000 50,000 215125 Civil Service Assessment 6,500 6,5005230 Office Insurance (ORM) 9,000 9,0005190 Dues & Subscriptions 11,000 7,500 225280 Office Supply Expenses 21,000 21,0005381 Financial Service Charges 50,000 50,0005180 Depreciation of Fixed Assets 64,000 64,0005260 Office Meeting Expenses 1,000 1,0005390 Utilities 11,000 10,000 235270 Miscellaneous 0 0

5105 Acquisitions 25,000 25,000

5350 Personal Services5350 Salaries 1,412,000 1,582,000 245290 Payroll Taxes (FICA + FUTA) 28,000 32,000 255340 Retirement Contributions 525,000 594,000 265220 Health Insurance (SEGBP) 141,000 175,000 275400 Other Post Employment Benefits (OPEB) 156,000 100,000 285152 Board Member Per Diem 30,000 30,000

Professional Services5110 Accounting 25,000 30,000 295250 Legal 25,000 25,0005295 Information Systems 120,000 125,000 305297 Property Management 40,000 40,0005296 Temp. Labor 20,000 20,0005600 Prescription Monitoring Program 80,000 90,000 31

Staff Expenses5361 Travel - Executive Director 10,000 10,0005365 Travel - General Counsel 10,000 10,0005373 Travel - Assistant Executive Director 10,000 10,0005363 Travel - Compliance Officers 5,000 7,000 32

5371+72 Travel - Compliance Officers - Rental & Fuel 17,500 17,5005368 Education - Compliance Officers 10,000 14,000 335366 Travel & Education - Office Staff 1,000 1,000

5362+64+67+74 Mileage - entire staff 20,000 20,000

5153 Board Expenses Meeting Expenses 15,000 15,0005155 Committee Expenses 8,000 8,0005154 Conventions 15,000 20,000 345151 Mileage 15,000 15,000

5286+87+88 President's Expenses 10,000 10,000TOTAL EXPENSES 3,064,000 3,309,500 35

Expenses


FY 16-17 FY 16-17Acct. No. Original Amend. #1

Income Statement

Total Revenue 3,079,000 3,309,500

Total Expenses 3,064,000 3,309,500

Net Ordinary Income 15,000 0

Other Income & Expenses

6003 Investments 0 0

2350 Reserve Accounts (15,000) 0

Net Income 0 0

FY 15-16 FY 16-17 FY 16-17Actual Budget Amend #1

Fund Balance

Beginning Fund Balance 363,796 363,796 1,293,857

Total Income 3,512,690 3,079,000 3,309,500

Total Expenses 2,582,629 3,079,000 3,309,500

Ending Fund Balance 1,293,857 363,796 1,293,857

Reservations of Fund Balance 772,000 1,750,000 1,750,000

Unreserved Fund Balance 521,857 (1,386,204) (456,143)

Notes on Reservation of Fund Balance

Debt Service Payable 0 0 0Net Pension Liability 0 1,000,000 1,000,000Other Post Employment Benefits Payable 572,000 500,000 500,000Continuing Payroll Obligations 150,000 150,000 150,000Land & Building Maintenance 50,000 100,000 100,000

Total 772,000 1,750,000 1,750,000

Summary


Revenue1 Using historical data, estimate 8,150 pharmacists renewing @ $100 each2 Using historical data, estimate 615 new pharmacists @ $300 each3 Using historical data, estimate 6,700 technicians renewing @ $50 each4 Using historical data, estimate 1,400 new candidates @ $25 each5 Using historical data, estimate 2,000 permits renewing + 400 new permits @ $1256 Using historical data7 Using historical data, estimate 480 permits renewing @ $25 each8 Using historical data, estimate 680 permits renewing @ $125 each9 Using historical data, estimate 365 applicants @ $150 each10 Using historical data, estimate 600 applicants @ $100 each11 Using historical data12 Using historical data13 Using historical data14 Using historical data, estimate 80 requests @ $150 each15 Using historical data16 Using historical data17 Reflects 67% of FY 16 collections and 9% of amended revenue projection for FY 1718 Using historical data19 Using historical data, estimate 20,400 assessments @ $25 each20 Reflects 8% increase over original budget, but 5% decrease from FY 16 revenue

Expenses 21 Using historical data, no board member election in FY 1722 Using historical data23 Using historical data24 No performance adjustment; four new positions25 Calculated value: 2% of salaries + temp labor26 Calculated value: 37.2% of salaries27 Calculated value: 11% of salaries28 Using historical data29 Includes accountant fees + fee from legislative auditor30 Includes software maintenance fee + upgrade31 Includes software maintenance fee + upgrade32 Using historical data 33 Includes allowance for two new staff persons34 Using historical data35 Reflects 8% increase over original budget and 28% increase from FY 16 expenses

Notes





Application Review Committee







Reciprocity Committee



NOTE: Pursuant to the Open Meetings Law at La. R.S. 42:16, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, (4) discussions regarding personnel matters, or other purposes itemized at La. R.S. 42:17.



www.pharmacy.la.gov ~ E-mail: [email protected] NOTICE IS HEREBY GIVEN that a meeting of the Reciprocity Committee has been ordered and called for 8:30 a.m. on Wednesday, August 10, 2016 at the Board office, for the purpose to wit:


Revised 08-04-2016 A. Call to Order B. Quorum Call C. Call for Additional Agenda Items & Adoption of Agenda D. Opportunity for Public Comment E. Consideration of Applications

1. PST Applicant ~ Nitesh Ambalal Patel (FL) F. Adjourn







Violations Committee







Impairment Committee



NOTE: Pursuant to the Open Meetings Law at La. R.S. 42:16, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, (4) discussions regarding personnel matters, or other purposes itemized at La. R.S. 42:17..



www.pharmacy.la.gov ~ E-mail: [email protected] NOTICE IS HEREBY GIVEN that a meeting of the Impairment Committee has been ordered and called for 1:00 p.m. on Tuesday, August 9, 2016 at the Board office, for the purpose to wit:


Revised 07-16-2016 1. Call to Order 2. Quorum Call 3. Call for Additional Agenda Items & Adoption of Agenda 4. Opportunity for Public Comment 5. Review of Docket

A. For Acceptance of Voluntary Surrenders of Credentials i. Case No. 16-0153 ~ PST.013683 – Ricky Thomas Guidry

B. Petitions For Reinstatement of Suspended or Lapsed Credentials

i. Case No. 16-0123 ~ PST.020382 – Ashley Elizabeth Reynolds ii. Case No. 16-0161 ~ PST.020248 – Kacie Dore Keith iii. Case No. 16-0171 ~ PST.016606 – Ginger Allen Teekell

C. Petitions for Modification of Previous Orders i. Case No. 16-0149 ~ PST.011925 – Ronald Allen Barrett

D. Applications for a Credential

E. Appearances for Informal Conference

F. Appearances for Guidance

i. Case No. 16-0157 ~ CPT.007011 – Carrie Denise Merritt ii. Case No. 16-0145 ~ CPT.010932 – Samuel Joseph Carruthers

6. Adjourn







Reinstatement Committee






www.pharmacy.la.gov ~ Email: [email protected] NOTICE IS HEREBY GIVEN that a meeting of the Reinstatement Committee has been ordered and called for 8:30 a.m. on Tuesday, August 9, 2016 in the Board office, for the purpose to wit:


Revised 08-04-2016 1. Call to Order 2. Quorum Call 3. Call for Additional Agenda Items & Adoption of Agenda 4. Opportunity for Public Comment 5. Consideration of Applications

A. Petitions for Reinstatement (suspended + lapsed > 5 years)

i. Case No. 16-0111 ~ PST.010943 – Sumitra B. Patel ii. Case No. 16-0200 ~ CPT.006473 – Koya George Williams iii. Case No. 16-0170 ~ CPT.006096 – Stephanie Ann Doyle iv. Case No. 16-0172 ~ PST.013109 – Robin Kaye Kelly v. Case No. 16-0168 ~ CPT.002681 – LueShanda Anise Freeman

B. Petitions for Modification of Previous Orders

i. Case No. 16-0169 ~ PST.016284 – Charles Jude Mitchell, Jr. ii. Case No. 16-0173 ~ PST.010983 – Aaron Wayne Nash

C. Petitions for Return of Inactive Licenses to Active Status

[Note: Appearances are not required for the remaining applicants.]

D. Petitions for Reinstatement (suspended + lapsed > 5 years + chair’s discretion)

i. CPT.017729 – Materra Cotton Comer ii. PST.013109 – Robin Kaye Kelly

E. Applications for Reinstatement of CDS Licenses Lapsed > 5 years

i. CDS.024516.MD – Steven L. Silas ii. CDS.032932.PA – Sharon Elizabeth Robichaux Barras iii. AMS.010010.X – Lane Regional Medical Center Pharmacy iv. CDS.026709.MD – Craig Hannie Crawford v. CDS.024380.MD – Timothy Grant Hammond vi. CDS.036494.DVM – Jennifer Acosta Reeb vii. CDS.08848.DVM - Michael L. Barrington




F. Applications for Reinstatement of CDS Licenses Previously Suspended Secondary

to Action by Another Agency

G. Discretionary Approvals by Committee Chair (lapsed > 1 year but < 5 years) i. CPT.009178 – Joyce Cierra Taylor ii. CDS.038016.MD – Uma Menon iii. CPT.007560 – Katherine Denicola Ferris iv. CDS.033687.MD – Stephen Fitzgerald v. CDS.037256.MD – Uri Gedalia vi. CDS.020164.MD – Arvind Venkata Peddada vii. CDS.044100.MD - Torrance Tremayne Green viii. CDS.037910.MD - Kiran K. Anand ix. CDS.041896.DVM – Billie Michelle Zeller-Barrett x. PST.009927 – Anthony John Bouligny xi. CDS.029681.DPM – Charlotte Vang xii. CDS.034127.PA - Brianne L. Hamilton xiii. CPT.009524 – Kwydwn Kwola Shields xiv. PST.018048 – Lanier Cito Evans xv. CPT.011905 – Rosemary Etchi Agbor xvi. CPT.009763 – Dashun Omar Fairley xvii. PST.019029 – Victoria Lynn Lotzow xviii. CPT.009616 – Victoria Lee Stains xix. CDS.03250.DVM – Mark Joseph Acierno xx. CDS.022686.MD – William H. Reinbold xxi. CDS.011202.MD – Therryll L. Johnson xxii. CDS.034838.APN – Angela Marie Fellows xxiii. CDS.033507.APN – Catherine Ann Pourciau xxiv. CDS.044605.MD – Grady P. Creek xxv. CDS.044515.DDS – Frank Von Westernhagen xxvi. CDS.045036.MD – George Mina xxvii. CDS.024189.MD – Virgina Herbert McDougall xxviii. CDS.044091.MD – Christopher Alan Sanchez xxix. CPT.009028 – Treshone Monique Turner

H. Staff Approvals by Board Policy (lapsed < 1 year)

i. CDS.044215.MD – Lauren Keegan Dozier ii. CPT.010551 - Katie A. Hondroulis iii. CDS.044285.MD – Douglas Michael Hildrew iv. CDS.031728.MD – Christian Aldrich Hall v. CDS.033237.DDS – Jovain S. Monette vi. CDS.044275.DVM – Lucy Yvonne Newsom vii. CDS.016951.DVM – Melanie Kristine Tichenor viii. CDS.041894.APN – Angela Marie Bradley-Byers ix. CDS.046073.HOS – Ochsner Children’s Health Center x. CDS.045527.APN – Nancy Hopper Miller xi. CDS.035307.RES – Yunfeng Zhao xii. CDS.042778.DVM – Mark Anthony Gentry xiii. CDS.043681.DVM – Jessica Marie Kappler Hamilton xiv. CDS.045614.MD – Ryan Michael Rhodes xv. CDS.036821.DVM – Lauren T. Harper


xvi. CDS.041543.MD – Sandra A. Rhoden xvii. CDS.016118.DDS – Maureen Sheridan Fenton xviii. CDS.043738.DDS – Chrishelle Williams Hemphill xix. CDS.046086.MD – Andrew Rushing Conger xx. CDS.044048.MD – Leeor Moshe Jaffe xxi. CDS.046064.APN – Amanda Kay Hundley xxii. CDS.044024.PA – Trenise Robinson Martinez xxiii. CDS.020956.DDS – Laura Anne Earnest xxiv. CDS.019103.DDS – Ellis D. Braud, Jr. xxv. CDS.046144.APN – Dorothy Ewen xxvi. CDS.042933.APN - Wanda Lynn Pezant xxvii. PHY.006848.NR - Biomed Pharmaceuticals xxviii. CPT.009653 - Ashley Rena Johnson xxix. CDS.036468.RES – Jason D. Gardner xxx. PST.020580 - Rhondreka Jeannine Hughes xxxi. CDS.040163.MD - Avinash Shrinivas Deshpande xxxii. CDS.026100.MD - Mark Bernard Carbon xxxiii. CPT.06147 - Rickey O'Neal Watkins xxxiv. CDS.040318.MD - Thirumalini Dasari xxxv. DME.000442 - All Star Home Medical Equipment xxxvi. CDS.030280.DDS - Damaris D. Bastian xxxvii. CDS.016975.DVM - Roberta Dicks McKowen xxxviii. CDS.045397.MD - Jennifer Coleen Creedon xxxix. CDS.043132.MD - Michael John Heffernan

xl. CDS.033076.MD - Mark Wayne Morgan xli. CDS.046265.MD - Amy Michele Wood xlii. PHY.006117.NR – ARJ Infusion Services xliii. PST.017690 – Letrece Denise Scott xliv. CDS.041560.MD – William W. Lunn xlv. CDS.045429.APN – Shawanna Marie Guillory xlvi. CDS.046253.DVM – Allyson Babin Gammill xlvii. CDS.037458.APN – Amber L. Berry xlviii. CDS.024940.DVM – Jeffery C. Aguillard xlix. CDS.030691.MD – Cheryl Denise Randal Knatt

l. CPT.007823 – Sarah Rebecca Sonderman li. CDS.027916.MD - Godwin Chukwuma Ogbuokiri lii. CDS.035446.DDS - Paola Maria Donaire liii. CDS.023369.MD - Joshua Kaufman liv. CDS.020448.MD - Kathleen Marie Jones lv. CDS.020338.MD - Diane Emily Pierce lvi. CDS.021060.MD - Ali Mansouri lvii. CDS.039820.APN – Margaret S. Evans lviii. CDS.037840.HOS – Bastrop Rehabilitation Hospital, LLC lix. CDS.036675.MD – Marga F. Massey

6. Adjourn





Tripartite Committee







Regulation Revision Committee



Louisiana Administrative Code

Title 46 – Professional and Occupational Standards

Part LIII: Pharmacists Chapter 23. Nonresident Pharmacy … §2303. Nonresident Pharmacy Requirements … §2305. Nonresident Permit Requirements … §2307. Pharmacist-in-Charge

A. The opportunity to accept an appointment as the pharmacist-in-charge (PIC) of a pharmacy is a professional privilege. The following requirements are attached to a PIC privilege:

1. The acquisition of the PIC privilege shall require: a. Possession of an active Louisiana pharmacist license; b. Possession of an active license in the state in which the pharmacy is located, and

further, said license shall not have any restrictions which prohibit the position of pharmacist-in-charge;

c. Active practice as a pharmacist for a minimum of two years under the jurisdiction of any board of pharmacy in the United States; and

d. The completion of the Affidavit of Responsibility and Duties described below. 2. The PIC shall be present and practicing at the pharmacy for which he holds the PIC position

no less than 20 hours per week during the pharmacy’s ordinary course of business. In the event the pharmacy’s normal hours of business are less than 20 hours per week, the PIC shall be present and practicing at least 50 percent of the normal business hours.

B. An initial and renewal pharmacy permit application shall designate and identify the licensed pharmacist-in-charge.

C – J. …

AUTHORITY NOTE: Promulgated in accordance with R.S. 37:1182. HISTORICAL NOTE: Promulgated by the Department of Health and Hospitals, Board of Pharmacy, LR 14:708 (October 1988), effective January 1, 1989, amended LR 18:1381 (December 1992) effective January 1, 1993, amended LR 29:2100 (October 2003), effective January 1, 2004, amended LR 33:1133 (June 2007), amended LR … §2317. Nonresident Pharmacy Closure Procedures …




Summary of Testimony & Public Comments re

Regulatory Project 2016-2 ~ Pharmacist-in-Charge in Nonresident Pharmacies at

May 25, 2016 Public Hearing No comments were received prior to or during the public hearing or prior to the deadline. We did receive a letter from John Rocchio on behalf of CVS Health after the deadline; it is included in the compilation for the Board’s consideration. On behalf of CVS Health, Dr. Rocchio objects to the proposed amendment requiring the pharmacist-in-charge to have acquired at least two years of licensed pharmacist practice, as well as to the proposed amendment requiring the pharmacist-in-charge to be physically present and practicing in the pharmacy for any period of time. In particular, the objection points to the potential for therapy interruption when the pharmacist-in-charge leaves that position and there is no qualified pharmacist-in-charge to replace the departing pharmacist.



WCVSHea1th One CVS DriveWoonsockel, RI 02895

May 25, 2016

Louisiana Board of PharmacyMalcolm BroussardExecutive Director3388 Brentwood DriveBaton Rouge, LA 70809

Dear Mr. Broussard,

I am writing to you in my capacity as Director of Regulatory Affairs for CVS Health and its familyof pharmacies located across the United States. CVS Health appreciates the opportunity to submitcomments on the proposed amendments to LAC 46:L[1L2519. Medication Synchronization, andLAC 46:LIll.2307, Nonresident Pharmacist in Charge.

Re: [SAC 46:LLII.2519 Medication Synchronization

CVS Health supports this amendment.

This amendment serves to assist pharmacists in aligning the often complex schedule of prescriptionmedications to assist patients in adherence to treatment. CVS Health commends the Board on theirefforts to enable pharmacists to adjust dispensed quantities to assist their patients, leading to fewermissed doses and better outcomes.

Re: [SAC 46:LJII.2307 Pharmacist in Charge

CVS Health opposes these amendments.

CVS Health understands the Board has initiated the rulemaking process to amend LAC461111.2307 for the Pharmacist-in-Charge (PlC) of a nonresident pharmacy to require his or herphysical presence in the pharmacy for a certain amount of hours per week and to have completed aminimum duration of !icensure.

These amendments, specifically A(l)(c) and A(2). place requirements on a nonresident PlC thatwhile on its face appear to be equivalent to the requirements for an in-state PlC. but in effect put adisproportionate burden on a nonresident pharmacy when compared to the effect of the proposedamendment to an in-state pharmacy.

A nonresident pharmacy. by the nature of being located outside of the state of Louisiana. wouldhave a limited number of Louisiana licensed pharmacists as compared to pharmacies withinLouisiana. Therefore. when a nonresident pharmacy experiences the turnover of the Louisiananonresident PlC, the pharmacy may have to cease dispensing to the residents of the state ofLouisiana until the Louisiana nonresident PlC is replaced. This existing hardship is compoundedby the proposed amendments limiting the pool of viable nonresident PlC candidates to those thathave practiced for 2 years and that meet the minimum hourly on site requirements. The ensuing

CVS pharmacy / caremark / minute clinic / specialty

*CVSHealth

delay of identifying a successor could cause an immediate impact to patient safety with thepotential resultant lapse in therapy.

Any disparate application of regulations, that burdens interstate commerce without the benefit ofprotecting the safety or health of the citizens of the state of Louisiana, is subject to scrutiny underthe Commerce Clause of the United States Constitution. CVS Health strongly believes that theapplication of the in-state licensure duration requirement, as well as, the in-state physical presencein the pharmacy for a certain amount of time per week requirement would burden nonresidentpharmacy practice disproportionately to in state pharmacy practice. We ask the Board to weigh thebenefit of added requirements to nonresident PlC licensure compared to the potential negativeeffect on the residents of the state of Louisiana, and to provide clarity around the specific patientsafety concerns which prompted the amendments.

CVS Health appreciates the opportunity to submit comments for the proposed amendments. It is ourstrong recommendation that the Board of Pharmacy carefully study the value of requiring anonresident PlC to meet in state requirements compared to the potential safety and health issuesthat may occur when the inevitable lapse of therapy occurs. It is our belief that the proposedamendments to chapter 2307 place an additional, disproportionate burden on nonresidentpharmacies compared to Louisiana pharmacies. CVS Health would welcome the opportunity toparticipate in a joint Board of Pharmacy and industry work group to review current nonresidentpermit requirements. If you have any questions or require additional information, please contact medirectly at 617-599-9091.

Sincerely,

/4 .0’ / .—

VJohn N. Rocchio PharmD. RPh.Director, Pharmacy Regulatory Affairs

CVS pharmacy / caremark / minute clinic / specialty

Malcolm J. Broussard

From: Malcolm J. BroussardSent: Tuesday, May31, 2016 10:46AMTo: ‘Rocchio, John N.’Subject: RE: CVS Health Comments

Dr. Rocchio,

This will confirm receipt of your letter in our office on Thursday, May 26, 2016. I will relay your comments to the Boardfor their consideration; however, lam obliged to inform them your letter arrived after the deadline for receipt of suchcomments.

Thank you for your interest in our rulemaking process.

Malcolm J BroussardExecutive DirectorLouisiana Board of Pharmacy3388 Brentwood DriveBaton Rouge, LA 70809-1700United States of AmericaTelephone +1.225.925.6481Telecopier [email protected]

From: Rocchio, John N. [mailto:[email protected]: Thursday, May 26, 2016 7:12 AMTo: Malcolm J. BroussardCc: Rocchio, John N.Subject: CVS Health Comments

Malcolm,

I hope this message finds you well. I had hoped to provide the attached comments prior to the deadline yesterday butunfortunately matters did not work out as intended. That being said, I feel it is important to provide our thoughts on theamendments. Please let me know if you would like to discuss further or if you have any questions. Thank you and Ihope to see you soon.

Sincerely,

John

John N. Rocchio PharmU. RPh.Director, Phanriacy Regulatory AffairsCVS HealthCell: 617-599-9091Fax: 401-733-0469

1

Regulatory Proposal 2016-A ~ Marijuana Pharmacy Draft #4

Page 1 of 22

Louisiana Administrative Code 1 2

Title 46 – Professional and Occupational Standards 3 4

Part LIII: Pharmacists 5 6 Chapter 24. Limited Service Providers 7 8

Subchapter E. Marijuana Pharmacy 9 10 §2440. Preamble; warning; consultation suggested 11

A. Pursuant to Act 261 of the Regular Session of the 2015 Louisiana Legislature as well as the subsequent 12 amendment found in Act 96 of the Regular Session of the 2016 Louisiana Legislature, the Louisiana 13 Board of Pharmacy was directed to: 14 1. Develop an annual, nontransferable specialty license for a pharmacy to dispense recommended 15

marijuana for therapeutic use, to limit the number of such licenses to a maximum of ten, and to 16 adopt rules regarding the geographical locations of dispensing pharmacies in the state; and 17

2. Adopt rules relating to the dispensing of recommended marijuana for therapeutic use, with such 18 rules to include, at a minimum, the following: 19 a. Standards, procedures, and protocols for the effective use of recommended marijuana for 20

therapeutic use as authorized by state law and related rules; 21 b. Standards, procedures, and protocols for the dispensing and tracking of recommended 22

therapeutic marijuana; 23 c. Procedures and protocols to provide that no recommended therapeutic marijuana may be 24

dispensed from, produced from, obtained from, sold to, or transferred to a location outside of 25 this state; 26

d. Standards, procedures, and protocols for determining the amount of usable recommended 27 therapeutic marijuana that is necessary to constitute an adequate supply to ensure 28 uninterrupted availability for a period of one month, including amount for topical treatments; 29

e. Standards, procedures, and protocols to ensure all recommended therapeutic marijuana 30 dispensed is consistently pharmaceutical grade; 31

f. Standards and procedures for the revocation, suspension, and nonrenewal of licenses; 32 g. Other licensing, renewal, and operational standards deemed necessary by the Louisiana Board 33

of Pharmacy; 34 h. Standards and procedures for testing recommended therapeutic marijuana samples for levels 35

of tetrahydrocannabinols (THC) or other testing parameters deemed appropriate by the 36 Louisiana Board of Pharmacy; 37

i. Standards for the protection of health, safety, and security for dispensers of recommended 38 therapeutic marijuana; 39

j. Standards for the licensure of dispensers of recommended therapeutic marijuana; and 40 k. Standards for financial capacity to operate a marijuana pharmacy. 41

B. Marijuana is classified as a Schedule I controlled substance by the U.S. Department of Justice, Drug 42 Enforcement Administration. 43 1. As provided by the federal Controlled Substances Act, the procurement, possession, prescribing, 44

distribution, dispensing, or administering of any Schedule I controlled substance, including 45 marijuana, is a violation of federal law. 46

2. Neither Louisiana law nor the board’s rules can preempt federal law. Therefore, the provisions of 47 this Subchapter notwithstanding, persons engaged in the activities described herein remain subject 48 to the full force of federal law enforcement, including arrest and prosecution of criminal charges, 49 the assessment of civil fines and forfeitures, as well as administrative consequences such as 50 forfeiture of federal controlled substance registrations and exclusion from Medicare and other 51 federal payer programs. 52


Page 2 of 22

C. For the foregoing reasons, pharmacists and other persons credentialed by the board may wish to 53 consult with their own legal counsel as well as any health care facility, private or governmental payor 54 with which they are affiliated, professional liability insurers, and financial institutions with which they 55 maintain depository relationships before engaging in the activities described herein. 56

57 AUTHORITY NOTE: Promulgated in accordance with R.S. 40:1046. 58 HISTORICAL NOTE: Promulgated by the Department of Health, Board of Pharmacy, LR 59 60 §2441. Definitions 61

A. As used in this Subchapter, the following terms shall have the meaning ascribed to them in this 62 Section: 63 1. Administer means the direct application of marijuana to the body of a qualifying patient by 64

ingestion or any other means. 65 2. Advertisement means all representations disseminated in any manner or by any means, other than 66

by labeling, for the purpose of inducing, or which are likely to induce, directly or indirectly, the 67 purchase of marijuana. 68

3. Agent means an authorized person who acts on behalf of or at the direction of another person. It 69 does not include a common or contract carrier, public warehouseman, or employee of the carrier 70 or warehouseman. 71

4. Approved safe means a safe which conforms to or exceeds all of the following standards: 72 a. Shall have the following specifications or the equivalent: 30 man-minutes against 73

surreptitious entry, 10 man-minutes against forced entry, 20 man-hours against lock 74 manipulation, and 20 man-hours against radiological techniques; 75

b. If it weighs less than 750 pounds, is bolted or cemented to the floor or wall in such a way it 76 cannot be readily removed; and 77

c. Depending upon the quantities stored, is equipped with an alarm system which, upon 78 attempted unauthorized entry, shall transmit a signal directly to a central protection company 79 or a local or state police agency which has a legal duty to respond, or a 24-hour control station 80 operated by the licensee, or such other protection as the board or its designee may approve. 81

5. Approved vault means: 82 a. A vault constructed before, or under construction on, September 1, 1971, which is of 83

substantial construction with a steel door, combination or key lock, and an alarm system; or 84 b. A vault constructed after September 1, 1971: 85

i. The walls, floors, and ceilings of which are constructed of at least eight inches of 86 reinforced concrete or other substantial masonry, reinforced vertically and horizontally 87

with one-half inch steel rods tied six inches on center, or the structural equivalent to such 88 reinforced walls, floors, and ceilings; 89 ii. The door and frame unit of which vault shall conform to the following specifications or 90 the equivalent: 30 man-minutes against surreptitious entry, 10 man-minutes against 91 forced entry, 20 man-hours against lock manipulation, and 20 man-hours against 92 radiological techniques; 93 iii. Which vault, if operations require it to remain open for frequent access, is equipped with 94 a “day gate” which is self-closing and self-locking or the equivalent, for use during the 95 hours of operation in which the vault door is open; 96 iv. The walls or perimeter of which are equipped with an alarm which, upon unauthorized 97

entry, shall transmit a signal directly to a central station protection company, or a local or 98 state police agency which has a legal responsibility to respond, or a 24-hour control 99 station operated by the licensee, or such other protection as the board or its designee may 100 approve, and if necessary, alarm buttons at strategic points of entry to the perimeter area 101 of the vault; 102

v. The door of which shall be equipped with one or more contact switches; and 103 vi. Which vault has one of the following: 104

(a) Complete electrical lacing of the walls, floor and ceiling; 105 (b) Sensitive ultrasonic equipment within the vault; 106


Page 3 of 22

(c) Sensitive sound accumulator system; or 107 (d) Such other device designed to detect illegal entry as may be approved by the 108

board. 109 6. Board means the Louisiana Board of Pharmacy. 110 7. CFR means Code of Federal Regulations. 111 8. Deliver or delivery means the actual, constructive or attempted transfer from one person to another 112

of marijuana, whether or not there is an agency relationship. 113 9. Financial interest means any actual, or a future right to, ownership, investment or compensation 114

arrangement with another person, either directly or indirectly, through business, investment or 115 immediate family. Financial interest does not include ownership of investment securities in a 116 publicly-held corporation that is traded on a national exchange or over-the-counter market, 117 provided the investment securities held by such person do not exceed five per cent of the total 118 number of shares issued by the corporation. 119

10. Immediate family shall have the same meaning as provided in La. R.S. 42:1102, i.e., his children 120 and the spouses of his children, his brothers and their spouses, his sisters and their spouses, his 121 parents, his spouse, and the parents of his spouse. 122

11. LDAF means the Louisiana Department of Agriculture and Forestry. 123 12. LDH means the Louisiana Department of Health. 124 13. Louisiana Medical Marijuana Tracking System (LMMTS) means the required seed-to-sale tracking 125

system that tracks medical marijuana from either the seed or immature plant stage until the 126 product is sold to a pharmacy or is destroyed. 127

14. Marijuana means all parts of plants of the genus Cannabis, whether growing or not, the seeds 128 thereof, the resin extracted from any part of such plant, and every compound, manufacture, salt, 129 derivative, mixture, or preparation of such plant, its seeds or resin, but shall not include the mature 130 stalks of such plant, fiber produced from such stalks, oil or cake made from the seeds of such 131 plant, any other compound, manufacture, salt, derivative, mixture, or preparation of such mature 132 stalks (except the resin extracted therefrom), fiber, oil, or cake, or the sterilized seed of such plant 133 which is incapable of germination. 134

15. Marijuana pharmacy means that area within a facility where marijuana is stored, dispensed, and 135 sold. If a facility does not offer any products or services other than marijuana and/or related 136 supplies, the entire facility is a marijuana pharmacy for the purposes of this Subchapter. 137

16. Marijuana pharmacy owner means any person with an ownership interest in a marijuana 138 pharmacy, except the term does not include a person with an investment interest through a 139 publicly-held company provided the interest held by such person does not exceed five per cent of 140 the total ownership or interest rights in such pharmacy and such person does not participate 141 directly or indirectly in the control, management, or operation of the pharmacy. 142

17. Marijuana product means any product containing marijuana, including raw materials, that requires 143 no further processing and that is packaged for sale to pharmacies, qualifying patients and primary 144 caregivers. 145

18. Owner’s managing officer means the person designated by the organization owning the pharmacy 146 to be responsible to the board for the proper operation of the pharmacy in compliance with all 147 applicable laws and regulations. 148

19. Pharmaceutical grade marijuana means marijuana or marijuana products that are not adulterated 149 and are: 150 a. Processed, packaged and labeled according to the United States Food & Drug 151

Administration’s “Current Good Manufacturing Practice in Manufacturing, Packaging, 152 Labeling, or Holding Operations for Dietary Supplements” as found in 21 CFR 111 or its 153 successor; 154

b. Labeled with the results of an active ingredient analysis, a microbiological contaminants 155 analysis, a mycotoxin analysis, a heavy metal analysis, and a pesticide chemical residue 156 analysis which have been completed on a batch basis by a laboratory; and 157

c. Where each step of the production, cultivating, trimming, curing, manufacturing, processing, 158 and packaging method has been documented by using standard operation procedures 159 approved by the Commissioner of the Louisiana Department of Agriculture and Forestry. 160


Page 4 of 22

20. Pharmacist means an individual currently licensed by the board to engage in the practice of 161 pharmacy. 162

21. Pharmacy technician means an individual who assists in the practice of pharmacy under the direct 163 and immediate supervision of a licensed pharmacist and is currently certified to do so by the 164 board. 165

22. Physician means an individual currently licensed by the Louisiana State Board of Medical 166 Examiners to engage in the practice of medicine. 167

23. Prescription monitoring program (PMP) means the electronic prescription drug monitoring 168 program established by La. R.S. 40:1001 et seq. 169

24. Producer means a person licensed by the Louisiana Department of Agriculture and Forestry to 170 cultivate marijuana for therapeutic use. 171

25. Production or produce means the manufacture, planting, preparation, cultivation, growing, 172 harvesting, propagation, compounding, conversion or processing of marijuana, either directly or 173 indirectly by extraction from substances of natural origin, or independently by means of chemical 174 synthesis, or by a combination of extraction and chemical synthesis, and includes any packaging 175 or repackaging of the substance or labeling or relabeling of its container, except that this term does 176 not include the preparation or compounding of marijuana by a patient or caregiver for the patient’s 177 use. 178

26. Production facility means a secure, indoor facility where the production of marijuana occurs and 179 that is operated by a person to whom the Louisiana Department of Agriculture and Forestry has 180 issued a producer license. 181

27. Sale is any form of delivery, which includes barter, exchange or gift, or offer therefor, and each 182 such transaction made by any person whether as principal, proprietor, agent, servant, or employee. 183

28. Usable marijuana means the dried leaves and flowers of the marijuana plant, and any mixtures or 184 preparations of such leaves and flowers, that are appropriate for the therapeutic use of marijuana, 185 but does not include the seeds, stalks, and roots of the marijuana plan. 186

187 AUTHORITY NOTE: Promulgated in accordance with R.S. 40:1046. 188 HISTORICAL NOTE: Promulgated by the Department of Health, Board of Pharmacy, LR 189 190 §2443. Marijuana products 191

A. Exclusive Source. 192 1. The exclusive source of marijuana products shall be the producer licensed for that activity by the 193

Louisiana Department of Agriculture and Forestry (LDAF). 194 2. That producer shall prepare pharmaceutical grade marijuana products for distribution to the 195

marijuana pharmacies licensed by the board. 196 3. Marijuana products from any other source shall be deemed misbranded and/or adulterated and 197

shall not be distributed to any marijuana pharmacy, nor may such misbranded and/or adulterated 198 products be dispensed by any marijuana pharmacy. 199

B. Laboratory Testing. 200 1. Prior to manufacturing any marijuana product, the producer shall segregate all harvested 201

marijuana into homogenized batches. 202 2. A producer shall make available each such batch at the production facility for testing by a 203

laboratory approved by LDAF. The laboratory employee shall select a random sample from each 204 batch. The laboratory shall test each sample for microbiological contaminants, mycotoxins, heavy 205 metals, pesticide chemical residue, residual solvents, homogeneity, and for the purpose of 206 conducting an active ingredient analysis. 207

3. From the time that a batch of marijuana has been homogenized for sample testing and eventual 208 packaging and sale to a pharmacy until the laboratory provides the results from its tests and 209 analyses, the producer shall segregate and withhold from use the entire batch with the exception of 210 the samples removed by the laboratory for testing. During this period of segregation, the producer 211 shall maintain the marijuana batch in a secure, cool and dry location so as to prevent the marijuana 212 from becoming contaminated or losing its efficacy. Under no circumstances shall a producer 213 include marijuana in a marijuana product or sell it to a pharmacy prior to the time the laboratory 214


Page 5 of 22

has completed its testing and analysis and provided those results, in written or electronic form, to 215 the producer or the producer’s designated employee. 216

4. The laboratory shall immediately return or dispose of any marijuana upon the completion of any 217 testing, use, or research. When the laboratory disposes of marijuana, the laboratory shall comply 218 with the marijuana disposal rules promulgated by LDAF. 219

5. In the event a sample of marijuana does not pass the microbiological, mycotoxin, heavy metal, 220 pesticide chemical residue, residual solvent, or homogeneity test based on the standards set forth 221 in this Section, the producer shall dispose of the entire batch from which the sample was taken, in 222 compliance with the marijuana disposal rules promulgated by LDAF. 223 a. With respect to the microbiological test, a marijuana sample shall be deemed to have passed if 224

it satisfies the standards set forth in Chapter 1111 – Microbiological Examination of 225 Nonsterile Products: Acceptance Criteria for Pharmaceutical Preparations and Substances 226 for Pharmaceutical Use of the United States Pharmacopeia (USP), available at www.usp.org. 227

b. With respect to the mycotoxins test, a marijuana sample shall be deemed to have passed it 228 meets the following standards: 229 i. Aflatoxin B1 < 20 parts per billion (ppb); 230 ii. Aflatoxin B2 < 20 ppb; 231 iii. Aflatoxin G1 < 20 ppb; 232 iv. Aflatoxin G2 < 20 ppb; and 233 v. Ochratoxin A < 20 ppb. 234

c. With respect to the heavy metals test, a marijuana sample shall be deemed to have passed if it 235 meets the following standards: 236 i. Arsenic < 10 parts per million (ppm); 237 ii. Cadmium < 4.1 ppm; 238 iii. Lead < 10 ppm; and 239 iv. Mercury < 2 ppm 240

d. With respect to the pesticide chemical residue test, a marijuana sample shall be deemed to 241 have passed if it satisfies the most stringent acceptable standard for a pesticide chemical 242 residue in any food item as set forth in Subpart C of the United States Environmental 243 Protection Agency’s “Tolerances and Exemptions for Pesticide Chemical Residues in Food”, 244 as found in 40 CFR 180 or its successor. 245

e. With respect to the residual solvent test, a marijuana sample shall be deemed to have passed if 246 the following solvents are below the listed limits: 247 i. Butanes < 800 ppm; 248 ii. Heptanes < 500 ppm; 249 iii. Benzene < 1 ppm; 250 iv. Toluene < 1 ppm; 251 v. Hexanes < 10 ppm; and 252 vi. Total Xylenes < 1 ppm. 253

f. With respect to the test for homogeneity, a marijuana sample shall be deemed to have failed if 254 ten percent of the sample contains more than twenty percent of the total active ingredient. 255

g. With respect to the analysis of active ingredients, the following substances, when present, 256 shall be identified and measured. The maximum variance permitted is fifteen percent from 257 the labeled amount. For example, a product labeled as containing 10 milligrams of 258 tetrahydrocannabinol (THC) shall contain no less than 8.5 milligrams THC and no more than 259 11.5 milligram THC. 260 i. THC (tetrahydrocannabinol); 261 ii. THCA (tetrahydrocannabinolic acid); 262 iii. CBD (cannabidiol); and 263 iv. CBDA (cannabidiolic acid). 264

6. If a sample of marijuana passes the microbiological, mycotoxin, heavy metal, pesticide chemical 265 residue, residual solvent, and homogeneity tests, the laboratory shall release the entire batch for 266 immediate manufacturing, packaging, and labeling for sale to a marijuana pharmacy. 267

http://www.usp.org/


Page 6 of 22

7. In the event of any test failure, the laboratory shall transmit to LDAF an electronic copy of such 268 test result at the same time it transmits those results to the producer. 269

8. The laboratory shall comply with all rules applicable to the testing of marijuana promulgated by 270 LDAF. 271

9. A producer shall provide the laboratory test results to the marijuana pharmacy for each batch of 272 marijuana used in a product acquired by the marijuana pharmacy. The pharmacy shall make such 273 testing results available upon request to their patients, caregivers, and physicians who 274 recommended such marijuana products dispensed to their patients. 275

C. Product Dosage Forms. 276 1. The producer shall limit their production of pharmaceutical grade marijuana products to the 277

following dosage forms: 278 a. Oils, extracts, tinctures, or sprays; 279 b. Capsules or pills; 280 c. Topical applications, oils or lotions; 281 d. Transdermal patches; or 282 e. Suppositories. 283

2. No marijuana product shall: 284 a. Include alcoholic liquor, dietary supplements, or any drug, except for pharmaceutical grade 285

marijuana. For purposes of this provision, alcoholic liquor does not include any liquid or 286 solid containing less than one-half of one percent of alcohol by volume, or ethanol-based 287 tinctures; 288

b. Be manufactured or sold as a beverage or confectionary; 289 c. Be manufactured or sold in a form or with a design that: 290

i. Is obscene or indecent; 291 ii. May encourage the use of marijuana for recreational purposes; 292 iii. May encourage the use of marijuana for a condition other than a debilitating medical 293 condition; or 294 iv. Is customarily associated with persons under the age of eighteen; or 295

d. Have had pesticide chemicals or organic solvents used during the production or 296 manufacturing process other than those which may be approved by the Commissioner of 297 LDAF. 298

3. Any marijuana product not incompliance with the provisions of this Paragraph shall be deemed 299 adulterated. 300

D. Packaging and Labeling Requirements. 301 1. Packaging. 302

a. The producer shall ensure every product intended for dispensing to a patient is placed within a 303 child-resistant, light-resistant, tamper-evident container prior to sale or transport to the 304 pharmacy. 305 i. A package shall be deemed child-resistant if it satisfies the standard for ‘special 306 packaging’ as set forth in the United States Consumer Product Safety Commission’s 307 Poison Prevention Packaging as found in 16 CFR 1700.1(b)(4) or its successor. 308 ii. A package shall be deemed light-resistant if it satisfies the standard set forth in Chapter 309 671 – Containers: Performance Testing of the United States Pharmacopeia (USP). 310 iii. A package shall be deemed tamper-evident if it clearly indicates prior access to the 311 container. 312

b. Any product containing pharmaceutical grade marijuana or its principal psychoactive 313 constituent tetrahydrocannabinol (THC) shall be packaged so that one dose contains no more 314 than 10 milligrams of THC. 315

c. If it is not intended for the entire product to be used at a single time, the packaging must be re-316 sealable in a manner that maintains its child-resistant property for multiple openings. Single 317 doses may be placed in a package with other single doses; however, the total amount of active 318 THC contained within the larger packaging shall not exceed 100 milligrams. 319

d. No single container shall contain more than a one month supply of marijuana. 320 e. Packaging selected by the producer shall be subject to the following restrictions. 321


Page 7 of 22

i. Shall not specifically target individuals under the age of 21 years; 322 ii. Shall not bear any resemblance to a trademarked, characteristic or product-specialized 323 packaging of any commercially available candy, snack, baked good or beverage; 324 iii. Shall not use the words “candy” or “candies”; 325 iv. Shall not use a cartoon, color scheme, image, graphic or feature that might make the 326 package attractive to children; and 327 v. Shall not use a seal, flag, crest, coat of arms or other insignia that could reasonably lead 328 any person to believe the product has been endorsed, manufactured by, or used by any 329 state, parish, municipality, or any agent thereof. 330

2. Labeling. 331 a. Each product shall be labeled by the producer prior to its sale to the marijuana pharmacy. 332

Each label shall be securely affixed to the package and shall include, at a minimum: 333 i. The batch or lot number assigned by the producer to the marijuana plant(s) from which 334 the marijuana used in the product was harvested; 335 ii. A complete list of solvents, chemicals, and pesticides used in the creation of any 336 marijuana concentrate; 337 iii. A complete list of all ingredients used to manufacture the product, which may include a 338 list of any potential allergens contained within, or used in the manufacture of, a product; 339 iv. The potency of the THC and CBD in the product, expressed in milligrams for each 340 cannabinoids; 341 v. The net weight, using a standard of measure compatible with the LMMTS, of the 342 product prior to its placement in the shipping container; 343 vi. A product expiration date, upon which the product will no longer be fit for use. Once a 344 label with an expiration date has been affixed to a product, the producer shall not 345 alter that date or affix a new label with a later date; and 346 vii. A statement the product has been tested for contaminants, that there were no adverse 347 findings, and the date of such testing. 348

b. The labeling text on any marijuana product shall not make any false or misleading statements 349 regarding health or physical benefits to the consumer. Further, each label shall include all of 350 the following statements: 351 i. “Contains Marijuana. For Medical Use Only. KEEP OUT OF THE REACH OF 352 CHILDREN.” 353 ii. “Marijuana can impair concentration, coordination, and judgment. Do not operate a 354 vehicle or machinery under the influence of this drug.” 355 iii. “There may be additional health risks associated with the consumption of this product 356 for women who are pregnant, breastfeeding, or planning to become pregnant.” 357 iv. A statement that it is illegal for any person to possess or consume the contents of the 358 package other than the patient for whom it was recommended. 359

c. The labeling text required by this Section shall be no smaller than 1/16 of an inch, shall be 360 printed in English, and must be unobstructed and conspicuous. 361

E. Distribution of Marijuana Products to Marijuana Pharmacies. 362 1. The producer shall maintain complete inventory records in the Louisiana Medical Marijuana 363

Tracking System (LMMTS), as required and delineated in rules promulgated by LDAF. 364 2. The producer shall maintain comprehensive records in LMMTS of all marijuana products 365

distributed to the marijuana pharmacies, whether by transport and delivery to the pharmacy or by 366 transfer to the agent of the pharmacy at the production facility. 367

3. In the event the producer delivers the products to the pharmacy, such activities must be in 368 compliance with the rules for that activity promulgated by LDAF. 369

4. In the event the pharmacy elects to send an agent to the production facility to retrieve products 370 ordered by the pharmacy, the personnel at the production facility shall verify the identity and 371 credentials of the pharmacy’s agent before releasing the products to the agent. 372 a. The producer shall provide a copy of the transport manifest generated by LMMTS, which 373

shall contain the following information: 374 i. The name and address of the producer selling the product; 375


Page 8 of 22

ii. The name and address of the pharmacy purchasing the product; 376 iii. The name and quantity (by weight or unit) of marijuana products included in the 377 delivery; 378 iv. The date of transport and time of departure from the production facility; 379

v. The make, model, and license plate number of the delivery vehicle; 380 vi. The date and time of arrival at the pharmacy; and 381 vii. The name and signature of the pharmacy’s agent. 382

b. The pharmacy’s agent shall compare the transport manifest to the products transferred to his 383 possession, and when correct, shall return a signed copy of the manifest to the producer before 384 departing from the production facility. 385

c. The pharmacy’s agent shall place the products in a locked, safe, and secure storage 386 compartment that is part of the motor vehicle, or in the alternative, in a locked storage 387 container that has a separate key or combination pad, and further, the product shall not visible 388 or recognizable from outside the vehicle, and further, the vehicle shall not bear the name of 389 the pharmacy or any markings to indicate the vehicle contains marijuana 390

d. The pharmacy’s agent shall maintain physical control of the vehicle at all times during the 391 transport, and shall not leave the vehicle unattended at any time. 392

e. The pharmacy’s agent shall have access to a secure form of communication with the 393 pharmacy as well as the ability to contact law enforcement through the 911 emergency 394 system. 395

f. Upon arrival at the pharmacy, the pharmacy’s agent shall deliver the product to a pharmacist 396 for verification of receipt; the pharmacist shall time, date, and sign the delivery manifest. 397

398 AUTHORITY NOTE: Promulgated in accordance with R.S. 40:1046. 399 HISTORICAL NOTE: Promulgated by the Department of Health, Board of Pharmacy, LR 400 401 §2445. Marijuana pharmacy permit 402

A. The board shall develop and configure a pharmacy permit designated as a marijuana pharmacy permit. 403 B. The dispensing of marijuana for therapeutic purposes shall be restricted to those pharmacies holding a 404

marijuana pharmacy permit issued by the board, and only when that permit is in active or restricted 405 status. 406

C. When issued to a successful applicant, the permit will authorize the operation of a marijuana pharmacy 407 in compliance with the provisions of this Subchapter. 408

D. When the permit is issued, it shall be valid only for the owner and the specific location noted on the 409 application and recorded on the permit. 410

E. A marijuana pharmacy permit is non-transferable from one owner to another owner, and moreover, in 411 the event the ownership of the organization that acquired the permit changes by fifty percent or more, 412 then the ownership will be deemed sufficiently different as to require a new marijuana pharmacy 413 permit. A marijuana pharmacy permit owner continuing to operate a marijuana pharmacy after its 414 ownership has changed by fifty percent or more without obtaining a new marijuana pharmacy permit 415 shall be deemed guilty of operating a pharmacy without a valid permit, in violation of R.S. 37:1221. 416

F. Although a change of ownership of less than fifty percent shall not require a new pharmacy permit, any 417 proposed change of ownership shall require prior notice to the board, and further, approval by the 418 board. 419

G. The board shall not have more than ten active marijuana pharmacy permits at any given time. To 420 facilitate compliance with that legislative restriction, the board recognizes the nine regions previously 421 declared by the Department of Health, to wit: 422 1. Metropolitan, composed of the parishes of Jefferson, Orleans, Plaquemines, and St. Bernard; 423 2. Capitol, composed of the parishes of Ascension, East Baton Rouge, East Feliciana, Iberville, 424

Pointe Coupee, West Baton Rouge, and West Feliciana; 425 3. Teche, composed of the parishes of Assumption, Lafourche, St. Charles, St. James, St. John, St. 426

Mary, and Terrebonne; 427 4. Acadian, composed of the parishes of Acadia, Evangeline, Iberia, Lafayette, St. Landry, St. 428

Martin, and Vermilion; 429


Page 9 of 22

5. Southwest, composed of the parishes of Allen, Beauregard, Calcasieu, Cameron, and Jefferson 430 Davis; 431

6. Central, composed of the parishes of Avoyelles, Catahoula, Concordia, Grant, LaSalle, Rapides, 432 Vernon, and Winn; 433

7. Northwest, composed of the parishes of Bienville, Bossier, Caddo, Claiborne, DeSoto, 434 Natchitoches, Red River, Sabine, and Webster; 435

8. Northeast, composed of the parishes of Caldwell, East Carroll, Franklin, Jackson, Lincoln, 436 Madison, Morehouse, Ouachita, Richland, Tensas, Union, and West Carroll; and 437

9. Southeast, composed of the parishes of Livingston, St. Helena, St. Tammany, Tangipahoa, and 438 Washington. 439

H. To achieve an equitable distribution of the marijuana pharmacy permits across the state, the board shall 440 reserve one marijuana pharmacy permit for each of the nine regions identified above. In the event the 441 board is convinced of the need for a second permit in one region, it may issue that permit following the 442 procedures identified in this Subchapter. Further expansion will require a legislative amendment of the 443 original restriction. 444

I. When the board is prepared to receive and process applications for and issue marijuana pharmacy 445 permits, it shall publish on its internet web site, and in such other places as the board deems 446 appropriate, a notice to that effect. Such notice shall include, but not be limited to: 447 1. The maximum number of permits to be awarded; 448 2. Information on how to obtain an application; 449 3. The deadline for receipt of applications; 450 4. Acceptable methods for submitting an application; 451 5. The preferred locations, if any, for the marijuana pharmacy permits; and 452 6. The criteria that shall be considered in awarding the marijuana pharmacy permits. 453

J. Following the deadline for receipt of applications, the board shall evaluate each complete and timely 454 submitted application and award marijuana pharmacy permits on a competitive basis based on the 455 criteria set out in the notice for applications. In the event the board determines there are an insufficient 456 number of qualified applicants to award all of the marijuana pharmacy permits the board has 457 determined are desirable, the board may republish, in accordance with this section, a notice of open 458 applications for marijuana pharmacy permits. 459

K. The board shall have the right to amend the notice of open applications prior to the deadline for 460 submitting an application. Such amended notice shall be published in the same manner as the original 461 notice of open applications. 462

L. The board shall have the right to cancel a notice of open applications prior to the award of a marijuana 463 pharmacy permit. 464

465 AUTHORITY NOTE: Promulgated in accordance with R.S. 40:1046. 466 HISTORICAL NOTE: Promulgated by the Department of Health, Board of Pharmacy, LR 467 468 §2447. Licensing procedures 469

A. Application for Initial Issuance of Permit 470 1. The board shall develop an application form suitable for the marijuana pharmacy permit. The 471

board may revise that application form on its own initiative in order to collect the information it 472 deems necessary to properly evaluate an applicant. 473

2. The board shall not process applications received by facsimile, or that are incomplete, or 474 submitted with the incorrect fee. 475

3. The applicant shall fully disclose the ownership of the entity that will own the permit as well as 476 any additional holding companies that may exist, such that any natural person with any ownership 477 interest shall be fully identified. 478

4. In the event any person holding any ownership interest in the entity submitting an application for a 479 marijuana pharmacy permit has engaged in any of the following activities, the entity shall be 480 disqualified and the board shall not issue a marijuana pharmacy permit to that applicant: 481


Page 10 of 22

a. Within the five year period preceding the date of the application, has made a contribution to a 482 candidate in a Louisiana election governed by the provisions of the Campaign Finance 483 Disclosure Act [R.S. 14:1481]; or 484

b. Within the two year period preceding the date of the application, the person or any member of 485 the person’s immediate family held a position in state service, including but not limited to, a 486 legislator, statewide public official, state employee, or member of the board. 487

5. The applicant shall provide a complete street address reflecting the location at which the applicant 488 proposes to operate the marijuana pharmacy. 489

6. The applicant shall provide the following information and records in the application process: 490 a. A detailed description of any other services or products to be offered by the marijuana 491

pharmacy; 492 b. Details regarding the applicant’s plans to maintain adequate control against the diversion, 493

theft, or loss of marijuana; 494 c. Documents or information sufficient to establish the applicant is authorized to conduct 495

business in Louisiana and that all applicable state and local building, fire and zoning 496 requirements, and local ordinances will be met; 497

d. Text and graphic materials showing the exterior appearance of the proposed marijuana 498 pharmacy and its site compatibility with commercial or residential structures already 499 constructed or under construction within the immediate neighborhood; 500

e. A blueprint of the proposed marijuana pharmacy which shall, at a minimum, show and 501 identify: 502 i. The square footage of the area which will constitute the prescription department; 503 ii. The square footage of the overall marijuana pharmacy; 504 iii. The square footage and location of areas used as storerooms or stockrooms; 505 iv. The size of the counter that will be used for the dispensing and sale of marijuana; 506 v. The location of the marijuana pharmacy sink and refrigerator, if any; 507 vi. The location of all approved safes and vaults that will be used to store marijuana; 508 vii. The location of the toilet facilities; 509 viii. The location of the break room and location of lockers for personal belongings; 510 ix. The location and size of the patient counseling area(s); 511 x. The location(s) where any other products or services will be offered; and 512 xi. The location of all areas that may contain marijuana showing the location of walls, 513 partitions, counters, and all areas of ingress and egress. 514

f. Such other documents and information reasonably required by the board to determine the 515 applicant’s suitability for permitting or to protect the public’s health and safety. 516

7. The owner’s managing officer and the pharmacist-in-charge shall be fully identified within the 517 application and they both shall sign and date the application form. 518

8. The applicant shall direct the following persons to submit to the criminal history record check 519 process used by the board, at the applicant’s expense: 520 a. The owner’s managing officer; 521 b. The pharmacist-in-charge; and 522 c. Any person holding any share of ownership in the entity; provided however that any person 523

not holding any share of ownership but holding a corporate officer position in the entity may 524 be required to submit to the criminal history record check. 525

9. The requirement for a criminal history record check may be waived by the board in the event the 526 person has already completed that process for the board within the two year period prior to the 527 date of the application. 528

10. The applicant shall supplement the application form with sufficient documentation of the 529 applicant’s financial capacity to properly operate a marijuana pharmacy, including but not limited 530 to, evidence of his escrow account, letter of credit, or surety bond of at least one million dollars in 531 a financial institution headquartered in Louisiana. 532 a. The pharmacy’s one million dollar escrow account, letter of credit, or surety bond shall be 533 payable to the board in the event the board determines after a due process hearing that the 534 pharmacy has failed to timely and successfully complete the construction of the pharmacy or 535


Page 11 of 22

to operate such pharmacy in compliance with the provisions of this Subchapter. 536 b. The board shall permit the pharmacy’s escrow account, letter of credit, or surety bond to be 537 reduced by two hundred fifty thousand dollars upon the successful achievement of each of the 538 following milestones: 539 i. A determination by the board that the pharmacy is fully operational and able to commence 540 and has begun dispensing of marijuana as provided in this Subchapter; 541 ii. A determination by the board that the pharmacy remained operational and without 542 substantial interruption and without any violation of law or regulation for a one year 543 period; and 544 iii. A determination by the board that the pharmacy remained operational and without 545 substantial interruption and without any violation of law or regulation for a second one 546 year period. 547 iv. The pharmacy shall maintain the escrow account, letter of credit, or surety bond for a 548 minimum of two hundred fifty thousand dollars for the remainder of its operation. 549 c. In the event a pharmacy voluntarily chooses not to renew the pharmacy permit and follows 550 proper closure procedures, the board shall extinguish the obligations under the escrow 551 account, letter of credit, or surety bond at the end of the permit’s term. 552

11. In the event any information contained in the application or accompanying documents changes 553 after being submitted to the board, the applicant shall immediately notify the board in writing and 554 provide corrected information in a timely manner so as not to disrupt the application processing or 555 permit selection process. 556

12. The board may verify information contained in each application and accompanying documentation 557 in order to assess the applicant’s character and fitness to operate a marijuana pharmacy. The 558 board may verify the information and assess the applicant’s character and fitness by, among other 559 actions: 560 a. Contacting the applicant by telephone, electronic mail, mail, or such other means as is 561

reasonable under the circumstances; 562 b. Conducting one or more on-site visits of the location for the proposed marijuana pharmacy, or 563

other pharmacies associated with the applicant or any of the applicant’s owners; 564 c. Conducting background checks or contacting references of the applicant, its managing officer, 565

any of the corporate officers, or any shareholder, as well as the pharmacist-in-charge; 566 d. Contacting state regulators in any other states where the applicant, the applicant’s owners or 567

corporate officers, or its pharmacist-in-charge are engaged in, or have sought to be engaged 568 in, any aspect of that state’s medical marijuana program; or 569

e. Requiring a personal meeting with the owner’s managing officer and the pharmacist-in-charge 570 and the submission of additional information or documents. 571

13. The application shall be accompanied by payment of the permit fees and administrative hearing 572 fee authorized by La. R.S. 37:1184 and 40:1013. 573

14. When the staff has determined an entity’s application package is complete, the application shall be 574 referred to the board’s Application Review Committee, and further, the applicant shall be properly 575 notified at least thirty days prior to the committee’s hearing during which their application will be 576 considered. 577

15. During the hearing held by the board’s Application Review Committee, the members shall 578 consider, but are not limited to, the following criteria when evaluating an application for a 579 marijuana pharmacy permit: 580 a. The character and fitness of the owner’s managing officer, the pharmacist-in-charge, any of 581

the owners and any other person who may have control or influence over the operation of the 582 proposed marijuana pharmacy; 583

b. The location for the proposed marijuana pharmacy including, but not limited to: 584 i. Its proximity to previously approved marijuana pharmacies or locations of proposed 585 marijuana pharmacies with pending applications; 586 ii. Whether the patient population in the area proposed by the marijuana pharmacy permit 587

applicant justifies the need for a marijuana pharmacy, or an additional marijuana 588 pharmacy, in that area; 589


Page 12 of 22

iii. Whether the proximity of the proposed marijuana pharmacy will have a detrimental 590 effect upon any place used primarily for religious worship, public or private school, 591 convent, charitable institution, whether supported by private or public funds, hospital or 592 veterans' home or any camp or military establishment; or 593

iv. Whether the number of marijuana pharmacies in the locality is such that the granting of a 594 permit is detrimental to the public interest. In reaching a conclusion in this respect, the 595 board may consider the population of, the number of like permits and number of all -596 permits existent in, the particular municipality and the immediate neighborhood 597 concerned, the effect that a new permit may have on such town or neighborhood or on 598 like permits existent in such municipality or neighborhood. 599

c. The applicant’s ability to maintain adequate control against the diversion, theft and loss of 600 marijuana; 601 d. The applicant’s ability to maintain the knowledge, understanding, judgment, procedures, 602

security controls and ethics to ensure optimal safety and accuracy in the dispensing and sale 603 of marijuana; and 604

e. The extent to which the applicant or any of the applicant’s owners have a financial interest in 605 any other permittee, licensee, registrant, or other applicant currently or previously 606 credentialed by the board; and 607

f. Any other reason provided by any federal law or rule or state law or rule that is not 608 inconsistent with the Act. 609

16. Following their evaluation of the applications for a marijuana pharmacy permit, the committee 610 shall develop a recommendation for presentation to the board at the board’s next meeting. The 611 board may accept the committee’s recommendation, select an alternative applicant, reject all of the 612 applicants, or return all the applicants to the committee for their reconsideration. 613

17. The board may disqualify any applicant who: 614 a. Submits an incomplete, false, inaccurate, or misleading application; 615 b. Fails to submit an application by the published deadline; or 616 c. Fails to pay all applicable fees. 617

18. The decision of the board to award or not to award a marijuana pharmacy permit to an applicant 618 shall be final. 619

19. Upon the approval of an application, the board shall issue the marijuana pharmacy permit and state 620 controlled dangerous substance license to the applicant. 621

20. If an applicant has been awarded a marijuana pharmacy permit and has not commenced operation 622 of such pharmacy within 180 days of being notified of the marijuana pharmacy permit award, the 623 board may, in the board’s discretion, rescind such marijuana pharmacy permit, unless such delay 624 was caused by force majeure. A marijuana pharmacy shall be deemed to have commenced 625 operation if the pharmacy is capable of operating in accordance with the applicant’s approved 626 application. In the event a marijuana pharmacy permit is rescinded pursuant to this subsection, the 627 board shall award a marijuana pharmacy permit by selecting among the qualified applicants who 628 applied for the marijuana pharmacy permit that was rescinded. If no other qualified applicant 629 applied for such marijuana pharmacy permit or satisfied the criteria for awarding a permit, the 630 board shall publish, in accordance with this section, a notice of open applications for marijuana 631 pharmacy permits. 632

B. Application for Renewal of Permit 633 1. All marijuana pharmacy permits expire at midnight on December 31 of every year, regardless of 634

the date of its initial issuance. 635 2. The owner’s managing officer and pharmacist-in-charge of the marijuana pharmacy permit shall 636

complete, sign and date a permit renewal application form supplied by the board, and further, shall 637 include all information requested on the form and include the pharmacy permit renewal fee and 638 state controlled dangerous substance license renewal fee authorized in R.S. 37:1184 prior to the 639 expiration the pharmacy permit. 640

3. The board shall not process applications received by facsimile, or that are incomplete, or 641 submitted with the incorrect fees. 642


Page 13 of 22

4. In the event the pharmacy does not submit a properly completed renewal application form and fee 643 to the board prior to the expiration of the permit, the permit shall be rendered null and void. A 644 marijuana pharmacy shall not operate with an expired permit. Evidence it has done so will 645 provide sufficient basis for the board to discipline the permit for violation of R.S. 37:1241(12). 646

5. An application for the late renewal of an expired (lapsed) marijuana pharmacy permit that is 647 received in the board office no later than thirty days after the expiration date of the permit may be 648 processed by the board staff, provided the appropriate delinquent fee authorized in R.S. 37:1184 is 649 included with the application. 650

6. A marijuana pharmacy permit not renewed by thirty days after the expiration date shall be 651 automatically terminated by the board. 652

7. An application for the reinstatement of a terminated marijuana pharmacy permit shall be referred 653 to the board’s Reinstatement Committee for its consideration. 654

C. Application for Reinstatement of Terminated, Suspended, or Revoked Marijuana Pharmacy Permits 655 1. The applicant shall complete an application form for this specific purpose supplied by the board; 656

the application shall require the inclusion of the annual renewal fee, the delinquent fee, the 657 administrative hearing fee, and the reinstatement fees authorized in R.S. 37:1184 and the program 658 fee authorized in R.S. 40:1013. 659

2. An application for the reinstatement of a marijuana pharmacy permit previously terminated, 660 suspended or revoked by the board may only be approved following a preliminary hearing to 661 determine whether the reinstatement of the permit is in the public’s best interest. 662

D. Maintenance of Marijuana Pharmacy Permit 663 1. A marijuana pharmacy permit is valid only for the entity or person to whom it is issued and shall 664

not be subject to sale, assignment or other transfer, voluntary or involuntary, nor shall the permit 665 be valid for any premises other than the business location recorded thereon. 666

2. A duplicate or replacement permit shall be issued upon the written request of the licensee and 667 payment of the fee authorized in R.S. 37:1184. A duplicate or replacement license shall not serve 668 or be used as an additional or second license. 669

3. Prior to any person affiliating with a marijuana pharmacy, including any change in the ownership 670 of the permit, such person shall comply with the credentialing requirements of the board. No 671 person shall commence their affiliation with a marijuana pharmacy until approved by the board. 672

4. Prior to making any change in the marijuana pharmacy’s name or trade name, the owner of the 673 permit shall notify the board and request approval of the contemplated name or trade name. The 674 board shall reasonably accommodate such requests, unless there is cause not to do so, e.g., 675 duplicative or misleading names. The marijuana pharmacy shall not change its name or trade 676 name until approved by the board. 677

5. Prior to any modification, remodeling, expansion, reduction, other physical, non-cosmetic 678 alteration of the marijuana pharmacy, the owner of the permit shall notify the board and request 679 approval of the contemplated change(s). The board shall reasonably accommodate such request, 680 unless there is cause not to do so, e.g., inconsistent with operating requirements. The marijuana 681 pharmacy shall not make such changes until approved by the board. 682

6. Prior to any change in the location of a marijuana pharmacy, the owner of the permit shall submit 683 an application form for that purpose supplied by the board and pay the appropriate fee authorized 684 in R.S. 37:1184. The board may require an inspection of the new location prior to the issuance of 685 the permit for the new location. No marijuana pharmacy shall commence operation in a new 686 location until approved by the board. 687

7. The owner of the pharmacy permit shall notify the board no later than ten days following a change 688 in the pharmacist-in-charge for the marijuana pharmacy permit. 689

8. The owner of the pharmacy permit shall notify the board no later than ten days following a change 690 in the owner’s managing officer for the marijuana pharmacy permit. 691

9. In the event a marijuana pharmacy contemplates permanent closure, the pharmacist-in-charge shall 692 notify the board in accordance with the rules governing the permanent closure of a pharmacy as 693 described in Chapter 11 of the board’s rules. 694

695 AUTHORITY NOTE: Promulgated in accordance with R.S. 40:1046. 696


Page 14 of 22

HISTORICAL NOTE: Promulgated by the Department of Health, Board of Pharmacy, LR 697 698 §2449. Marijuana pharmacy personnel; therapeutic marijuana designation 699

A. No person shall be employed by, or affiliated with, a marijuana pharmacy prior to their eighteenth 700 birthday. 701

B. The owner’s managing officer and all persons holding a professional credential from the board shall 702 first obtain a Therapeutic Marijuana (TM) designation from the board before affiliating with a 703 marijuana pharmacy. 704

C. The board may issue a TM designation to a person who has filed the application for that designation 705 supplied by the board and has completed a criminal background check for the board within the two 706 year period prior to the date of the application for the TM designation, and that person: 707 1. Has been listed as an owner’s managing officer on an application for a marijuana pharmacy 708

permit, or on a request to become a replacement owner’s managing officer for an existing 709 marijuana pharmacy permit; or 710

2. Holds one of the following professional credentials issued by the board – pharmacist, pharmacy 711 intern, or certified pharmacy technician – and further, that professional credential was issued by 712 the board at least two years prior to the date of the application for the TM designation, is in active 713 status and has not been disciplined by the board within the two year period prior to the date of the 714 application for the TM designation. 715

D. The board may restrict, suspend, or revoke a TM designation for cause, but only pursuant to the 716 Administrative Procedure Act. 717

E. No pharmacist, pharmacy intern, or certified pharmacy technician may practice within a marijuana 718 pharmacy in the absence of an active professional credential, an active TM designation, as well as 719 access privileges to the state prescription monitoring program. A pharmacist may elect to not allow a 720 pharmacy intern or pharmacy technician to function as his delegate with respect to access privileges to 721 the state prescription monitoring program, but the pharmacist shall have such access. A pharmacy 722 technician candidate shall not practice in a marijuana pharmacy. 723

F. A pharmacist shall first acquire a Pharmacist-in-Charge (PIC) privilege, as described in §1105 of the 724 board’s rules, and the TM designation, as described in this Section, before accepting an appointment as 725 the PIC of a marijuana pharmacy. 726 1. The PIC of the marijuana pharmacy shall comply with the requirements of §1105 of the board’s 727

rules. 728 2. The PIC shall be responsible for notice to the board of all pharmacists, pharmacy interns, and 729

pharmacy technicians practicing at the marijuana pharmacy. The PIC shall cause such notice to be 730 received in the board office in written form (mail, fax, or electronic mail) no later than ten days 731 after the arrival or departure of the pharmacist, pharmacy intern, or pharmacy technician. 732

G. The PIC shall insure and document the initial and continuing competency of the entire professional 733 staff to provide the pharmacy care services rendered at the marijuana pharmacy. At a minimum, the 734 PIC shall provide access to education and training in the following domains: 735 1. Policies and procedures of the pharmacy, especially those relating to the tasks and functions that 736

employee is expected to perform; 737 2. Professional conduct, ethics, and patient confidentiality; and 738 3. Developments in the therapeutic use of marijuana. 739 Further, the PIC shall document such education and training, provide such records to the board when 740 requested, and retain such records for at least two years after the employee disassociates with the 741 pharmacy. 742

H. The PIC shall comply with the professional supervision rules and ratios found in Chapter 7 (pharmacy 743 interns) and Chapter 9 (pharmacy technicians) of the board’s rules. 744

I. In addition to the scope of practice limitations found in Chapter 9 of the board’s rules, pharmacy 745 technicians practicing in a marijuana pharmacy shall not: 746 1. Consult with a patient or the patient’s caregiver regarding marijuana or other drugs, either before 747

or after marijuana has been dispensed, or regarding any medical information contained in a patient 748 medication record; 749


Page 15 of 22

2. Consult with the physician who issued the recommendation/prescription/order for marijuana to the 750 patient, or the physician’s agent, regarding a patient or any medical information pertaining to the 751 patient’s marijuana or any other drug the patient may be taking; 752

3. Interpret the patient’s clinical data or provide medical advice; 753 4. Perform professional consultations with physicians, nurses, or other health care professionals or 754

their authorized agents; or 755 5. Determine whether a different brand or formulation of marijuana should be dispensed for the 756

marijuana product or formulation recommended/prescribed/ordered by the physician or requested 757 by the patient or his caregiver. 758

759 AUHORITY NOTE: Promulgated in accordance with R.S. 40:1046. 760 HISTORICAL NOTE: Promulgated by the Department of Health, Board of Pharmacy, LR 761 762 §2451. Operation of marijuana pharmacy 763

A. No person may operate a marijuana pharmacy without a marijuana pharmacy permit issued by the 764 board, and further, that permit shall be in active or restricted status. A pharmacist shall be on duty at 765 all times during the regular open hours of the marijuana pharmacy. 766

B. A marijuana pharmacy shall not dispense marijuana from, obtain marijuana from, or transfer marijuana 767 to, a location outside of the state of Louisiana. 768

C. A marijuana pharmacy shall not obtain, cultivate, deliver, transfer, transport, sell or dispense marijuana 769 except: 770 1. It may acquire marijuana from an authorized producer pursuant to the provisions of R.S. 40:1046; 771

and 772 2. It may dispense and sell marijuana to a patient with a recommendation/prescription/order for such 773

marijuana or the patient’s caregiver. 774 D. No person at a marijuana pharmacy shall provide marijuana samples. 775 E. A marijuana pharmacy shall sell marijuana products only in the original sealed containers 776

or packaging as delivered by the producer, except that a pharmacist may remove the marijuana product 777 from the producer’s child-resistant container or package and place the marijuana product in a non-778 child-resistant, secure and light-resistant container upon a written request from the patient or caregiver 779 so long as all original labeling is maintained with the product. 780

F. Only a pharmacist may dispense marijuana, and only a pharmacist, pharmacy intern, or pharmacy 781 technician may sell marijuana to patients and caregivers. A pharmacy intern or pharmacy technician 782 may assist, under the direct supervision of a pharmacist, in the dispensing of marijuana. 783 G. A marijuana pharmacy shall place all products sold to the patient or caregiver in an opaque package 784 that shall not indicate the contents of the package, the originating facility or in any other way cause 785 another person to believe that the package may contain marijuana. 786 H. A marijuana pharmacy shall not permit any person to enter the prescription department unless that 787

person’s responsibilities necessitate access to the department and then for only as long as necessary to 788 perform the person’s job duties. 789

I. While inside the pharmacy, all pharmacy employees shall wear name tags or similar forms of 790 identification that clearly identify them to the public, including their position at the pharmacy. 791 J. A marijuana pharmacy shall be open for qualifying patients and primary caregivers to purchase 792 marijuana products for a minimum of 10 hours per week. 793

1. A marijuana pharmacy that closes during its normal hours of operation shall implement 794 procedures to notify patients and caregivers of when the marijuana pharmacy will resume normal 795 hours of operation. Such procedures may include, but are not limited to, telephone system 796 messages and conspicuously posted signs. 797

2. In the event the pharmacist on duty leaves the prescription department, the prescription department 798 shall comply with the provisions of §1109 (temporary absence) or §1111 (closure) of the board’s 799 rules. 800

K. A marijuana pharmacy shall provide information to patients and caregivers regarding the possession 801 and use of marijuana. Such informational material shall include information related to: 802


Page 16 of 22

1. Limitations on the right to possess and use marijuana pursuant to R.S. 40:1046; 803 2. Safe techniques for proper use of marijuana and paraphernalia; 804 3. Alternative methods and forms of consumption by which one can use marijuana; 805 4. Signs and symptoms of substance abuse; and 806 5. Opportunities to participate in substance abuse programs. 807 L. The marijuana pharmacy shall establish, implement and adhere to a written alcohol-free, 808 drug-free and smoke-free work place policy, which shall be available to the board upon request. 809 M. The receipt of all deliveries from producers shall be carried out under the direct supervision of a 810

pharmacist who shall be present to accept the delivery. Upon delivery, the marijuana shall immediately 811 be placed in an approved safe or approved vault within the pharmacy where marijuana is stored. 812

N. No marijuana pharmacy shall sell anything other than marijuana products; however, the pharmacy may 813 elect to sell over-the-counter (OTC) medications and/or durable medical equipment (DME) from the 814 same premises but outside the prescription department. 815

O. No marijuana shall be administered on the premises of a marijuana pharmacy, except during patient 816 counseling, education or training. 817

P. No person associated with a marijuana pharmacy shall enter into any agreement with a physician or 818 health care facility concerning the provision of services or equipment that may adversely affect any 819 person's freedom to choose the marijuana pharmacy at which the patient or caregiver will purchase 820 marijuana. 821

Q. No marijuana shall be sold, dispensed or distributed via a delivery service or any other manner outside 822 of a marijuana pharmacy, except that a caregiver may deliver marijuana to the caregiver’s patient. 823

R. No marijuana shall be sold when the marijuana pharmacy is closed and not open for business. 824 S. Board representatives, local law enforcement or other federal, state or local government officials may 825

enter any area of a marijuana pharmacy if necessary to perform their governmental duties. 826 T. Right of inspection. The board, or its agent, representative, or designee, is authorized: 827

1. To enter a marijuana pharmacy at any time during its hours of operation, or any other place, 828 including a vehicle, wherein marijuana is held, dispensed, sold, or otherwise disposed of; 829

2. To inspect within reasonable limits and in a reasonable manner, such place and all pertinent 830 equipment, finished and unfinished material, containers and labeling, and all things therein, 831 including records, files, financial data, sales data, shipping data, pricing data, employee data, 832 research, papers, processes, controls and facilities; and 833

3. To inventory any stock of marijuana therein and obtain samples of any marijuana or marijuana 834 product, any labels or containers for marijuana, paraphernalia, and of any finished and unfinished 835 material. 836

U. Inspection of records. Every person required to prepare, obtain or keep records, logs, reports or other 837 documents, and every person in charge, or having custody, of such documents shall maintain such 838 documents in an auditable format for no less than two years. Upon request, such person shall make 839 such documents immediately available for inspection and copying by the board or its authorized 840 representative. In complying with this Section, no person shall use a foreign language or codes or 841 symbols to designate marijuana types or persons in the keeping of any required document. 842

843 AUTHORITY NOTE: Promulgated in accordance with R.S. 40:1046. 844 HISTORICAL NOTE: Promulgated by the Department of Health, Board of Pharmacy, LR 845 846 §2453. Security requirements for marijuana pharmacies 847

A. A marijuana pharmacy shall: 848 1. Store all marijuana in an approved safe or vault, as defined in this Subchapter, and in such a 849

manner as to prevent diversion, theft, or loss; 850 2. Maintain all marijuana in a secure area or location accessible only to specifically authorized 851

employees, which shall include only the minimum number of employees essential for efficient 852 operation; 853

3. Not permit any person less than eighteen years of age to enter the prescription department, with 854 the exception of patients being counseled by the pharmacist; 855


Page 17 of 22

4. Keep all approved safes and vaults securely locked and protected from entry, except for the actual 856 time required to remove or replace marijuana; 857

5. Keep all locks and security equipment in good working order; 858 6. Not allow keys to be left in the locks and not store or place keys in a location accessible to persons 859

other than specifically authorized employees; 860 7. Not allow other security measures, such as combination numbers, passwords or electronic or 861

biometric security systems, to be accessible to persons other than specifically authorized 862 employees; 863

8. Keep the pharmacy securely locked and protected from entry by unauthorized employees; 864 9. Keep the outside perimeter of the pharmacy premises well-lit; and 865 10. Post a sign at all entry ways into any area of the pharmacy containing marijuana, including a room 866

with an approved safe or vault, which sign shall be a minimum of twelve inches in height and 867 twelve inches in width which shall state: “Do Not Enter – Limited Access Area – Access Limited 868 to Authorized Employees Only” in lettering no smaller than one-half inch in height. 869

B. All pharmacies shall have an adequate security system to prevent and detect diversion, theft or loss of 870 marijuana utilizing commercial grade equipment, which shall include at a minimum: 871 1. A perimeter alarm; 872 2. Motion detector; 873 3. Video cameras in all areas that may contain marijuana and at all points of entry and exit, which 874

shall be appropriate for the normal lighting conditions of the area under surveillance. The 875 pharmacy shall direct cameras at all approved safes and vaults, dispensing areas, marijuana sales 876 areas and any other area where marijuana is being stored or handled. At entry and exit points, the 877 pharmacy shall angle cameras so as to allow for the capture of clear and certain identification of 878 any person entering or exiting the pharmacy. 879

4. Twenty-four hour recordings from all video cameras, which the pharmacy shall make available for 880 immediate viewing by the board or its authorized representative upon request and shall retain for 881 at least thirty days. If a pharmacy is aware of a pending criminal, civil, or administrative 882 investigation or legal proceeding for which a recording may contain relevant information, the 883 pharmacy shall retain an unaltered copy of the recording until the investigation or proceeding is 884 closed or the entity conducting the investigation or proceeding notifies the pharmacy that it is not 885 necessary to retain the recording. 886 a. All video recordings shall allow for the exporting of still images in an industry standard 887

image format, including .jpg, .bmp, and .gif. Exported video shall have the ability to be 888 archived in a proprietary format that ensures authentication of the video and guarantees that 889 no alteration of the recorded image has taken place. Exported video shall also have the ability 890 to be saved in an industry standard file format that ban be played on a standard computer 891 operating system. A pharmacy shall erase all recordings prior to disposal or sale of the 892 pharmacy. 893

5. Duress alarm, which for purposes of this Subsection means a silent security alarm system signal 894 generated by the entry of a designated code in into an arming station in order to signal that the 895 alarm user is being forced to turn off the system. 896

6. Panic alarm, which for purposes of this Subsection means an audible security alarm system signal 897 generated by the manual activation of a device intended to signal a life threatening or emergency 898 situation requiring a law enforcement response; 899

7. Holdup alarm, which for purposes of this Subsection means a silent alarm signal generated by the 900 manual activation of a device intended to signal a robbery in progress; 901

8. Automatic voice dialer, which for purposes of this Subsection means any electrical, electronic, 902 mechanical, or other device capable of being programmed to send a prerecorded voice message, 903 when activated, over a telephone line, radio or other communication system, to a law enforcement, 904 public safety or emergency services agency requesting dispatch; 905

9. A failure notification system that provides an audible, text or visual notification of any failure in 906 the surveillance system. The failure notification system shall provide an alert to the pharmacy 907 within five minutes of the failure, either by telephone, email, or text message; 908


Page 18 of 22

10. The ability to immediately produce a clear color still photo that is a minimum of 9600 dpi from 909 any camera image (live or recorded); 910

11. A date and time stamp embedded on all recordings. The date and time shall be synchronized and 911 set correctly and shall not significantly obscure the picture; and 912

12. The ability to remain operational during a power outage. 913 C. A pharmacy shall maintain all security system equipment and recordings in a secure location so as to 914

prevent theft, loss, destruction, or alterations. 915 1. A pharmacy shall keep all on-site surveillance rooms locked and shall not use such rooms for any 916

other function. 917 2. A pharmacy shall limit access to surveillance areas to persons that are essential to surveillance 918

operations, law enforcement agencies, security system service employees, and the board’s 919 authorized representative. 920

3. A pharmacy shall make available to the board upon request a current list of authorized employees 921 and service employees that have access to the surveillance room. 922

D. A pharmacy shall keep all security equipment in good working order and shall test such equipment no 923 less than two times per year. 924

E. When a pharmacy presents special security issues, such as an extremely large stock of marijuana, 925 exposed handling or unusual vulnerability to, or actual, diversion, theft or loss, the board may require 926 additional safeguards, including but not limited to, a supervised watchman service. 927

F. Any marijuana not stored in compliance with this Section, or stored at a location other than that for 928 which the pharmacy permit was issued, shall be subject to embargo or seizure by the board. 929

G. In the event any marijuana pharmacy permit is revoked, suspended, or not renewed, the pharmacy shall 930 dispose of its entire stock of marijuana in accordance with the disposal provisions in this Subchapter. 931

H. If a pharmacy has provided other safeguards which can be regarded in total as an adequate substitute 932 for some element of protection required of the pharmacy, such added protection may be taken into 933 account by the board in evaluating overall required security measures. 934

935 AUTHORITY NOTE: Promulgated in accordance with R.S. 40:1046. 936 HISTORICAL NOTE: Promulgated by the Department of Health, Board of Pharmacy, LR 937 938 §2455. Reportable security events 939

A. Upon becoming aware of discrepancies identified during inventory, diversion, theft, loss, or 940 unauthorized destruction of any marijuana, or of any loss or unauthorized alternation of records related 941 to marijuana or patients, a pharmacy shall immediately notify: 942 1. Appropriate law enforcement authorities; and 943 2. The board. 944

B. A pharmacy shall provide the written notice to the board by way of a signed statement which details 945 the circumstances of the event, including an accurate inventory of the quantity and brand names of the 946 marijuana diverted, stolen, lost, destroyed, or damaged, along with confirmation that the local law 947 enforcement authorities were notified. A pharmacy shall make such notice no later than twenty-four 948 hours after discovery of the event. 949

C. A pharmacy shall notify the board no later than the next business day, followed by written notification 950 no later than ten business days, of any of the following: 951 1. An alarm activation or other event that requires response by public safety personnel; 952 2. A breach of security; 953 3. The failure of the security alarm system due to a loss of electrical support or mechanical 954

malfunction that is expected to last longer than eight hours; and 955 4. Corrective measures taken, if any. 956

D. A pharmacy shall maintain and shall make available all documentation related to an occurrence that is 957 reportable. 958

959 AUTHORITY NOTE: Promulgated in accordance with R.S. 40:1046. 960 HISTORICAL NOTE: Promulgated by the Department of Health, Board of Pharmacy, LR 961


Page 19 of 22

962 §2457. Standards of practice 963

A. Environmental Standards 964 1. The prescription department shall be of sufficient size commensurate with the nature and scope of 965

practice. The space occupied by the prescription department shall be restricted to authorized 966 personnel only, as determined by the pharmacist-in-charge, and shall not be accessible to the 967 general public. 968

2. The prescription department shall contain sufficient fixtures, equipment, and supplies 969 commensurate with the nature and scope of practice for that pharmacy. 970

3. The prescription department shall include a sink with a hot and cold water supply, exclusive of 971 restroom facilities, with approved sewage disposal. 972

4. All areas where drugs and devices are stored shall be dry, well-lighted, well-ventilated, and 973 maintained at temperatures which will ensure the integrity of drugs during their storage and prior 974 to their dispensing as stipulated by the United States Pharmacopeia and/or manufacturer’s or 975 distributor’s product labeling unless otherwise indicated by the board. 976

5. The prescription department shall be secured by one or more physical barriers with suitable locks 977 and a monitored alarm system capable of detecting unauthorized entry, and further, complies with 978 security requirements identified elsewhere in this Subchapter. 979

6. Prescription and other patient healthcare information shall be maintained in a manner that protects 980 the integrity and confidentiality of such information. 981

B. Minimum Staffing Requirements 982 1. There shall be at least one pharmacist on duty at all times the pharmacy is open for business. 983 2. Every pharmacist practicing in the pharmacy shall possess a Louisiana pharmacist license in active 984

status, a Therapeutic Marijuana designation, and access privileges to the state prescription 985 monitoring program. 986

3. A pharmacy intern may assist the pharmacist in the prescription department, but only when in 987 possession of a Louisiana pharmacy intern registration in active status as well as a Therapeutic 988 Marijuana designation. The supervising pharmacist may establish a delegate credential for the 989 pharmacy intern in the state prescription monitoring program. 990

4. A pharmacy technician may assist the pharmacist in the prescription department, but only when in 991 possession of a Louisiana pharmacy technician certificate in active status as well as a Therapeutic 992 Marijuana designation. The supervising pharmacist may establish a delegate credential for the 993 pharmacy technician in the state prescription monitoring program. 994

5. No pharmacy technician candidate may practice in a marijuana pharmacy. 995 6. Additional clerical personnel may also be present at the pharmacy. 996

C. Operational Standards 997 1. The marijuana pharmacy shall comply with the provisions of Chapters 11, 25, 27, 29, and 31 of 998

the board’s rules except when this Subchapter grants exceptions or imposes more stringent 999 requirements. 1000

2. In the event the marijuana pharmacy intends to close permanently, the pharmacist-in-charge (PIC) 1001 shall comply with the pharmacy closure procedures described in Chapter 11 of the board’s rules, 1002 and further, the owner of the pharmacy permit shall not prevent or interfere with the PIC’s 1003 performance of those tasks. 1004 a. In addition to the other closure requirements, the closing pharmacy shall include in its notice 1005

to the board and to the public the identification of the destination pharmacy where the closing 1006 pharmacy’s prescription records will be transferred. That destination pharmacy shall be the 1007 marijuana pharmacy nearest the closing pharmacy, unless otherwise approved by the board. 1008

D. Recordkeeping Requirements 1009 1. Prescription/recommendation/order (hereinafter, “request”) for marijuana 1010 a. The pharmacy shall not accept a verbal request. 1011 b. In the event the pharmacy receives a request in written form by facsimile, the pharmacy may 1012

begin the preparation of the product to be dispensed, but the pharmacist shall not dispense the 1013 product until the original form of the request is delivered to him in the pharmacy and he has 1014 compared it to the product prepared for dispensing. 1015


Page 20 of 22

c. The written request shall bear the manual signature of the authorized prescriber. No other 1016 form of signature shall be valid, including (but not limited to) stamps, computer generated 1017 signatures, or signatures of anyone other than the authorized prescriber. 1018

d. A request generated, signed, and transmitted in electronic format which is compliant with the 1019 standards for electronic prescribing of controlled substances identified in 21 CFR 1311 (or its 1020 successor) shall be construed as a validly formatted request. 1021

2. When the pharmacy receives a request for marijuana from an authorized prescriber in written 1022 form, the pharmacist shall cause the form to be scanned and filed using an electronic imaging 1023 system in compliance with §1123 of the board’s rules. 1024

3. Request forms (and electronic images thereof) shall be retained on the pharmacy’s premises for at 1025 least two years after the date of dispensing, and further, shall be readily retrievable upon request 1026 by the board. 1027

4. Inventory of marijuana product 1028 a. The pharmacist-in-charge shall develop and maintain a perpetual inventory of all marijuana 1029

products acquired, held, dispensed, and disposed by the pharmacy. 1030 b. The pharmacy shall access the LMMTS and enter all inventory-related transactions in that 1031 system. 1032 c. In the event the pharmacist-in-charge designates an agent to retrieve new marijuana product 1033 inventory from the production facility, the pharmacist shall verify the agent is at least twenty 1034 one years of age and is eligible to drive on public roadways. 1035

d. The pharmacist-in-charge shall conduct an annual inventory of all marijuana products in the 1036 possession of the pharmacy on any date which is within one year of the previous annual 1037 inventory, and further, shall conduct additional inventory counts on the following occasions: 1038

i. arrival of a new pharmacist-in-charge; 1039 ii. discovery of any significant loss, disappearance, or theft of marijuana product; 1040 iii. departure of a pharmacist-in-charge; and 1041 iv. permanent closure of the pharmacy. 1042 e. Inventory records shall be retained on the pharmacy’s premises for at least two years after the 1043 most recent entry. 1044 5. The pharmacy shall develop and maintain sufficient records to fully reveal the business 1045

transactions related to marijuana products, including their procurement and sale, for the current tax 1046 year as well as the two immediately preceding tax years, all of which shall be made available to 1047 the board upon request. 1048

6. The board may require any pharmacy or its owners to furnish such information as the board 1049 considers necessary for the proper administration of R.S. 40:1046, and may require a financial 1050 audit of the business of any marijuana pharmacy, and the expense thereof shall be paid by the 1051 marijuana pharmacy. 1052

E. Professional Practice Standards 1053 1. Prior to dispensing any marijuana product to a patient, the pharmacist shall review that patient’s 1054

records in the state prescription monitoring program. The pharmacist shall resolve any concerns 1055 identified in that review by consultation with the recommending physician. 1056

2. Labeling of marijuana product dispensed 1057 a. The pharmacist shall not dispense any marijuana product that does not bear the producer label 1058

required by the LDAF, and further, the pharmacy dispensing label shall not overlay or obscure 1059 the producer label in any way. 1060

b. The pharmacy’s dispensing label shall contain, at a minimum, the following data elements: 1061 i. Name and address of the pharmacy dispensing the product; 1062 ii. Telephone number or other contact information of the pharmacy dispensing the product; 1063 iii. Name of the authorized prescriber; 1064

iv. Name of the patient; 1065 v. Date the product was dispensed; 1066 vi. Prescription number, which shall be a unique identifier for that specific transaction; 1067 vii. Name of the marijuana product, including any concentration, strength, or other identifiers 1068 of the marijuana product; 1069


Page 21 of 22

viii. Quantity of marijuana dispensed; 1070 ix. Directions for use of the product as included in the prescriber’s request; 1071 x. Expiration date of the product, which shall not exceed the expiration date determined by 1072 the producer of the product; and 1073 xi. Other information selected by the dispensing pharmacist to inform the patient as to the 1074 best use of the product for the intended purpose. 1075

3. The pharmacist shall perform prospective drug utilization review and shall counsel every patient 1076 receiving marijuana product every time it is dispensed, in compliance with the rules on drug 1077 utilization review and patient counseling in Chapter 5 of the board’s rules. 1078

4. Reporting transactions to state prescription monitoring program. The pharmacy shall comply with 1079 the reporting requirements as found in Chapter 29 of the board’s rules. 1080

5. Disposal of marijuana product. 1081 a. A pharmacy may refuse to accept the delivery of marijuana product from a producer when it is 1082

determined to be misbranded, adulterated, expired, deteriorated, undesired, excess, 1083 unauthorized, or unfit for dispensing; however, once accepted by the pharmacy, no marijuana 1084 product may be returned to any producer. 1085

b. When the pharmacist determines a marijuana product is no longer suitable for dispensing, the 1086 product shall be removed from active dispensing stock and quarantined in the pharmacy 1087 pending its disposal, and further, the removal from active dispensing stock shall be recorded in 1088 the LMMTS. 1089

c. The pharmacist-in-charge shall render the waste unusable by grinding and incorporating the 1090 waste with other ground materials so the resulting mixture is at least 50% non-marijuana waste 1091 by volume. Material used to grind with the waste may include: 1092 i. Yard waste; 1093 ii. Paper waste; 1094 iii. Cardboard waste; 1095 iv. Plastic waste; or 1096 v. Soil or sand 1097 d. Waste shall be rendered unusable prior to leaving the pharmacy. Waste rendered unusable 1098 shall be disposed of by delivery to an approved solid waste facility for final disposition. 1099 Examples of acceptable permitted solid waste facilities include: 1100

i. Compost; anaerobic digester; 1101 ii. Landfill, incinerator; or 1102 iii. Waste-to-energy facility. 1103

e. The pharmacist-in-charge shall prepare a record of each disposal, and that record shall contain, 1104 at a minimum, the following information: 1105 i. Brand name and other specific identifiers of the marijuana product disposed; 1106 ii. Quantity of product disposed; 1107 iii. Manner of disposal; and 1108 iv. Signatures of the pharmacist-in-charge disposing the product plus at least one witness 1109 who is either a credentialed staff member of that pharmacy or an agent of the board. 1110

1111 AUTHORITY NOTE: Promulgated in accordance with R.S. 40:1046. 1112 HISTORICAL NOTE: Promulgated by the Department of Health, Board of Pharmacy, LR 1113 1114 §2459. Advertising 1115

A. The marijuana pharmacy shall not advertise through any public medium, including but not limited to 1116 newspapers, billboards, television, radio, internet, social media, or any other means designed to market 1117 its products to the general public. 1118

B. The marijuana pharmacy may market its products through direct mail, brochures, or other means to 1119 Louisiana-licensed physicians, but only when such advertising is directed solely to the practitioner and 1120 is not available to the general public. 1121

C. Any advertisement permitted in Paragraph B of this Section shall not: 1122 1. Make any deceptive, false, or misleading assertions or statements regarding any product; or 1123


Page 22 of 22

2. Assert that its products are safe because they are regulated by LDAF or the board. The pharmacy 1124 may advertise that its products have been tested by an approve laboratory, but shall not assert that 1125 its products are safe because they are tested by an approved laboratory. 1126

D. The marijuana pharmacy may attach a maximum of two separate signs to the exterior of the building 1127 which identify the business by its business or trade name, provided that neither sign exceeds the size 1128 limit of sixteen hundred square inches. 1129

1130 AUTHORITY NOTE: Promulgated in accordance with R.S. 40:1046. 1131 HISTORICAL NOTE: Promulgated by the Department of Health, Board of Pharmacy, LR 1132 1133





Executive Committee



Items in bold print are new since last report. Items in blue print sponsored by Board. Page 1 of 9




Final Legislative Brief

2016-0606 @ 1800

Regular Session of the 2016 Louisiana Legislature Convened 2016-0314 @ 1200 – Adjourned 2016-0606 @ 1800

Last Items Reviewed

HB 1,167 HR 250 HCR 154 HSR 6 HCSR 0 SB 477 SR 201 SCR 146 SSR 0 SCSR 3 Acts 681 Total = 2,404 Items on Watch List = 118

House of Representatives

Bills HB 81 Broadwater House & Governmental Affairs Requires public bodies to provide certain information concerning the custodian of records publicly available. 06-17-2016 Signed as Act 654; effective 08-01-2015. This appears to be duplicative from last year. In any event, we have a link to this information on the home page of our website. HB 232 Stokes Civil Law & Procedure Adds limitation of liability provisions to the Right to Try Act. 06-05-2016 Signed as Act 355; effective 08-01-2016. Amends the Right to Try Act to ensure that no cause of action is created by the law for the manufacturer of the drug taken, nor any person involved in the care of the patient. HB 267 G. Miller Administration of Criminal Justice Decreases criminal penalties for certain offenses involving drug paraphernalia. 05-26-2016 Signed as Act 246; effective 08-01-2016. Amends the controlled substances law to mirror the penalties for simple possession of marijuana. HB 441 Jackson Health & Welfare Provides relative to conditions for physician participation with Medicaid managed care organizations. 05-26-2016 Signed as Act 250; effective 08-01-2016. Prohibits Medicaid managed care organizations from terminating physicians whose medical licenses have been placed on probation by LSBME solely because of their probationary status.




HB 454 Richard Appropriations Provides for reporting, review, and approval by the Joint Legislative Committee on the Budget of certain professional, personal, and consulting contracts. 06-06-2016 Signed as Act 408; effective 06-06-2016. For FY 16 through FY 18, the Commissioner of Administration shall report all professional, personal, and social service contracts totaling $40,000 or more per year to the JLCB for their review. HB 480 Jackson Health & Welfare Provides relative to the practice of telemedicine in licensed healthcare facilities. 05-26-2016 Signed as Act 252; effective 05-26-2016. Prohibits the medical board from requiring a physician perform an in-person examination prior to prescribing any controlled substances via telemedicine in a licensed healthcare facility. HB 490 LeBas Insurance Provides for the submission of a remittance advice by health insurers to pharmacists. 05-10-2016 Signed as Act 51; effective 01-01-2017. Requires the remittance advice to be sent on the date of payment of the pharmacy claim and to include the network identifier. HB 570 Schroder Health & Welfare Provides relative to the practice of telemedicine. 06-17-2016 Signed as Act 630; effective 06-17-2016. Repeals the requirement from the medical board that a physician practicing telemedicine maintain an office practice location within the state, but retains the requirement the physician has a license to practice in this state. HB 579 R. Johnson Health & Welfare Provides relative to the delivery of nutrition services. 06-09-2016 Signed as Act 415; effective 08-01-2016. Authorizes licensed dietitians and nutritionists employed by facilities licensed by LDH to order dietary plans as well as order appropriate laboratory tests to monitor the effectiveness of the dietary plan, subject to approval of the facility’s medical staff or bylaws. HB 595 R. Johnson Health & Welfare Provides relative to the delivery of nutrition services through telehealth. 06-09-2016 Signed as Act 417; effective 08-01-2016. Adds dietitians and nutritionists to the list of healthcare providers authorized to use telehealth in their practice, subject to regulation by their licensing authority. HB 642 R. Johnson Health & Welfare Provides relative to the La. State Board of Examiners in Dietetics and Nutrition. 06-17-2016 Signed as Act 636; effective 08-01-2016. Repeals the domicile requirement, amends their provisional licensing timeframe, and authorizes the development of a fee schedule by rule, subject to maximums listed in the bill. HB 671 Moreno Health & Welfare Provides relative to redispensing of drugs in correctional center pharmacies. 06-02-2016 Signed as Act 310; effective 08-01-2016 Amends the Pharmacy Practice Act relative to the redispensing of drugs in correctional center pharmacies, and extends the current limitation to state-owned facilities to include local law enforcement agencies.


HB 688 LeBas Administration of Criminal Justice. Adds substances to Schedules II and IV of the Uniform Controlled Dangerous Substances Law. 05-10-2016 Signed as Act 62; effective 08-01-2016. As originally drafted, the bill mischaracterizes substances added to Schedule II; they are actually being added to groups of drugs excluded from Schedule II. One new drug is added to Schedule IV. HB 812 Schroder Appropriations Provides relative to maximizing the use of available office space in state buildings. 05-10-2016 Signed as Act 66; effective 08-01-2016. Requires the Div. of Administration to track all empty and under-utilized space in state buildings as well as all state agencies with resources located in buildings not owned by the state, and further, to allocate appropriate empty space to such agencies. Requires the agency head to reply to the offer within 90 days with a transitional relocation plan, or in the alternative, the reason the agency did not accept the offer. Requires such violations to be reported to the legislature by the Div. of Administration. HB 842 Broadwater Education Provides for the consolidation of certain boards and commissions into the Board of Regents. 06-02-2016 Signed as Act 314; effective 08-01-2016. Merges three minor agencies (including La. Student Financial Assistance Commission) into the Board of Regents. HB 864 LeBas Insurance Prohibits certain claims fees assessed by health insurers or pharmacy benefit managers. 05-19-2016 Signed as Act 148; effective 08-01-2016. Prohibits the charging of certain fees that are not apparent at the time of claim processing, are not identified on the remittance advice, after the initial claim is adjudicated. HB 909 Anders House & Governmental Affairs Provides with respect to limitation of terms of members of boards and commissions. 05-10-2016 Signed as Act 71; effective 05-10-2016. Repeals the 2008 law establishing term limits for members of boards and commissions. HB 934 Hoffmann Health & Welfare Provides relative to judicial review of administrative decisions rendered by the La. State Board of Dentistry. 06-05-2016 Signed as Act 369; effective 08-01-2016. Amends the Dental Practice Act relative to the amount of financial security required when appealing the Board’s disciplinary action to the judicial district court. Also provides relative to their subpoena power. HB 947 Pope Health & Welfare Requires all state departments to report to the legislature information concerning administration of the departments. 06-17-2016 Signed as Act 557; effective 08-01-2016. Requires inclusion of personnel information in departmental annual reports, including organizational chart showing all filled and vacant positions as well as the current salary of each filled position. HB 1007 Moreno Health & Welfare Provides relative to the storing and dispensing of naloxone and other opioid antagonists. 06-05-2016 Signed as Act 370; effective 06-05-2016. Amends the naloxone law to provide that anyone may possess naloxone or another opioid


antagonist, and further, anyone may dispense naloxone or another opioid antagonist as long as it is done for no charge and according to a standing order from a medical practitioner. Further, authorizes a pharmacist to dispense naloxone pursuant to a nonpatient-specific standing order from a medical practitioner authorized to prescribe naloxone, according to rules promulgated by the Board of Pharmacy. HB 1099 Thibaut Agriculture, Forestry, Aquaculture & Rural Development Provides relative to the assessment of a license fee imposed by the Dept. of Agriculture & Forestry for the production of marijuana for therapeutic use. 06-17-2016 Signed as Act 567; effective 08-01-2016. Establishes an annual license fee of $100,000, an annual permit fee of $100, a nonrefundable application fee of $10,000, and requires remittance of 7% of the gross sales back to the department. HB 1151 R. Johnson Provides relative to notice and appeal in a change in coverage of medically necessary prescription drugs and intravenous infusions. 06-17-2016 Signed as Act 573; effective 01-01-2017. Requires insurer to give 60-day notice to insured before discontinuing coverage for prescription drugs or intravenous solutions; provides for an appeal process for the insured. HB 1161 D. Miller Provides relative to the composition of the La. State Board of Nursing. 06-17-2016 Signed as Act 598; effective 01-01-2017. Replaces the two ex-officio physician members with two voting consumer members. Resolutions HR 244 D. Miller Requests the La. State Board of Nursing and the La. State Board of Practical Nurse Examiners to study and report on a prospective merger of the two boards. 06-10-2016 Delivered to Secretary of State. Resolution indicates Louisiana is one of only three U.S. states that maintain separate boards for registered and practical nurses. Requests both boards to work jointly on a study of the desirability and feasibility of merging the two boards. Report is due no later than 60 days prior to beginning of 2017 regular legislative session. HR 248 Armes Urges and requests state entities that have a role in the implementation of Act 96 of the 2016 Regular Session relative to patient access to therapeutic marijuana to prioritize fully implementing the law as soon as possible. 06-10-2016 Delivered to Secretary of State. Resolution directed to La. State Board of Medical Examiners, La. Board of Pharmacy, and the Dept. of Agriculture & Forestry, urging and requesting those agencies to prioritize the activities necessary to implement the provisions of Act 96 of the 2016 Legislature. Concurrent Resolutions HCR 97 Hoffman Expresses the support of the legislature for the MyOldMeds campaign to promote safe storage and in-home disposal of prescription medications. 05-24-2016 Delivered to Secretary of State. Self-explanatory; apparently sponsored by PhRMA.


HCR 113 LeBas Health & Welfare Establishes the Louisiana Commission on Preventing Opioid Abuse.

06-08-2016 Delivered to Secretary of State. Creates a commission with representatives from 37 entities, co-chaired by the executive directors of the medical and pharmacy boards. Charged with duties, including an identification and evaluation of the causes of opioid abuse, an evaluation of the responsible use of opioid medications, including an assessment of the feasibility of statewide adoption of the recently-issued CDC Guidelines on Prescribing Opioids for Chronic Pain, an evaluation of medical training needs, an assessment of alternatives to incarceration and medical treatment, and recommendation of changes to any statutes or rules to mitigate opioid abuse. Commission to be housed at DHH; shall meet no less than bi-monthly; and shall tender report to the Governor and Legislature no later than February 1, 2017. HCR 134 Jackson Health & Welfare Directs the Louisiana State Board of Medical Examiners to study and make recommendations concerning a potential tiered approach for placing physicians on probation and a best practice for the reporting of the probationary status of a physician to patients. 06-08-2016 Delivered to Secretary of State. Since the LSBME website already contains the history of disciplinary information for a physician, the new information desired is the basis for the disciplinary action. Amended in the Senate to change the resolution from “authorize and direct” to “urge and request.” Study Resolutions Concurrent Study Resolutions

Senate Bills SB 49 Long Finance Requires approval of the Joint Legislative Committee on the Budget before certain salary increases in the executive branch are effective in the last ninety days of an administration. 06-13-2016 Signed as Act 517; effective 07-01-2016. Applies to all budget units and all other agencies in the executive branch, as well as all unclassified employees in those agencies. SB 56 Johns Health & Welfare Provides for retention, archiving, and destruction of records in the state prescription monitoring program. 05-26-2016 Signed as Act 189; effective 08-01-2016. Sponsored by the Board of Pharmacy; requires rule-making by the Board. SB 57 Bishop Senate & Governmental Affairs Prohibits the increase in salary for executive branch employees, agency employees, and cabinet members for a period commencing on gubernatorial election day and concluding on inauguration day. 06-17-2016 Signed as Act 588; effective 06-17-2016. Applies to all unclassified employees, and requires Dept. of Civil Service to adopt similar rules for classified employees. Exception applies to postsecondary or higher education institutions. SB 107 Barrow Health & Welfare Provides for the re-creation of the Dept. of Health & Welfare and to change the name to the Dept. of Health.


06-02-2016 Signed as Act 300; effective 06-30-2016. This is the ‘sunset’ bill which affects every executive branch level department. As originally drawn, the Board of Pharmacy remains within the department, and the department will face their next sunset at the end of Fiscal Year 2021. SB 114 LaFleur Health & Welfare Requires approval by the secretary of the Dept. of Health & Hospitals for any salary adjustments or cost-of-living adjustments for certain management boards falling under the auspices of the department.

06-02-2016 Signed as Act 338; effective 06-02-2016. Original bill includes all health care licensing agencies. Amended to allow boards to retain their authority for salary adjustments, but requires reporting of all raises to DHH Secretary. SB 117 Mills Health & Welfare Provides for the Medicaid Pharmaceutical & Therapeutics Committee 06-02-2016 Signed as Act 339; effective 06-02-2016. Amends the source of nominations of physician and pharmacist members of the committee. SB 131 Johns Health & Welfare Limits costs for pharmacists’ services. 06-17-2016 Signed as Act 527; effective 08-01-2016. Amends the state insurance law to provide that no individual shall be required to make a payment for pharmacists’ services in an amount greater than the amount the pharmacist providing the service may retain from all payment sources. SB 148 Gatti Senate & Governmental Affairs Abolishes boards and commissions, authorities, districts, and like entities that are inactive. 06-17-2016 Signed as Act 614; effective 08-01-2016. Twelve entities named in original measure; ten entities named in final act. SB 180 Mills Judiciary-C Provides exemption from prosecution for anyone lawfully in possession of medical marijuana. 06-02-2016 Signed as Act 343; effective 08-01-2016. Amends the state controlled substance law to provide immunity from prosecution for possession of marijuana for any Louisiana resident who is a patient of the Louisiana medical marijuana program, as well as for the parent of a child who is a patient in the program. SB 189 Johns Health & Welfare Provides for pharmacist dispensing exceptions. 05-26-2016 Signed as Act 192; effective 05-26-2016. Amends the state controlled substance law, and more specifically adds another exception to the dispensing limitation for prescriptions written for opioid derivatives in Schedules II or III written by prescribers not licensed in this state. The first exception, adopted last year, includes those states whose prescription monitoring program information is accessible to the dispensing pharmacist. This proposal includes when the prescriber includes a diagnosis of cancer or terminal illness on the prescription form. SB 258 Luneau Insurance Provides for coverage for refills for prescription eye drops. 05-26-2016 Signed as Act 206; effective 08-01-2016. Amends the state insurance law to require insurance coverage for refills of prescription eye drops; imposes requirements on such prescriptions.


SB 271 Mills Health & Welfare Provides for medical marijuana.

05-19-2016 Signed as Act 96; effective 05-19-2016. Amends the medical marijuana law passed last year to change ‘prescribe’ to ‘recommend’, and further, expands the list of eligible medical conditions. Finally, it removes requirements whose deadlines have already passed. SB 291 Mills Health & Welfare Provides for patient access to physical therapy services without a prescription or referral from a physician. 06-06-2016 Signed as Act 396; effective 06-06-2016. Permits a physical therapist holding a doctorate degree plus five years experience to initial physical therapy services without a prescription from a medical practitioner; however, if the patient has not achieved functional improvement after 30 days, referral to a medical practitioner is required.. SB 360 Mills Health & Welfare Provides for the La. Physician Orders for Scope of Treatment (La. POST). 06-13-2016 Signed as Act 486; effective 06-13-2016. Final orders for terminally ill patients, to complement advance directives. SB 429 Barrow Health & Welfare Provides for the Louisiana State Board of Medical Examiners. 06-17-2016 Signed as Act 584; effective 08-01-2016. Revises the source of nominations for members, with less input from the La. State Medical Society. SB 460 LaFleur Finance Provides for the disposition and reporting of fees and self-generated revenues by state agencies and the state treasurer. 06-17-2016 Signed as Act 587; effective 06-17-2016. Requires all budget units with unexpended appropriate funds remaining at the conclusion of the fiscal year to transfer those funds to the state general fund. SB 471 Martiny Provides relative to the La. State Board of Dentistry. 06-13-2016 Signed as Act 491; effective 01-01-2018. Changes the deadline for that board to change their domicile from the City of New Orleans to East Baton Rouge Parish from January 1, 2017 to January 1, 2018. Concurrent Resolutions SCR 65 Mills Health & Welfare Creates a task force to study meaningful oversight of the professional healthcare licensing boards statutorily created within the Dept. of Health and Hospitals 05-25-2016 Delivered to Secretary of State. Creates a task force composed of one representative from each of the 25 healthcare licensing boards within DHH, with a DHH representative to serve as chair, and an Attorney General representative to serve as vice chair. Group shall meet at least monthly beginning before 09-01-2016 and shall submit their report to the joint legislative committees on health and welfare before 01-01-2017, with recommendations on several topics as identified in the resolution, including composition of the boards and a process for meaningful oversight of the boards by the department so as to ensure compliance with North Carolina State Board of Dental Examiners v. Federal Trade Commission, 135 S.Ct. 1101(2015).


SCR 87 Johns Health & Welfare Requests the Louisiana Board of Pharmacy to study and make recommendations regarding the use of the terms “specialty drug” and “specialty pharmacy.” 06 -06-2016 Delivered to Secretary of State. Given the generic use of the term by different stakeholders to mean different things, there is a concern that use of the term within this state may cause problems with patient access to certain medications. Board directed to study and make recommendations to the legislature no later than February 1, 2017.


Summary for August 10, 2016 Board Meeting 1. The following bills require an update to the Louisiana Pharmacy Law Book. > HB 267 (Act 246) amended R.S. 40:1025, relative to penalties for drug paraphernalia. > HB 671 (Act 310) amended R.S. 37:1226.3, relative to recycling drugs to offenders in

correctional facilities. (*)(**) > HB 688 (Act 062) amended R.S. 40:964, relative to scheduling actions in C-II and C-IV. (**) > HB 1007 (Act 370) amended R.S. 40:978.2, relative to dispensing of naloxone. (*)(**) > HC 1099 (Act 567) amended R.S. 40:1046, relative to licensing fees for marijuana. > SB 056 (Act 189) amended R.S. 40:1006, relative to record retention in the PMP. (*)(**) > SB 180 (Act 343) amended R.S. 40:966, relative to penalties for medical marijuana. > SB 189 (Act 192) amended R.S. 40:978.E.3, relative to dispensing limitations on certain

prescriptions for opioid derivatives when prescribed by practitioners not licensed in Louisiana. (*)(**)

> SB 271 (Act 096) amended R.S. 40:1046, 1047, relative to medical marijuana. (*)(**) All of the amended laws have been posted to the Laws & Rules page on the Board’s website. 2. Certain measures were made effective earlier than the standard August 1 date and required notice to the pharmacy community. We issued Bulletin 16-01 on July 15 describing the asterisked (*) items listed above. We had more room in the July 2016 edition of the Board’s newsletter, so we provided additional and reinforcing information on the double-asterisked (**) items listed above. 3. Certain measures should be evaluated for rule-making activities. In particular: > HB 671 (Act 310) amended the portion of the Pharmacy Practice Act requiring pharmacies

dispensing drugs to offenders in state correctional facilities to accept returns for redispensing to the same offender community. We promulgated the chapter of rules for penal pharmacy permits to keep those recycled drugs out of the general community. With the expansion of the law to include offenders in local law enforcement agencies, we may need to revise the rules relative to penal pharmacy permits to include that new population of offenders.

> HB 1007 (Act 370) specifically requires the Board to promulgate rules to allow pharmacists to dispense naloxone or other opioid antagonists pursuant to nonpatient-specific standing orders issued by medical practitioners authorized to prescribe naloxone.

> SB 056 (Act 189) specifically requires the Board to develop standards for the retention, archiving, and destruction of prescription transaction information stored in the state PMP.

> SB 271 (Act 096) requires the Board to promulgate rules to implement the state medical marijuana program.

4. The legislature adopted several study resolutions which require participation by the Board: > HR 248 was adopted by the House of Representatives on the last day of the session. It urges

and requests the Board of Pharmacy, the Board of Medical Examiners, and the Dept. of Agriculture & Forestry to fully implement the state medical marijuana program as soon as possible so that Louisiana citizens may obtain the benefits therefrom.

> HCR 113 established the Louisiana Commission on Preventing Opioid Abuse, named 38 organizations to the commission, and directed the preparation of a report to be submitted no later than February 1, 2017 with recommendations on eight different aspects of opioid abuse. The resolution specified the co-chairs as the executive directors of the medical and pharmacy boards.

> SCR 065 established the Task Force on Meaningful Oversight of Boards & Commissions, to study the impact and implications of the recent North Carolina State Board of Dental Examiners v the Federal Trade Commission. The resolution identified the 25 healthcare licensing boards with the Dept. of Health which are to name a designee, and specified the chair as Secretary of LDH and the vice chair as the Attorney General. Their report is due by January 1, 2017.

> SCR 087 requires the Board to study and make recommendations regarding the use of the term ‘specialty drug’ and ‘specialty pharmacy’. The resolution identifies the type of stakeholders to be consulted and requires the submission of the report no later than February 1, 2017.





Report of Assistant Executive Director



Requests for Full Exemption from PMP Reporting

August 10, 2016

In accordance with LA.R.S:40.4.X-A.1006.C. The board may issue an exemption from the reporting

requirement to a dispenser whose practice activities are inconsistent with the intent of the program.

The board may rescind any previously issued exemption without the need for an informal or formal

hearing.

. PermitPermit Name Scope of Practice DEA City State

Type

6117 NR ARJ Infusion Services Inc Home lnfusionf Specialty Yes Lenexa KS

7276 NR Aureus Pharmacy Specialty Pharmacy Yes Cape Girardeau MO

7311 NR BeneVi Health Specialty Pharmacy Yes Cary NC

7339 NR Biologic5 Specialty Pharmacy Yes Cary NC

7314 NR BiologicTx Specialty Pharmacy Yes Totowa Ni

DeQuincy Memorial Hospital4441 HOS Hospital Pharmacy Yes Dequincy LA

Pharmacy

4594 NR Diamond Pharmacy Services Specialty Pharmacy Yes Indiana PA

6662 NR Eagle Pharmacy Specialty Pharmacy Yes Lakeland FL

7325 NR Elwyn Specialty Care Specialty Pharmacy Yes Garnet Valley PA

5609 NR Homescripts Specialty Pharmacy Yes Houston TX

4280 HOS Lakeview Reg Med Ctr Pharmacy Hospital Pharmacy Yes Covington LA

Louisiana Medical Center & Heart6464 HOS Hospital Pharmacy Yes Lacombe LA

Hospital

LSU Health Baton Rouge - Mid City6684 IR Retail Pharmacy Yes Baton Rouge LA

Pharmacy

7225 NR McKesson Patient Care Solutions Specialty Pharmacy Yes Moorestown I Ni

6565 NR Medex BioCare Specialty Pharmacy Yes Bartlett TN

7319 NR Mint Pharmacy and Skin Clinic Specialty Pharmacy NoPalm

FL

5220 IN DRTCA Methadone Clinic Yes Breaux Bridge LA

7309 NR Reliable Pharmacy Specialty Pharmacy Yes Marco Island FL

7324 NR Revival Animal Health Mail Order Pharmacy No Orange City IA

1048 HOS St. Charles Parish Hospital Hospital Pharmacy Yes Luling LA

6428 NR SVP MEDS Veterinary Pharmacy Yes Stafford TX

7208 NR V Medical Associates Inc. Specialty Pharmacy Yes Irving TX

Staff RecommendationApprove the proposed waivers conditioned upon execution of the standard Consent Agreement:

EXEMPTION TO PRESCRIPTION MONITORING PROGRAM REPORTING REQUIREMENTSCONSENT AGREEMENT

WHEREAS, in order to facilitate the pharmacy’s request for an exemption to the reporting requirements to theLouisiana Board of Pharmacy’s Prescription Monitoring Program (PMP) as required by law, the Pharmacyindicated below agrees to the following terms:

(1) The Pharmacy shall not be authorized to dispense any controlled dangerous substances (CDS) ordrugs of concern, with the exception of a hospital pharmacy permit’s inpatient dispensing, as identifiedby the Louisiana Board of Pharmacy (Board) by regulation.

(2) Upon the first instance of receipt of evidence by the Board indicating the Pharmacy dispensed CDS ordrugs of concern, the Pharmacy agrees to the following sanction:The Pharmacy agrees to pay a fine of $5,000.00 and reimburse the Board $250.00 in

administrative hearing costs, with total payment due the Board of $5,250.00, due by certifiedcheck or money order within 30 days of notice of this prohibited activity.

(3) Upon the second instance of receipt of evidence indicating the Pharmacy dispensed CDS or drugs ofconcern, the Pharmacy agrees to pay the above sanction, the termination of this exemption and theresumption of its reporting to the PMP.

(4) The Pharmacy shall post a copy of this agreement adjacent or attached to its pharmacy permit.

By signing this Consent Agreement, Respondent agrees that the Board has jurisdiction in this matter andwaives all rights to informal conference, to Notice of Hearing, to a formal Administrative Hearing, and to judicialreview of this Consent Agreement.

Lindsey Schultz

From: Joe FontenotSent Thursday, July 14, 2016 11:38 AMTo: Lindsey SchultzSubject: FW: Request for Exemption from PMP Reporting

PMP Exemption request for the August meeting.

From: Andrew Cash [mailto:AndrewClARJInfusion.com]Sent: Wednesday, July 13, 2016 10:00 AMTo: Joe FontenotSubject: Request for Exemption from PMP Reporting

Joe Fontenot,

lam sending this email to request an exemption from PMP reporting on behalf of my pharmacy ARJ Infusion. We are anout of state pharmacy located in KS. Below is our information requested by the LABP. We had previou5 contact last fallwith a Danielle Clau5en and we were informed that our license was not active at said time.

• Louisiana Pharmacy Permit Number, Name, and Addresso PHY.006117-OSo ARJ Infusion Serviceso 10049 Lakeview Avenue Lenexa, KS 66219

• DEA Registration Number (if applicable)o BA6894504

• Scope of Practiceo Home Infusion/Specialty

• Detailed explanation as to the reasons for requesting an exemptiono ARJ has no history of or Intention of sending controlled substances into LA

• Statement confirming that the pharmacy does not nor plan on dispensing any controlled substances or drugs ofconcern to Louisiana residents

o ARJ has no history of or Intention of sending controlled substances into LA• For a Hospital Pharmacy permit — statement confirming that the pharmacy is strictly in-patient and does not

dispen5e any out-patient prescriptionsN/A

Andrew Cash, CPhTPharmacy TechnicianARJ Infusion ServicesToll Free: (866) 451-8804Fax: (877) 451-8955AndrewC@ari ir.fusior, .com

AR! Mission Statement: To provide caring. comprehensive, cost-conscious infusion therapy to people affected by chronicdisorders.

CONFIDENTIALITY NOTICE This e-mail and any files transmitted with it are confidential and are intended solely for the use of the individual or entity to whichthey are addressed. This communication may also contain material protected and governed by the Health Insurance Portability and Accountability Act (HIR4A). Ifyou are not the intended recipient of this e-mail and the information it contains, or if you are not the employee or agent responsible for delivering this e-mail and theinformation it contains to the intended recipient, be advised that you have received this e-mail in error and that any use, dissemination, forwarding, printing orcopying of this e-mail is strictly prohibited If you have received this e-mail in error, please contact the sender of this message at ARJ tnfusion Services at (866)451-8804.

1

June 7, 2016

TO: Louisiana Board of Pharmacy

RE: Exemption request for reporting to PMP

PHARMACY: Aureus Pharmacy

61 Doctor’s Park

Cape Girardeau, MC 63703

LA License: PHY.007276-NR

DEA number: F54293534

We are requesting exemption from reporting to the LA PMP due to the fact that

we do not carry or order controlled subtances. Therefore, we would not

send/deliver/mail any controlled substances to patients in Louisiana. We are a

specialty pharmacy that takes care of Hepatitis C, RA, UC, Ps, etc patients. Our

main medications are Harvoni, Sovaldi, Viekira, Daklinza, Humira and Enbrel. I am

enclosing several of our past Controlled Inventory forms to provide proof of thisstatement. We also do not plan on ordering any controlled substances in the

future. If we do change this plan, we will notify the board immediately.

Thank you for your consideration.

Kelley/ipkin, RPh, CSP

Pharmacist in charge

Aureus PharmacyLA license: PST.021395

1.) 34RD OF PHARMIWYJ

MISSOURI DEPARTMENT OF HEALTH AND SENIOR SERVICES\ BUREAU OF NARCOTICS AND DANGEROUS DRUGS

ANNUAL INVENTORY OF CONTROLLED SUBSTANCES

(0

DRUG NAME

nb SSD-2649 (11-06) NDD-1 7

REGISTRANT NAME DATE OF ANNUAL INVENTORY

kuusHt&l+krvcLfJ LL UYvS ?arac

s—a-I’

SCHEDULES) INVENTOR)EO

1NVENTORY OF SCHEDULE II DRUGS ONLY (INDIVIDUALLY HAND COUNTED)INVENTORY OF SCHEDULES Ill-V DRUGS ONLY

(INVENTORY FOR SCHEDULE II DRUGS MUST BE ON SEPARATE FORM FROM III-V)TIME OF INVENTORY

[‘1NVENTORY TAKEN AT OPENING OF BUSINESSLI INVENTORY TAKEN AT CLOSING OF BUSINESS-AFTER HOURS

TIME OF DAY INVENTORY TAKEN, IF OPERATIONS ARE 24 HOURS A DAY

DRUG STRENGTH I DOSAGE FORM I QUANTITY

n 0 0

- - -t

.

ll-- -

-

MISSOURI DEPARTMENT OF HEALTH AND SENIOR SERVICES

BUREAU OF NARCOTICS AND DANGEROUS DRUGS

\4%i/ ANNUAL INVENTORY OF CONTROLLED SUBSTANCES ___,___I_7—, I.REGISTRANT NAME DAT OF ANNUAL INVENTORY ‘.-‘ I

4UUi j+R 5ry,ts, LLC 4SCHEDULE(S) INVENTORIED

INVENTORY OF SCHEDULE II DRUGS ONLY (INDIVIDUALLY HAND COUNTED)JNVENTORY OF SCHEDULES Ill-V DRUGS ONLY

(INVENTORY FOR SCHEDULE II DRUGS MUST BE ON SEPARATE FORM FROM lll-V)TIME OF INVENTORY

LINVENTORY TAKEN AT OPENING OF BUSINESSD IN VENTOHY TAKEN AT CLOSING OF BUSINESS-AFTER HOURS


DRUG NAME DRUG STRENGTH DOSAGE FORM QUANTITY

0 Q

MO 580-2849 (11-06)

32015-FaAo OF PIIARMAr

NOD.17

MISSOURI DEPARTMENT OF HEALTH AND SENIOR SERVICES 1CBUREAU OF NARCOTICS AND DANGEROUS DRUGS 1 N-ANNUAL INVENTORY OF CONTROLLED SUBSTANCES


Q U/eu 1&/1i1 krvi’ 4501-lED LE(S) INVENTORIED

JNVENTORY OF SCHEDULE II DRUGS ONLY (INDIVIDUALLY HAND COUNTED)%% NVENTORY OF SCHEDULES Ill-V DRUGS ONLY /7 4

(INVENTORY FOR SCHEDULE II DRUGS MUST BE ON SEPARATE FORM FROM IIIV) dli h IN0

TIME OF INVENTORY u£t\)

C INVENTORY TAKEN AT OPENING OF BUSINESSINVENTORY TAKEN AT CLOSING OF BUSINESS-AFTER HOURS ,pJt V



U D 0

iI4 JU1182018 i/iMO 580-2849 (11061 1! NQD-17



ANNUAL INVENTORY OF CONTROLLED SUBSTANCESucPI C


UreuSCHEDULE(S) INVENTORIED

INVENTORY OF SCHEDULE II DRUGS ONLY (INDIVIDUALLY HAND COUNTED)El INVENTORY OF SCHEDULES Ill-V DRUGS ONLY

(INVENTORY FOR SCHEDULE II DRUGS MUST BE ON SEPARATE FORM FROM III-V)

TIME OF INVENTORY

U INVENTORY TAKEN AT OPENING OF BUSINESS / / 4 /9 , ç- LINVENTORY TAKEN AT CLOSING OF BUSINESS-AFTER HOURS J’Nj3/7jffl r1pt—’L— ftc

TIME OF DAY INVENTORY TAKEN, IF OPERATIONS ARE 24 HOURS A DAYr U


0 0 U

FI•n1’

MO 580-2849 (11-06) N DO-i?



ANNUAL INVENTORY OF CONTROLLED SUBSTANCESREGISTRANT NAME DATE OF ANNUAL INVENTORY

AflUSCH ULE(S) INVENTORIED

SINVENTORY OF SCHEDULE II DRUGS ONLY (INDIVIDUALLY HAND COUNTED)LTINVENTORY OF SCHEDULES Ill-V DRUGS ONLY

(INVENTORY FOR SCHEDULE II DRUGS MUST BE ON SEPARATE FORM FROM III-V)

TIME OF INVENTORY

INVENTORY TAKEN AT OPENING OF BUSINESSD INVENTORY TAKEN AT CLOSING OF BUSINESS-AFTER HOURS



0 0 0

[NOD-i?MO 580-2549 (1106I

Lindsey Schultz

From: Joe FontenotSent: Wednesday, May 11, 2016 1:48 PMTo: Lindsey SchultzSubject: EW: Exemption from reporting

Please add to the list of exemption requests for the Board’s August meeting.

From: Phyllis Smith [mailto:[email protected]]Sent: Wednesday, May 11, 2016 11:57 AMTo: Joe FontenotSubject: Exemption from reporting

Dear Mr. Fontenot,

BeneVi Health LLC13000 Weston Parkway, Suite 105Cary, NC 27513Pharmacy permit It PHY.007311.NRDEA #FB5896076

BeneVi Health LLC will not stock nor dispense any Controlled Substances or drugs of concern to patients inLouisiana or any other state. Our facility is not opened as of yet since we are waiting for our 50 statepharmacy permits.BeneVi Health LLC pharmacy facility will provide clinical and drug distribution services to patients in support ofmanufacturer sponsored, IRB approved clinical trial programs as well as manufacturer sponsored free drug(PAP) services.

Therefore we are requesting an exemption from reporting to the prescription monitoring program.

Please let me know if there is anything I need to do to stay in compliance with the laws of Louisiana.

Thanks!Phyllis

Phyllis M. SmithClinical Oncology PharmacistClinical Research Services

BeneVi Health LLC13000 Weston Parkway, Suite 105Cary, NC 27513

T • 919-377-1330F • 919.377-1319 —

b1[i2oi6]1

LABOARDOFPHARMACY

Lindsey Schultz

From: Joe Fontenot

Sent: Monday, July 25, 2016 8:01 AM

To: Lindsey Schultz

Subject: FW: Biologics-Permit #PHY.007339-NR

PMP Exemption request for the August Board meeting.

From: Scott, Ferial [mailto: FScotUThbiologicsinc.com]Sent: Monday, July 18, 2016 4:42 PMTo: Joe FontenotSubject: Biologics-Permit #PHY.007339-NR

My name is Ferial Scott and I am a pharmacist at Biologics Inc (NABP: 3430369) in Cary, NC. We have a currentwaiver with your state that exempts us from reporting any controlled substances.

Recently, we underwent new ownership and our permit number has changed with your state. We are still Biologics,but under McKesson. None of our operations or our day-to-day activities have changed. Everything has stayed thesame and we still do not dispense any controlled substances.

My question for you is does my company need to reapply for a new waiver or is the one we have on file with youcurrently still active?

Thanks so much,

Ferial Scott, PharmDFill PharmacistPharmacy Services Group

Biologics, Inc.120 Weston Oaks CourtCary, NC 27513

T • 800.850.4306F • 800.823.4506

www.biolopicsinc.com

1

‘Bio1ogicT

March 6, 2015

Louisiana Board of Pharmacy3388 Brentwood DriveBaton Rouge, LA 70809-1700

To Whom It May Concern:

This letter is to request a waiver/exemption from daily prescription monitoring reporting forBiologicTx, LLC located at 40D Commerce Way, Totowa, New Jersey 07512 with Louisiana NonResident Pharmacy Permit PKY.007314-NR and DEA Registration Number FM3060287.

BiologicTx, LLC is a specialty pharmacy focusing on transplant therapy management fordesensitization, acute mediated rejection and post-transplant immunosuppressant medications.BiologicTx, LLC does NOT stock any ClI-CV drugs, drugs of concern [Tramadol, Butalbitalcontaining products), or ephedrine, pseudoephedrine, and phenylpropanolamine containingproducts which are considered Schedule V in Louisiana and will not dispense or ship intoLouisiana any Controlled Dangerous Substances (CII- CV), drugs of concern, or ephedrine,pseudoephedrine, and phenyipropanolamine containing products.

BiologicTx, LLC pharmacy does not nor have any plans on dispensing any controlled substancesor drugs of concern to Louisiana patients. It is with the complete understanding that if, in thefuture BiologicTx, LLC. finds a need to dispense or ship Controlled Dangerous Substances intoLouisiana we will perform the appropriate reporting to the Louisiana Prescription MonitoringProgram at that time.

Thank-you for considering BiologicTx request for waiver/exemption from daily prescriptionmonitoring reporting. If you need additional information please do not hesitate to contact me at877-567-8087 extension 103 or through email at [email protected]. I look forward toreceiving confirmation that waiver/exemption from PMP reporting has been granted by theLouisiana State Board of Pharmacy.

Best Regards1)

Karen B. Spano 3 Maria Rafanelli Sal RafanelliVP of Clinical Operations Pharmacist-in-Charge Pharmacy’s Managing Officer

40-D Commerce Way Totowa, NJ 07512 t: 877-567-8087 f: 877-567-8089

Lindsey Schultz

From: Joe FontenotSent: Wednesday, June 15, 2016 12:47 PMTo: Lindsey SchultzSubject: EW: DeQuincy Memorial Hospital Pharmacy Request for exempiton from PMP

PMP Exemption request for the August meeting

From: JOLAINE EDWARDS [mailto:][email protected]]Sent: Wednesday, June 15, 2016 12:00 PMTo: Joe FontenotSubject: DeQuincy Memorial Hospital Pharmacy Request for exempiton from PMP

Mr. Joe,I would like to request an exemption from PMP for Dequincy Memorial Hospital Pharmacy(PHY.004441-

HOS). We are a small critical care hospital that also fills prescriptions for our employees only ,but we DO NOTfill any controlled prescriptions and I would like to request an exemption of having to report zero quantity ofcontrolled prescriptions to the PMP Program.

Thanks,Jolaine Edwards, Pharmacist in ChargeDequincy Memorial Hospital337-786-1215

I

TO:Fax User COMPANY

Fax Server 5/23/2016 2:08:12 PM PAGE 2/002 Fax Server

PHARMACY SERVICES

May 23, 2016


Diamond Pharmacy Services provides controlled medications to correctional facilities in the state ofLouisiana. These medications are not put directly into the hands of the Inmates. Medications aredistributed to the inmates through a medical department within the institution. Due to the fact thatthese controlled medications are not being dispensed into the general public, Diamond Pharmacy isrequesting a waiver from reporting to the prescription monitoring program.

Louisiana Permit Number: PHY.0D4594-NR

DEA Number: 801753640

645 Kolter Drive Indiana, PA 15701

Matt ValasekDirector of Pharmacy Operations

- ‘

Controlled Substance Department645 Kolter DriveIndiana, PA 15701-3570

800.882.6337Fax 888.264.3784

.diamondpharmacy.com

Lindsey Schultz

From: Joe FontenotSent: Friday, June 17, 2016 10:37 AMTo: Lindsey SchultzSubject FW: PMP Exemption/Waiver

PMP Exemption request for the August Board meeting.

From: Butler, Gina [mailto:gbutlerüeanlepharmacy.comJSent: Tuesday, May 31, 2016 1:23 PMTo: Joe FontenotSubject: PMP Exemption/Waiver

Good Afternoon,lam sending this email to request a waiver form for my pharmacy (License No. PHY.006662-NR) because we

have not and will not dispense controlled substances into the state of Louisiana.

Jfzanñ you,

qata $ut&’c, &PA5Pharmacy TechnicianEagle Pharmacy®350 Eagles Landing DriveLakeland, FL 33810(855) 748-2663 ext. 6528gbutlerwelldynerx.com

Confidentiality NoticeThis e-mail message, including any attachments, is for the sole use of the intended recipient(s) and may containconfidential and privileged information. Any unauthorized review, use, disclosure or distribution is prohibited. If youare not the intended recipient, please contact the sender by reply e-mail and destroy all copies of the original message

1

Elwyn PHAPSXMACY GROUPELWYN. MED CENTERSPECIALTY CARE SPECIALTY PHARMACY

GLEN ROCKMEDICAL PHARMACY

JUN 152016 ‘

Dear Louisiana Board of Pharmacy,I am writing this letter to ask for exemption from reporting controlled substances.Elwyn Specialty Care does not dispense controlled substances to patients locatedoutside of Pennsylvania. Our license number is PHY.007325-NR. Our DEAnumber is FE0845860. Elwyn Specialty Care will be dispensing non-controlledmedications to any patient located in Louisiana. If Elwyn Specialty Care everdecided to change their current operation we would notify the board of pharmacyimmediately. If you have any further questions please do not hesitate to contactme. 610-545-6040 ext. 202 or rachele1wynpharrnacy.com

Ihe I.Iw4n rhaI.man! (;IOnp is comprised II:Fiwyn Specialty (‘arc & Fiwyn Pharmacy arc divisions of K&K Rs Services, II’Med Center S pedal ty P11 armacy is a div is i on of C MC’ Pliarm icy, t . LCGlen Rock Medical Pharmacy is a division of (1kM Pharmacy, LI.C3070 McCann Farm Drive, Suile 101, Garacl Valley, PA 10060.2131P11(11W (610) 545-6040 la (610) 545-6033

ELWYNPHARMACY

June 15, 2016

Louisiana Board of Pharmacy3388 Brentwood DriveBaton Rouge, LA 70809

Sincerely,

Rachel M. YeskelawitchExecutive Assistant

Page I

Lindsey Schultz

From: Connie Ewald <[email protected]>Sent: Saturday, April 30, 2016 11:31 AMTo: Lindsey SchultzCc: Charles R. Mccall; Connie Ewald; Jonathan Hendricks; Kristine Brito; Steven CobbSubject: Exemption to Reporting ZERO for Louisiana

Dear Mr. Broussard and Louisiana Board,

‘ (7 ERx Direct, Inc. d/b/a Homescripts U s & L uNewaddress:

H ton TX 77043Pkwy N. Suite #140 F

Louisiana Permit Number. Phy.005609 OSDEA # BR41 88391 LA BOARD OF PHARMACY

Rx Direct had two books of business each with individual NCPDP numbers (5904734 and 4590724) operatingfrom the old address:5001 C Stateline AveTexarkana, TX 75503

An executive decision to move locations and focus growing only one of these books of business was made toincrease business within Texas of our MHMR clinic business (4590724) and to pursue expanding intoadditional states.

Currently, the MHMR clinic book of business does not dispense Controlled Medications (C ll-V) or drugs ofconcern.If at a future date a business decision to dispense Controlled Medications or drugs of concern to a limitedspecialized group of Louisiana citizens is made reporting will be done through the Prescription MonitoringProgram.

Rx Direct, Inc. d/b/a Homeschpts has no plans to dispense Controlled Substances or drugs of concern. Thefocus of this business is to supply a limited set of medications for (some impoverished) mentally challengedindividuals. This is done by contractual agreements with the MHMR clinic center.

The reason for requesting an exemption is based on the following:• time requirements to report a ZERO report to all 49 states and Washington D.C. — even though we

are not dispensing to any state besides Texas (only legend drugs) at the present time, Rx Direct, Inc.d/b/a Homescripts has a license in all states.

• software systems changes and system failures— as we all know the PMP program nationwide changesASAP formats and reporting companies. Without a waiver, the software company could havedifficulties formatting to the proper requirements. I have seen software system and failure problems inthe past and want to be prepared for future problems, if necessary.

• new employees — always a possibility that daily production concerns can take focus away fromreporting.

• and Murphy’s Law, (do not mean to be disrespectful, however I have been a pharmacist for over 30years and I know that when dealing with a STATE Board I would much prefer to ASK for permissionthan suffer the consequences of begging for forgiveness. I use the analogy of the the rabbit cagebehind the garage” what happens if I forget to feed the rabbit? In this situation, there is NO_rabbit inthe cage to feed and therefore forgetting to report a ZERO though I do not expect this to happen —

what if it did? The best alternative is requesting an exemption and the Board allowing an

1

exemption. This is one of many requests to each state I am requesting to allow focus on ourcustomers and their care.


Sincerely,

Connie Stroud Ewald, R.Ph.Louisiana License# PST. 017557

Connie S. Ewald, R.Ph.voice: (800) 785-4197 ext. 23907

Rxdwcct‘N COO!’ ONA TEn

.Before printing this email, please consider the environment.

From: Lindsey Schultz Imailto:[email protected])Sent: Friday, April 29, 2016 12:39 PMTo: Connie Ewald <[email protected]>Subject: RE: Request for Waiver from Reporting ZERO to LA

Connie,

Please see the guidelines below in regards to applying for a PMP waiver:

EXEMPTIONS TO REPORTING:

The Louisiana Board of Pharmacy may issue an exemption from the reporting requirement to a dispenserwhose practice activities are inconsistent with the intent of the program. The Board will only consider requestfrom dispensers who do not dispense controlled substances or drugs of concern. For dispensers wanting torequest an exemption they must submit a detailed request to the Board office which must include but is notlimited to the following:

> Louisiana Pharmacy Permit Number, Name, and AddressDEA Registration Number (if applicable)

> Scope of Practice> Detailed explanation as to the reasons for requesting an exemption> Statement confirming that the pharmacy does not nor plan on dispensing any controlled substances or

drugs of concern to Louisiana residentsFor a Hospital Pharmacy permit — statement confirming that the pharmacy is strictly in-patient and doesnot dispense any out-patient prescriptions

This request can be mailed, emailed, or faxed. Once it is received, it will be added to the agenda for the nextBoard meeting. Once the Board has made a decision, you will receive a response from my office.

Please let me know if you have any questions.r

For the Board,

Lindsey Schultz

2 LABOARDOFPHARMACY

Lakeview Regional Medical Center

Date May, 31, 2016

Subject: Lakeview Regional Medical Center requesting wavier from Prescription Monitoring Program

To Whom it May Concern:

Pharmacy Name: Lakeview Regional Medical Center 95 Judge Tanner Blvd. Covington, Louisiana 70433

Pharmacy Permit Number: 4280-H

Pharmacy DEA Number: 8L6326133

Pharmacy Representative Name and Title: Diana Terry, Director of Pharmacy

Pharmacy Scope of Practice: See Attachment

Lakeview Regional Medical Center is requesting a waiver from the Prescription Monitoring Program

(PMP) due to the scope of practice at this facility. The Lakeview Regional Medical Center does not

dispense any CDS or drugs of concern prescriptions in form of take home medications to any patient

discharged from the hospital. All patients discharged from the Lakeview Regional Medical Center must

have their prescriptions refilled at a retail or independent pharmacy. If you should have any questions

please contact Diana Terry at 985-867-4239 or [email protected].

Respectfully,

Diana Terry

LA SO4RD OF PHARMACY

ILq85.8Gt3800

‘1 judge linnil Blvd.(.o,vi,n. IA 70433

Lindsey Schultz

From: Joe FontenotSent: Tuesday, May 31, 2016 3:27 PM

To: Lindsey Schultz

Subject FW: PMP Exemption Request/Permit 4280Attachments: PMP Exemption Request Permit 4280 Hospital.tif

PMP Exemption request letter attached. Please add to the August agenda.

From: Diana.Terryhcahealthcare.com [mailto:Diana.Terrv©hcahealthcare.com]Sent: Tuesday, May 31, 2016 11:45 AMTo: Lindsey Schultz; Joe FontenotSubject: PMP Exemption Request/Permit 4280

Hello Mr. Fontenot,

This e-mail is in request to Lakeview Regional Medical Center requesting a waiver from the Prescription MonitoringProgram (PMP) due to the scope of practice at this facility. Due to the Louisiana Board of Pharmacy Law Book Part X-ASection 1003 —(6) the pharmacy permitted by the board as a hospital pharmacy that only dispenses or distributes anycontrolled substance or drug monitored by the program for the purposes of inpatient health care can request anexemption. Lakeview Regional Medical Center has had a “Zero Upload Report” since the implementation of PMP. I’mattaching a copy of the Lakeview Regional Medical Center letter with this e-mail. Can you provide feedback if anyadditional paperwork is need to request the exemption?

Sincerely,

Øiana RpSerson ¶ThnyDirector ofP/annacyLa/teview R.cgiona(!7vIe&ca( Center9SYucfge tanner’BCvt[Covington, Louisiana 70433Office WurnBer:985-867-4239ThWum6er 985-867-4038e-maiEd?ana. teny@hcahea(tficare. corn

:

__ __ __

Connectwithusl

____

—

____ ____ ____

.1

Lakeview Regional

__

Medical Center

This e-mail and any files transmitted with it may contain Privileged or Confidential information and may be read or usedonly by the intended recipient. If you are not the intended recipient of the e-mail or any of its attachments, please beadvised that you have received this e-mail in error and that any use, dissemination, distribution, forwarding, printing orcopying of this e-mail or any attached file is strictly prohibited. If you have received this e-mail in error please immediatelypurge it and all attachments and notify the sender by reply e-mail.

Laeview an emp(cr of cfioice on the Won&Izore. ora viuaCtour ofourfaci[i, pasewww.lakeviewregional.com

1i_:i:3 12016

L” BO4RD OF PHAPMACY

Lindsey Schultz

From: Joe Fontenot

Sent Wednesday, June 22, 2016 2:00 PMTo: Lindsey Schultz

Subject: FW: Request for PMP Reporting Exemption

Please add this PMP exemption request to the agenda for the August Board meeting.

From: Peterson, Larry [mailto:Larrv.Peterson©louisianaheart.com]Sent: Wednesday, June 22, 2016 12:01 PMTo: Joe FontenotSubject: Request for PMP Reporting Exemption

Good Morning Joe,As a follow up to our telephone conversation and per your direction, this an official request for exemption status on thePMP reporting requirements. Our dispensing of controlled substances is only for use in patients with physician orderswhile physically in the hospital. Further, our owners have determined that we will continue as in the past to not fillemployee prescriptions or open an outpatient pharmacy. A snapshot of our pharmacy info is below as listed on theBoard website.

Please let me know if you need any additional information or have any questions.

Name Address fk1

64030 Highway 434Lacombe, LA 70445-3456

PHY.006464- Pharmacy - Hospital 01/05/2012 12/31/2016 :nth0utrestriction or H. Lawrence Peterson

Thanks,

£ar peterson, RØDirector of Pharmacy and LaboratoryLoniciana heart IIo.cp#al!ar’. yetersonailouiciaia aheart. ci,,,,

Louisiana Medical Center & Heart Hospital

Phone: 985-690-7823Fax: 985-690-7820

I

LSUHeaRhBeI:onRougeA Division of Our Lady of the Lake

May 31, 2016

To Whom It May Concern;

I am writing to request exemption from reporting of dispensed narcotic prescriptions through thePrescription Monitoring Program for LSU Health Baton Rouge Mid City Pharmacy. As a matter of policy,this pharmacy does not purchase or dispense controlled substances to any patients.

Pharmacy address:1401 N. Foster Dr.Baton Rouge, LA. 70806

Permit 4$ PHY.006684-IR

DEA 4$ FL3797074


Please let me know if you have questions or require additional information.

Adria A Kerr, R.Ph. Retail Pharmacy ManagerLSU Health Baton Rouge Mid City PharmacyA Division of Our Lady of the Lake Regional Medical Center1401 N. Foster Dr. I Baton Rouge, La 70806 r1225) 987-9114 (phone) 1(225) 765-9014 (fax) I www.ololrmc.com

JUN 062016RPQFPHARM

Enclosure:Pharmacy Policy PH2407

OUR LADY OF THE LAKE REGIONAL MEDICAL CENTER

Policy Manual: Pharmacy Section: Retail Pharmacy

TitlcMidCity Retail Pharmacy Controlled Policy Reference #: PH2407Substance and Drugs of Concern Supersedes #:

Datc of Origination: October21, 2013 Last Date Reviewed: 05/31/2016

Last Date Revised: 05/31/16

PURPOSE:

This policy defines the dispensing of controlled substances in the LSU Health Baton Rouge MidCityClinic Pharmacy.

DEFINITIONS:A. Controlled Substance — any drug determined by the Louisiana State Board of Pharmacy and/or

Federal Drug Enforcement Administration to have a potential for abuse and classified in drugschedule CI. Cli. CIII. CIV. CV

B. Drugs of Concern — any drug determined by the Louisiana State Board of Pharmacy and/orFederal Drug Enforcement Administration to be of concern due to potential to pose risks forthose who abuse them.

POLICY:A. The pharmacy will not dispense drugs of concern or controlled substance including schedules

CII. CIII. CIV, or CV.B. Prescriptions that have multiple orders including a controlled substance on the same page may be

filled according to Louisiana Board of Pharmacy regulations, voided by use of a stamp across thewriting of the prescriptions filled, copy maintained in the pharmacy, and original returned to thepatient to fill at an area pharmacy of their choosing.

C. Zero reports will be submitted to the Prescription Monitoring Program by QSI pharmacysoftware system daily. Records of these transmissions will be stored electronically.

D. Annual inventory will be taken and stored eLectronically in the pharmacy shared folder underAnnual Controlled Pharmacy Inventory.

REFERENCES:Louisiana Board of Pharmacy Law and Regulations section on Controlled Substances

-7

JUN 062016APP OFPHARM

Policy Reference NumberPage 1 of 1

McKESSON

McKesson Patient Care Solutions

Joe Fontenot, R.Ph.

Assistant Executive Director


3388 Brentwood Drive

Baton Rouge, LA 70809-1700

September 18, 2016

RE: Mckesson Patient Care Solutions Exemption to Reporting Request

Dear Mr. Fontenot,

Please be advised that our facility below is requesting an exemption to report:

McKesson Patient Care SolutionsTwo Twosome Drive, Moorestown, NJ 08057

Louisiana Pharmacy Permit U PHY.007225-NR

The Scope of Practice at McKesson Patient Care Solutions is wound care, ostomy, urologic supplies, and

diabetic testing supplies.

McKesson Patient Care Solutions does not stock nor do we dispense controlled substances of any class.

In addition we do not provide injectable or compounding services. Our Rx inventory consists of Sterile

Saline 0.9% (bottles, prefilled syringes, vials), Sterile Water for Irrigation (Bottles and vials), Heparin flush

(prefilled syringes and vials), Insulin syringes and various TB syringes, and Insulin.

Furthermore, we do not anticipate stocking or dispensing CDS or drugs of concern at anytime in the

foreseeable future.

Licensee Contact Information:

Warren Bruce Bell, RPh, PlC

Louisiana 4 PST 018773

888-216-5500

Fax 856-273-9987Warren.bell mckesson.com

Please don’t hesitate to contact my office if you have questions or require additional information.

Sincerely —

/ -

Warren B. Bell

McKc,isi,n Patient Care S.,Ititiotts Inc. - —

2 Twosci me I) nyc Ii —

M cioncstow I, • N.J 1)8057 J ) 1

[888.907.8775 IL: MAY 242016 II’I 888.71% 50Th J

Lindsey Schultz

From: Joe FontenotSent: Thursday, June 09, 2016 2:56 PMTo: Lindsey SchultzSubject: FW: Requesting Zero Reporting Waiver

PMP Exemption request for the August meeting of the Board — please add to the agenda

From: Katrina Dirkes [mailto:Katrina.Dirkes©MedexBiocare.com]Sent: Wednesday, June 08, 2016 2:22 PMTo: Joe FontenotSubject: Requesting Zero Reporting Waiver

Facility: Medex BioCareFacility address: 8024 Stage Hills Blvd., #107, Bartlett, TN 38133Phone number: 800-962-6339Pharmacy license number: PHY.006565DEA number: FF3020271Pharmacist in Charge: Katrina Dirkes (TN-35751 / LA PST.021400)Statement indicating why you are requesting a waiver form:Medex BioCare does not currently stock or dispense any controlled substances (5cheduled ll-V) to any patients residingin the State of Louisiana. If we begin stocking and dispensing to Louisiana patients, we will immediately notify you andbegin providing data to the program including zero reports.

Kafrmna (Kate) Dirkes, Pharm.D., CGPPharmacist-In-ChargeMedex BloCarea Matrix Health Group Company8024 Stage Hills Blvd., #107Bartlett, TN 38133800-962-6339 Toll Free901-380-5899 Office901-382-3091 Office Fax866-755-6339 Pharmacy Fax

All information in this communication, including attachments, Is 5trictly confidential and Intended solely for delivery to and authorizeduse by the addressee(s) Identified above, and may contain privileged, confidential, proprietary and/or trade secret Information entitledto protection and/or exempt from disclosure under applicable law. If you are not the intended recipient, please take notice that any use,distribution, or copying of this communication, and/or any action taken or omitted to be taken In reliance upon it, Is unauthorized andmay be unlawful. If you have received this communication in error, please notify the sender and delete this communication from yourcomputer.

1

% PbarmaMadllxPharmaMedRx LLCMint Pharmacy and Skin Clinic1201 US Hwy 1, Suite 1North Palm Beach, FL 33408866-855-6468

May 19, 2016

Louisiana Board of PharmacyDepartment of Prescription Monitoring Program3388 Brentwood Dr # A,Baton Rouge, LA 70809

RE: Waiver for Zero Reporting Request

Louisiana Non Resident Pharmacy Permit Number: PHY.007319-NR


Mint Pharmacy and Skin Clinic does not dispense any controlled substances, nor do we haveany future plans to dispense controlled substances. Mint Pharmacy and Skin Clinic focuses onprescriptions for the hair, skin and nails and those treatments do not include controlled drugs.Mint Pharmacy and Skin Clinic does not have a DEA number nor plans to register with the DEA.For the above-mentioned reasons, Mint Pharmacy and Skin Clinic is requesting a waiver for zeroreporting.

Mint Pharmacy and Skin Clinic does not see any circumstances that would tend to negate theneed for a waiver. Mint Pharmacy and Skin Clinic would immediately notify the Louisiana Boardof Pharmacy if our business model changes to include controlled substances.

Mint Pharmacy and Skin Clinic would like to request this waiver for the maximum allowabletime possible.


Sincerely,

Jennifer Mooney-Thompson, PharmDDirector of Pharmacy OperationsPharmaMedRx LLC

PhormoMedRx LIC • 4623 Sudley Road • Catharpin VA 20143

Opiate Replacement Therapy Centers of America

648 Latiolais Drive

Breaux Bridge, LA 70517

(337)332-4878

Fax: (337)332-4866

40/

98

4ic#

c251

A:’

oflY/

JUN 032016

7ARPOFPHRM •-:

1

7e/O

DA frM

PHI. Slzo-Th

Lindsey Schultz

From: Joe FontenotSent Friday, May 06, 2016 2:04 PMTo: Lindsey SchultzSubject: FW: Exempt reporting

Lindsey,

Please add to the list of pharmacies requesting an exemption to the PMP reporting requirements for theAugust meeting of the Board.

Sincerely.

Joe Fontenot, R.Ph.Assistant Executive Director

Louisiana Board of Pharmacy3388 Brentwood DriveBaton Rouge. LA 70809-1 700Office 225.922.0094Fax 225.923.5670E-mail: jfontenotpharmacy.Ia.govWebsite: www.pharmacy.Ia.gov

From: Tammy.Salasp4mpharmaceuticals.com [maiIto:Tammy.Salas4mpharmaceuticaIs.com1Sent: Friday, May 06, 2016 1:57 PMTo: Joe FontenotSubject: Exempt reporting

Reliable Pharmacy1757 San Marco RD #BMarco Island Fl. 34145239-970-0415

LOUISIANA PERMIT# PHY.007309-NRPlC MARLIA ANN BURKE LIOUSIANA PERMIT #PST.021296FLORIDA DEA #FR5031050

Joe Fontenot,This letter is to be Exempt from Reporting, For Reliable Pharmacy is a retail pharmacy specializing in diabetic suppliesand only obtained a DEA license for in the state of Florida you are required to obtain and keep a DEA license in order toget the Pharmacy license. Reliable Pharmacy does not except prescription for controlled substances. Reliable Pharmacydoes not stock or dispense any controlled substances and does not plan on doing so in the future.

Thankvou

(2O15

LA BOARD OF PHARMACY

Lindsey Schultz

From: Megan Deiong <[email protected]>Sent: Monday, June 06, 2016 2:52 PMTo: Lindsey Schultz; infoSubject: Request for exemption from reporting controlled substances or drugs of concern


Revival Animal Health out of state pharmacy’1700 Albany Place SEOrange City IA51041

License number PHY.007324-NR

To whom it may concern,

We are writing this to you concerning to our out of state license and asking for an exception for reporting of controlledsubstances and other drugs of concern. We do not dispense controlled substances in our pharmacy nor will dispensecontrolled substance in the state of Louisiana, please read our description of our pharmacy;

Description of PharmacyRevival Animal Health pharmacy is a mail order pharmacy, taking orders for prescription drugs over the phone, on theinternet, fax and mail in orders. Orders are not released to ship until a script is received from the patient’s vet and allinformation matches and is verified.

The types of prescription drugs that are carried in our pharmacy include antibiotics, heartworm prevention, flea and tickcontrol, also medications for animal health. When prescriptions are sent out a help sheet is included for the customersharing with them the side effects that can be seen, when it is not appropriate to give this medication, along with how tostore the prescription item.

Revival Animal health does not have DEA number.

Please review our pharmacy to be exempt from reporting controlled substances, please respond that you have receivedour request to be reviewed for exemption and if this will be added to the agenda for August board meeting.

If there is anything else you need please let me know.

Thank you,

fla

Revival Animal HealhPharmacy Technician712-737-5555 ext 854

1

Managed by

St Charles S OchsnerParish Hospital Health System

To whom it may concern, 6/28/2016

I, Peter Ng, Pharmacist-in-Charge at St. Charles Parish Hospital would like to request for LA PMP Waiver:

-Louisiana Pharmacy Permit Number: 1048H

-Name, and Address: St. Charles Parish Hospital, 1057 Paul Maillard Rd., Luling 70070

-DEA Registration Number: AT3406659

-Scope of Practice: Inpatient Hospital Managed by St. Charles Hospital/Ochsner

-Detailed Reasons: St. Charles Hospital is a hospital setting; therefore, we only dispense medicationsincluding controlled substances to in-patient

-Statement: St. Charles Hospital Pharmacy does not nor plan on dispensing any controlled substances ordrugs of concern to Louisiana residents.

-Hospital Pharmacy permit statement: St. Charles Hospital Pharmacy is strictly in-patient and does notdispense any out-patient prescriptions.

Your approval for this request will be very much appreciated.

Thanks,

Sincely,

Pe(er Ng, /Director of PharmacySt. Charles Parish Hospital/Ochsner1057 Paul Maillard RoadLuling, LA 70070Office: 985-785-3697Fax: 985-785-5675Email: pngochsner.org

1057 Paul Maillard Road. - Luling, LA 70070 • phone 985-785-6242

Wednesday. July 13, 2016

4159 Bluebonnet Drive Stafford, Texas 77477877-673-3705

Joe Fontenot, R.Ph.Assistant Executive DirectorLouisiana Board of Pharmacy3388 Brentwood DriveBaton Rouge, LA 70809-1700

We wish to apply for a waiver for PMP reporting ininto the state of Louisiana. Our license number issterile veterinary products in accordance to the law.have all been zero reports. Thank you very much in

Alexia LuthyeLicense: P1C020500Specialty Veterinary Pharmacy PharmacistLicense: PIIY.006428-NR4159 Blucbonnet DriveStafford, Texas 77477Tel. 877.673.3705

2016 as we S0 not dispense any control substanceslisted below and we compound sterile and nonOur PMP submission reports for 2015 and 2016your attention to this request.

JUL 152016Thnp W ‘PM

To whom it may concern:

Lindsey Schultz

From: Kevin Vu <[email protected]>Sent: Monday, July 11, 2016 1:54 PMTo: Lindsey SchultzSubject: RE: LA PMP Waiver

Ms. Schultz,

I am requesting PMP waiver for V Medical and the following are the information needed for the board to consider ourapplication.

Pharmacy Name: Y Medical Associates Inc.

Address: 8840 N Macarthur Blvd. Irving, TX 75063

Phone No.: 972 714 0777

LA Pharmacy Permit Number: PHV.007208-NR

DEA No.: BV2603288

Scope of Practice: YMA is a specialty pharmacy concentrated on serving Hemophilia, IVIG and Hepatitis C patients.

Explanation for requesting an exemption: This pharmacy does not dispense any controlled substances schedule II, Ill, IVor V to LA patients.

Statement: I represent a pharmacy that never possesses or dispenses controlled substance Il-V prescriptions and requesta PMP waiver/zero reporting.

9(jvzn gcu 9JA.

•VrMEDICAL

ASSOCIATES

8840 N MacArthur Blvd. Irving, TX 75063(972) 714-0777 FAX (972) 714-0888VISIT OUR WEBSITE @ www.ymedical.com

1





Report of General Counsel







Report of Executive Director



of 4




August 10, 2016 Agenda Item 11-L: Report of Executive Director 1. Meeting Activity 2. Reports 3. Examinations 4. Operations 5. State Activities 6. National Activities 7. International Activities 1. Meeting Activity

In addition to Board and committee meetings, I have also participated in or attended the following meetings since the last Board meeting.

May 14-17 NABP Annual Meeting – San Diego, CA May 21-22 WHPA Conference on Regulation – Geneva, CH May 26-28 LSHP Annual Meeting – New Orleans, LA June 13 Marijuana Team Meeting – Dept. of Agriculture & Forestry July 7 .Pharmacy Executive Board Meeting – Mount Prospect, IL August 1 Marijuana Team Meeting – Dept. of Agriculture & Forestry

2. Reports (all in the Boardroom Library) A. Census Reports

1. Compliance Division – Practitioner Recovery Program & Discipline 2. Credentials Division – CDS & Pharmacy Programs

B. Credentials Division Production Reports 1. Licensure Activity Report [new credentials in previous quarter] 2. Application Activity Report [pending applications count]

C. Exceptions Report 1. PIC in Multiple Locations 2. Resurrected Credentials / Special Work Permits D. Annual Statistical Summary for Compliance Division

3. Examinations

A. MPJE – the results for the first trimester of 2016 are available. Mr. Fontenot and I will be participating in the annual review of our state’s item

bank, to ensure all of the questions are still correct based upon the changes in our laws and rules since the last review session last year.

B. NAPLEX – the results for the first trimester of 2016 are available.

The NAPLEX test is undergoing some program changes; we posted a memo from NABP describing those changes.



of 4

C. PARE – our last administration of this test was in July 2014. D. PTCB – the results for the first semester of 2016 are not yet available.

4. Operations A. Credentials Division

We completed the renewal cycle for pharmacy technicians, EDK permits, and AMS registrations on June 30.

• CPT Certificates. Of the 6,906 technicians we sent renewal reminders, 92% renewed their certificates in a timely manner, and of that number, 91% did so online.

• EDK Permits. Of the 486 permits we sent renewal reminders, 91% renewed their permits in a timely manner.

• AMS Registration. Of the 483 registrations we sent renewal reminders, 77% of them renewed their registrations in a timely manner.

We opened the 60-day renewal cycle for DME permits on July 1. We mailed renewal reminders to the 622 permit holders with active credentials on June 30. Their permits are scheduled to expire on August 31 unless renewed sooner.

B. Compliance Division

Our 5 pharmacist compliance officers are responsible for inspecting all the pharmacies and other facilities holding controlled substances (CDS). The census reports available for this meeting reflect 1,477 pharmacies within the state, as well as approximately 600 various types of facilities for CDS visits, including hospitals, rural health clinics, animal control shelters, researchers, etc.

In addition to their routine site visits, the compliance officers are also responsible for investigating complaints filed with the Board. We began the fiscal year with 214 cases pending from the prior fiscal year. We entered 411 new cases and closed 401, leaving 224 cases open for the new fiscal year. Of the 401 cases closed this past fiscal year, 47% were disposed of through staff activities and the balance through committee and Board action.

C. Administrative Division

The Legislative Auditor began their annual audit earlier this month. Our mutual objective is to complete the audit prior to the end of this month.

Part of our routine management review focuses on the staffing level in the various divisions, to ensure we have the right number and type of staff for the tasks we have to perform. While we believe we finally have the right number and talent mix in our Credentials Division, we believe it necessary to add additional personnel for the Compliance and Administrative Divisions. In particular, we believe it appropriate to engage one new pharmacist compliance officer, raising the number of staff compliance officers to six, and further, to engage a chief compliance officer. We are suggesting the chief compliance officer should share in the inspection and investigation caseload, working from their home like the other compliance officers. Given the electronic nature of most of their documents and communications, we suggest a minimum amount of time would be necessary in the board office – perhaps one day per week. In addition to the compliance officers, we believe it appropriate to engage two new administrative assistants, one to assist the Prescription Monitoring Program and the other to assist the administrative officers (Joe, Carlos, and Malcolm). The costs for the four new personnel have been included in the proposed budget amendment submitted to the Finance Committee for their review.

5. State Activities A. 2016 Louisiana Legislature

The Regular Session adjourned on June 6, and it was ‘book-ended’ between two

of 4

special sessions. Just over 2,400 bills were filed for consideration during the Regular Session. Of the bills passed, the Governor signed 679 Acts, all with varying effective dates. During the session we followed 118 bills which impacted either pharmacy practice or the agency operations. Of that number, 47 measures were passed – either bills or resolutions. These 47 items are described in the Final Legislative Brief that we posted in the Boardroom Library.

The Board’s Executive Committee reviewed the Final Legislative Brief. Some of the items require no action by the Board. Some will require changes to the Louisiana Pharmacy Law Book. Some will require rulemaking by the Board. Some will require the Board to study certain issues and report to the Legislature before the 2017 Regular Session. The Executive Committee will make their recommendations during the Board meeting.

6. National Activities

A. National Association of Boards of Pharmacy (NABP) For your planning purposes, the 2017 meeting will be held May 20-23 at the Hyatt

Regency Orlando Hotel in Orlando, FL. This conference is one of the three meetings for which your travel expenses are eligible for reimbursement, subject to the limitations itemized in the Board’s travel policy as well as the state’s travel policy in PPM-49.

NABP President Hal Wand has completed the appointment process for the association’s committees and task forces. Appointees from Louisiana include Pam Reed to the Task Force on Pharmacist Interactive Communication Skills Examination, which will be meeting on December 13-14, 2016 as well as Malcolm Broussard to the Task Force on Expanding International Membership, which will be meeting on November 8-9, 2016.

B. NABP-AACP District 6 Annual Meeting

For your planning purposes, the 2016 meeting will be held Sep. 11-14 in Portland, OR. This conference is one of the three meetings for which your travel expenses are eligible for reimbursement, subject to the limitations itemized in the Board’s travel policy as well as the state’s travel policy in PPM-49.

You should have already received and acted upon the conference registration materials. We have received interim notice the initial room block at the conference hotel is full. The organizer is attempting to negotiate an increase in the size of the room block, but for now, they are directing registrants to nearby hotels. For those of our members anticipating re-appointment, we have secured a waiver from the late registration fee, but only until August 27. That is the registration deadline and the final count for the caterer. The conference agenda includes a free afternoon on Tuesday. The organizer has identified several options for tours; please remember the deadline to reserve those optional activities is this Friday, August 12.

Please remember the procedures for booking air travel; you must use Short’s Travel Service. Tickets booked elsewhere are not eligible for reimbursement.

Finally, the District 6 representative to the NABP Executive Committee has resigned for personal health reasons. There are just under two years remaining for the term, which will expire at the 2018 NABP Annual Meeting. The district will conduct a special nomination election at the 2016 meeting, to nominate one or more candidates who will stand for a special election at the 2017 NABP Annual Meeting. The winner of that special election will serve the final year of the unexpired term. In the interim, in accordance with NABP Bylaws, the NABP Executive Committee has selected someone to serve the remainder of the current year, or until the 2017 NABP Annual Meeting.

C. MALTAGON For your planning purposes, the 2016 meeting will be held Oct. 9-12 in Austin,

TX. This conference is one of the three meetings for which your travel expenses are eligible for reimbursement, subject to the limitations itemized in the Board’s travel policy as well as the state’s travel policy in PPM-49.

We recently distributed the conference registration information. Please remember

of 4

the procedures for booking air travel; you must use Short’s Travel Service. Tickets booked elsewhere are not eligible for reimbursement.

7. International Activities

A. International Pharmaceutical Federation (FIP) Buenos Aires, Argentina will host the 76th World Congress of Pharmacy &

Pharmaceutical Sciences on Aug. 28 to Sep. 1. The theme for this year’s conference is “Rising to the Challenge – Reducing the Global Burden of Disease.”

Respectfully submitted, Malcolm J Broussard Executive Director




Compliance Division Census Report

August 10, 2016 Practitioner Recovery Program • Probation Completion Report

05-17-2016 PST.011172 Scott Davis Nealy 05-17-2016 PST.020150 Catherine Powell Kain

• Active Probation 47 Pharmacist 1 Pharmacy intern

1 Technician • Active Suspension 42 Pharmacist

2 Pharmacy intern 16 Technician 4 Technician candidate

Disciplinary Restrictions • Probation Completion Report

05-07-2016 PTC.021390 Breanna Michelle Williamson 05-08-2016 PTC.021392 Tiffanie Lakayma Lebby 07-01-2016 CPT.008216 Oretha Levette Lewis 07-01-2016 PHY.005564 Our Lady of Guadalupe Pharmacy 07-01-2016 PHY.005835 CVS Pharmacy No. 5327

• Active Probation 21 Pharmacist 7 Technician 7 Technician candidate

7 Pharmacy permit 3 CDS-PHY license 1 DME permit • Active Suspension 40 Pharmacist

1 Pharmacy intern 65 Technician 15 Technician candidate 13 Pharmacy permit 69 CDS license for practitioners



Louisiana Board of PharmacyCredentials DivisionPharmacy Program

06/30/07 06/30/08 06/30/09 06/30/10 06/30/11 06/30/12 06/30/13 06/30/14 06/30/15 06/30/16PST.VI LA 0 0 0 0 12 10 9 9 13 16

NR 0 0 0 0 9 10 15 14 15 16Total 0 0 0 0 21 20 24 23 28 32

PST-GVI LA 0 0 0 0 0 6 13 13 12 15NR 0 0 0 0 0 0 3 5 5 5Total 0 0 0 0 0 6 16 18 17 20

PST-M LA 0 0 0 0 3 5 3 1 2 1NR 0 0 0 0 11 11 11 13 10 10Total 14 16 14 14 12 11

PST-G LA 0 0 0 0 158 157 164 166 186 204NR 0 0 0 0 30 35 32 31 31 35Total 0 0 0 0 188 192 196 197 217 239

PST LA 4,522 4,612 4,750 4,860 4,654 4,933 4,981 5,140 5,408 5,304NR 1,975 1,964 2,029 2,098 2,079 2,212 2,527 2,479 2,471 2,835Total 6,497 6,576 6,779 6,958 6,733 7,145 7,508 7,619 7,879 8,139PST 6,497 6,576 6,779 6,958 6,935 7,353 7,758 7,871 8,108 8,441

PNT LA 1,079 1,074 1,035 965 907 938 942 948 952 957NR 117 67 84 153 137 128 128 127 143 127Total 1,196 1,141 1,119 1,118 1,044 1,066 1,070 1,075 1,095 1,084

PNT-FPG Total 0 0 0 0 5 0 3 6 2 4PNT 1,196 1,141 1,119 1,118 1,049 1,066 1,073 1,081 1,097 1,088

CPT LA 4,587 4,780 4,733 5,363 5,720 5,509 5,751 6,463 6,584 6,815NR 152 144 109 144 145 120 112 138 141 152Total 4,739 4,924 4,842 5,507 5,865 5,629 5,863 6,601 6,725 6,967

CPT-M Total 0 0 0 0 1 0 1 2 1 2CPT 4,739 4,924 4,842 5,507 5,866 5,629 5,864 6,603 6,726 6,969

PTC LA 1,389 1,446 1,510 1,679 1,574 1,665 1,658 1,870 1,929 1,813NR 32 23 32 35 35 39 37 37 52 48PTC 1,421 1,469 1,542 1,714 1,609 1,704 1,695 1,907 1,981 1,861

PHY CH 12 11 12 14 12 12 12 12 12 12HOS 164 167 167 165 151 154 158 164 163 160HOX 0 0 0 0 19 18 14 11 8 7IN 36 37 37 27 14 10 12 12 11 11INX 0 0 0 0 11 14 13 11 10 10IR 620 588 592 587 570 568 558 583 588 576IRX 0 0 0 0 21 19 17 10 10 7NR 240 250 256 286 318 361 387 422 473 513NRN 0 0 0 0 0 0 0 9 9 8NRP 0 0 0 0 0 0 0 1 2 2NU 16 16 16 16 15 15 15 15 14 15PEN 0 0 0 0 0 0 0 0 0 0PEX 0 0 0 0 0 0 1 2 2 2SAT 0 0 0 0 0 0 0 1 3 6RC 491 534 545 562 576 587 597 619 649 671PHY 1,579 1,603 1,625 1,657 1,707 1,758 1,784 1,872 1,954 2,000

AMS AMS 212 255 306 361 55 64 349 92 456 113AMS-X 0 0 0 0 301 302 289 359 356 367AMS 212 255 306 361 356 366 638 451 812 480

EDK EDK 412 439 388 503 417 435 421 464 474 454EDK-X 0 0 0 0 13 13 10 10 10 10EDK 412 439 388 503 430 448 431 474 484 464

DME LA 223 160 209 336 345NR 218 281 267 287DME 378 490 603 622

CDTM 41 41 52 59MAR 1,617 2,037 2,383 2,603SWP 58 78 126 38 54 48

TOTAL 21,405 22,865 24,254 24,635

Louisiana Board of PharmacyCredentials Division

CDS Program

06/30/09 06/30/10 06/30/11 06/30/12 06/30/13 06/30/14 06/30/15 06/30/16

ACS Animal Control Shelter 0 1 1 1 1 1 1 0AMS Automated Medication Sys 0 0 0 0 0 26 29 22AMX Automated Medication Sys - Exempt 0 0 0 0 0 2 1 0APN APRN 607 758 889 1,015 1,103 1,479 1,954 2,296ASC Ambulatory Surgical Ctr 106 113 90 88 85 89 87 21CRX Correctional Ctr - Exempt 0 0 7 6 5 6 4 1DDS Dentist 2,267 2,363 2,027 2,048 1,902 2,123 2,133 2,134DET Drug Detection / Canine 20 22 14 12 10 11 11 9DEX Drug Detection / Canine - Exempt 1 1 0DIS Distributor 363 400 279 288 273 324 319 301DPM Podiatrist 161 165 139 136 118 133 142 152DVM Veterinarian 1,000 1,065 922 901 852 1,002 1,045 1,085DYS Dialysis Ctr 63 63 6 4 3 4 0 0EMC Emergency Medical Ctr 17 18 14 16 17 22 26 5EMS Emergency Medical Service 63 66 54 50 45 50 49 16ETC Animal Euthanasia Tech - Cert 44 49 16 7 6 6 5 5ETL Animal Euthanasia Tech - Lead 0 0 12 20 21 23 23 22HOS Hospital 405 438 280 267 263 272 271 289HOX Hospital - Exempt 0 0 12 14 5 6 6 5LAB Laboratory 14 15 8 6 7 8 8 8LAX Laboratory - Exempt 0 0 4 5 5 5 5 4MD Physician 14,599 15,269 12,362 11,727 10,698 11,913 12,124 12,360

MDT Physician on Telemedicine 0 0 0 0 0 2 1 0MED Medical Clinic 88 102 77 81 68 78 71 3MEX Medical Clinic - Exempt 0 0 3 5 14 11 10 0MFR Manufacturer 52 58 48 50 45 42 42 37MIS Miscellaneous 58 59 11 10 9 11 9 0MIX Miscellaneous - Exempt 0 0 9 4 3 2 2 0MP Medical Psychologist 50 58 65 67 69 78 82 86OD Optometrist 269 278 275 287 279 309 316 326PA Physician Assistant 232 272 294 326 344 449 487 610

PHX Pharmacy - Exempt 0 0 50 47 41 30 24 21PHY Pharmacy 0 0 1,307 1,318 1,329 1,357 1,379 1,367REP Sales Representative 66 88 29 20 7 0 0 0RES Researcher 119 156 109 110 98 113 113 108RHC Rural Health Clinic 21 23 17 12 11 12 11 2ROF Registered Outsourcing Facility 0 0 0 0 0 0 8 14SAC Substance Abuse Clinic 14 17 7 9 9 9 9 7SAX Subst. Abuse Clinc - Exempt 0 0 0 0 0 0 1 0

Total 20,698 21,916 19,437 18,957 17,745 20,009 20,809 21,316

Total Credentials Under Management

Pharmacy 16,601 17,818 18,260 18,625 21,405 22,865 24,254 24,635CDS 20,698 21,916 19,437 18,957 17,745 20,009 20,809 21,316

Total 37,299 39,734 37,697 37,582 39,150 42,874 45,063 45,951

Classification

Louisiana Board of PharmacyCensus Report

3/17/1995 6/30/1996 3/19/1997 6/30/1998 6/30/1999 6/30/2000 6/30/2001 6/30/2002 6/30/2003 6/30/2004 6/30/2005

PharmacistsIn-state 3,642 3,660 4,143 4,247 4,269 4,830 3,887 4,386 4,435 4,486 4,532Out-of-state 377 446 1,339 1,435 1,421 944 1,901 1,453 1,455 1,484 1,686TOTAL 4,019 4,106 5,482 5,682 5,690 5,774 5,788 5,839 5,890 5,970 6,218

Pharmacy InternsIn-stateOut-of-stateTOTAL 957 976 929 995 1,154

Pharmacy TechniciansIn-stateOut-of-stateTOTAL 3,216 3,453 3,505 4,114 4,455

Pharmacy Technician CandidatesIn-stateOut-of-stateTOTAL 2,896 2,372 1,336 1,069 1,074

Pharmacy PermitsIR 651 634 636 609 621 585 584 576 573 633 729RC 464 473 471 493 505 520 528 535 541 555 473H 177 174 171 175 172 171 171 174 179 181 181IN 46 45 38 39 19 17 18 19 27 36NU 9 10 10 9 10 12 14 13 13 13CH 4 4 4 7 4 8 9 11 12 12PENOS 122 152 168 175 216 223 262 313 353 339 200PE 78 104 102 120 102 95 94 0CO 13 12 12 12 12 12 13 13 0TOTAL 1,564 1,608 1,612 1,639 1,668 1,663 1,717 1,771 1,818 1,760 1,644

Equipment PermitsAMS 0 109 136 158 174EDK 468 461 474 444 471

6/30/2006 6/30/2007 6/30/2008 6/30/2009 6/30/2010 6/30/2011 6/30/2012 6/30/2013 6/30/2014 6/30/2015 6/30/2016

PharmacistsIn-state 4,460 4,522 4,612 4,750 4,860 5,000 5,095 5,170 5,329 5,596 5,540Out-of-state 1,915 1,975 1,964 2,029 2,098 2,179 2,258 2,588 2,542 2,512 2,901TOTAL 6,375 6,497 6,576 6,779 6,958 7,179 7,353 7,758 7,871 8,108 8,441

Pharmacy InternsIn-state 980 1,079 1,074 1,035 965 917 938 945 950 953 959Out-of-state 109 117 67 84 153 137 128 128 131 144 129TOTAL 1,089 1,196 1,141 1,119 1,118 1,054 1,066 1,073 1,081 1,097 1,088

Pharmacy TechniciansIn-state 4,552 4,587 4,780 4,733 5,363 5,722 5,509 5,752 6,463 6,585 6,815Out-of-state 163 152 144 109 144 145 120 112 138 141 152TOTAL 4,715 4,739 4,924 4,842 5,507 5,867 5,629 5,864 6,601 6,726 6,967

Pharmacy Technician CandidatesIn-state 1,081 1,389 1,446 1,510 1,679 1,574 1,665 1,658 1,870 1,929 1,813Out-of-state 32 32 23 32 35 35 39 31 37 52 48TOTAL 1,113 1,421 1,469 1,542 1,714 1,609 1,704 1,695 1,907 1,981 1,861

Pharmacy PermitsIR 681 620 588 592 587 591 587 575 583 598 583RC 430 491 534 545 562 576 587 597 619 649 671H 167 164 167 167 165 170 172 172 175 174 173IN 35 36 37 37 27 25 24 25 23 21 21NU 17 16 16 16 16 15 15 15 15 14 15CH 12 12 11 12 14 12 12 12 12 12 12PEN 1 2 2 2NR 226 240 250 256 286 318 361 387 432 484 523TOTAL 1,568 1,579 1,603 1,625 1,657 1,707 1,758 1,784 1,861 1,954 2,000

Equipment PermitsAMS 173 212 255 306 361 356 366 638 451 812 480EDK 428 412 439 388 503 430 448 431 474 484 464DME 223 378 490 603 622

Special Activity CDTM 41 41 52 59MAR 1,617 2,037 2,383 2,603

Special Work Permit 58 78 126 38 54 48

Type of Credential

Type of Credential

Louisiana Board of PharmacyCDS Program - Census Report

6/30/2008 6/30/2009 6/30/2010 6/30/2011 6/30/2012 6/30/2013 6/30/2014 6/30/2015 6/30/2016

ACS Animal Control Shelter 0 0 1 1 1 1 1 1 0AMS Automated Medication System 0 0 0 0 0 0 28 30 22APN Advanced Practice Registered Nurse 479 607 758 889 1,015 1,103 1,479 1,954 2,296ASC Ambulatory Surgical Center 101 106 113 90 88 85 89 87 21CRX Correctional Center 0 0 0 7 6 5 6 4 1DDS Dentist 2,177 2,267 2,363 2,027 2,048 1,902 2,123 2,133 2,134DET Drug Detection Canine 20 20 22 14 12 10 11 12 9DIS Distributor 322 363 400 279 288 273 324 319 301

DPM Podiatrist 153 161 165 139 136 118 133 142 152DVM Veterinarian 936 1,000 1,065 922 901 852 1,002 1,045 1,085DYS Dialysis Center 63 63 63 6 4 3 4 0 0EMC Emergency Medical Center 17 17 18 14 16 17 22 26 5EMS Emergency Medical Service 58 63 66 54 50 45 50 49 16ETC Animal Euthanasia Tech - Cert 39 44 49 28 27 27 29 28 27HOS Hospital 387 405 438 292 281 268 278 277 294LAB Analytical Laboratory 14 14 15 12 11 12 13 13 12MD Physician 13,876 14,599 15,269 12,362 11,727 10,698 11,913 12,124 12,360

MDT Physician on Telemedicine 0 0 0 0 0 0 2 1 0MED Medical Clinic 78 88 102 80 86 82 89 81 3MFR Manufacturer 43 52 58 48 50 45 42 42 37MIS Other 73 58 59 20 14 12 13 11 0MP Medical Psychologist 44 50 58 65 67 69 78 82 86OD Optometrist 253 269 278 275 287 279 309 316 326PA Physician's Assistant 194 232 272 294 326 344 449 487 610

PHY Pharmacy 0 0 0 1357 1,365 1,370 1,387 1,403 1,388REP Sales Representative 65 66 88 29 20 7 0 0 0RES Researcher 110 119 156 109 110 98 113 113 108RHC Rural Health Clinic 20 21 23 17 12 11 12 11 2ROF Registered Outsourcing Facility 0 0 0 0 0 0 0 8 14SAC Substance Abuse Clinic 14 14 17 7 9 9 9 10 7

TOTAL 19,502 20,663 21,916 19,437 18,957 17,745 20,009 20,809 21,316

Pharmacy Program 16,407 16,601 17,818 18,260 18,625 21,405 22,865 24,254 24,635CDS Program 19,536 20,698 21,916 19,437 18,957 17,745 20,009 20,809 21,316TOTAL 35,943 37,299 39,734 37,697 37,582 39,150 42,874 45,063 45,951

Classification

Total Credentials Under Board Management

Prefix Subcategory CredentialType TotalAMS Automated Medication System 31AMS X Automated Medication System - Exempt 41

72CDS AMS CDS License - Automated Medication System 9CDS APN CDS License - APRN 423CDS DDS CDS License - Dentist 100CDS DIS CDS License - Distributor 29CDS DPM CDS License - Podiatrist 7CDS DVM CDS License - Veterinarian 83CDS ETC CDS License - Animal Euthanasia Technician, Certified (AET-C) 1CDS ETL CDS License - Animal Euthanasia Technician, Lead (AET-L) 3CDS HOS CDS License - Hospital 25CDS HOX CDS License - Hospital - Exempt 1CDS MD CDS License - Physician 829CDS MFR CDS License - Manufacturer 4CDS MP CDS License - Medical Psychologist 6CDS OD CDS License - Optometrist 15CDS PA CDS License - Physician Assistant 144CDS PHY CDS License - Pharmacy 87CDS RES CDS License - Researcher 7CDS ROF CDS License - Registered Outsourcing Facility 8CDS SAC CDS License - Substance Abuse Clinic 1

1782CDTM Collaborative Drug Therapy Management (V) 3

3CPT Certified Pharmacy Technician 641

641DME Durable Medical Equipment (DME) Provider 81

81EDK Emergency Drug Kit 40

40LB Law Book 4

4MA Medication Administration (V) 374

374PHY HOS Pharmacy - Hospital Inpatient 10PHY IN Pharmacy - Institutional 1PHY IR Pharmacy - Community ~ Independent 38PHY NR Pharmacy - Nonresident 102PHY NU Pharmacy - Nuclear 1PHY RC Pharmacy - Community ~ Chain 47PHY SAT Pharmacy - Hospital Off-Site Satellite 2

201PIC Pharmacist-in-Charge (V) 228

228PMP CDS PMP - CDS Credential 855PMP PST PMP - Pharmacist 268

1123PNT Pharmacy Intern 302PNT FPG Pharmacy Intern - Foreign Pharmacy Graduate 3

305PST Pharmacist 509

509PTC Pharmacy Technician Candidate 1281

1281SWP Special Work Permit 50

506694

Prefix Totals

Prefix Totals

Prefix Totals

Prefix Totals

Prefix Totals

Prefix Totals

Prefix Totals

Prefix Totals

Prefix Totals

Grand Totals

Prefix Totals

Prefix Totals

Prefix Totals

Prefix Totals

Prefix Totals

Prefix Totals

Prefix Subcat. CredentialType 02/16/15 05/06/15 07/21/15 11/3/2015 02/12/16 04/26/16 08/03/16AMS Automated Medication System 3 4 2 3 2 5 3CPT Certified Pharmacy Technician 47 56 39 50 30 40 54DME Durable Medical Equipment 12 14 15 17 15 16 27EDK Emergency Drug Kit 1PHY CH Pharmacy - CharitablePHY HOS Pharmacy - Hospital Inpatient 6 7 4 5 3 2 3PHY IN Pharmacy - Institutional 1PHY IR Pharmacy - Community ~ Independent 18 11 16 13 17 19 16PHY NR Pharmacy - Nonresident 63 72 75 84 92 96 89PHY NRN Pharmacy - Nonresident NuclearPHY NU Pharmacy - Nuclear 1 1PHY PEN Pharmacy - PenalPHY RC Pharmacy - Community ~ Chain 3 4 11 13 13 7 4PHY SAT Pharmacy - Hospital Off-Site Satellite 4 4 2 1 1PIC Pharmacist-in-Charge 1 1 1 1PNT FPG Pharmacy Intern - Foreign Graduate 3 2 2 1PNT Pharmacy Intern 42 50 74 90 31 30 58PST Pharmacist 276 389 431 281 257 254 419PTC Pharmacy Technician Candidate 410 394 377 352 358 353 346

888 1008 1050 909 820 824 1021

Prefix Subcat. CredentialType 02/16/15 05/06/15 07/21/15 11/3/2015 02/12/16 04/26/16 08/03/16CDS ACS CDS - Animal Control Shelter 2CDS AMS CDS - Automated Medication System 1 1CDS APN CDS - APRN 17 16 19 11 13 7 6CDS DDS CDS - Dentist 3 1 1 1 1CDS DET CDS - Drug Detection / Canine 1 1 1 1CDS DIS CDS - Distributor 7 7 7 5 11 4 6CDS DPM CDS - Podiatrist 1CDS DVM CDS - Veterinarian 2 2 2 1 3CDS ETC CDS - Animal Euthanasia Tech, CertifiedCDS ETL CDS - Animal Euthanasia Tech, Lead 1CDS HOS CDS - Hospital 7CDS MD CDS - Physician 13 20 19 7 8 10 9CDS MFR CDS - Manufacturer 1 1 1CDS MP CDS - Medical PsychologistCDS OD CDS - Optometrist 1 2CDS PA CDS - Physician Assistant 8 7 6 8 8 3 4CDS PHY CDS - Pharmacy 24 13 27 27 31 23 20CDS PHX CDS - Pharmacy - ExemptCDS REP CDS - Sales RepresentativeCDS RES CDS - Researcher 1 1 1 1 8 6CDS ROF CDS - Registered Outsourcing Facility 1 3CDS SAC CDS - Substance Abuse Clinic 1 2 1

75 70 87 65 77 58 65

Prefix Subcat. CredentialType 02/16/15 05/06/15 07/21/15 07/21/15 02/12/16 04/26/16 08/03/16CDTM Collaborative Drug Therapy ManagementLB Law Book 3 6 6 6 6MA Medication Administration 7 7 7 2 3 4 3PMP PMP - CDS Credential 88 85 85 69 62 61 55PMP PMP - MIS CredentialPMP PMP - PST Credential 16 13 18 79 8 6 7SWP Special Work Permit 103 120 140 164 46 48 62

217 231 256 320 125 119 127

TOTAL 1180 1309 1393 1294 1022 1001 1213

Pending Applications

Subtotal

OTHER CREDENTIALS

PHARMACY CREDENTIALS

CDS CREDENTIALS

Subtotal

Subtotal

of 3




August 10, 2016 Agenda Item 11-L: Report of Executive Director Section 2.C – Exceptions Report 1. PIC at Multiple Pharmacies

Board Policy I.A.4 permits the Executive Director to approve requests from pharmacists wishing to serve as the Pharmacist-in-Charge (PIC) of more than one pharmacy at the same time. The policy requires the concurrence of the President, as well as notice to the Board at its next meeting. As authorized by the President, the Executive Director has delegated this authority to the General Counsel and the Assistant Executive Director.

• On July 15, 2016, Mr. Aron and Mr. Fontenot concurred to grant a request from Peggy E. Dean (PST.013100) for temporary dual PIC privileges at Woman’s Hospital Pharmacy (PHY.006583-HOS) in Baton Rouge and Woman’s Retail Pharmacy (PHY-Applicant) also in Baton Rouge for a limited period of time (approximately 3 weeks) with the authority set to expire on September 16, 2016.

2. Special Work Permits for military-trained applicants and their spouses

LAC Title 46: LIII §904 authorizes the Board to provide preferential licensing procedures for military-trained applicants and their spouses. As authorized by the President, the Executive Director has delegated this authority to the General Counsel and the Assistant Executive Director.

• (None since last report.) 3, Special Work Permits

Board Policy I.A.7 permits the Executive Director to issue Special Work Permits to document the resurrection of expired non-renewable credentials and for other purposes as authorized by the Board. The policy requires the concurrence of the President, as well as notice to the Board at its next meeting. As authorized by the President, the Executive Director has delegated this authority to the General Counsel and the Assistant Executive Director.

• On May 4, 2016, Mr. Aron and Mr. Finalet concurred to grant a request from Steven Eric Muse. He had previously obtained PTC.018337 which expired on June 20, 2013. Should he pass the PTCB examination no later than November 1, 2016 he is authorized to receive a Special Work Permit for one year to earn 600 hours of practical experience.

• On May 5, 2016, Mr. Aron and Mr. Finalet concurred to grant a request from Heidi Renee Brusseau. She had previously obtained PTC.020900 which expired on July 17, 2015. She is PTCB-certified and was issued a Special Work Permit for one year to earn 600 hours of practical experience.

• On May 5, 2016, Mr. Aron and Mr. Finalet concurred to grant a request from Ceddrekia Kenyale Foster. She had previously obtained PTC.020452 which expired on March 5, 2015. Should she pass the PTCB examination no later than November 1, 2016 she is authorized to receive a Special Work Permit for one year to earn 600 hours of practical experience.

• On May 5, 2016, Mr. Aron and Mr. Finalet concurred to grant a request from Hannah Kathleen Haire. She had previously obtained PTC.019238 which expired on March 18, 2014. Should she pass the PTCB examination no later than November 1, 2016 she is authorized to receive a Special Work Permit for one year to earn 600 hours of practical experience.

• On May 10, 2016, Mr. Aron and Mr. Finalet concurred to grant a request from Rayni Lynn



of 3

Ortego. She had previously obtained PTC.018097 which expired on April 25, 2013. Should she pass the PTCB examination no later than November 1, 2016 she is authorized to receive a Special Work Permit for one year to earn 600 hours of practical experience.

• On May 12, 2016, Mr. Aron and Mr. Finalet concurred to grant a request from Danielle Nicole Sampy. She had previously obtained PTC.022031 which expired on May 3, 2016. Should she pass the PTCB examination no later than November 1, 2016 she is authorized to receive a Special Work Permit for one year to earn 600 hours of practical experience.

• On May 20, 2016, Mr. Aron and Mr. Finalet concurred to grant a request from Alisha Lenette Crump. She had previously obtained PTC.013094 which expired on February 8, 2009. Should she pass the PTCB examination no later than November 1, 2016 she is authorized to receive a Special Work Permit for one year to earn 600 hours of practical experience.

• On May 20, 2016, Mr. Aron and Mr. Finalet concurred to grant a request from Sonja Michelle Davis. She had previously obtained PTC.013896 which expired on October 27, 2009. Should she pass the PTCB examination no later than November 1, 2016 she is authorized to receive a Special Work Permit for one year to earn 600 hours of practical experience.

• On May 23, 2016, Mr. Aron and Mr. Finalet concurred to grant a request from Oratia Jenay Price. She had previously obtained PTC.020531 which expired on April 1, 2015. Should she pass the PTCB examination no later than November 1, 2016 she is authorized to receive a Special Work Permit for one year to earn 600 hours of practical experience.

• On May 25, 2016, Mr. Aron and Mr. Finalet concurred to grant a request from Shemika Jamila Hampton. She had previously obtained PTC.019897 which expired on October 17, 2014. Should she pass the PTCB examination no later than November 1, 2016 she is authorized to receive a Special Work Permit for one year to earn 600 hours of practical experience.

• On June 1, 2016, Mr. Aron and Mr. Finalet concurred to grant a request from Lerionne Tyshai Larkin. She had previously obtained PTC.022054 which expired on May 12, 2016. Should she pass the PTCB examination no later than December 1, 2016 she is authorized to receive a Special Work Permit for one year to earn 600 hours of practical experience.

• On June 3, 2016, Mr. Aron and Mr. Finalet concurred to grant a request from Lakesha Dianne Doyle. She had previously obtained PTC.021718 which expired on February 12, 2016. Should she pass the PTCB examination no later than December 1, 2016 she is authorized to receive a Special Work Permit for one year to earn 600 hours of practical experience.

• On June 6, 2016, Mr. Aron and Mr. Finalet concurred to grant a request from Omega Osborne Centill Lewis. She had previously obtained PTC.020440 which expired on March 3, 2015. Should she pass the PTCB examination no later than December 1, 2016 she is authorized to receive a Special Work Permit for one year to earn 600 hours of practical experience.

• On June 10, 2016, Mr. Aron and Mr. Finalet concurred to grant a request from Jacqueline Michelle Barrois. She had previously obtained PTC.018877 which expired on November 30, 2013. She is PTCB-certified and was issued a Special Work Permit for one year to earn 600 hours of practical experience.

• On June 10, 2016, Mr. Aron and Mr. Finalet concurred to grant a request from Dewona Katrice Hawkins. She had previously obtained PTC.009559 which expired on September 13, 2008. She is PTCB-certified and was issued a Special Work Permit for one year to earn 600 hours of practical experience.

• On June 6, 2016, Mr. Aron and Mr. Finalet concurred to grant a request from Emily Lauren Thomas. She had previously obtained PTC.020755 which expired on June 3, 2015. Should she pass the PTCB examination no later than December 1, 2016 she is authorized to receive a Special Work Permit for one year to earn 600 hours of practical experience.

• On June 15, 2016, Mr. Aron and Mr. Finalet concurred to grant a request from Kate

of 3

Allyson Harwell Aultman. She had previously obtained PTC.008284 which expired on November 6, 2003. Should she pass the PTCB examination no later than December 1, 2016 she is authorized to receive a Special Work Permit for one year to earn 600 hours of practical experience.

• On June 16, 2016, Mr. Aron and Mr. Finalet concurred to grant a request from Heather Lee Monistere. She had previously obtained PTC.019391 which expired on April 25, 2014. She is PTCB-certified and was issued a Special Work Permit for one year to earn 600 hours of practical experience.

• On June 21, 2016, Mr. Aron and Mr. Finalet concurred to grant a request from Brandi Danelle Manuel. She had previously obtained PTC.018151 which expired on May 8, 2013. Should she pass the PTCB examination no later than December 1, 2016 she is authorized to receive a Special Work Permit for one year to earn 600 hours of practical experience.

• On June 22, 2016, Mr. Aron and Mr. Finalet concurred to grant a request from Jamesha Ja'mes Theophile. She had previously obtained PTC.020050 which expired on November 21, 2014. Should she pass the PTCB examination no later than December 1, 2016 she is authorized to receive a Special Work Permit for one year to earn 600 hours of practical experience.

• On June 24, 2016, Mr. Aron and Mr. Finalet concurred to grant a request from Gwendolyn Holmes-Lee. She had previously obtained PTC.021768 which expired on February 19, 2016. Should she pass the PTCB examination no later than December 1, 2016 she is authorized to receive a Special Work Permit for one year to earn 600 hours of practical experience.

• On June 27, 2016, Mr. Aron and Mr. Finalet concurred to grant a request from Kourtney Rene Brazzell. She had previously obtained PTC.021992 which expired on April 27, 2016. Should she pass the PTCB examination no later than December 1, 2016 she is authorized to receive a Special Work Permit for one year to earn 600 hours of practical experience.

• On July 7, 2016, Mr. Aron and Mr. Finalet concurred to grant a request from Lindy Marie Aultman. She had previously obtained PTC.020797 which expired on June 17, 2015. Should she pass the PTCB examination no later than January 1, 2017 she is authorized to receive a Special Work Permit for one year to earn 600 hours of practical experience.

• On July 8, 2016, Mr. Aron and Mr. Finalet concurred to grant a request from Portia McElroy. She had previously obtained PTC.018805 which expired on November 1, 2013. She is PTCB-certified and was issued a Special Work Permit for one year to earn 600 hours of practical experience.

• On July 13, 2016, Mr. Aron and Mr. Finalet concurred to grant a request from Janet LaTrice Wyatt. She had previously obtained PTC.011171 which expired on December 25, 2006. She is PTCB-certified and was issued a Special Work Permit for one year to earn 600 hours of practical experience.

• On July 15, 2016, Mr. Aron and Mr. Finalet concurred to grant a request from Enjoli Sharnice Williams. She had previously obtained PTC.021121 which expired on September 5, 2015. She is PTCB-certified and was issued a Special Work Permit for one year to earn 600 hours of practical experience.

• On July 15, 2016, Mr. Aron and Mr. Finalet concurred to grant a request from Keyanta Maria Woods. She had previously obtained PTC.020704 which expired on May 15, 2015. She is PTCB-certified and was issued a Special Work Permit for one year to earn 600 hours of practical experience.

• On July 20, 2016, Mr. Aron and Mr. Finalet concurred to grant a request from Tracy Karilyn Wissing. She had previously obtained PTC.017919 which expired on March 8, 2013. She is PTCB-certified and was issued a Special Work Permit for one year to earn 600 hours of practical experience.

• On July 26, 2016, Mr. Aron and Mr. Finalet concurred to grant a request from Davielle Shanta Maria Calais. She had previously obtained PTC.016909 which expired on April 25, 2012. Should she pass the PTCB examination no later than January 1, 2017 she is authorized to receive a Special Work Permit for one year to earn 600 hours of practical experience.

Louisiana Board of Pharmacy - Compliance DivisionStatistical Summary for Fiscal Year 2015-2016

Individual Performance Data

Cases Audits ReportsCDS Rx Total Assigned Completed Submitted

1st Qtr. 8 23 72 4 0 62nd Qtr. 32 44 76 9 1 23rd Qtr. 27 48 75 4 0 74th Qtr. 11 76 87 8 0 6

Total 78/127 191/211 310/331 25 1 21Completion Rate: 61% 91% 94%

Collins, Stephen L. (Retired 11-15-2015) Dennis, Daniel M. (Started 03-01-2016)

1st Qtr 4 22 26 0 0 02nd Qtr 3 29 32 0 0 03rd Qtr 1 13 14 1 0 04th Qtr 12 121 133 8 0 2


Savoie, Huey J.1st Qtr 2 62 64 17 0 42nd Qtr 6 38 44 21 0 213rd Qtr 12 35 47 14 1 154th Qtr 5 78 83 12 0 7


Trisler, Rayland M.1st Qtr 5 59 64 4 0 32nd Qtr 9 37 44 6 0 63rd Qtr 14 51 65 5 0 44th Qtr 36 44 80 2 0 4


Whaley, Benjamin S.1st Qtr 5 59 64 20 0 132nd Qtr 14 49 63 10 0 163rd Qtr 10 64 74 17 0 134th Qtr 1 70 71 3 1 17


Fontenot, M. Joseph1st Qtr 0 0 0 10 0 132nd Qtr 0 0 0 5 0 103rd Qtr 0 0 0 3 0 44th Qtr 0 0 0 2 0 0

Total 0 0 0 20 0 27

Finalet, Carlos M.1st Qtr 0 0 0 61 0 522nd Qtr 0 0 0 65 0 653rd Qtr 0 0 0 52 0 404th Qtr 0 0 0 36 0 47

Total 0 0 0 214 0 204

Broussard, Malcolm J.1st Qtr 0 0 0 2 0 52nd Qtr 0 0 0 5 0 33rd Qtr 0 0 0 1 0 34th Qtr 0 0 0 2 0 1

Total 0 0 0 10 0 12Agency Summary

1st Qtr 24 225 249 118 0 962nd Qtr 64 197 261 121 0 1233rd Qtr 64 211 275 97 1 864th Qtr 65 389 454 73 0 84

TOTAL 217/535 1022/1542 1239/2077 409 1 389Completion Rate 41% 66% 60%

Inspections Investigations

Aaron, Cary D.

Louisiana Board of Pharmacy - Compliance DivisionStatistical Summary for Fiscal Year 2015-2016

Summary of Investigations and AdjudicationsNumber of Cases Pending from Prior Fiscal Year(s) 214

Number of Complaints Received during Current Fiscal Year: 411

Number of Complaints Closed during Current Fiscal Year: 401

Number of Complaints Pending at End of Fiscal Year: 224Disposition of Closed Complaints:

Withdrawn 18

No violations found 48

Administrative/Field corrections 80

Referred to another agency 7

Administrative sanction 13

Termination of previously imposed probationary periods 23

Referred to appropriate Board Committee 212401 Total

Committee Action on Referrals:37 Case dismissed163 Voluntary Consent Agreement

18 Assessment

6 Denial / Refusal to Issue

2 Letter of Warning

35 Letter of Reprimand

13 Voluntary Surrender

21 Probation

13 Suspension

6 Revocation

49 Other decisions12 Formal Hearing

1 Probation

1 Suspension

10 RevocationAnalysis of Adjudications by Type of Credential

PST PNT CPT PTC PHY CDS TOTALDenial / Refusal to Issue 3 0 0 2 1 0 6

Reinstatement 2 0 4 0 1 1 8

Modification of Previous Orders 4 0 0 0 0 0 4

Assessment 2 0 2 0 17 0 21

Letter of Warning 0 0 0 0 2 0 2

Letter of Reprimand 17 0 13 0 3 0 33

Voluntary Surrender 6 0 4 0 0 0 10

Probation 11 1 3 6 2 0 23

Suspension 0 0 1 0 0 16 17

Revocation 0 0 7 5 3 0 15

TOTAL 45 1 34 13 29 17 139

Louisiana Board of Pharmacy - Compliance DivisionStatistical Summary - Cumulative Data

Last update: 08-01-2016

FY FY FY FY FY FY FY FY FY FY02-03 03-04 04-05 05-06 06-07 07-08 08-09 09-10 10-11 11-12

Summary of Complaint Investigations

Complaints Pending from Prior Year(s) 46 96 132 124 98 82 112 140 127 197

Complaints Received During Year 355 315 273 250 239 280 519 356 432 349

Complaints Closed During Year 305 279 281 276 255 250 491 369 362 389

Complaints Pending at Year End 96 132 124 98 82 112 140 127 197 157Disposition of Closed Complaints

Withdrawn 20 11 7 4 10 3 23 16 26 23

No violations found 36 46 31 36 30 39 49 41 58 51

Field/administrative corrections 25 34 47 70 40 73 65 76 54 83

Referred to another agency 1 1 3 7 11 2 6 7 5 6

Administrative sanction 89 78 73 37 34 38 255 72 42 46

Termination of probationary period

Referred for Board action 134 109 120 122 130 95 93 157 177 180Total 305 279 281 276 255 250 491 369 362 389

Committee Action on Referrals

Cases Dismissed 43 17 16 25 20 19 38 24 39 20

Voluntary Consent Agreements 79 80 91 90 97 67 47 124 132 150

Assessment only 11 11 7 2 4 38 25 18 10 12

Denial / Refusal to Issue 1 9 1

Letter of Warning 20 14 12 26 18 7 3 5 6 3

Letter of Reprimand 13 5 19 12 18 13 13 30 35 17

Voluntary Surrender 9 10 23 25 17 6 8 34 23 21

Probation 9 17 10 13 16 20 5 17 21 31

Suspension 6 10 4 1 5 10 5 2 2 10

Revocation 11 13 16 11 19 9 4 17 11 28

Other decisions 15 27

Formal Hearings 12 12 13 7 13 9 8 9 6 10

Assessment only 0 0 0 0 1 3 0 0 0 0

Denial / Refusal to Issue 0 0 0 0 0 0 0 0 0 0

Letter of Warning 0 2 0 0 0 0 0 0 0 0

Letter of Reprimand 0 0 1 0 0 0 0 0 0 0

Probation 0 1 0 2 2 0 0 0 1 0

Suspension 4 2 2 0 3 3 0 3 2 2

Revocation 8 7 10 5 7 4 8 6 3 8

Interlocutory Hearings 0 2 3 0 1 0 0 0 0 0

Summary Suspension 0 0 2 0 1 0 0 0 0 0

Louisiana Board of Pharmacy - Compliance DivisionStatistical Summary - Cumulative Data

Last update: 08-01-2016

FY FY FY FY12-13 13-14 14-15 15-16 Totals

Summary of Complaint Investigations

Complaints Pending from Prior Year(s) 218 255 252 214 1879

Complaints Received During Year 392 479 404 411 4,643

Complaints Closed During Year 355 482 442 401 4,536

Complaints Pending at Year End 255 252 214 224 1,986Disposition of Closed Complaints

Withdrawn 25 13 18 18 199

No violations found 32 86 83 48 618

Field/administrative corrections 67 107 113 80 854

Referred to another agency 3 11 7 7 70

Administrative sanction 24 15 21 13 824

Termination of probationary period 24 27 15 23 39

Referred for Board action 180 223 185 212 1905Total 355 482 442 401 4,509

Committee Action on Referrals

Cases Dismissed 21 41 31 37 354

Voluntary Consent Agreements 157 155 125 163 1394

Assessment only 9 18 28 18 193

Denial / Refusal to Issue 5 5 2 6 23

Letter of Warning 3 13 5 2 135

Letter of Reprimand 19 7 14 35 215

Voluntary Surrender 21 25 15 13 237

Probation 29 31 16 21 235

Suspension 22 6 2 13 85

Revocation 19 5 14 6 177

Other decisions 30 46 29 49 147

Formal Hearings 2 27 29 12 157

Assessment only 0 0 0 0 4

Denial / Refusal to Issue 0 3 2 0 5

Letter of Warning 0 0 0 0 2

Letter of Reprimand 0 0 0 0 1

Probation 0 0 1 1 7

Suspension 1 20 23 1 65

Revocation 1 4 3 10 74

Interlocutory Hearings 0 0 0 0 6

Summary Suspension 0 0 0 0 3




Multistate Pharmacy Jurisprudence Examination (MPJE™)

January 1 – April 30, 2016

School Reports Interpretation of Scores

Frequency Distribution of Scaled Scores Cumulative Record (since January 2000)

August 10, 2016



Multistate Pharmacy Jurisprudence Examination (MPJE™) This computer adaptive competency assessment is administered by the National Association of Boards of Pharmacy (NABP). The examination blueprint is designed to assess the applicant’s competency in federal and state laws relative to pharmacy practice and is therefore specific for a given state. The examination is administered via an open window process; applicants may schedule the examination at a local testing center at any time following approval by the state board and receipt of an Authorization to Test (ATT) document from NABP. Individual scores are available to applicants via secure web posting approximately 7-10 days following the examination. Summary reports are provided to the state boards on a calendar trimester basis.

Table of Contents Current Trimester Report for ULM School of Pharmacy 03 Cumulative Report (since January 2000) for ULM School of Pharmacy 07 Current Trimester Report for Xavier College of Pharmacy 12 Cumulative Report (since January 2000) for Xavier College of Pharmacy 16

MPJE-23-2016 Trimester 1

Multistate Pharmacy Jurisprudence Examination® (MPJE®) School

Summary Report

University of Louisiana at Monroe

Test Window: January 1, 2016 - April 30, 2016

Page 1 of 4

Candidates who did not answer enough questions to receive a score are reflected in pass

rate data as a fail but are not included in mean scaled score data.

41 100

All Candidates 41 100

Scaled Score Range 0 100

National 6351 87.62% 81.10 5.82

Table 3 contains information on the range of

scaled scores achieved by FT ACPE (First-Time,

ACPE-Accredited) candidates as well as the

pool of all candidates. It also shows the

boundaries of the Scaled Score Range.

Table 3 Total Scaled Score Min/Max

Min Max

FT ACPE

Out of state 73 98.63% 84.04 5.24

State 133 90.23% 80.92 5.31

Candidates Pass Rate %Total Scaled

Score Mean

Standard

Deviation

In-state 7 100.00% 80.14 3.85

Table 2 All Candidates

Out of state 69 98.55% 84.23 5.27

State 111 92.79% 81.58 5.32

In-state 7 100.00% 80.14 3.85

National 5112 90.71% 81.84 5.70

This MPJE score report provides summary information for first-time examinees from ACPE-accredited schools/colleges

and for all examinees, regardless of repeater status and/or the educational institution. Tables 1 and 2 contain school,

state, and national pass rate information as well as total score means.

MPJE in-state: Examinees taking the MPJE for the same jurisdiction as respective pharmacy program

MPJE out of state: Examinees testing in different jurisdiction than respective pharmacy program

Table 1 First-Time Candidates, ACPE-Accredited Programs Only


Score Mean

Standard

Deviation

Page 2 of 4

[0,4] 0

[5,9] 0

[10,14] 0

[15,19] 0

[20,24] 0

[25,29] 0

[30,34] 0

[35,39] 0

[40,44] 0

[45,49] 0

[50,54] 0

[55,59] 0

[60,64] 0

[65,69] 0

[70,74] 0

[75,79] 3

[80,84] 3

[85,89] 1

[90,94] 0

[95,100] 0

[90,94] 0 100%

[95,100] 0 100%

[80,84] 3 86%

[85,89] 1 100%

[70,74] 0 0%

[75,79] 3 43%

[60,64] 0 0%

[65,69] 0 0%

[50,54] 0 0%

[55,59] 0 0%

[40,44] 0 0%

[45,49] 0 0%

[30,34] 0 0%

[35,39] 0 0%

[20,24] 0 0%

[25,29] 0 0%

[10,14] 0 0%

[15,19] 0 0%

[0,4] 0 0%

[5,9] 0 0%

Scaled Score Range Frequency

Cumulative Percent of

the Upper Limit of the

Interval

The following tables and graphs are scaled score frequency distributions for MPJE candidates who tested in-state.

Candidates who did not answer enough questions to receive a score are not reflected in the frequency distributions.

Table 4 & Graph 1 School Frequency Distribution of Scaled Scores

7Based on First-Time Candidates from ACPE-Accredited Programs N =

0

0.5

1

1.5

2

2.5

3

3.5

Freq

ue

ncy

Scaled Score Interval

Page 3 of 4

[0,4] 0

[5,9] 0

[10,14] 0

[15,19] 0

[20,24] 0

[25,29] 0

[30,34] 0

[35,39] 0

[40,44] 0

[45,49] 0

[50,54] 0

[55,59] 0

[60,64] 1

[65,69] 15

[70,74] 68

[75,79]170

[80,84]204

[85,89]104

[90,94] 33

[95,100] 3

[90,94] 33 99%

[95,100] 3 100%

[80,84] 204 77%

[85,89] 104 94%

[70,74] 68 14%

[75,79] 170 42%

[60,64] 1 0%

[65,69] 15 3%

[50,54] 0 0%

[55,59] 0 0%

[40,44] 0 0%

[45,49] 0 0%

[30,34] 0 0%

[35,39] 0 0%

[20,24] 0 0%

[25,29] 0 0%

[10,14] 0 0%

[15,19] 0 0%

[0,4] 0 0%

[5,9] 0 0%

Table 5 & Graph 2 National Frequency Distribution of Scaled Scores

Based on First-Time Candidates from ACPE-Accredited Programs N = 598




Interval

0

50

100

150

200

250

Fre

qu

en

cy


Page 4 of 4

Multistate Pharmacy Jurisprudence Examination (MPJE)


Jan - Jun Jul - Dec Jan - Jun Jul - Dec Jan - Jun Jul - Dec Jan - Jun Jul - Dec

TOTAL CANDIDATE GROUP

No. of Candidates 125 82 100 57 59 123 77 119

School Average Score: 83.27 82.76 80.84 81.37 80.17 80.41 78.57 80.04

State Average Score: 81.64 80.49 80.64 80.32 80.34 79.41 77.32 78.87

National Average Score: 82.24 81.75 82.25 81.51 90.78 79.85 79.92 79.33

School Pass Rate: 94.40 91.46 90.00 91.23 88.14 88.62 77.92 88.24

State Pass Rate: 89.89 86.25 87.84 90.00 92.00 85.98 72.88 84.67

National Pass Rate: 91.37 90.50 91.22 90.54 90.78 84.93 84.52 82.61

FIRST-TIME CANDIDATE GROUP

No. of Candidates 117 78 92 51 55 111 59 110




School Pass Rate: 96.58 93.59 90.22 90.20 89.09 88.29 81.36 88.18

State Pass Rate: 92.59 87.32 88.06 89.77 91.49 86.32 75.00 86.55


2000 2001 2002 2003





No. of Candidates 62 110 59 146 68 111 50 151




School Pass Rate: 91.94 91.82 89.83 87.67 88.24 92.79 90.00 92.05

State Pass Rate: 86.90 92.55 90.55 87.03 91.09 92.39 87.18 90.39



No. of Candidates 52 104 55 132 60 102 43 140




School Pass Rate: 92.31 92.31 89.09 87.12 91.67 94.12 95.35 93.57

State Pass Rate: 90.14 92.53 91.38 88.69 92.31 93.53 91.18 92.49


2004 2005 2006 2007



Jan - Jun Jul - Dec Jan - AprMay - Aug Sep - Dec Jan - AprMay - Aug Sep - Dec Jan - AprMay - Aug Sep - Dec


No. of Candidates 61 137 42 120 36 38 104 35 5 71 12

Mean Scaled Score - School 81.26 81.99 80.95 82.58 80.75 81.47 82.14 81.89 82.60 82.73 83.83

Mean Scaled Score - State 81.33 81.34 79.57 81.69 80.35 81.37 80.88 81.64 81.01 80.41

Mean Scaled Score - National 81.59 81.27 80.29 82.39 80.25 80.45 82.51 80.57 80.27 82.23 80.46

School Pass Rate: 96.72 91.97 88.10 95.00 86.11 94.74 90.38 91.43 100.00 97.18 100.00

State Pass Rate: 91.75 91.05 81.03 94.52 85.92 90.00 92.64 95.79 89.91 90.99

National Pass Rate: 90.31 89.92 86.23 93.74 87.04 89.09 94.83 89.35 86.43 92.17 86.24


No. of Candidates 58 127 37 117 34 34 96 30 5 66 11




School Pass Rate: 96.55 91.34 89.19 94.87 88.24 97.06 93.75 93.33 100.00 100.00 100.00

State Pass Rate: 92.31 91.95 80.77 94.34 89.66 93.44 92.92 97.56 94.06 94.32


20112008 2009 2010



Jan - Apr May - Aug Sep - Dec Jan - Apr May - Aug Sep - Dec Jan - Apr May - Aug Sep - Dec Jan - Apr May - Aug Sep - Dec


No. of Candidates 4 126 87 47 94 30 32 122 39 42 122 56* testing in same/different state 72 / 54 11 / 34 11 / 36 40 / 54 2 / 28 5 / 27 62 / 60 6 / 33 13 / 29 68 / 54 13 / 43Mean Scale Score - School * 82.25 82.44/82.70 80.09/79.85 81.45/84.03 82.50/82.59 80.50/82.79 79.40/81.41 81.44/83.32 78.50/81.42 76.85/81.90 81.44/84.13 79.85/83.12* testing in same/different stateMean Scaled Score - State 81.18 80.91 79.62 81.33 80.82 80.43 80.36 80.18 80.13 79.81 80.56 80.05

Mean Scaled Score - National 80.41 82.43 80.55 80.92 82.50 80.52 81.04 82.52 81.08 81.32 82.40 80.91

School Pass Rate: * 100.00 97.22/90.74 90.91/85.29 100/97.22 95.00/98.15 100 / 92.86 100 / 85.19 95.16/96.67 83.33/87.88 76.92/93.10 94.12/98.15 84.62/95.35* testing in same/different stateState Pass Rate: 90.41 90.69 81.61 93.98 90.51 85.21 82.52 86.08 82.69 80.69 88.14 86.55

National Pass Rate: 84.54 92.76 86.85 87.18 92.98 87.01 87.62 93.28 88.50 88.20 93.04 87.78


No. of Candidates 4 124 70 44 93 28 29 119 33 38 120 49* testing in same/different state 72 / 52 10 / 29 10 / 34 39 / 54 1 / 27 5 / 24 62 / 57 3 / 30 11 / 27 68 / 52 7 / 42Mean Scaled Score - School * 82.25 82.44/83.02 80.62/79.90 81.80/84.26 82.77/82.59 82.00/83.19 79.40/82.29 81.44/83.58 78.00/81.97 76.91/82.04 81.44/84.40 78.71/83.14* testing in same/different stateMean Scaled Score - State 81.75 81.03 80.21 81.90 81.03 81.08 81.05 80.62 81.13 80.63 80.62 80.81


School Pass Rate: * 100.00 97.22/92.31 89.66/90.00 100.00/97.0697.44/98.15 100 / 96.30 100 / 91.67 95.16/98.25 66.67/90.00 72.73/92.59 94.12/98.08 85.71/95.24* testing in same/different stateState Pass Rate: 93.22 91.03 85.71 97..22 91.88 87.29 85.88 89.29 84.96 83.61 88.77 91.06


2012 2013 2014 2015



Jan - Apr May - Aug Sep - Dec Jan - Apr May - Aug Sep - Dec Jan - Apr May - Aug Sep - Dec Jan - Apr May - Aug Sep - Dec


No. of Candidates 80* testing in same/different state 7 / 73Mean Scale Score - School * 80.14/84.04* testing in same/different stateMean Scaled Score - State 80.92

Mean Scaled Score - National 81.10

School Pass Rate: * 100 / 98.63* testing in same/different stateState Pass Rate: 90.23

National Pass Rate: 87.62


No. of Candidates 76* testing in same/different state 7 / 69Mean Scaled Score - School * 80.14/84.23* testing in same/different stateMean Scaled Score - State 81.58


School Pass Rate: * 100 / 98.55* testing in same/different stateState Pass Rate: 92.79


2016 2017 2018 2019

MPJE-24-2016 Trimester 1

Multistate Pharmacy Jurisprudence Examination® (MPJE®) School

Summary Report

Xavier University of Louisiana


Page 1 of 4



41 100



National 6351 87.62% 81.10 5.82

Table 3 contains information on the range of

scaled scores achieved by FT ACPE (First-Time,

ACPE-Accredited) candidates as well as the

pool of all candidates. It also shows the

boundaries of the Scaled Score Range.


Min Max

FT ACPE

Out of state 98 82.65% 79.34 5.52

State 133 90.23% 80.92 5.31


Score Mean

Standard

Deviation

In-state 13 53.85% 75.15 4.06


Out of state 84 88.10% 79.99 5.43

State 111 92.79% 81.58 5.32

In-state 10 50.00% 74.90 4.48

National 5112 90.71% 81.84 5.70

This MPJE score report provides summary information for first-time examinees from ACPE-accredited schools/colleges

and for all examinees, regardless of repeater status and/or the educational institution. Tables 1 and 2 contain school,

state, and national pass rate information as well as total score means.

MPJE in-state: Examinees taking the MPJE for the same jurisdiction as respective pharmacy program

MPJE out of state: Examinees testing in different jurisdiction than respective pharmacy program



Score Mean

Standard

Deviation

Page 2 of 4

[0,4] 0

[5,9] 0

[10,14] 0

[15,19] 0

[20,24] 0

[25,29] 0

[30,34] 0

[35,39] 0

[40,44] 0

[45,49] 0

[50,54] 0

[55,59] 0

[60,64] 0

[65,69] 1

[70,74] 4

[75,79] 3

[80,84] 2

[85,89] 0

[90,94] 0

[95,100] 0

[90,94] 0 100%

[95,100] 0 100%

[80,84] 2 100%

[85,89] 0 100%

[70,74] 4 50%

[75,79] 3 80%

[60,64] 0 0%

[65,69] 1 10%

[50,54] 0 0%

[55,59] 0 0%

[40,44] 0 0%

[45,49] 0 0%

[30,34] 0 0%

[35,39] 0 0%

[20,24] 0 0%

[25,29] 0 0%

[10,14] 0 0%

[15,19] 0 0%

[0,4] 0 0%

[5,9] 0 0%




Interval

The following tables and graphs are scaled score frequency distributions for MPJE candidates who tested in-state.

Candidates who did not answer enough questions to receive a score are not reflected in the frequency distributions.


10Based on First-Time Candidates from ACPE-Accredited Programs N =

0

0.5

1

1.5

2

2.5

3

3.5

4

4.5

Freq

ue

ncy


Page 3 of 4

[0,4] 0

[5,9] 0

[10,14] 0

[15,19] 0

[20,24] 0

[25,29] 0

[30,34] 0

[35,39] 0

[40,44] 0

[45,49] 0

[50,54] 0

[55,59] 0

[60,64] 1

[65,69] 15

[70,74] 68

[75,79]170

[80,84]204

[85,89]104

[90,94] 33

[95,100] 3

[90,94] 33 99%

[95,100] 3 100%

[80,84] 204 77%

[85,89] 104 94%

[70,74] 68 14%

[75,79] 170 42%

[60,64] 1 0%

[65,69] 15 3%

[50,54] 0 0%

[55,59] 0 0%

[40,44] 0 0%

[45,49] 0 0%

[30,34] 0 0%

[35,39] 0 0%

[20,24] 0 0%

[25,29] 0 0%

[10,14] 0 0%

[15,19] 0 0%

[0,4] 0 0%

[5,9] 0 0%






Interval

0

50

100

150

200

250

Fre

qu

en

cy


Page 4 of 4


Xavier College of Pharmacy



No. of Candidates 25 94 53 126 43 122 71 158




School Pass Rate: 80.00 80.85 69.81 88.10 81.40 77.05 67.61 75.95

State Pass Rate: 89.89 86.25 87.84 90.00 92.00 85.98 72.88 84.67



No. of Candidates 23 86 38 107 38 102 53 122




School Pass Rate: 78.26 80.23 71.05 86.92 86.84 78.43 71.70 78.69

State Pass Rate: 92.59 87.32 88.06 89.77 91.49 86.32 75.00 86.55


2000 2001 2002 2003





No. of Candidates 66 123 82 135 139 181 77 169




School Pass Rate: 78.79 80.49 76.83 82.22 87.77 86.19 77.92 87.57

State Pass Rate: 86.90 92.55 90.55 87.03 91.09 92.39 87.18 90.39



No. of Candidates 56 101 63 121 121 156 62 154




School Pass Rate: 80.36 84.16 79.37 85.12 87.60 89.10 85.48 88.96

State Pass Rate: 90.14 92.53 91.38 88.69 92.31 93.53 91.18 92.49


2004 2005 2006 2007



Jan - Jun Jul - Dec Jan - AprMay - Aug Sep - Dec Jan - AprMay - Aug Sep - Dec Jan - AprMay - Aug Sep - Dec


No. of Candidates 55 208 63 162 68 42 160 83 10 77 44




School Pass Rate: 80 83.17 74.60 88.27 77.94 80.95 88.75 78.31 70.00 81.82 81.82

State Pass Rate: 91.75 91.05 81.03 94.52 85.92 90.00 92.64 95.79 89.91 90.99



No. of Candidates 45 181 44 150 47 32 157 61 7 67 29




School Pass Rate: 88.89 85.64 79.55 88.67 82.98 84.38 89.17 78.69 85.71 86.57 89.66

State Pass Rate: 92.31 91.95 80.77 94.34 89.66 93.44 92.92 97.56 94.06 94.32


2008 2009 2010 2011



Jan - Apr May - Aug Sep - Dec Jan - Apr May - Aug Sep - Dec Jan - Apr May - Aug Sep - Dec Jan - Apr May - Aug Sep -Doc


No. of Candidates 13 181 87 53 188 115 52 193 128 81 215 103* testing in same/different state 94 / 87 23 / 65 6 / 47 95 / 93 46 / 69 12 / 40 82 / 111 43 / 85 26 / 55 105 / 110 33 / 70Mean Scaled Score - School * 79.69 79.27/78.48 76.96/79.95 78.17/79.09 79.46/79.55 77.33/78.72 76 / 79.28 78.35/79.98 77.05/80.62 75.27/79.70 79.39/80.75 78.36/80.64* testing in same/different stateMean Scaled Score - State 81.18 80.91 79.62 81.33 80.82 80.43 80.36 80.18 80.13 79.81 80.56 80.05


School Pass Rate: * 84.62 84.04/81.61 60.87/86.15 83.33/76.60 85.26/81.72 71.74/76.81 50 / 82.50 76.83/90.09 65.12/90.59 50.00/72.73 81.90/89.09 78.79/85.71* testing in same/different stateState Pass Rate: 90.41 90.69 81.61 93.98 90.51 85.21 82.52 86.08 82.69 80.69 88.14 86.55



No. of Candidates 9 163 70 43 171 86 43 176 98 65 193 73* testing in same/different state 87 / 76 11 / 54 3 / 40 89 / 82 31 / 55 8 / 35 76 / 100 24 / 74 14 / 51 94 / 99 14 / 59Mean Scaled Score - School * 79.78 79.34/78.70 77.55/80.57 81.33/79.38 79.66/79.94 77.03/78.85 76.63/79.31 78.83/80.23 77.33/80.86 76.29/80.28 79.24/81.07 79.00/81.47* testing in same/different stateMean Scaled Score - State 81.75 81.03 80.21 81.90 81.03 81.08 81.05 80.62 81.13 80.63 80.62 80.81


School Pass Rate: * 88.89 83.91/84.24 63.64/87.04 100 / 77.50 87.64/82.93 67.74/74.55 50 / 80 80.26/90.00 62.5 / 91.89 57.14/78.43 80.85/91.92 92.86/91.53* testing in same/different stateState Pass Rate: 93.22 91.03 85.71 97.22 91.88 87.29 85.88 89.29 84.96 83.61 88.77 91.06


2012 2013 2014 2015



Jan - Apr May - Aug Sep - Dec Jan - Apr May - Aug Sep - Dec Jan - Apr May - Aug Sep - Dec Jan - Apr May - Aug Sep -Doc




School Pass Rate: * 53.85/82.65* testing in same/different stateState Pass Rate: 90.23





School Pass Rate: * 50.00/88.10* testing in same/different stateState Pass Rate: 92.79


2016 2017 2018 2019


Baton Rouge, Louisiana 70809-1700 Telephone 225.925.6496 ~ Facsimile 225.6499

www.pharmacy.la.gov ~ E-mail: [email protected] North American Pharmacist Licensure Examination (NAPLEX™)

January 1 – April 30, 2016

School Reports Interpretation of Scores

Frequency Distribution of Scaled Scores Cumulative Record (since January 2000)

August 10, 2016



North American Pharmacist Licensure Examination (NAPLEX™) This computer adaptive competency assessment is administered by the National Association of Boards of Pharmacy (NABP). The examination blueprint is designed to assess the applicant’s competency in basic pharmacy practice and is recognized by pharmacy regulatory authorities in all of the states and territories within the USA. The examination is administered via an open window process; applicants may schedule the examination at a local testing center at any time following approval by the state board and receipt of an Authorization to Test (ATT) document from NABP. Individual scores are available to applicants via secure web posting approximately 7-10 days following the examination. Summary reports are provided to the state boards on a calendar trimester basis.

Table of Contents Current Trimester Report for ULM College of Pharmacy 03 Cumulative Report (since January 2000) for ULM College of Pharmacy 07 Current Trimester Report for Xavier College of Pharmacy 12 Cumulative Report (since January 2000) for Xavier College of Pharmacy 16

NAPLEX-23-2016 Trimester 1

North American Pharmacist Licensure Examination® (NAPLEX®) School

Summary Report



Page 1 of 4


Area 2 Scaled

Score Mean

Standard

Deviation

School 1 0.00% 31.00 - 8.00 - 8.00


Score Mean

Standard

Deviation

Area 1 Scaled

Score Mean

Standard

Deviation

This NAPLEX score report consists of two levels of scores: aggregated school scores and individual candidate scores.

Beginning November 1, 2015, individual (unidentified) scores are reported in the NAPLEX Roster excel file. Summary

information is provided separately for first-time examinees from ACPE-accredited schools/colleges and for all examinees,

regardless of repeater status and/or the educational institution.

Tables 1 and 2 contain school, state, and national pass rate information as well as total score means and area score

means for each of the two main NAPLEX content domains:

Area 1 - Ensure Safe and Effective Pharmacotherapy and Health Outcomes (67%)

Area 2 - Safe and Accurate Preparation, Compounding, Dispensing and Administration of Medications

and Provision of Healthcare Products (33%)

National 213 57.75% 78.95 20.55 11.47

-

State 4 0.00% 47.33 21.73 9.33 1.53 9.67 2.08

1.33 11.46 1.75



Score Mean

Standard

Deviation

Area 1 Scaled

Score Mean

Standard

Deviation

Area 2 Scaled

Score Mean

Standard

Deviation

School 4 0.00% 60.25 20.30 10.25 1.50 10.50 1.73

State 18 22.22% 66.88 16.36 10.59 1.23 11.12 1.32

1.31 11.27 1.64

Table 3 contains information on the range of scaled

scores achieved by FT ACPE (First-Time, ACPE-

Accredited) candidates as well as the pool of all

candidates. It also shows the boundaries of the Scaled

Score Range.


Min Max

FT ACPE 28 125

National 918 48.80% 74.52 19.81 11.15



Interpretation and Uses of Candidate Scores

At the candidate level, two sets of scores are produced: an overall, composite score and area scores. Only overall scores

are used to make pass/fail decisions. Area scores are intended to provide insight into performances in each of the

content area domains independent of one another.

There are a total of two area scores, one per main competency area. Area scores are reported on a scale of [6,18], where

a score of 6 is the lowest possible score and a score of 18 is the highest possible score. This reporting scale does not have

a number-correct interpretation. In other words, a score of 6 does not mean that the candidate answered 6 questions

correctly. Instead, area scores are computed from ability estimates that are created for sets of items that map to each of

the two content areas.



Page 2 of 4

[0,4] 0

[5,9] 0

[10,14] 0

[15,19] 0

[20,24] 0

[25,29] 0

[30,34] 1

[35,39] 0

[40,44] 0

[45,49] 0

[50,54] 0

[55,59] 0

[60,64] 0

[65,69] 0

[70,74] 0

[75,79] 0

[80,84] 0

[85,89] 0

[90,94] 0

[95,99] 0

[100,104]0

[105,109]0

[110,114]0

[115,119]0

[120,124]0

[125,129]0

[130,134]0

[135,139]0

[140,144]0

[145,150]0

The following tables and graphs are scaled score frequency distributions for NAPLEX candidates. Candidates who did not

answer enough questions to receive a score are not reflected in the frequency distributions.


Based on First-Time Candidates N = 1

[5,9] 0 0%

[10,14] 0 0%




Interval[0,4] 0 0%

[25,29] 0 0%

[30,34] 1 100%

[15,19] 0 0%

[20,24] 0 0%

[45,49] 0 100%

[50,54] 0 100%

[35,39] 0 100%

[40,44] 0 100%

[65,69] 0 100%

[70,74] 0 100%

[55,59] 0 100%

[60,64] 0 100%

[85,89] 0 100%

[90,94] 0 100%

[75,79] 0 100%

[80,84] 0 100%

[105,109] 0 100%

[110,114] 0 100%

[95,99] 0 100%

[100,104] 0 100%

[125,129] 0 100%

[130,134] 0 100%

[115,119] 0 100%

[120,124] 0 100%

[145,150] 0 100%

[135,139] 0 100%

[140,144] 0 100%

0

0.2

0.4

0.6

0.8

1

1.2

Freq

uen

cy


Page 3 of 4

[0,4] 0

[5,9] 0

[10,14] 0

[15,19] 0

[20,24] 0

[25,29] 1

[30,34] 5

[35,39] 2

[40,44] 3

[45,49] 4

[50,54] 8

[55,59] 14

[60,64] 18

[65,69] 14

[70,74] 12

[75,79] 18

[80,84] 20

[85,89] 20

[90,94] 15

[95,99] 18

[100,104]10

[105,109]6

[110,114]11

[115,119]2

[120,124]2

[125,129]1

[130,134]0

[135,139]0

[140,144]0

[145,150]0



[5,9] 0 0%

[10,14] 0 0%




Interval[0,4] 0 0%

[25,29] 1 0%

[30,34] 5 3%

[15,19] 0 0%

[20,24] 0 0%

[45,49] 4 7%

[50,54] 8 11%

[35,39] 2 4%

[40,44] 3 5%

[65,69] 14 34%

[70,74] 12 40%

[55,59] 14 18%

[60,64] 18 27%

[85,89] 20 68%

[90,94] 15 75%

[75,79] 18 49%

[80,84] 20 58%

[105,109] 6 92%

[110,114] 11 98%

[95,99] 18 84%

[100,104] 10 89%

[125,129] 1 100%

[130,134] 0 100%

[115,119] 2 99%

[120,124] 2 100%

[145,150] 0 100%

[135,139] 0 100%

[140,144] 0 100%

0

5

10

15

20

25

Freq

uen

cy


Page 4 of 4

North American Pharmacist Licensure Examination (NAPLEX)


Jan - Apr May - Aug Sept - Dec Jan - Apr May - Aug Sept - Dec Jan - Apr May - Aug Sept - Dec Jan - Apr May - Aug Sept - Dec


No. of Candidates 76 47 18 40 30 10 13 62 27 10 70 24

School Average Score: 96.51 91.62 88.61 88.93 87.30 87.00 82.85 100.24 89.56 78.40 101.44 92.50

State Average Score: 96.75 88.52 86.05 84.66 93.82 82.05 75.50 101.46 87.48 77.50 99.40 87.33

National Average Score: 91.78 99.86 91.21 90.25 101.70 90.50 90.81 101.21 90.02 91.50 101.40 89.40

School Pass Rate: 96.05 82.98 88.89 85.00 90.00 90.00 84.62 85.48 77.78 60.00 95.71 87.50

State Pass Rate: 92.50 78.57 77.27 75.86 89.29 70.00 50.00 85.90 70.37 62.50 94.90 80.00



No. of Candidates 71 33 9 37 20 6 13 61 20 2 64 16




School Pass Rate: 95.77 96.97 100.00 83.78 85.00 100.00 84.62 85.25 75.00 50.00 96.88 100.00

State Pass Rate: 94.59 93.18 84.62 83.33 91.84 73.33 77.78 90.28 70.00 66.67 95.65 90.48


2000 2001 2002 2003





No. of Candidates 3 64 18 9 72 17 2 60 10 3 90 23




School Pass Rate: 100.00 96.88 94.44 88.89 90.28 94.12 100.00 93.33 80.00 100.00 95.56 78.26

State Pass Rate: 83.33 96.12 100.00 100.00 87.83 78.57 77.78 89.17 79.31 63.64 95.52 74.51



No. of Candidates 2 58 17 5 70 11 2 58 4 3 89 19




School Pass Rate: 100.00 100.00 94.12 80.00 91.43 100.00 100.00 94.83 100.00 100.00 95.51 78.95

State Pass Rate: 100.00 100.00 100.00 100.00 90.09 88.89 100.00 90.38 70.59 100.00 96.69 76.74


2004 2005 2006 2007





No. of Candidates 11 98 12 6 91 8 3 67 6 2 91 9

Mean Scaled Score - School 94.73 106.39 93.83 97.83 113.84 77.25 98.00 99.97 93.17 67.50 97.40 87.22

Mean Scaled Score - State 93.70 103.31 95.41 94.80 108.26 84.32 83.15 94.22 80.13 99.66 85.27


School Pass Rate: 90.91 92.86 83.33 83.33 95.60 50.00 100.00 95.52 100.00 0.00 89.01 77.78

State Pass Rate: 90.00 90.34 82.76 80.00 92.64 63.16 61.54 83.24 65.00 90.81 73.17



No. of Candidates 3 97 5 3 88 3 0 67 2 1 87 3




School Pass Rate: 100.00 93.81 80.00 66.67 96.59 33.33 0.00 95.52 100.00 0.00 93.10 66.67

State Pass Rate: 83.33 92.35 82.35 57.14 93.04 60.00 66.67 84.15 83.33 93.18 74.07


2008 2009 2010 2011




S+O/N+DTOTAL CANDIDATE GROUP

No. of Candidates 6 80 17 3 40 7 1 68 11 4 79 9 / 3

Mean Scaled Score - School 75.33 97.14 85.41 92.00 100.45 88.43 101.00 95.10 82.27 82.00 94.93 83.89/89.67

Mean Scaled Score - State 81.25 98.42 86.95 77.25 98.66 86.88 73.85 96.45 80.88 82.15 95.51 85.60/73.62

Mean Scaled Score - National 83.15 102.81 88.15 80.17 102.78 87.03 80.22 101.71 89.22 83.84 100.46 88.25/73.84

School Pass Rate: 83.33 92.50 82.35 100.00 90.00 100.00 100.00 89.71 63.64 50.00 89.87 77.78/100

State Pass Rate: 68.75 93.82 76.19 55.56 92.95 81.82 53.85 90.75 70.59 69.23 88.24 76.00/46.15

National Pass Rate: 68.33 95.21 77.86 61.07 94.65 75.91 63.24 93.86 79.77 67.06 92.29 77.64/46.27


No. of Candidates 2 80 9 3 38 4 1 68 3 1 78 5 / 0

Mean Scaled Score - School 49.50 97.14 87.11 92.00 101.68 92.00 101.00 95.10 92.00 74.00 94.62 83.60 / 0

Mean Scaled Score - State 84.00 99.47 91.00 80.75 99.30 88.33 85.00 96.96 83.34 77.00 96.08 86.50 / 0

Mean Scaled Score - National 94.87 104.13 95.75 92.48 104.02 92.69 90.89 102.80 93.94 94.01 101.53 91.24 / 0

School Pass Rate: 50.00 92.50 77.78 100.00 92.11 100.00 100.00 89.71 66.67 0.00 89.74 80.00 / 0

State Pass Rate: 75.00 95.35 72.73 75.00 94.08 83.33 100.00 92.12 73.68 33.33 89.34 75.00 / 0

National Pass Rate: 87.69 97.19 90.14 85.14 96.57 84.46 83.15 95.61 85.36 84.96 93.86 81.88 / 0

2012 2013 2014 2015





No. of Candidates 4

Mean Scaled Score - School 60.25

Mean Scaled Score - State 66.88


School Pass Rate: 0.00

State Pass Rate: 22.22



No. of Candidates 1







2016 2017 2018 2019

NAPLEX-24-2016 Trimester 1

North American Pharmacist Licensure Examination® (NAPLEX®) School

Summary Report

Xavier University of Louisiana


Page 1 of 4


Area 2 Scaled

Score Mean

Standard

Deviation

School 4 25.00% 63.67 21.73 10.67 1.53 10.00


Score Mean

Standard

Deviation

Area 1 Scaled

Score Mean

Standard

Deviation

This NAPLEX score report consists of two levels of scores: aggregated school scores and individual candidate scores.

Beginning November 1, 2015, individual (unidentified) scores are reported in the NAPLEX Roster excel file. Summary

information is provided separately for first-time examinees from ACPE-accredited schools/colleges and for all examinees,

regardless of repeater status and/or the educational institution.

Tables 1 and 2 contain school, state, and national pass rate information as well as total score means and area score

means for each of the two main NAPLEX content domains:

Area 1 - Ensure Safe and Effective Pharmacotherapy and Health Outcomes (67%)

Area 2 - Safe and Accurate Preparation, Compounding, Dispensing and Administration of Medications

and Provision of Healthcare Products (33%)

National 213 57.75% 78.95 20.55 11.47

1.73

State 4 0.00% 47.33 21.73 9.33 1.53 9.67 2.08

1.33 11.46 1.75



Score Mean

Standard

Deviation

Area 1 Scaled

Score Mean

Standard

Deviation

Area 2 Scaled

Score Mean

Standard

Deviation

School 16 25.00% 61.87 18.40 10.33 1.29 10.60 1.59

State 18 22.22% 66.88 16.36 10.59 1.23 11.12 1.32

1.31 11.27 1.64

Table 3 contains information on the range of scaled

scores achieved by FT ACPE (First-Time, ACPE-

Accredited) candidates as well as the pool of all

candidates. It also shows the boundaries of the Scaled

Score Range.


Min Max

FT ACPE 28 125

National 918 48.80% 74.52 19.81 11.15



Interpretation and Uses of Candidate Scores

At the candidate level, two sets of scores are produced: an overall, composite score and area scores. Only overall scores

are used to make pass/fail decisions. Area scores are intended to provide insight into performances in each of the

content area domains independent of one another.

There are a total of two area scores, one per main competency area. Area scores are reported on a scale of [6,18], where

a score of 6 is the lowest possible score and a score of 18 is the highest possible score. This reporting scale does not have

a number-correct interpretation. In other words, a score of 6 does not mean that the candidate answered 6 questions

correctly. Instead, area scores are computed from ability estimates that are created for sets of items that map to each of

the two content areas.



Page 2 of 4

[0,4] 0

[5,9] 0

[10,14] 0

[15,19] 0

[20,24] 0

[25,29] 0

[30,34] 0

[35,39] 1

[40,44] 0

[45,49] 0

[50,54] 0

[55,59] 0

[60,64] 0

[65,69] 0

[70,74] 1

[75,79] 0

[80,84] 1

[85,89] 0

[90,94] 0

[95,99] 0

[100,104]0

[105,109]0

[110,114]0

[115,119]0

[120,124]0

[125,129]0

[130,134]0

[135,139]0

[140,144]0

[145,150]0

The following tables and graphs are scaled score frequency distributions for NAPLEX candidates. Candidates who did not

answer enough questions to receive a score are not reflected in the frequency distributions.


Based on First-Time Candidates N = 3

[5,9] 0 0%

[10,14] 0 0%




Interval[0,4] 0 0%

[25,29] 0 0%

[30,34] 0 0%

[15,19] 0 0%

[20,24] 0 0%

[45,49] 0 33%

[50,54] 0 33%

[35,39] 1 33%

[40,44] 0 33%

[65,69] 0 33%

[70,74] 1 67%

[55,59] 0 33%

[60,64] 0 33%

[85,89] 0 100%

[90,94] 0 100%

[75,79] 0 67%

[80,84] 1 100%

[105,109] 0 100%

[110,114] 0 100%

[95,99] 0 100%

[100,104] 0 100%

[125,129] 0 100%

[130,134] 0 100%

[115,119] 0 100%

[120,124] 0 100%

[145,150] 0 100%

[135,139] 0 100%

[140,144] 0 100%

0

0.2

0.4

0.6

0.8

1

1.2

Freq

uen

cy


Page 3 of 4

[0,4] 0

[5,9] 0

[10,14] 0

[15,19] 0

[20,24] 0

[25,29] 1

[30,34] 5

[35,39] 2

[40,44] 3

[45,49] 4

[50,54] 8

[55,59] 14

[60,64] 18

[65,69] 14

[70,74] 12

[75,79] 18

[80,84] 20

[85,89] 20

[90,94] 15

[95,99] 18

[100,104]10

[105,109]6

[110,114]11

[115,119]2

[120,124]2

[125,129]1

[130,134]0

[135,139]0

[140,144]0

[145,150]0



[5,9] 0 0%

[10,14] 0 0%




Interval[0,4] 0 0%

[25,29] 1 0%

[30,34] 5 3%

[15,19] 0 0%

[20,24] 0 0%

[45,49] 4 7%

[50,54] 8 11%

[35,39] 2 4%

[40,44] 3 5%

[65,69] 14 34%

[70,74] 12 40%

[55,59] 14 18%

[60,64] 18 27%

[85,89] 20 68%

[90,94] 15 75%

[75,79] 18 49%

[80,84] 20 58%

[105,109] 6 92%

[110,114] 11 98%

[95,99] 18 84%

[100,104] 10 89%

[125,129] 1 100%

[130,134] 0 100%

[115,119] 2 99%

[120,124] 2 100%

[145,150] 0 100%

[135,139] 0 100%

[140,144] 0 100%

0

5

10

15

20

25

Freq

uen

cy


Page 4 of 4





No. of Candidates 10 80 43 28 85 40 22 69 48 19 90 40




School Pass Rate: 60.00 77.50 62.79 57.14 85.88 82.50 54.55 79.71 85.42 68.42 90.00 75.00

State Pass Rate: 92.50 78.57 77.27 75.86 89.29 70.00 50.00 85.90 70.37 62.50 94.90 80.00



No. of Candidates 1 77 23 10 74 29 8 63 40 8 83 26




School Pass Rate: 100.00 77.92 65.22 50.00 90.54 82.76 75.00 84.13 90.00 87.50 90.36 80.77

State Pass Rate: 94.59 93.18 84.62 83.33 91.84 73.33 77.78 90.28 70.00 66.67 95.65 90.48


2000 2001 2002 2003





No. of Candidates 10 82 19 6 95 30 20 94 48 17 81 56




School Pass Rate: 70.00 96.34 84.21 83.33 86.32 56.67 50.00 82.98 77.08 52.94 83.95 64.29

State Pass Rate: 83.33 96.12 100.00 100.00 87.83 78.57 77.78 89.17 79.31 63.64 95.52 74.51



No. of Candidates 2 79 10 3 90 19 5 87 31 3 68 46




School Pass Rate: 50.00 98.73 100.00 66.67 88.89 68.42 40.00 86.21 77.42 100.00 92.65 71.74

State Pass Rate: 100.00 100.00 100.00 100.00 90.09 88.89 100.00 90.38 70.59 100.00 96.69 76.74


2004 2005 2006 2007





No. of Candidates 22 138 55 18 138 28 19 148 52 25 124 45




School Pass Rate: 68.18 81.88 76.36 61.11 83.33 71.43 42.11 75.00 59.62 64.00 87.10 75.56

State Pass Rate: 90.00 90.34 82.76 80.00 92.64 63.16 61.54 83.24 65.00 90.81 73.17



No. of Candidates 5 124 36 6 127 12 6 143 16 6 115 33




School Pass Rate: 80.00 84.68 80.56 50.00 86.61 66.67 50.00 76.92 75.00 16.67 92.17 81.82

State Pass Rate: 83.33 92.35 82.35 57.14 93.04 60.00 66.67 84.15 83.33 93.18 74.07


2008 2009 2010 2011




S+O/N+DTOTAL CANDIDATE GROUP

No. of Candidates 13 120 21 10 136 43 18 138 27 15 141 22 / 9




School Pass Rate: 46.15 90.00 61.90 40.00 86.03 65.12 50.00 92.75 70.37 53.33 85.11 86.36/22.22

State Pass Rate: 68.75 93.82 76.19 55.56 92.95 81.82 53.85 90.75 70.59 69.23 88.24 76.00/46.15



No. of Candidates 3 111 12 1 131 29 3 131 18 4 137 10 / 1




School Pass Rate: 66.67 93.69 91.67 0.00 89.31 68.97 66.67 93.89 72.22 75.00 87.59 80.00 / 0

State Pass Rate: 75.00 95.35 72.73 75.00 94.08 83.33 100.00 92.12 73.68 33.33 89.34 75.00/33.33


2014 20152012 2013





No. of Candidates 16








No. of Candidates 4







2016 2017 2018 2019

TO: EXECUTIVE OFFICERS – STATE BOARDS OF PHARMACY

FROM: Carmen A. Catizone, Executive Director/Secretary

DATE: July 28, 2016

RE: NAPLEX Program Notification _________________________________________________________________________________ The National Association of Boards of Pharmacy (NABP) would like to notify the boards of pharmacy regarding the implementation of the upcoming changes to the North American Pharmacist Licensure Examination (NAPLEX) and the Association’s efforts to alert candidates with open, active registrations for the current exam.

The NAPLEX program will transition to a new administration model in November 2016, and the upcoming changes were detailed in a memo sent to the member boards on March 3, 2016. Changes to the NAPLEX include an increase in the number of items from 185 to 250, an increase in testing time to six hours, and an increase in the registration fee from $505 to $575. In addition, effective November 1, 2016, the NAPLEX waiting period will be 45 days. Candidates must wait at least 45 days to schedule another attempt after obtaining a failing score on the NAPLEX.

Via email, NABP will be notifying candidates with open, active NAPLEX registrations of the following deadlines:

• The last day to take the current NAPLEX is October 22, 2016. Candidates wishing to take the current exam must:

o Register by October 3, 2016, o Be granted eligibility and receive an Authorization to Test, and o Schedule and take the exam by October 22, 2016.

• The NAPLEX will not be administered October 24-31, 2016. • The new NAPLEX will launch on November 1, 2016.

For candidates with open, active registrations who are unable to test by October 22, 2016, their registrations will remain active and they may schedule an appointment to take the new NAPLEX on or after November 1, 2016.

Candidates who graduate in 2017 should not register for the current NAPLEX since they are not eligible to sit for the current exam. Should any such candidates register for the current exam, their record will be closed and a partial refund granted per the NABP refund policy. The

EXECUTIVE OFFICERS – STATE BOARDS OF PHARMACY July 28, 2016 Page 2

candidate would then need to register for the new NAPLEX after November 1, 2016, and pay the new fee of $575.

Detailed information on the changes to the exam and the above deadlines will be published the week of August 1, 2016 on the NABP website (in the NAPLEX section, under Programs) and in the NAPLEX/MPJE Candidate Registration Bulletin. This information has also been provided to the schools and colleges of pharmacy.

If there are any questions regarding the updates to the NAPLEX program, please contact Maria Incrocci, competency assessment senior manager, at [email protected] or 847/391-4400.

cc: NABP Executive Committee NABP Advisory Committee on Examinations





Final Legislative Brief

2016-0606 @ 1800

Regular Session of the 2016 Louisiana Legislature Convened 2016-0314 @ 1200 – Adjourned 2016-0606 @ 1800

Last Items Reviewed

HB 1,167 HR 250 HCR 154 HSR 6 HCSR 0 SB 477 SR 201 SCR 146 SSR 0 SCSR 3 Acts 681 Total = 2,404 Items on Watch List = 118

House of Representatives

Bills HB 81 Broadwater House & Governmental Affairs Requires public bodies to provide certain information concerning the custodian of records publicly available. 06-17-2016 Signed as Act 654; effective 08-01-2015. This appears to be duplicative from last year. In any event, we have a link to this information on the home page of our website. HB 232 Stokes Civil Law & Procedure Adds limitation of liability provisions to the Right to Try Act. 06-05-2016 Signed as Act 355; effective 08-01-2016. Amends the Right to Try Act to ensure that no cause of action is created by the law for the manufacturer of the drug taken, nor any person involved in the care of the patient. HB 267 G. Miller Administration of Criminal Justice Decreases criminal penalties for certain offenses involving drug paraphernalia. 05-26-2016 Signed as Act 246; effective 08-01-2016. Amends the controlled substances law to mirror the penalties for simple possession of marijuana. HB 441 Jackson Health & Welfare Provides relative to conditions for physician participation with Medicaid managed care organizations. 05-26-2016 Signed as Act 250; effective 08-01-2016. Prohibits Medicaid managed care organizations from terminating physicians whose medical licenses have been placed on probation by LSBME solely because of their probationary status.

